{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "4fa87b82",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "import pickle\n",
    "import glob\n",
    "import warnings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "85c0aaa1",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\carte\\AppData\\Local\\Temp\\ipykernel_29620\\2979320123.py:3: DtypeWarning: Columns (4) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  df = pd.read_csv(ret_sample_path)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index(['id', 'date', 'ret_eom', 'gvkey', 'iid', 'excntry', 'stock_ret', 'year', 'month', 'char_date',\n",
      "       ...\n",
      "       'betadown_252d', 'prc_highprc_252d', 'corr_1260d', 'betabab_1260d', 'rmax5_rvol_21d', 'age', 'qmj', 'qmj_prof', 'qmj_growth', 'qmj_safety'], dtype='object', length=159)\n"
     ]
    }
   ],
   "source": [
    "ret_sample_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.csv'\n",
    "\n",
    "df = pd.read_csv(ret_sample_path)\n",
    "\n",
    "print(df.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "c98591b8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "             date\n",
      "1695191  20101130\n",
      "5021799  20210831\n",
      "1109133  20081128\n",
      "3941632  20180531\n",
      "2214206  20120831\n",
      "677865   20070629\n",
      "3413785  20160831\n",
      "4202991  20190329\n",
      "405709   20060721\n",
      "4193811  20190228\n",
      "1377171  20091029\n",
      "3649416  20170630\n",
      "6369671  20250530\n",
      "83198    20050531\n",
      "3856221  20180228\n",
      "449196   20060929\n",
      "2960688  20150227\n",
      "5884210  20240131\n",
      "4654061  20200731\n",
      "4325633  20190731\n",
      "6295073  20250331\n",
      "3201820  20151230\n",
      "148835   20050831\n",
      "2303098  20121228\n",
      "1256409  20090529\n",
      "4453515  20191231\n",
      "1898712  20110729\n",
      "621200   20070430\n",
      "4542759  20200331\n",
      "4155784  20190130\n",
      "447084   20060929\n",
      "5997297  20240531\n",
      "104683   20050630\n",
      "5108882  20211130\n",
      "3042563  20150630\n",
      "1326575  20090831\n",
      "1114031  20081230\n",
      "6386094  20250630\n",
      "2774267  20140731\n",
      "3925624  20180430\n",
      "1761546  20110228\n",
      "1014558  20080829\n",
      "452082   20060928\n",
      "1121113  20081230\n",
      "1415676  20091230\n",
      "195749   20051031\n",
      "5188294  20220228\n",
      "5629329  20230428\n",
      "2481787  20130731\n",
      "975004   20080630\n",
      "2273765  20121129\n",
      "5051515  20210930\n",
      "2377526  20130329\n",
      "4369177  20190930\n",
      "461199   20060929\n",
      "447251   20060929\n",
      "4127906  20181231\n",
      "1600034  20100730\n",
      "727386   20070831\n",
      "3825386  20171229\n",
      "2994432  20150430\n",
      "1759391  20110228\n",
      "1856421  20110630\n",
      "5122636  20211230\n",
      "2084800  20120330\n",
      "3251114  20160229\n",
      "3647586  20170630\n",
      "5410970  20220929\n",
      "3683149  20170707\n",
      "1095537  20081128\n",
      "677369   20070629\n",
      "3847603  20180131\n",
      "1040790  20080930\n",
      "6168452  20241031\n",
      "2954689  20150227\n",
      "5667104  20230630\n",
      "5979977  20240430\n",
      "4379170  20190930\n",
      "4993375  20210730\n",
      "6198127  20241129\n",
      "6224854  20241231\n",
      "256473   20060131\n",
      "113831   20050729\n",
      "2989328  20150430\n",
      "4077127  20181031\n",
      "1660009  20101029\n",
      "2870292  20141128\n",
      "742074   20070928\n",
      "2140349  20120531\n",
      "4225011  20190329\n",
      "455162   20060929\n",
      "5030799  20210930\n",
      "202370   20051031\n",
      "66915    20050429\n",
      "5619750  20230428\n",
      "13943    20050216\n",
      "3946840  20180531\n",
      "3870724  20180228\n",
      "1897380  20110729\n",
      "1297119  20090731\n"
     ]
    }
   ],
   "source": [
    "ret_sample_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.csv'\n",
    "pd.set_option(\"display.max_rows\", 1000)\n",
    "df = pd.read_csv(ret_sample_path, usecols=['date'])\n",
    "print(df.sample(100))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "80e73c54",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting the memory-efficient script to split data by company ID.\n",
      "Created output directory: C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\csv_by_id\n",
      "Reading data from C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.csv in chunks of 1000000 rows...\n",
      "--- Processing Chunk 1 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 1 processed successfully.\n",
      "Unique IDs found so far: 29651\n",
      "--- Processing Chunk 2 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 2 processed successfully.\n",
      "Unique IDs found so far: 33335\n",
      "--- Processing Chunk 3 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 3 processed successfully.\n",
      "Unique IDs found so far: 36931\n",
      "--- Processing Chunk 4 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 4 processed successfully.\n",
      "Unique IDs found so far: 41556\n",
      "--- Processing Chunk 5 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 5 processed successfully.\n",
      "Unique IDs found so far: 46895\n",
      "--- Processing Chunk 6 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 6 processed successfully.\n",
      "Unique IDs found so far: 51042\n",
      "--- Processing Chunk 7 ---\n",
      "Cleaning 'gvkey' column and preparing for grouping...\n",
      "Grouping by 'gvkey' and saving to files...\n",
      "Chunk 7 processed successfully.\n",
      "Unique IDs found so far: 52268\n",
      "\n",
      "Processing complete. All chunks have been processed and files saved.\n",
      "Total unique IDs found and files created: 52268\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "\n",
    "def process_csv_in_chunks(input_csv_path, output_dir, chunk_size=1000000):\n",
    "    \"\"\"\n",
    "    Reads and processes a large CSV in chunks to avoid memory errors. It\n",
    "    uses the 'gvkey' column to save separate CSV files for each unique ID.\n",
    "\n",
    "    Args:\n",
    "        input_csv_path (str): The path to the input CSV file.\n",
    "        output_dir (str): The directory where the output CSVs will be saved.\n",
    "        chunk_size (int): The number of rows to process in each chunk.\n",
    "    \"\"\"\n",
    "    # Create the output directory if it doesn't exist\n",
    "    if not os.path.exists(output_dir):\n",
    "        os.makedirs(output_dir)\n",
    "        print(f\"Created output directory: {output_dir}\")\n",
    "\n",
    "    # This set will keep track of which files we have already written the header for\n",
    "    created_files = set()\n",
    "    \n",
    "    try:\n",
    "        print(f\"Reading data from {input_csv_path} in chunks of {chunk_size} rows...\")\n",
    "        \n",
    "        # Use the 'chunksize' parameter to create an iterator\n",
    "        chunk_iterator = pd.read_csv(input_csv_path, low_memory=False, chunksize=chunk_size)\n",
    "        \n",
    "        # Loop through each chunk (a smaller DataFrame) from the file\n",
    "        for i, chunk in enumerate(chunk_iterator):\n",
    "            print(f\"--- Processing Chunk {i+1} ---\")\n",
    "\n",
    "            # --- ID Transformation using 'gvkey' column ---\n",
    "            print(\"Cleaning 'gvkey' column and preparing for grouping...\")\n",
    "            # Drop rows where gvkey is missing\n",
    "            chunk.dropna(subset=['gvkey'], inplace=True)\n",
    "            # Convert gvkey to integer type to remove decimals (e.g., 1081.0 -> 1081)\n",
    "            chunk['gvkey'] = chunk['gvkey'].astype(int)\n",
    "            \n",
    "            # --- Append rows to the correct files ---\n",
    "            print(\"Grouping by 'gvkey' and saving to files...\")\n",
    "            # Group the current chunk by the integer 'gvkey'\n",
    "            grouped_chunk = chunk.groupby('gvkey')\n",
    "            \n",
    "            # Loop through each unique ID found in this chunk\n",
    "            for current_id, group_df in grouped_chunk:\n",
    "                file_name = f\"{current_id}.csv\"\n",
    "                output_path = os.path.join(output_dir, file_name)\n",
    "                \n",
    "                # If we haven't created this file yet, write with a header.\n",
    "                # Otherwise, append without the header.\n",
    "                if output_path not in created_files:\n",
    "                    group_df.to_csv(output_path, index=False, mode='w', header=True)\n",
    "                    created_files.add(output_path) # Mark this file as created\n",
    "                else:\n",
    "                    group_df.to_csv(output_path, index=False, mode='a', header=False)\n",
    "            \n",
    "            print(f\"Chunk {i+1} processed successfully.\")\n",
    "            # Add a running counter after each chunk is processed\n",
    "            print(f\"Unique IDs found so far: {len(created_files)}\")\n",
    "\n",
    "        print(\"\\nProcessing complete. All chunks have been processed and files saved.\")\n",
    "        # Add a final count at the end of the script\n",
    "        print(f\"Total unique IDs found and files created: {len(created_files)}\")\n",
    "\n",
    "    except FileNotFoundError:\n",
    "        print(f\"Error: The file '{input_csv_path}' was not found. Please check the path.\")\n",
    "    except Exception as e:\n",
    "        print(f\"An unexpected error occurred: {e}\")\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    print(\"Starting the memory-efficient script to split data by company ID.\")\n",
    "    \n",
    "    # 1. Set the path to your input CSV file.\n",
    "    input_file_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.csv'\n",
    "    \n",
    "    # 2. Set the path for the output folder.\n",
    "    output_folder_name = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\csv_by_id'\n",
    "    \n",
    "    # 3. Run the main function.\n",
    "    process_csv_in_chunks(input_file_path, output_folder_name)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "b436e8bb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<bound method NDFrame.head of             date      cik file_type                                                                                                                                                                                                       rf  \\\n",
      "177795  20050103    16099       10Q                                                                                                                                                                                                            \n",
      "177791  20050103   779544       10K                                                                                                                                                                                                            \n",
      "177794  20050103   831641       10K                                                                                                                                                                                                            \n",
      "177790  20050103   866415       10K                                                                                                                                                                                                            \n",
      "177793  20050103  1141240       10Q                                                                                                                                                                                                            \n",
      "...          ...      ...       ...                                                                                                                                                                                                      ...   \n",
      "195708  20051229  1100983       10K                                                                                                                                                                                                            \n",
      "195726  20051229  1122668       10K  ITEM 1A. RISK FACTORS\\n\\n This Report contains forward-looking statements based on the current\\nexpectations, assumptions, estimates and projections about us and our industry.\\nOur actual results ...   \n",
      "195718  20051229  1310094       10K                                                                                                                                                                                                            \n",
      "195714  20051229  1311396       10K  Item 1A. \\n\\nRisk Factors ITEM 1A. Risk Factors \\n\\nAviza\\nwill need to raise capital in order to support its operations, which capital\\nmay not be available on terms acceptable to Aviza, or at al...   \n",
      "195737  20051230    16099       10Q                                                                                                                                                                                                            \n",
      "\n",
      "                                                                                                                                                                                                           mgmt     gvkey      cusip  year  \n",
      "177795  Item 2 Management s Discussion and Analysis of Financial Condition and Results of Operations \\n\\n18 Item 2. Management s Discussion and Analysis of Financial Condition of\\nOperations \\n\\nManagemen...    6831.0  549282101  2005  \n",
      "177791  Item 7. Management's Discussion and Analysis of Financial Condition and Results\\n of Operations\\n\\nAccounting period\\n\\nThe Company's fiscal year ends on the Saturday nearest September 30. The Com...   11872.0  040712101  2005  \n",
      "177794  Item 7 \\n \\n Management's Discussion and Analysis of Financial Condition and Results of Operations \\n \\n 30 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Opera...   24783.0  88162G103  2005  \n",
      "177790  ITEM 7. Management's Discussion and Analysis of Financial\\n Condition and Results of Operations 17\\n\\nRISK FACTORS Item 7\\n- - Management's Discussion and Analysis of Financial Condition and Resul...   61721.0  459412102  2005  \n",
      "177793  Item\\n 2 Management s Discussion and Analysis of Financial Condition and Results\\n of Operations Item 2. Management s Discussion and Analysis of\\nFinancial Condition and Results of Operations \\n\\n...  146117.0  53634X100  2005  \n",
      "...                                                                                                                                                                                                         ...       ...        ...   ...  \n",
      "195708  Item 7. Management s Discussion and Analysis\\nof Financial Condition and Results of Operations \\n\\nThe information required herein is\\nincorporated by reference from pages 6 to16 of the 2005 Annua...  133506.0  71086E107  2005  \n",
      "195726  ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION\\n AND RESULTS OF OPERATIONS...................................33 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI...  141007.0  68382T101  2005  \n",
      "195718  ITEM 7. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS When you read this section of this Form 10K, it is important that you also read the\\nfinancial stateme...  162956.0  00430L103  2005  \n",
      "195714  Item\\n 7. \\n\\nManagement s\\n Discussion and Analysis of Financial Condition and Results of Operations Item 7. Management s Discussion and Analysis of\\nFinancial Condition and Results of \\n\\n23 \\n\\...  165666.0  05381A105  2005  \n",
      "195737  Item 2. \\n\\nManagement s\\n Discussion and Analysis of Financial\\n Condition and Results of\\n Operations \\n\\nManagement's\\n discussion and analysis of financial condition and results of operations\\...    6831.0  549282101  2005  \n",
      "\n",
      "[16857 rows x 8 columns]>\n",
      "Index(['date', 'cik', 'file_type', 'rf', 'mgmt', 'gvkey', 'cusip', 'year'], dtype='object')\n"
     ]
    }
   ],
   "source": [
    "# rf and mgmnt are the risk factors and management discussion and analysis respectively. \n",
    "pd.set_option('display.max_columns', None)\n",
    "\n",
    "# 2. Set display width: This is the key setting to prevent line wrapping.\n",
    "#    We set it to a very large number to ensure pandas tries to fit everything on one line.\n",
    "pd.set_option('display.width', 300) # You can increase this number if needed\n",
    "pd.set_option('display.max_colwidth', 200)\n",
    "\n",
    "# Optional: If you also want to see more rows in your output\n",
    "pd.set_option('display.max_rows', 100) # This will show up to 100 rows\n",
    "\n",
    "directory_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'\n",
    "\n",
    "pickle_pattern = os.path.join(directory_path, '**', '*.pkl')\n",
    "all_pickle_files = glob.glob(pickle_pattern, recursive=True)\n",
    "\n",
    "if all_pickle_files:\n",
    "\n",
    "    first_file_path = all_pickle_files[0]\n",
    "\n",
    "    df = pd.read_pickle(first_file_path)\n",
    "\n",
    "    print(df.head)\n",
    "    print(df.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "2b300c03",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\myenv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading model 'ProsusAI/finbert'... (This may take a moment on first run)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\myenv\\Lib\\site-packages\\huggingface_hub\\file_download.py:143: UserWarning: `huggingface_hub` cache-system uses symlinks by default to efficiently store duplicated files but your machine does not support them in C:\\Users\\carte\\.cache\\huggingface\\hub\\models--ProsusAI--finbert. Caching files will still work but in a degraded version that might require more space on your disk. This warning can be disabled by setting the `HF_HUB_DISABLE_SYMLINKS_WARNING` environment variable. For more details, see https://huggingface.co/docs/huggingface_hub/how-to-cache#limitations.\n",
      "To support symlinks on Windows, you either need to activate Developer Mode or to run Python as an administrator. In order to activate developer mode, see this article: https://docs.microsoft.com/en-us/windows/apps/get-started/enable-your-device-for-development\n",
      "  warnings.warn(message)\n",
      "Xet Storage is enabled for this repo, but the 'hf_xet' package is not installed. Falling back to regular HTTP download. For better performance, install the package with: `pip install huggingface_hub[hf_xet]` or `pip install hf_xet`\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model loaded successfully.\n",
      "\n",
      "--- FinBERT Sentiment Analysis Results ---\n",
      "  Sentence:   'The company's earnings exceeded expectations, driven by strong sales growth.'\n",
      "  Sentiment:  Positive (Confidence: 95.96%)\n",
      "\n",
      "  Sentence:   'Regulatory concerns and rising costs have negatively impacted our outlook.'\n",
      "  Sentiment:  Negative (Confidence: 94.92%)\n",
      "\n",
      "  Sentence:   'The new factory is expected to begin operations in the third quarter.'\n",
      "  Sentiment:  Neutral (Confidence: 87.01%)\n",
      "\n",
      "  Sentence:   'Despite a challenging market, the firm maintained its dividend payout.'\n",
      "  Sentiment:  Positive (Confidence: 95.12%)\n",
      "\n",
      "  Sentence:   'Profits have plummeted following the product recall.'\n",
      "  Sentiment:  Negative (Confidence: 97.40%)\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Xet Storage is enabled for this repo, but the 'hf_xet' package is not installed. Falling back to regular HTTP download. For better performance, install the package with: `pip install huggingface_hub[hf_xet]` or `pip install hf_xet`\n"
     ]
    }
   ],
   "source": [
    "# First, you need to install the 'transformers' library from Hugging Face.\n",
    "# You can do this by opening your terminal or command prompt and running:\n",
    "# pip install transformers torch\n",
    "\n",
    "import torch\n",
    "from transformers import AutoTokenizer, AutoModelForSequenceClassification\n",
    "\n",
    "def analyze_sentiment(text_list):\n",
    "    \"\"\"\n",
    "    Analyzes the sentiment of a list of financial texts using a pre-trained FinBERT model.\n",
    "\n",
    "    Args:\n",
    "        text_list (list of str): A list of sentences to analyze.\n",
    "\n",
    "    Returns:\n",
    "        list of dict: A list of dictionaries, each containing the original text,\n",
    "                      the predicted sentiment (Positive, Negative, Neutral),\n",
    "                      and the model's confidence score.\n",
    "    \"\"\"\n",
    "    # 1. Load the Pre-trained FinBERT Model and Tokenizer\n",
    "    # =======================================================\n",
    "    # We are using a version of FinBERT that has been specifically fine-tuned for\n",
    "    # sentiment analysis on financial text.\n",
    "    model_name = \"ProsusAI/finbert\"\n",
    "    print(f\"Loading model '{model_name}'... (This may take a moment on first run)\")\n",
    "    tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "    model = AutoModelForSequenceClassification.from_pretrained(model_name)\n",
    "    print(\"Model loaded successfully.\")\n",
    "\n",
    "    # 2. Tokenize the Input Text\n",
    "    # ==========================\n",
    "    # The tokenizer converts our human-readable sentences into a format of numbers (tokens)\n",
    "    # that the model can understand. `padding=True` and `truncation=True` handle\n",
    "    # sentences of different lengths.\n",
    "    inputs = tokenizer(text_list, padding=True, truncation=True, return_tensors=\"pt\")\n",
    "\n",
    "    # 3. Get Model Predictions\n",
    "    # ========================\n",
    "    # We run the tokenized inputs through the model. `torch.no_grad()` is a performance\n",
    "    # optimization that tells PyTorch we are not training the model, just using it.\n",
    "    with torch.no_grad():\n",
    "        outputs = model(**inputs)\n",
    "\n",
    "    # 4. Interpret the Results\n",
    "    # ========================\n",
    "    # The model's output (logits) are raw scores. We apply a softmax function to\n",
    "    # convert them into probabilities between 0 and 1.\n",
    "    predictions = torch.nn.functional.softmax(outputs.logits, dim=-1)\n",
    "    \n",
    "    # The model was trained on three labels: positive, negative, neutral.\n",
    "    labels = [\"positive\", \"negative\", \"neutral\"]\n",
    "    \n",
    "    results = []\n",
    "    for i in range(len(text_list)):\n",
    "        # Find the index of the highest probability score\n",
    "        sentiment_idx = torch.argmax(predictions[i]).item()\n",
    "        # Get the corresponding label\n",
    "        sentiment = labels[sentiment_idx]\n",
    "        # Get the confidence score for that prediction\n",
    "        confidence = predictions[i][sentiment_idx].item()\n",
    "        \n",
    "        results.append({\n",
    "            \"text\": text_list[i],\n",
    "            \"sentiment\": sentiment.capitalize(),\n",
    "            \"confidence\": f\"{confidence:.2%}\" # Format as percentage\n",
    "        })\n",
    "        \n",
    "    return results\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    # Define some example financial sentences to analyze\n",
    "    example_sentences = [\n",
    "        \"The company's earnings exceeded expectations, driven by strong sales growth.\",\n",
    "        \"Regulatory concerns and rising costs have negatively impacted our outlook.\",\n",
    "        \"The new factory is expected to begin operations in the third quarter.\",\n",
    "        \"Despite a challenging market, the firm maintained its dividend payout.\",\n",
    "        \"Profits have plummeted following the product recall.\"\n",
    "    ]\n",
    "\n",
    "    # Get the sentiment analysis results\n",
    "    sentiment_results = analyze_sentiment(example_sentences)\n",
    "\n",
    "    # Print the results in a clean format\n",
    "    print(\"\\n--- FinBERT Sentiment Analysis Results ---\")\n",
    "    for result in sentiment_results:\n",
    "        print(f\"  Sentence:   '{result['text']}'\")\n",
    "        print(f\"  Sentiment:  {result['sentiment']} (Confidence: {result['confidence']})\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "0e37d39e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Searching for pickle files in 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'...\n",
      "Found files. Loading the first one: 'text_us_2005.pkl'\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\carte\\AppData\\Local\\Temp\\ipykernel_19912\\3822597473.py:33: DeprecationWarning: numpy.core.numeric is deprecated and has been renamed to numpy._core.numeric. The numpy._core namespace contains private NumPy internals and its use is discouraged, as NumPy internals can change without warning in any release. In practice, most real-world usage of numpy.core is to access functionality in the public NumPy API. If that is the case, use the public NumPy API. If not, you are using NumPy internals. If you would still like to access an internal attribute, use numpy._core.numeric._frombuffer.\n",
      "  filings_df = pickle.load(f)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found a suitable filing for inspection at index 179123.\n",
      "Extracting data for CIK: 879526, Filing Date: 20050303\n",
      "\n",
      "Success! The content has been written to 'filing_example.txt'\n",
      "You can now open this file to see the raw text.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import glob\n",
    "import pickle\n",
    "import pandas as pd # Import pandas to handle the DataFrame\n",
    "\n",
    "def inspect_first_filing(data_directory, output_filename=\"filing_example.txt\"):\n",
    "    \"\"\"\n",
    "    Finds the first pickle file, searches for the first row with non-empty text\n",
    "    sections, and saves that filing's text to a file for inspection.\n",
    "\n",
    "    Args:\n",
    "        data_directory (str): The root path where the text data is stored.\n",
    "        output_filename (str): The name of the text file to create.\n",
    "    \"\"\"\n",
    "    print(f\"Searching for pickle files in '{data_directory}'...\")\n",
    "    \n",
    "    # 1. Find the first pickle file automatically\n",
    "    # ============================================\n",
    "    pickle_pattern = os.path.join(data_directory, '**', '*.pkl')\n",
    "    all_pickle_files = glob.glob(pickle_pattern, recursive=True)\n",
    "\n",
    "    if not all_pickle_files:\n",
    "        print(\"Error: No pickle files were found. Please check the directory path.\")\n",
    "        return\n",
    "\n",
    "    first_file_path = all_pickle_files[0]\n",
    "    print(f\"Found files. Loading the first one: '{os.path.basename(first_file_path)}'\")\n",
    "\n",
    "    # 2. Load the data from the pickle file\n",
    "    # =======================================\n",
    "    try:\n",
    "        with open(first_file_path, 'rb') as f:\n",
    "            filings_df = pickle.load(f)\n",
    "            \n",
    "            if filings_df.empty:\n",
    "                print(\"The pickle file contains an empty DataFrame.\")\n",
    "                return\n",
    "\n",
    "            # --- NEW: Loop to find the first valid row ---\n",
    "            # We'll search for the first row that has meaningful content in both key sections.\n",
    "            valid_filing_series = None\n",
    "            for index, row in filings_df.iterrows():\n",
    "                # The correct column names are 'rf' (Risk Factors) and 'mgmt' (MD&A)\n",
    "                risk_text = row.get('rf')\n",
    "                mda_text = row.get('mgmt')\n",
    "\n",
    "                # Check if both sections exist and have a reasonable length (e.g., > 100 characters)\n",
    "                if pd.notna(risk_text) and len(str(risk_text).strip()) > 100 and \\\n",
    "                   pd.notna(mda_text) and len(str(mda_text).strip()) > 100:\n",
    "                    valid_filing_series = row\n",
    "                    print(f\"Found a suitable filing for inspection at index {index}.\")\n",
    "                    break # Exit the loop once a good example is found\n",
    "            \n",
    "            if valid_filing_series is None:\n",
    "                print(\"Error: Could not find a single filing with complete text sections in this file.\")\n",
    "                return\n",
    "\n",
    "            # 3. Extract data from the VALID filing row\n",
    "            # ==========================================================\n",
    "            cik = valid_filing_series.get('cik', 'CIK not found')\n",
    "            filing_date = valid_filing_series.get('date', 'Date not found')\n",
    "            risk_factors_text = valid_filing_series.get('rf', 'Section not found.')\n",
    "            mda_text = valid_filing_series.get('mgmt', 'Section not found.')\n",
    "\n",
    "            print(f\"Extracting data for CIK: {cik}, Filing Date: {filing_date}\")\n",
    "\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while loading or processing the pickle file: {e}\")\n",
    "        return\n",
    "\n",
    "    # 4. Write the extracted text to a plain text file\n",
    "    # =================================================\n",
    "    try:\n",
    "        with open(output_filename, 'w', encoding='utf-8') as f:\n",
    "            f.write(\"=\"*80 + \"\\n\")\n",
    "            f.write(f\"EXAMPLE FILING FOR INSPECTION\\n\")\n",
    "            f.write(f\"CIK: {cik} | DATE: {filing_date}\\n\")\n",
    "            f.write(\"=\"*80 + \"\\n\\n\")\n",
    "\n",
    "            f.write(\"--- RISK FACTORS ---\\n\\n\")\n",
    "            f.write(str(risk_factors_text)) # Use str() to handle potential non-string data\n",
    "            f.write(\"\\n\\n\")\n",
    "\n",
    "            f.write(\"=\"*80 + \"\\n\\n\")\n",
    "\n",
    "            f.write(\"--- MANAGEMENT'S DISCUSSION AND ANALYSIS (MD&A) ---\\n\\n\")\n",
    "            f.write(str(mda_text)) # Use str() to handle potential non-string data\n",
    "        \n",
    "        print(f\"\\nSuccess! The content has been written to '{output_filename}'\")\n",
    "        print(\"You can now open this file to see the raw text.\")\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while writing the file: {e}\")\n",
    "\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    # !! IMPORTANT: Make sure this path points to your unzipped text data directory !!\n",
    "    text_data_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'\n",
    "    \n",
    "    inspect_first_filing(text_data_path)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "3f89f8d8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Searching for pickle files in 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'...\n",
      "Found files. Loading the first one: 'text_us_2005.pkl'\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\carte\\AppData\\Local\\Temp\\ipykernel_19912\\383267985.py:92: DeprecationWarning: numpy.core.numeric is deprecated and has been renamed to numpy._core.numeric. The numpy._core namespace contains private NumPy internals and its use is discouraged, as NumPy internals can change without warning in any release. In practice, most real-world usage of numpy.core is to access functionality in the public NumPy API. If that is the case, use the public NumPy API. If not, you are using NumPy internals. If you would still like to access an internal attribute, use numpy._core.numeric._frombuffer.\n",
      "  filings_df = pickle.load(f)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found a suitable filing for inspection at index 179123.\n",
      "['Item 7B Risk Factors.................................................................... 24 ITEM 7B - RISK FACTORS', 'You should carefully consider the risks described below in addition to other information contained or incorporated by reference in this Report before investing in our securities. Realization of any of the following risks could have a material adverse effect on our business, financial condition, cash flows and results of operations.', 'RISKS RELATED TO OUR BUSINESS, STRATEGY AND OPERATIONS\\nWE HAVE GENERATED SIGNIFICANT LOSSES IN RECENT PERIODS.', 'We incurred significant net losses during the three years prior to 2004. In 2004, we reported net income of 58.4 million, but we reported net losses of 232.2 million, 56.2 million and 57.2 million for the years ended December 31, 2001, 2002 and 2003, respectively. Our ability to achieve and sustain profitability in the future will depend on the successful continued implementation of measures to reduce costs and achieve sales goals, as well as the ability to pass on to customers increases in raw materials and components. While we have taken steps to lower operating costs and reduce interest expense, and have seen our sales improve in recent periods, we cannot assure you that our cost-reduction measures will be successful, sales will be sustained or increased or that we will achieve a sustained return to profitability.', 'OUR INVENTORIES ARE NOT MANAGED BY PERPETUAL INVENTORY CONTROL SYSTEMS.', 'The systems and processes we use to manage and value our inventories require significant manual intervention and the verification of actual quantities requires physical inventories, which we take several times a year. Breakdowns of these systems and processes, and errors in inventory estimates derived from these systems and processes, could go undetected until the next physical inventory and adversely affect our operations and financial results.', 'AN ADVERSE CHANGE IN OUR CUSTOMER RELATIONSHIPS OR IN THE FINANCIAL CONDITION OF OUR CUSTOMERS COULD ADVERSELY AFFECT OUR BUSINESS.', 'We have relationships with a number of customers where we supply the requirements of these customers. We do not have binding agreements with these customers. Our success is dependent, to a significant extent, upon the continued strength of these relationships and the growth of our core customers. We often are unable to predict the level of demand for our products from these customers, or the timing of their orders. In addition, the same economic conditions that adversely affect us also often adversely affect our customers. As some of our customers are highly leveraged and have limited access to capital, their continued existence may be uncertain. One of our customers, Grupo Transportation Marititma Mexicana SA (TMM), which is located in Mexico, has been experiencing financial difficulties even though it restructured its debt in August 2004, and is in the process of selling certain of its assets. Payments from TMM to us are currently behind schedule. The customer owes us 7.3 million as of December 31, 2004 secured by highly specialized RoadRailer(R) equipment, which due to the nature of the equipment, has a minimal recovery value. The loss of a significant customer or unexpected delays in product purchases could adversely affect our business and results of operations.', 'OUR TECHNOLOGY AND PRODUCTS MAY NOT ACHIEVE MARKET ACCEPTANCE, WHICH COULD ADVERSELY AFFECT OUR COMPETITIVE POSITION.', 'We continue to introduce new products, such as the DuraPlateHD(R) and the Freight-Pro(R) trailer. We cannot assure you that these or other new products or technologies will achieve sustained market acceptance. In addition, new technologies or products that our competitors introduce may render our products obsolete or uncompetitive. We have taken steps to protect our proprietary rights in our new products. However, the steps we have taken to protect them may not be sufficient or may not be enforced by a court of law. If we are unable to protect our proprietary rights, other parties may attempt to copy or otherwise obtain or use our products or technology. If competitors are able to use our technology, our ability to compete effectively could be harmed.', 'WE HAVE A LIMITED NUMBER OF SUPPLIERS OF RAW MATERIALS; AN INCREASE IN THE PRICE OF RAW MATERIALS OR THE INABILITY TO OBTAIN RAW MATERIALS COULD ADVERSELY AFFECT OUR RESULTS OF OPERATIONS.', 'We currently rely on a limited number of suppliers for certain key components in the manufacturing of truck trailers, such as tires, landing gear, axles and specialty steel coil used in DuraPlate(R) panels. From time to time, there have been and may in the future continue to be shortages of supplies of raw materials or our suppliers may place us on allocation, which would have an adverse impact on our ability to meet demand for our products. Raw material shortages and allocations may result in inefficient operations and a build-up of inventory, which can negatively affect our working capital position. In addition, if the price of raw materials were to increase and we were unable to increase our selling prices or reduce our operating costs to offset the price increases, our operating margins would be adversely affected. The loss of any of our suppliers or their inability to meet our price, quality, quantity and delivery requirements could have a significant impact on our results of operations.', 'DISRUPTION OF OUR MANUFACTURING OPERATIONS OR MANAGEMENT INFORMATION SYSTEMS WOULD HAVE AN ADVERSE EFFECT ON OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS.', 'We manufacture our products at two trailer manufacturing facilities in Lafayette, Indiana, and one hardwood floor facility in Harrison, Arkansas. Our primary manufacturing facility accounts for approximately 85 of our manufacturing output. An unexpected disruption in our production at either of these facilities or in our management information systems for any length of time would have an adverse effect on our business, financial condition and results of operations.', 'THE LOSS OF KEY PERSONNEL COULD ADVERSELY AFFECT OUR RESULTS OF OPERATIONS.', 'Many of our executive officers, including our CEO William P. Greubel and COO Richard J. Giromini, are critical to the management and direction of our business. Our future success depends, in large part, on our ability to retain these officers and other capable management personnel. The unexpected loss of the services of any of our key personnel could have an adverse effect on the operation of our business, as we may be unable to find suitable management to replace departing executives on a timely basis.', 'THE INABILITY TO REALIZE ADDITIONAL COSTS SAVINGS COULD WEAKEN OUR COMPETITIVE POSITION.', 'If we are unable to continue to successfully implement our program of cost reduction and continuous improvement, we may not realize additional anticipated cost savings, which could weaken our competitive position.', 'WE ARE SUBJECT TO CURRENCY EXCHANGE RATE FLUCTUATIONS, WHICH COULD ADVERSELY AFFECT OUR FINANCIAL PERFORMANCE.', 'We are subject to currency exchange rate risk related to sales through our factory-owned retail distribution centers in Canada. For the years ended December 31, 2004 and 2003, currency exchange rate fluctuations had a favorable impact of 0.5 million and 5.3 million, respectively, on our results of operations. We cannot assure you that future currency exchange rate fluctuations will not have an adverse affect on our results of operations.', 'RESTRICTIVE COVENANTS IN OUR DEBT INSTRUMENTS COULD LIMIT OUR FINANCIAL AND OPERATING FLEXIBILITY AND SUBJECT US TO OTHER RISKS.', 'The agreements governing our indebtedness include certain covenants that restrict, among other things, our ability to:', '- incur additional debt;', '- pay dividends on our common stock in excess of 10 million per year;', '- repurchase our common stock;', '- consolidate, merge or transfer all or substantially all of our assets;', '- make certain investments, mergers and acquisitions; and', '- create certain liens.', 'Additionally, should our available borrowing capacity drop below 40 million, we would be subject to a minimum fixed charge coverage ratio which could limit our ability to make capital expenditures and further limit the amount of dividends we could pay.', 'Our ability to comply with such agreements may be affected by events beyond our control, including prevailing economic, financial and industry conditions. In addition, upon the occurrence of an event of default under our debt agreements, the lenders could elect to declare all amounts outstanding under our debt agreements, together with accrued interest, to be immediately due and payable.', 'RISKS PARTICULAR TO THE INDUSTRY IN WHICH WE OPERATE\\nOUR BUSINESS IS HIGHLY CYCLICAL, WHICH COULD ADVERSELY AFFECT OUR SALES AND RESULTS OF OPERATIONS.', \"The truck trailer manufacturing industry historically has been and is expected to continue to be cyclical, as well as affected by overall economic conditions. New trailer production for the trailer industry reached its most recent peak of approximately 306,000 units in 1999, falling to approximately 140,000 by 2001 and rebounding to approximately 229,000 units in 2004. Customers historically have replaced trailers in cycles that run from five to twelve years, depending on service and trailer type. Poor economic conditions can adversely affect demand for new trailers and in the past have led to an overall aging of trailer fleets beyond this typical replacement cycle. Customers' buying patterns can also reflect regulatory changes, such as the new federal hours-of-service rules and anticipated 2007 federal emissions standards. Our business is likely to continue to be highly cyclical based on current and expected economic conditions and regulatory factors.\", 'SIGNIFICANT COMPETITION IN THE INDUSTRY IN WHICH WE OPERATE MAY RESULT IN OUR COMPETITORS OFFERING NEW OR BETTER PRODUCTS AND SERVICES OR LOWER PRICES, WHICH COULD RESULT IN A LOSS OF CUSTOMERS AND A DECREASE IN OUR REVENUES.', 'The truck trailer manufacturing industry is highly competitive. We compete with other manufacturers of varying sizes, some of which may have greater financial resources than we do. Barriers to entry in the standard truck trailer manufacturing industry are low. As a result, it is possible that additional competitors could enter the market at any time. In the recent past, the manufacturing over-capacity and high leverage of some of our competitors, along with the bankruptcies and financial stresses that affected the industry, contributed to significant pricing pressures.', 'If we are unable to compete successfully with other trailer manufacturers, we could lose customers and our revenues may decline. In addition, competitive pressures in the industry may affect the market prices of our new and used equipment, which, in turn, may adversely affect our sales margins and results of operations.', 'WE ARE SUBJECT TO EXTENSIVE GOVERNMENTAL LAWS AND REGULATIONS, AND OUR COSTS RELATED TO COMPLIANCE WITH, OR OUR FAILURE TO COMPLY WITH, EXISTING OR FUTURE LAWS AND REGULATIONS COULD ADVERSELY AFFECT OUR BUSINESS AND RESULTS OF OPERATIONS.', 'The length, height, width, maximum weight capacity and other specifications of truck trailers are regulated by individual states. The Federal government also regulates certain truck trailer safety features, such as lamps, reflective devices, tires, air-brake systems and rear-impact guards. Changes or anticipation of changes in these regulations can have a material impact on our financial results, as our customers may defer purchasing decisions and we may have to reengineer products. In addition, we are subject to various environmental laws and regulations dealing with the transportation, storage, presence, use, disposal and handling of hazardous materials, discharge of storm water and underground fuel storage tanks and may be subject to liability associated with operations of prior owners of acquired property. In 2004, we paid 0.4 million and agreed to a compliance agreement with the EPA related to violations of the federal Clean Water Act at our former Huntsville, Tennessee manufacturing facility.', 'If we are found to be in violation of applicable laws or regulations in the future, it could have an adverse effect on our business, financial condition and results of operations. Our costs of complying with these or any other current or future environmental regulations may be significant. In addition, if we fail to comply with existing or future laws and regulations, we may be subject to governmental or judicial fines or sanctions.', 'A DECLINE IN THE VALUE OF USED TRAILERS COULD ADVERSELY AFFECT OUR RESULTS OF OPERATIONS.', 'General economic and industry conditions, as well as the supply of used trailers, influence the value of used trailers. As part of our normal business practices, we maintain used trailer inventories and have entered into finance contracts secured by used trailers, as well as residual guarantees and purchase commitments for used trailers. Declines in the market value for used trailers or the need to dispose of excess inventories has had, and could in the future have, an adverse effect on our business, financial condition and results of operations.', 'PRODUCT LIABILITY AND OTHER CLAIMS.', 'As a manufacturer of products widely used in commerce, we are subject to regular product liability claims as well as warranty and similar claims alleging defective products. From time to time claims may involve material amounts and novel legal theories, and any insurance we carry may prove inadequate to insulate us from material liabilities for these claims.', 'RISKS RELATED TO AN INVESTMENT IN OUR COMMON STOCK\\nOUR COMMON STOCK HAS EXPERIENCED, AND MAY CONTINUE TO EXPERIENCE, PRICE VOLATILITY AND A LOW TRADING VOLUME.', 'The trading price of our common stock has been and may continue to be subject to large fluctuations. Our common stock price may increase or decrease in response to a number of events and factors, including:', '- trends in our industry and the markets in which we operate;', '- changes in the market price of the products we sell;', '- the introduction of new technologies or products by us or our competitors;', '- changes in expectations as to our future financial performance, including financial estimates by securities analysts and investors;', '- operating results that vary from the expectations of securities analysts and investors;', '- announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, financings or capital commitments;', '- changes in laws and regulations; and', '- general economic and competitive conditions.', 'This volatility may adversely affect the prices of our common stock regardless of our operating performance. The price of our common stock also may be adversely affected by the amount of common stock issuable upon conversion of our 3 1/4 convertible senior notes due 2008. Assuming 125 million in aggregate principal amount of these notes are converted at a conversion price of 19.20, the number of shares of our common stock outstanding would increase by 6.5 million, or approximately 21 . The conversion feature of our 3 1/4 convertible senior notes is subject to adjustment in connection with the payment of cash dividends. As a result of any future payment of a cash dividend, upon any conversion of the notes we would be required to issue additional shares of common stock.', 'In addition, our common stock has experienced low trading volume in the past.']\n",
      "Extracting data for CIK: 879526, Filing Date: 20050303\n",
      "\n",
      "Success! The content has been written to 'filing_example_titles.txt'\n",
      "You can now open this file to see the raw text with parsed risk factors.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import glob\n",
    "import pickle\n",
    "import pandas as pd\n",
    "import re # Import the regular expression module\n",
    "\n",
    "def is_title(line):\n",
    "    \"\"\"\n",
    "    Heuristic to determine if a line of text is a title.\n",
    "    A line is considered a title if it's all uppercase, doesn't end with a period,\n",
    "    and has a reasonable length.\n",
    "    \"\"\"\n",
    "    # Increased the word count limit to 35 to catch longer titles.\n",
    "    return line.isupper() and len(line.split()) < 35 and not line.strip().endswith('.') and len(line) > 5\n",
    "\n",
    "def parse_risk_factors(raw_text):\n",
    "    \"\"\"\n",
    "    Parses the raw text of a 'Risk Factors' section to intelligently combine titles\n",
    "    with their corresponding paragraphs. This version is more robust.\n",
    "\n",
    "    Args:\n",
    "        raw_text (str): The full text of the risk factors section.\n",
    "\n",
    "    Returns:\n",
    "        str: A formatted string with titles reliably merged with their paragraphs.\n",
    "    \"\"\"\n",
    "    if not isinstance(raw_text, str):\n",
    "        return \"Invalid text input.\"\n",
    "\n",
    "    # Split the entire text block into paragraphs based on one or more empty lines.\n",
    "    raw_paragraphs = re.split(r'\\n\\s*\\n', raw_text.strip())\n",
    "    \n",
    "    # Clean up whitespace, join any internally wrapped lines, and filter out page numbers.\n",
    "    clean_paragraphs = []\n",
    "    for para in raw_paragraphs:\n",
    "        clean_para = ' '.join(para.split())\n",
    "        # Add a check to filter out paragraphs that are just numbers (page numbers)\n",
    "        if clean_para and not clean_para.isdigit():\n",
    "            clean_paragraphs.append(clean_para)\n",
    "\n",
    "    # --- New, More Robust Merging Logic ---\n",
    "    parsed_chunks = []\n",
    "    held_title = \"\"\n",
    "    for para in clean_paragraphs:\n",
    "        if is_title(para):\n",
    "            # If we were already holding a title, it means we found two titles in a row.\n",
    "            # The previous one must have been a standalone title or sub-header.\n",
    "            if held_title:\n",
    "                parsed_chunks.append(held_title)\n",
    "            # Now, hold the new title, waiting for its paragraph.\n",
    "            held_title = para\n",
    "        else: # This is a regular content paragraph.\n",
    "            # If we have a title waiting, prepend it to this paragraph and reset.\n",
    "            if held_title:\n",
    "                parsed_chunks.append(f\"{held_title}\\n{para}\")\n",
    "                held_title = \"\" # Clear the held title as it has been used\n",
    "            else:\n",
    "                # This is just a regular paragraph with no title immediately before it.\n",
    "                parsed_chunks.append(para)\n",
    "\n",
    "    # After the loop, if there's a title left over (i.e., the very last item was a title),\n",
    "    # make sure to add it to the final list.\n",
    "    if held_title:\n",
    "        parsed_chunks.append(held_title)\n",
    "    print(parsed_chunks)  \n",
    "    return \"\\n\\n\".join(parsed_chunks)\n",
    "\n",
    "\n",
    "def inspect_first_filing(data_directory, output_filename=\"filing_example_titles.txt\"):\n",
    "    \"\"\"\n",
    "    Finds the first pickle file, searches for the first row with non-empty text\n",
    "    sections, and saves that filing's text to a file for inspection.\n",
    "    \"\"\"\n",
    "    print(f\"Searching for pickle files in '{data_directory}'...\")\n",
    "    \n",
    "    # 1. Find the first pickle file automatically\n",
    "    # ============================================\n",
    "    pickle_pattern = os.path.join(data_directory, '**', '*.pkl')\n",
    "    all_pickle_files = glob.glob(pickle_pattern, recursive=True)\n",
    "\n",
    "    if not all_pickle_files:\n",
    "        print(\"Error: No pickle files were found. Please check the directory path.\")\n",
    "        return\n",
    "\n",
    "    first_file_path = all_pickle_files[0]\n",
    "    print(f\"Found files. Loading the first one: '{os.path.basename(first_file_path)}'\")\n",
    "\n",
    "    # 2. Load the data from the pickle file\n",
    "    # =======================================\n",
    "    try:\n",
    "        with open(first_file_path, 'rb') as f:\n",
    "            filings_df = pickle.load(f)\n",
    "            \n",
    "            if filings_df.empty:\n",
    "                print(\"The pickle file contains an empty DataFrame.\")\n",
    "                return\n",
    "\n",
    "            valid_filing_series = None\n",
    "            for index, row in filings_df.iterrows():\n",
    "                risk_text = row.get('rf')\n",
    "                mda_text = row.get('mgmt')\n",
    "\n",
    "                if pd.notna(risk_text) and len(str(risk_text).strip()) > 100 and \\\n",
    "                   pd.notna(mda_text) and len(str(mda_text).strip()) > 100:\n",
    "                    valid_filing_series = row\n",
    "                    print(f\"Found a suitable filing for inspection at index {index}.\")\n",
    "                    break\n",
    "            \n",
    "            if valid_filing_series is None:\n",
    "                print(\"Error: Could not find a single filing with complete text sections in this file.\")\n",
    "                return\n",
    "\n",
    "            # 3. Extract data from the VALID filing row\n",
    "            # ==========================================================\n",
    "            cik = valid_filing_series.get('cik', 'CIK not found')\n",
    "            filing_date = valid_filing_series.get('date', 'Date not found')\n",
    "            risk_factors_text_raw = valid_filing_series.get('rf', 'Section not found.')\n",
    "            mda_text = valid_filing_series.get('mgmt', 'Section not found.')\n",
    "            \n",
    "            # --- Use the NEW, more robust parsing function ---\n",
    "            risk_factors_text_parsed = parse_risk_factors(risk_factors_text_raw)\n",
    "\n",
    "            print(f\"Extracting data for CIK: {cik}, Filing Date: {filing_date}\")\n",
    "\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while loading or processing the pickle file: {e}\")\n",
    "        return\n",
    "\n",
    "    # 4. Write the extracted text to a plain text file\n",
    "    # =================================================\n",
    "    try:\n",
    "        with open(output_filename, 'w', encoding='utf-8') as f:\n",
    "            f.write(\"=\"*80 + \"\\n\")\n",
    "            f.write(f\"EXAMPLE FILING FOR INSPECTION\\n\")\n",
    "            f.write(f\"CIK: {cik} | DATE: {filing_date}\\n\")\n",
    "            f.write(\"=\"*80 + \"\\n\\n\")\n",
    "\n",
    "            f.write(\"--- RISK FACTORS (PARSED) ---\\n\\n\")\n",
    "            f.write(str(risk_factors_text_parsed)) # Write the newly parsed text\n",
    "            f.write(\"\\n\\n\")\n",
    "\n",
    "            f.write(\"=\"*80 + \"\\n\\n\")\n",
    "\n",
    "            f.write(\"--- MANAGEMENT'S DISCUSSION AND ANALYSIS (MD&A) ---\\n\\n\")\n",
    "            f.write(str(mda_text))\n",
    "        \n",
    "        print(f\"\\nSuccess! The content has been written to '{output_filename}'\")\n",
    "        print(\"You can now open this file to see the raw text with parsed risk factors.\")\n",
    "\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while writing the file: {e}\")\n",
    "\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    # !! IMPORTANT: Make sure this path points to your unzipped text data directory !!\n",
    "    text_data_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'\n",
    "    \n",
    "    inspect_first_filing(text_data_path)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "e0569317",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Searching for pickle files in 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'...\n",
      "Loading file: 'text_us_2005.pkl'\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\carte\\AppData\\Local\\Temp\\ipykernel_19912\\708864471.py:30: DeprecationWarning: numpy.core.numeric is deprecated and has been renamed to numpy._core.numeric. The numpy._core namespace contains private NumPy internals and its use is discouraged, as NumPy internals can change without warning in any release. In practice, most real-world usage of numpy.core is to access functionality in the public NumPy API. If that is the case, use the public NumPy API. If not, you are using NumPy internals. If you would still like to access an internal attribute, use numpy._core.numeric._frombuffer.\n",
      "  filings_df = pickle.load(f)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  > Found valid filing #1 at index 179123.\n",
      "  > Found valid filing #2 at index 179477.\n",
      "  > Found valid filing #3 at index 179927.\n",
      "  > Found valid filing #4 at index 180158.\n",
      "  > Found valid filing #5 at index 180050.\n",
      "  > Found valid filing #6 at index 180115.\n",
      "  > Found valid filing #7 at index 180558.\n",
      "  > Found valid filing #8 at index 180635.\n",
      "  > Found valid filing #9 at index 180394.\n",
      "  > Found valid filing #10 at index 181003.\n",
      "\n",
      "Found 10 valid filings. Writing to 'filing_examples_raw.txt'...\n",
      "Success! The file has been created with raw, unformatted text.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import glob\n",
    "import pickle\n",
    "import pandas as pd\n",
    "\n",
    "def inspect_multiple_filings(data_directory, num_to_inspect=10, output_filename=\"filing_examples_raw.txt\"):\n",
    "    \"\"\"\n",
    "    Finds and processes a specified number of valid filings and saves their raw,\n",
    "    unformatted risk factor sections to a single text file for comparison.\n",
    "    \"\"\"\n",
    "    print(f\"Searching for pickle files in '{data_directory}'...\")\n",
    "    \n",
    "    pickle_pattern = os.path.join(data_directory, '**', '*.pkl')\n",
    "    all_pickle_files = glob.glob(pickle_pattern, recursive=True)\n",
    "\n",
    "    if not all_pickle_files:\n",
    "        print(\"Error: No pickle files were found. Please check the directory path.\")\n",
    "        return\n",
    "\n",
    "    valid_filings_found = []\n",
    "    \n",
    "    # Loop through the pickle files until we find enough examples\n",
    "    for file_path in all_pickle_files:\n",
    "        if len(valid_filings_found) >= num_to_inspect:\n",
    "            break\n",
    "\n",
    "        print(f\"Loading file: '{os.path.basename(file_path)}'\")\n",
    "        try:\n",
    "            with open(file_path, 'rb') as f:\n",
    "                filings_df = pickle.load(f)\n",
    "            \n",
    "            if filings_df.empty:\n",
    "                continue # Skip empty dataframes\n",
    "\n",
    "            # Loop through rows to find filings with complete text\n",
    "            for index, row in filings_df.iterrows():\n",
    "                risk_text = row.get('rf')\n",
    "                mda_text = row.get('mgmt')\n",
    "\n",
    "                if pd.notna(risk_text) and len(str(risk_text).strip()) > 100 and \\\n",
    "                   pd.notna(mda_text) and len(str(mda_text).strip()) > 100:\n",
    "                    \n",
    "                    valid_filings_found.append(row)\n",
    "                    print(f\"  > Found valid filing #{len(valid_filings_found)} at index {index}.\")\n",
    "                    \n",
    "                    if len(valid_filings_found) >= num_to_inspect:\n",
    "                        break # Stop searching rows if we have enough\n",
    "        \n",
    "        except Exception as e:\n",
    "            print(f\"An error occurred while processing {os.path.basename(file_path)}: {e}\")\n",
    "\n",
    "    if not valid_filings_found:\n",
    "        print(\"Could not find any valid filings to inspect.\")\n",
    "        return\n",
    "\n",
    "    # Now, write all found examples to a single file\n",
    "    print(f\"\\nFound {len(valid_filings_found)} valid filings. Writing to '{output_filename}'...\")\n",
    "    try:\n",
    "        with open(output_filename, 'w', encoding='utf-8') as f:\n",
    "            for i, filing_series in enumerate(valid_filings_found):\n",
    "                cik = filing_series.get('cik', 'N/A')\n",
    "                filing_date = filing_series.get('date', 'N/A')\n",
    "                # --- MODIFICATION: Use the raw text directly ---\n",
    "                risk_factors_raw = filing_series.get('rf', '')\n",
    "                \n",
    "                f.write(\"=\"*80 + \"\\n\")\n",
    "                f.write(f\"--- EXAMPLE {i+1} of {len(valid_filings_found)} ---\\n\")\n",
    "                f.write(f\"CIK: {cik} | DATE: {filing_date}\\n\")\n",
    "                f.write(\"=\"*80 + \"\\n\\n\")\n",
    "                \n",
    "                # Write the raw, unparsed text to the file\n",
    "                f.write(str(risk_factors_raw))\n",
    "                f.write(\"\\n\\n\\n\")\n",
    "\n",
    "        print(\"Success! The file has been created with raw, unformatted text.\")\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while writing the file: {e}\")\n",
    "\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    # !! IMPORTANT: Make sure this path points to your unzipped text data directory !!\n",
    "    text_data_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'\n",
    "    \n",
    "    inspect_multiple_filings(text_data_path, num_to_inspect=10)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "89b0d51f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Searching for pickle files in 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'...\n",
      "Loading file: 'text_us_2005.pkl'\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\carte\\AppData\\Local\\Temp\\ipykernel_19912\\1484652006.py:100: DeprecationWarning: numpy.core.numeric is deprecated and has been renamed to numpy._core.numeric. The numpy._core namespace contains private NumPy internals and its use is discouraged, as NumPy internals can change without warning in any release. In practice, most real-world usage of numpy.core is to access functionality in the public NumPy API. If that is the case, use the public NumPy API. If not, you are using NumPy internals. If you would still like to access an internal attribute, use numpy._core.numeric._frombuffer.\n",
      "  with open(file_path, 'rb') as f: filings_df = pickle.load(f)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  > Found valid filing #1 at index 179123.\n",
      "  > Found valid filing #2 at index 179477.\n",
      "  > Found valid filing #3 at index 179927.\n",
      "  > Found valid filing #4 at index 180158.\n",
      "  > Found valid filing #5 at index 180050.\n",
      "  > Found valid filing #6 at index 180115.\n",
      "  > Found valid filing #7 at index 180558.\n",
      "  > Found valid filing #8 at index 180635.\n",
      "  > Found valid filing #9 at index 180394.\n",
      "  > Found valid filing #10 at index 181003.\n",
      "\n",
      "Found 10 valid filings. Writing to 'filing_examples_parsed.txt'...\n",
      "Success! The file has been created with clear separators for each risk chunk.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import glob\n",
    "import pickle\n",
    "import pandas as pd\n",
    "import re # Import the regular expression module\n",
    "\n",
    "def is_header_heuristic(chunk):\n",
    "    \"\"\"\n",
    "    A new, more precise heuristic based on user findings. A chunk is a header if:\n",
    "    1. It is a single sentence.\n",
    "    2. It starts with a capital letter and ends with a period.\n",
    "    3. It is relatively short (under 25 words).\n",
    "    This avoids flagging longer, single-sentence content paragraphs as headers.\n",
    "    \"\"\"\n",
    "    if not isinstance(chunk, str):\n",
    "        return False\n",
    "        \n",
    "    stripped_chunk = chunk.strip()\n",
    "\n",
    "    # Rule 1 & 2: Must be a single sentence starting with a cap and ending with a period.\n",
    "    # We check if there's exactly one period and it's at the end.\n",
    "    is_single_sentence = stripped_chunk.count('.') == 1 and stripped_chunk.endswith('.')\n",
    "    if not is_single_sentence:\n",
    "        return False\n",
    "\n",
    "    # Check that it starts with a capital letter.\n",
    "    if not stripped_chunk[0].isupper():\n",
    "        return False\n",
    "        \n",
    "    # Rule 3: Must be relatively short to be considered a title.\n",
    "    is_short = len(stripped_chunk.split()) < 40\n",
    "    if not is_short:\n",
    "        return False\n",
    "\n",
    "    # If it passes all checks, it's very likely a title.\n",
    "    return True\n",
    "\n",
    "def clean_and_structure_risks(raw_text):\n",
    "    \"\"\"\n",
    "    Intelligently parses raw risk factor text and returns a LIST of structured\n",
    "    risk items, where each item is a header plus its content.\n",
    "    \"\"\"\n",
    "    if not isinstance(raw_text, str):\n",
    "        return []\n",
    "\n",
    "    # 1. Split text into logical chunks based on empty lines.\n",
    "    chunks = re.split(r'\\n\\s*\\n', raw_text.strip())\n",
    "    \n",
    "    # 2. Clean up each chunk and filter out noise.\n",
    "    cleaned_chunks = []\n",
    "    for chunk in chunks:\n",
    "        processed_chunk = ' '.join(chunk.split())\n",
    "        if processed_chunk and not processed_chunk.isdigit():\n",
    "            cleaned_chunks.append(processed_chunk)\n",
    "\n",
    "    # 3. Group chunks into structured risk items (header + content).\n",
    "    if not cleaned_chunks:\n",
    "        return []\n",
    "\n",
    "    structured_items = []\n",
    "    current_item_chunks = []\n",
    "\n",
    "    for chunk in cleaned_chunks:\n",
    "        if is_header_heuristic(chunk):\n",
    "            if current_item_chunks:\n",
    "                structured_items.append(\"\\n\".join(current_item_chunks))\n",
    "            current_item_chunks = [chunk]\n",
    "        else:\n",
    "            if not current_item_chunks:\n",
    "                current_item_chunks = [chunk]\n",
    "            else:\n",
    "                current_item_chunks.append(chunk)\n",
    "    \n",
    "    if current_item_chunks:\n",
    "        structured_items.append(\"\\n\".join(current_item_chunks))\n",
    "\n",
    "    return structured_items\n",
    "\n",
    "\n",
    "def inspect_multiple_filings(data_directory, num_to_inspect=10, output_filename=\"filing_examples_parsed.txt\"):\n",
    "    \"\"\"\n",
    "    Finds and processes a specified number of valid filings and saves their\n",
    "    intelligently parsed risk factor sections to a single text file.\n",
    "    \"\"\"\n",
    "    print(f\"Searching for pickle files in '{data_directory}'...\")\n",
    "    \n",
    "    pickle_pattern = os.path.join(data_directory, '**', '*.pkl')\n",
    "    all_pickle_files = glob.glob(pickle_pattern, recursive=True)\n",
    "\n",
    "    if not all_pickle_files:\n",
    "        print(\"Error: No pickle files were found. Please check the directory path.\")\n",
    "        return\n",
    "\n",
    "    valid_filings_found = []\n",
    "    \n",
    "    for file_path in all_pickle_files:\n",
    "        if len(valid_filings_found) >= num_to_inspect: break\n",
    "        print(f\"Loading file: '{os.path.basename(file_path)}'\")\n",
    "        try:\n",
    "            with open(file_path, 'rb') as f: filings_df = pickle.load(f)\n",
    "            if filings_df.empty: continue\n",
    "\n",
    "            for index, row in filings_df.iterrows():\n",
    "                risk_text = row.get('rf')\n",
    "                mda_text = row.get('mgmt')\n",
    "\n",
    "                if pd.notna(risk_text) and len(str(risk_text).strip()) > 100 and \\\n",
    "                   pd.notna(mda_text) and len(str(mda_text).strip()) > 100:\n",
    "                    valid_filings_found.append(row)\n",
    "                    print(f\"  > Found valid filing #{len(valid_filings_found)} at index {index}.\")\n",
    "                    if len(valid_filings_found) >= num_to_inspect: break\n",
    "        \n",
    "        except Exception as e:\n",
    "            print(f\"An error occurred while processing {os.path.basename(file_path)}: {e}\")\n",
    "\n",
    "    if not valid_filings_found:\n",
    "        print(\"Could not find any valid filings to inspect.\")\n",
    "        return\n",
    "\n",
    "    print(f\"\\nFound {len(valid_filings_found)} valid filings. Writing to '{output_filename}'...\")\n",
    "    try:\n",
    "        with open(output_filename, 'w', encoding='utf-8') as f:\n",
    "            for i, filing_series in enumerate(valid_filings_found):\n",
    "                cik = filing_series.get('cik', 'N/A')\n",
    "                filing_date = filing_series.get('date', 'N/A')\n",
    "                risk_factors_raw = filing_series.get('rf', '')\n",
    "                \n",
    "                # This function now returns a list of strings\n",
    "                risk_items_list = clean_and_structure_risks(risk_factors_raw)\n",
    "                \n",
    "                f.write(\"=\"*80 + \"\\n\")\n",
    "                f.write(f\"--- EXAMPLE FILING {i+1} of {len(valid_filings_found)} ---\\n\")\n",
    "                f.write(f\"CIK: {cik} | DATE: {filing_date}\\n\")\n",
    "                f.write(\"=\"*80 + \"\\n\\n\")\n",
    "                \n",
    "                if not risk_items_list:\n",
    "                    f.write(\"--> No risk chunks could be parsed for this filing.\\n\\n\")\n",
    "                else:\n",
    "                    for j, risk_item in enumerate(risk_items_list):\n",
    "                        f.write(f\"---------- Risk Chunk {j+1} ----------\\n\")\n",
    "                        f.write(risk_item)\n",
    "                        f.write(\"\\n\\n\") # Add extra space after each chunk\n",
    "                \n",
    "                f.write(\"\\n\\n\") # Extra space between filings\n",
    "\n",
    "        print(\"Success! The file has been created with clear separators for each risk chunk.\")\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while writing the file: {e}\")\n",
    "\n",
    "\n",
    "# --- How to use this script ---\n",
    "if __name__ == \"__main__\":\n",
    "    text_data_path = r'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\text_data'\n",
    "    inspect_multiple_filings(text_data_path, num_to_inspect=10)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "cedf1496",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Loading data from 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.parquet' ---\n",
      "Data loaded successfully.\n",
      "\n",
      "--- Analyzing Top 1% Performers ---\n",
      "Found 64015 observations with returns >= 59.14%\n",
      "\n",
      "--- Summary of Top 1% Performers (Grouped by Country & Type) ---\n",
      "                        stock_ret         age       qmj  betadown_252d  prc_highprc_252d  count\n",
      "excntry security_type                                                                          \n",
      "USA     Other            2.699218  177.113595 -0.841639       1.076764          0.412847  10467\n",
      "AUS     Warrant          1.101760  183.681911 -0.536992       1.098127          0.486230   9796\n",
      "HKG     Warrant          1.113656  289.557014 -0.477659       0.878736          0.580091   6323\n",
      "CAN     Common Stock     1.125791  152.998500 -0.721148       1.101458          0.499535   5334\n",
      "KOR     Warrant          0.941709  283.945376 -0.405381       1.014208          0.618231   5309\n",
      "GBR     Warrant          1.457628  193.445761 -0.617220       0.909791          0.415438   4812\n",
      "JPN     Warrant          1.008159  321.071659 -0.523362       1.067063          0.649398   4033\n",
      "CHN     Warrant          0.919923  397.614944 -0.308452       1.179710          0.764840   3667\n",
      "DEU     Warrant          2.149545  219.685034 -0.658118       0.553296          0.370661   3067\n",
      "TWN     Warrant          0.953539  341.912601 -0.483515       0.941313          0.726492   2357\n",
      "SGP     Warrant          1.098702  322.336624 -0.592957       1.228020          0.534398   2026\n",
      "SWE     Warrant          1.129444  169.142088 -0.681220       0.769420          0.463935   1858\n",
      "FRA     Warrant         53.940324  219.198220 -0.640360       0.835924          0.484879   1685\n",
      "ISR     Warrant         10.745730  242.622590 -0.780694       0.995275          0.463384    726\n",
      "NOR     Warrant          1.133989  224.427065 -0.742922       0.967482          0.412471    569\n",
      "ITA     Warrant         10.097415  272.269461 -0.706432       0.745940          0.535119    334\n",
      "DNK     Warrant          1.158135  208.828794 -0.717768       0.618322          0.492593    257\n",
      "NZL     Warrant          1.088731  249.373391 -0.722496       1.195139          0.558046    233\n",
      "BEL     Warrant        203.178310  282.455026 -0.758518       0.705311          0.480749    189\n",
      "CHE     Warrant          1.511607  251.408602 -1.009111       0.724281          0.408523    186\n",
      "ESP     Warrant          2.067692  294.603261 -0.587776       0.825871          0.490418    184\n",
      "NLD     Warrant          1.064575  282.880000 -0.644302       0.841808          0.432383    125\n",
      "FIN     Warrant          0.957346  270.289720 -0.748616       0.808081          0.519383    107\n",
      "PRT     Warrant          1.085790  300.424528 -0.473523       0.512591          0.587275    106\n",
      "AUT     Warrant          1.911448  261.333333 -0.789517       0.838050          0.321897    102\n",
      "IRL     Warrant          1.002044  215.112360 -0.756787       0.784902          0.275615     89\n",
      "MEX     Warrant          2.136384  278.840580 -0.644535       0.982762          0.532296     69\n",
      "LUX     Warrant          0.756618  371.400000 -0.879517       0.556756          0.437540      5\n",
      "\n",
      "--- Analyzing Bottom 1% Performers ---\n",
      "Found 64015 observations with returns <= -38.17%\n",
      "\n",
      "--- Summary of Bottom 1% Performers (Grouped by Country & Type) ---\n",
      "                       stock_ret         age       qmj  betadown_252d  prc_highprc_252d  count\n",
      "excntry security_type                                                                         \n",
      "USA     Other          -0.503769  168.902286 -0.855910       1.060067          0.407147  15443\n",
      "AUS     Warrant        -0.482966  187.298393 -0.515343       1.116993          0.442392   8834\n",
      "GBR     Warrant        -0.512589  199.170394 -0.628558       0.857741          0.411440   6350\n",
      "CAN     Common Stock   -0.495346  152.016667 -0.692740       1.218237          0.437016   5040\n",
      "HKG     Warrant        -0.505234  278.858146 -0.577814       0.853604          0.496790   4413\n",
      "KOR     Warrant        -0.504915  239.200763 -0.711025       0.944511          0.467252   4194\n",
      "DEU     Warrant        -0.539557  202.329606 -0.818335       0.652696          0.351805   4114\n",
      "JPN     Warrant        -0.506317  282.225615 -0.684534       0.986582          0.497305   2194\n",
      "SWE     Warrant        -0.505748  166.448196 -0.764980       0.787918          0.378567   2162\n",
      "CHN     Warrant        -0.442848  378.405431 -0.391703       1.102572          0.663308   2136\n",
      "FRA     Warrant        -0.517252  210.889406 -0.800040       0.780881          0.332932   1935\n",
      "SGP     Warrant        -0.488608  314.720045 -0.666766       1.261941          0.496482   1761\n",
      "TWN     Warrant        -0.476930  282.643507 -0.669593       0.939396          0.527927   1209\n",
      "ISR     Warrant        -0.497790  230.027837 -0.837234       0.979152          0.428538    934\n",
      "NOR     Warrant        -0.520393  226.548043 -0.751265       1.037148          0.385429    843\n",
      "ITA     Warrant        -0.510035  290.939577 -0.975284       0.743271          0.402115    331\n",
      "DNK     Warrant        -0.494961  205.221865 -0.711365       0.719577          0.442231    311\n",
      "CHE     Warrant        -0.541364  251.063670 -0.964445       0.924151          0.384641    267\n",
      "NZL     Warrant        -0.508985  246.662921 -0.844791       0.928421          0.479220    267\n",
      "BEL     Warrant        -0.530464  284.415020 -0.792934       0.834645          0.470348    253\n",
      "NLD     Warrant        -0.528675  288.291667 -0.777407       0.937610          0.427109    192\n",
      "ESP     Warrant        -0.489453  283.261780 -0.858386       0.962554          0.457877    191\n",
      "AUT     Warrant        -0.536193  240.434524 -0.577280       0.908418          0.455613    168\n",
      "FIN     Warrant        -0.480673  261.230769 -0.763620       0.763532          0.477595    130\n",
      "IRL     Warrant        -0.511445  219.712000 -0.561454       0.953308          0.393838    125\n",
      "MEX     Warrant        -0.494707  300.230088 -0.431215       1.080682          0.543666    113\n",
      "PRT     Warrant        -0.514724  329.860215 -0.420705       0.966006          0.564821     93\n",
      "LUX     Warrant        -0.489258  249.333333 -0.138675       0.826947          0.410955     12\n"
     ]
    }
   ],
   "source": [
    "# This script analyzes stock return data to identify characteristics of top-performing securities.\n",
    "\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "def analyze_performers(df, percentile, ascending=False):\n",
    "    \"\"\"\n",
    "    Analyzes the characteristics of stocks in a given performance percentile.\n",
    "\n",
    "    Args:\n",
    "        df (pd.DataFrame): The input DataFrame with stock data.\n",
    "        percentile (float): The percentile to analyze (e.g., 0.99 for top 1%).\n",
    "        ascending (bool): Whether to sort returns ascendingly (for bottom performers).\n",
    "\n",
    "    Returns:\n",
    "        pd.DataFrame: A summary DataFrame with analysis results.\n",
    "    \"\"\"\n",
    "    label = \"Top\" if not ascending else \"Bottom\"\n",
    "    print(f\"\\n--- Analyzing {label} {100 * (1-percentile):.0f}% Performers ---\")\n",
    "\n",
    "    # Determine the return threshold for the given percentile\n",
    "    return_threshold = df['stock_ret'].quantile(percentile)\n",
    "\n",
    "    if not ascending:\n",
    "        subset_df = df[df['stock_ret'] >= return_threshold].copy()\n",
    "        print(f\"Found {len(subset_df)} observations with returns >= {return_threshold:.2%}\")\n",
    "    else:\n",
    "        # For bottom performers, the percentile is low (e.g., 0.01)\n",
    "        return_threshold = df['stock_ret'].quantile(1-percentile)\n",
    "        subset_df = df[df['stock_ret'] <= return_threshold].copy()\n",
    "        print(f\"Found {len(subset_df)} observations with returns <= {return_threshold:.2%}\")\n",
    "\n",
    "    if subset_df.empty:\n",
    "        print(\"No data in this performance bracket.\")\n",
    "        return None\n",
    "\n",
    "    # --- Feature Engineering: Identify Security Type ---\n",
    "    # Ensure 'id' is a string before using .str accessor\n",
    "    subset_df['id'] = subset_df['id'].astype(str)\n",
    "    \n",
    "    conditions = [\n",
    "        subset_df['id'].str.endswith('W'),\n",
    "        subset_df['id'].str.endswith('C')\n",
    "    ]\n",
    "    choices = ['Warrant', 'Common Stock']\n",
    "    subset_df['security_type'] = np.select(conditions, choices, default='Other')\n",
    "\n",
    "    # --- Group and Analyze ---\n",
    "    # Define the characteristics we want to analyze by taking their mean\n",
    "    analysis_cols = {\n",
    "        'stock_ret': 'mean',\n",
    "        'age': 'mean',           # Company age\n",
    "        'qmj': 'mean',           # Quality-Minus-Junk factor\n",
    "        'betadown_252d': 'mean', # Downside Beta (risk)\n",
    "        'prc_highprc_252d': 'mean' # Price vs 1-year high (momentum)\n",
    "    }\n",
    "    \n",
    "    # Add a column for counting observations in each group\n",
    "    subset_df['count'] = 1\n",
    "    analysis_cols['count'] = 'sum'\n",
    "\n",
    "\n",
    "    # Group by country and security type and aggregate\n",
    "    summary = subset_df.groupby(['excntry', 'security_type']).agg(analysis_cols)\n",
    "    \n",
    "    # Make the count an integer\n",
    "    summary['count'] = summary['count'].astype(int)\n",
    "\n",
    "    return summary.sort_values(by='count', ascending=False)\n",
    "\n",
    "\n",
    "# --- Main Execution Block ---\n",
    "if __name__ == \"__main__\":\n",
    "    file_path = r\"C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.parquet\"\n",
    "    print(f\"--- Loading data from '{file_path}' ---\")\n",
    "\n",
    "    try:\n",
    "        df = pd.read_parquet(file_path)\n",
    "        print(\"Data loaded successfully.\")\n",
    "\n",
    "        # Set pandas display options for better readability\n",
    "        pd.set_option('display.width', 120)\n",
    "        pd.set_option('display.max_rows', 100)\n",
    "\n",
    "        # Analyze the top 1% of performers\n",
    "        top_performers_summary = analyze_performers(df, 0.99, ascending=False)\n",
    "        if top_performers_summary is not None:\n",
    "            print(\"\\n--- Summary of Top 1% Performers (Grouped by Country & Type) ---\")\n",
    "            print(top_performers_summary)\n",
    "\n",
    "        # You could also analyze the bottom 1% for comparison\n",
    "        bottom_performers_summary = analyze_performers(df, 0.99, ascending=True)\n",
    "        if bottom_performers_summary is not None:\n",
    "            print(\"\\n--- Summary of Bottom 1% Performers (Grouped by Country & Type) ---\")\n",
    "            print(bottom_performers_summary)\n",
    "\n",
    "\n",
    "    except FileNotFoundError:\n",
    "        print(f\"Error: The file was not found at '{file_path}'\")\n",
    "    except KeyError as e:\n",
    "        print(f\"Error: A required column is missing from the Parquet file: {e}\")\n",
    "    except Exception as e:\n",
    "        print(f\"An unexpected error occurred: {e}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "382362f7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Loading data from 'C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.parquet' ---\n",
      "Data loaded successfully.\n",
      "\n",
      "--- Analyzing country distribution for 20 specific IDs... ---\n",
      "\n",
      "--- Comparison of Country Proportions ---\n",
      "(Sample vs. Entire Dataset of Unique Stocks)\n",
      "        sample_proportion overall_proportion enrichment\n",
      "excntry                                                \n",
      "SGP                 5.00%              1.94%      2.58x\n",
      "IRL                 5.00%              0.14%     35.64x\n",
      "USA                35.00%             25.58%      1.37x\n",
      "DEU                25.00%              3.15%      7.94x\n",
      "CAN                15.00%              4.53%      3.31x\n",
      "FRA                15.00%              2.69%      5.59x\n",
      "ESP                 0.00%              0.79%      0.00x\n",
      "PRT                 0.00%              0.16%      0.00x\n",
      "AUT                 0.00%              0.27%      0.00x\n",
      "MEX                 0.00%              0.37%      0.00x\n",
      "NZL                 0.00%              0.42%      0.00x\n",
      "FIN                 0.00%              0.47%      0.00x\n",
      "NLD                 0.00%              0.48%      0.00x\n",
      "BEL                 0.00%              0.53%      0.00x\n",
      "DNK                 0.00%              0.59%      0.00x\n",
      "CHE                 0.00%              0.72%      0.00x\n",
      "ISR                 0.00%              1.50%      0.00x\n",
      "NOR                 0.00%              1.10%      0.00x\n",
      "ITA                 0.00%              1.33%      0.00x\n",
      "SWE                 0.00%              2.65%      0.00x\n",
      "TWN                 0.00%              5.04%      0.00x\n",
      "HKG                 0.00%              5.44%      0.00x\n",
      "AUS                 0.00%              6.13%      0.00x\n",
      "KOR                 0.00%              6.61%      0.00x\n",
      "GBR                 0.00%              7.52%      0.00x\n",
      "CHN                 0.00%              9.68%      0.00x\n",
      "JPN                 0.00%             10.14%      0.00x\n",
      "LUX                 0.00%              0.07%      0.00x\n"
     ]
    }
   ],
   "source": [
    "# This script loads stock data, analyzes the country distribution for a specific list of IDs,\n",
    "# and compares it to the country distribution of the entire dataset.\n",
    "\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# --- Main Execution Block ---\n",
    "if __name__ == \"__main__\":\n",
    "    file_path = r\"C:\\_Files\\Personal\\Projects\\FIAM\\FIAM2025\\data\\ret_sample.parquet\"\n",
    "    print(f\"--- Loading data from '{file_path}' ---\")\n",
    "\n",
    "    # Define the list of specific IDs to look up from your images\n",
    "    ids_to_find = [\n",
    "        # Top Performers\n",
    "        'comp_278548_01W', 'comp_208686_02W', 'comp_240865_01W', \n",
    "        'comp_275020_01W', 'comp_166669_01C', 'comp_277578_01W', \n",
    "        'comp_065840_01C', 'comp_356061_01W', 'comp_210323_01W', \n",
    "        'comp_026353_01C',\n",
    "        # Bottom Performers\n",
    "        'crsp_19649', 'comp_321951_01W', 'crsp_19136', 'comp_314949_01W',\n",
    "        'crsp_21280', 'crsp_23267', 'crsp_13556', 'crsp_15375',\n",
    "        'crsp_12350', 'comp_298295_01W'\n",
    "    ]\n",
    "\n",
    "    try:\n",
    "        df = pd.read_parquet(file_path)\n",
    "        print(\"Data loaded successfully.\")\n",
    "\n",
    "        # Ensure the 'id' column is of string type for matching\n",
    "        df['id'] = df['id'].astype(str)\n",
    "\n",
    "        # --- Filter the DataFrame to find the specified IDs ---\n",
    "        print(f\"\\n--- Analyzing country distribution for {len(ids_to_find)} specific IDs... ---\")\n",
    "        \n",
    "        results_df = df[df['id'].isin(ids_to_find)]\n",
    "\n",
    "        if not results_df.empty:\n",
    "            # --- 1. Calculate proportion for the sample list of unique stocks ---\n",
    "            # We drop duplicates to count each stock only once\n",
    "            unique_sample_stocks = results_df.drop_duplicates(subset=['id'])\n",
    "            sample_proportions = unique_sample_stocks['excntry'].value_counts(normalize=True).rename('sample_proportion')\n",
    "\n",
    "            # --- 2. Calculate proportion for all unique stocks in the entire dataset ---\n",
    "            # This provides a fair baseline for comparison\n",
    "            unique_total_stocks = df.drop_duplicates(subset=['id'])\n",
    "            overall_proportions = unique_total_stocks['excntry'].value_counts(normalize=True).rename('overall_proportion')\n",
    "\n",
    "            # --- 3. Combine, compare, and display the two distributions ---\n",
    "            comparison_df = pd.concat([sample_proportions, overall_proportions], axis=1).fillna(0)\n",
    "            \n",
    "            # Calculate an \"enrichment\" factor to see how over/under-represented each country is\n",
    "            comparison_df['enrichment'] = (comparison_df['sample_proportion'] / comparison_df['overall_proportion']).replace([np.inf, -np.inf], 0)\n",
    "\n",
    "            # Format the columns for better readability\n",
    "            comparison_df['sample_proportion'] = comparison_df['sample_proportion'].map('{:.2%}'.format)\n",
    "            comparison_df['overall_proportion'] = comparison_df['overall_proportion'].map('{:.2%}'.format)\n",
    "            comparison_df['enrichment'] = comparison_df['enrichment'].map('{:.2f}x'.format)\n",
    "\n",
    "            print(\"\\n--- Comparison of Country Proportions ---\")\n",
    "            print(\"(Sample vs. Entire Dataset of Unique Stocks)\")\n",
    "            print(comparison_df.sort_values(by='sample_proportion', ascending=False))\n",
    "            \n",
    "        else:\n",
    "            print(\"Could not find any of the specified IDs in the dataset.\")\n",
    "\n",
    "    except FileNotFoundError:\n",
    "        print(f\"Error: The file was not found at '{file_path}'\")\n",
    "    except KeyError as e:\n",
    "        print(f\"Error: A required column is missing from the Parquet file: {e}\")\n",
    "    except Exception as e:\n",
    "        print(f\"An unexpected error occurred: {e}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "01f48787",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--- Analysis for column: 'ret_eom' ---\n",
      "Total rows: 6,100,030\n",
      "Empty rows: 0\n",
      "Percent empty: 0.00%\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import os\n",
    "\n",
    "# Define the path to the Parquet file\n",
    "pq_path = r'C:\\_Files\\School\\Competitions\\FIAM2025\\data\\quant_data\\ret_sample.parquet'\n",
    "\n",
    "try:\n",
    "    # Read the Parquet file into a DataFrame\n",
    "    df = pd.read_parquet(pq_path)\n",
    "\n",
    "    # Define the target column\n",
    "    column_name = 'ret_eom'\n",
    "\n",
    "    if column_name in df.columns:\n",
    "        # Calculate the number of empty (NaN) values\n",
    "        missing_count = df[column_name].isna().sum()\n",
    "        \n",
    "        # Calculate the total number of rows\n",
    "        total_count = len(df[column_name])\n",
    "        \n",
    "        # Calculate the percentage of empty values\n",
    "        if total_count > 0:\n",
    "            percent_empty = (missing_count / total_count) * 100\n",
    "            print(f\"--- Analysis for column: '{column_name}' ---\")\n",
    "            print(f\"Total rows: {total_count:,}\")\n",
    "            print(f\"Empty rows: {missing_count:,}\")\n",
    "            print(f\"Percent empty: {percent_empty:.2f}%\")\n",
    "        else:\n",
    "            print(f\"The DataFrame is empty. Cannot calculate percentage.\")\n",
    "            \n",
    "    else:\n",
    "        print(f\"Error: Column '{column_name}' not found in the Parquet file.\")\n",
    "        print(\"Available columns are:\")\n",
    "        print(df.columns.tolist())\n",
    "\n",
    "except Exception as e:\n",
    "    print(f\"An error occurred: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "53616d62",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<bound method NDFrame.head of                   document_id  \\\n",
      "0        FF-QR3-2023-SBB B-SS   \n",
      "1        FF-QR3-2019-ATORX-SS   \n",
      "2           FF-AR-2022-LUG-SS   \n",
      "3         FF-AR-2020-SINCH-SS   \n",
      "4     FF-QR1-2022-VOLCAR B-SS   \n",
      "...                       ...   \n",
      "5224     FF-QR1-2020-HAV B-SS   \n",
      "5225     FF-QR4-2015-TOBII-SS   \n",
      "5226       FF-QR1-2024-AZA-SS   \n",
      "5227      FF-QR3-2015-VIVE-SS   \n",
      "5228   FF-QR3-2022-ATRLJ B-SS   \n",
      "\n",
      "           section_5_management_discussion_and_analysis  \\\n",
      "0     SBB Interim Report, JanuarySeptember 2023 Pag...   \n",
      "1      activities. Partnering/out-licensing Initial ...   \n",
      "2      2022 ANNUAL REPORT Dear Fellow Shareholders, ...   \n",
      "3     tober, Sinch launched Sinch Conversation API, ...   \n",
      "4     uity instruments in Luminar which are listed, ...   \n",
      "...                                                 ...   \n",
      "5224  nedskrivning av Avvecklingsportfljens framtid...   \n",
      "5225  Tobii Tech continues as planned to invest in t...   \n",
      "5226  rim Report JanuaryMarch 2024, Avanza Bank Hol...   \n",
      "5227   after Alceco International S.A, with about 20...   \n",
      "5228  Seasonal effects The operating surplus is affe...   \n",
      "\n",
      "                                 section_7_risk_factors  \\\n",
      "0     nd there is currently no ongoing legal dispute...   \n",
      "1     ily be converted to cash and is subject to an ...   \n",
      "2     quarterly instalments and matures in June 2026...   \n",
      "3     lders assess our sustainability work, threats ...   \n",
      "4     RIM REPORT FIRST QUARTER 2022 | GOTHENBURG 28 ...   \n",
      "...                                                 ...   \n",
      "5224  ket performed well up to the middle of Februar...   \n",
      "5225  y into their own products. The business unit i...   \n",
      "5226   Maturity structure of interest-bearing securi...   \n",
      "5227   audit. Accordingly, we do not express an audi...   \n",
      "5228  Seasonal effects The operating surplus is affe...   \n",
      "\n",
      "                                           company_name company_ticker  \\\n",
      "0     SamhAllsbyggnadsbolaget i Norden AB. - Ordinar...          SBB B   \n",
      "1                               Alligator Bioscience AB          ATORX   \n",
      "2                                       Lundin Gold Inc            LUG   \n",
      "3                                              Sinch AB          SINCH   \n",
      "4              Volvo Car AB - Ordinary Shares - Class B       VOLCAR B   \n",
      "...                                                 ...            ...   \n",
      "5224  Havsfrun Investment AB - Ordinary Shares - Cla...          HAV B   \n",
      "5225                                           Tobii AB          TOBII   \n",
      "5226                             Avanza Bank Holding AB            AZA   \n",
      "5227                                         Vivesto AB           VIVE   \n",
      "5228    Atrium Ljungberg AB - Ordinary Shares - Class B        ATRLJ B   \n",
      "\n",
      "              figi composite_figi                sector  \\\n",
      "0     BBG007DM2053   BBG007DM1SP1               Finance   \n",
      "1     BBG00F5R5G37   BBG000R333K1      HealthTechnology   \n",
      "2     BBG007RB7SS1   BBG007RB7SR2     NonEnergyMinerals   \n",
      "3     BBG00B0DSW69   BBG00B0DSW50    TechnologyServices   \n",
      "4     BBG012TCC1K8   BBG00CW2CXR8      ConsumerDurables   \n",
      "...            ...            ...                   ...   \n",
      "5224  BBG000BLQ7P9   BBG000BLQ6R9               Finance   \n",
      "5225  BBG008D1PTQ6   BBG008D1PTP7  ElectronicTechnology   \n",
      "5226  BBG000BWT638   BBG000BWT5W8               Finance   \n",
      "5227  BBG000QWP8S5   BBG000QWP896      HealthTechnology   \n",
      "5228  BBG000DCK6L9   BBG000DCK5M0               Finance   \n",
      "\n",
      "                           industry stock_exchange  region country  is_listed  \\\n",
      "0             RealEstateDevelopment             SS  Europe  Sweden       True   \n",
      "1                     Biotechnology             SS  Europe  Sweden       True   \n",
      "2                    PreciousMetals             SS  Europe  Sweden       True   \n",
      "3                  PackagedSoftware             SS  Europe  Sweden       True   \n",
      "4                     MotorVehicles             SS  Europe  Sweden       True   \n",
      "...                             ...            ...     ...     ...        ...   \n",
      "5224             InvestmentManagers             SS  Europe  Sweden       True   \n",
      "5225  ElectronicProductionEquipment             SS  Europe  Sweden       True   \n",
      "5226       InvestmentBanksOrBrokers             SS  Europe  Sweden       True   \n",
      "5227         PharmaceuticalsGeneric             SS  Europe  Sweden       True   \n",
      "5228          RealEstateDevelopment             SS  Europe  Sweden       True   \n",
      "\n",
      "                  name              type period_end_date          filing_date  \\\n",
      "0     Quarterly Report  Financial Filing      2023-09-30  2023-11-13 08:00:00   \n",
      "1     Quarterly Report  Financial Filing      2019-09-30  2019-10-24 08:00:00   \n",
      "2        Annual Report  Financial Filing      2022-12-31  2023-04-26 00:00:00   \n",
      "3        Annual Report  Financial Filing      2020-12-31  2021-04-23 21:03:00   \n",
      "4     Quarterly Report  Financial Filing      2022-03-31  2022-04-28 07:01:00   \n",
      "...                ...               ...             ...                  ...   \n",
      "5224  Quarterly Report  Financial Filing      2020-03-31  2020-04-29 14:00:00   \n",
      "5225  Quarterly Report  Financial Filing      2015-12-31  2016-02-16 08:00:00   \n",
      "5226  Quarterly Report  Financial Filing      2024-03-31  2024-04-19 07:45:00   \n",
      "5227  Quarterly Report  Financial Filing      2015-09-30  2015-12-03 08:15:00   \n",
      "5228  Quarterly Report  Financial Filing      2022-09-30  2022-10-14 07:30:00   \n",
      "\n",
      "       timezone default_language  \n",
      "0     UTC+01:00          Swedish  \n",
      "1     UTC+01:00          Swedish  \n",
      "2     UTC+01:00          Swedish  \n",
      "3     UTC+01:00          Swedish  \n",
      "4     UTC+01:00          Swedish  \n",
      "...         ...              ...  \n",
      "5224  UTC+01:00          Swedish  \n",
      "5225  UTC+01:00          Swedish  \n",
      "5226  UTC+01:00          Swedish  \n",
      "5227  UTC+01:00          Swedish  \n",
      "5228  UTC+01:00          Swedish  \n",
      "\n",
      "[5021 rows x 19 columns]>\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd \n",
    "\n",
    "text = pd.read_pickle(r'C:\\_Files\\School\\Competitions\\FIAM2025\\data\\global_text_data\\SS.pkl')\n",
    "\n",
    "print(text.head)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "17ed1c09",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-10-30 17:42:01,729 - INFO - --- Starting Part 1: Country Discovery ---\n",
      "2025-10-30 17:42:01,729 - INFO - Scanning for .pkl files in: C:\\_Files\\School\\Competitions\\FIAM2025\\data\\global_text_data\n",
      "2025-10-30 17:42:01,730 - INFO - Found 26 pickle files to scan.\n",
      "2025-10-30 17:42:01,731 - INFO - Scanning: AT.pkl\n",
      "2025-10-30 17:42:02,298 - INFO - Scanning: AV.pkl\n",
      "2025-10-30 17:42:02,420 - INFO - Scanning: BB.pkl\n",
      "2025-10-30 17:42:02,539 - INFO - Scanning: CG.pkl\n",
      "2025-10-30 17:42:03,696 - INFO - Scanning: CT.pkl\n",
      "2025-10-30 17:42:04,544 - INFO - Scanning: DC.pkl\n",
      "2025-10-30 17:42:04,722 - INFO - Scanning: FH.pkl\n",
      "2025-10-30 17:42:04,806 - INFO - Scanning: FP.pkl\n",
      "2025-10-30 17:42:05,091 - INFO - Scanning: GF.pkl\n",
      "2025-10-30 17:42:05,567 - INFO - Scanning: HK.pkl\n",
      "2025-10-30 17:42:09,135 - INFO - Scanning: ID.pkl\n",
      "2025-10-30 17:42:10,132 - INFO - Scanning: IM.pkl\n",
      "2025-10-30 17:42:10,201 - INFO - Scanning: IT.pkl\n",
      "2025-10-30 17:42:10,246 - INFO - Scanning: JT.pkl\n",
      "2025-10-30 17:42:10,319 - INFO - Scanning: KP.pkl\n",
      "2025-10-30 17:42:11,092 - INFO - Scanning: LN.pkl\n",
      "2025-10-30 17:42:11,797 - INFO - Scanning: LX.pkl\n",
      "2025-10-30 17:42:11,994 - INFO - Scanning: MF.pkl\n",
      "2025-10-30 17:42:12,055 - INFO - Scanning: NA.pkl\n",
      "2025-10-30 17:42:12,167 - INFO - Scanning: NO.pkl\n",
      "2025-10-30 17:42:12,272 - INFO - Scanning: PL.pkl\n",
      "2025-10-30 17:42:12,334 - INFO - Scanning: SN.pkl\n",
      "2025-10-30 17:42:12,460 - INFO - Scanning: SP.pkl\n",
      "2025-10-30 17:42:12,650 - INFO - Scanning: SS.pkl\n",
      "2025-10-30 17:42:12,939 - INFO - Scanning: TT.pkl\n",
      "2025-10-30 17:42:13,830 - INFO - Scanning: XW.pkl\n",
      "2025-10-30 17:42:14,159 - INFO - --- Discovery Complete ---\n",
      "2025-10-30 17:42:14,159 - INFO - Found 26 unique countries across all files:\n",
      "2025-10-30 17:42:14,160 - INFO - Please use this list to build your 'COUNTRY_TO_REGION_MAP' in script 2.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- Unique Country List ---\n",
      "Australia\n",
      "Austria\n",
      "Belgium\n",
      "Canada\n",
      "China\n",
      "Denmark\n",
      "Finland\n",
      "France\n",
      "Germany\n",
      "Hong Kong\n",
      "Ireland\n",
      "Israel\n",
      "Italy\n",
      "Japan\n",
      "Luxembourg\n",
      "Mexico\n",
      "Netherlands\n",
      "Norway\n",
      "Portugal\n",
      "Singapore\n",
      "South Korea\n",
      "Spain\n",
      "Sweden\n",
      "Switzerland\n",
      "Taiwan\n",
      "United Kingdom\n",
      "----------------------------\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "import glob\n",
    "import logging\n",
    "\n",
    "# --- Configuration ---\n",
    "logging.basicConfig(level=logging.INFO, format='%(asctime)s - %(levelname)s - %(message)s')\n",
    "\n",
    "# --- !! IMPORTANT: SET THESE PATHS !! ---\n",
    "# 1. The directory containing your exchange pickle files\n",
    "#    (e.g., r'D:\\market_data\\text_data\\WORLD_EXCHANGES')\n",
    "PICKLE_BASE_DIR = r'C:\\_Files\\School\\Competitions\\FIAM2025\\data\\global_text_data'\n",
    "\n",
    "# 2. The exact name of the country column in your DataFrames\n",
    "COUNTRY_COLUMN = 'country' \n",
    "\n",
    "# --- Script ---\n",
    "\n",
    "def discover_countries(pickle_dir):\n",
    "    \"\"\"\n",
    "    Scans all .pkl files in the specified directory to find and print\n",
    "    a unique list of all country names.\n",
    "    \"\"\"\n",
    "    logging.info(\"--- Starting Part 1: Country Discovery ---\")\n",
    "    if PICKLE_BASE_DIR == 'PLEASE_SET_THIS_PATH':\n",
    "        logging.error(\"Please update the 'PICKLE_BASE_DIR' variable in this script.\")\n",
    "        return\n",
    "\n",
    "    logging.info(f\"Scanning for .pkl files in: {pickle_dir}\")\n",
    "    \n",
    "    # Find all .pkl files. \n",
    "    # Use '*.pkl' for a flat directory.\n",
    "    # Use '**/*.pkl' (and set recursive=True) if they are in subfolders.\n",
    "    try:\n",
    "        pickle_files = glob.glob(os.path.join(pickle_dir, '*.pkl'), recursive=False)\n",
    "    except Exception as e:\n",
    "        logging.error(f\"Error finding pickle files: {e}\")\n",
    "        return\n",
    "\n",
    "    if not pickle_files:\n",
    "        logging.warning(f\"No .pkl files found in {pickle_dir}. Check the path.\")\n",
    "        return\n",
    "        \n",
    "    logging.info(f\"Found {len(pickle_files)} pickle files to scan.\")\n",
    "    \n",
    "    all_countries_set = set()\n",
    "\n",
    "    for pkl_file in pickle_files:\n",
    "        try:\n",
    "            logging.info(f\"Scanning: {os.path.basename(pkl_file)}\")\n",
    "            df = pd.read_pickle(pkl_file)\n",
    "            \n",
    "            if COUNTRY_COLUMN not in df.columns:\n",
    "                logging.warning(f\" Skipping... '{COUNTRY_COLUMN}' not found in this file.\")\n",
    "                continue\n",
    "                \n",
    "            # Get all unique, non-null country names from the column\n",
    "            unique_in_file = df[COUNTRY_COLUMN].dropna().unique()\n",
    "            \n",
    "            if len(unique_in_file) > 0:\n",
    "                # Add the new countries to our master set\n",
    "                all_countries_set.update(unique_in_file)\n",
    "                \n",
    "        except Exception as e:\n",
    "            logging.error(f\" Error reading {pkl_file}: {e}\", exc_info=False)\n",
    "\n",
    "    # --- Finished ---\n",
    "    logging.info(\"--- Discovery Complete ---\")\n",
    "    \n",
    "    if not all_countries_set:\n",
    "        logging.error(\"No countries found. Please check your data and configuration.\")\n",
    "        return\n",
    "        \n",
    "    sorted_countries = sorted(list(all_countries_set))\n",
    "    \n",
    "    logging.info(f\"Found {len(sorted_countries)} unique countries across all files:\")\n",
    "    print(\"\\n--- Unique Country List ---\")\n",
    "    for country in sorted_countries:\n",
    "        print(country)\n",
    "    print(\"----------------------------\\n\")\n",
    "    logging.info(\"Please use this list to build your 'COUNTRY_TO_REGION_MAP' in script 2.\")\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    discover_countries(PICKLE_BASE_DIR)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "5d761d1b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-10-30 18:04:41,363 - INFO - --- Starting Part 2: Regional Corpus Build ---\n",
      "2025-10-30 18:04:41,364 - INFO - Opening 8 output files...\n",
      "2025-10-30 18:04:41,365 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\GERMANIC_MAINLAND_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,365 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\LATAM_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,366 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\MIDDLE_EAST_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,366 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\ASIA_PACIFIC_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,367 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\CANADA_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,368 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\ANGLOSPHERE_COMMONLAW_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,368 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\SOUTHERN_EUROPE_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,369 - INFO - Opened D:\\market_data\\text_data\\REGIONS\\NORDICS_corpus.txt for writing.\n",
      "2025-10-30 18:04:41,369 - INFO - Scanning for .pkl files in: C:\\_Files\\School\\Competitions\\FIAM2025\\data\\global_text_data\n",
      "2025-10-30 18:04:41,370 - INFO - Found 26 pickle files to process.\n",
      "2025-10-30 18:04:41,370 - INFO - Processing: AT.pkl\n",
      "2025-10-30 18:04:42,496 - INFO -  Processed 5,000 total rows | Written 7,876 segments | Rate: 4441.0 rows/s\n",
      "2025-10-30 18:04:43,084 - INFO -  Processed 10,000 total rows | Written 15,869 segments | Rate: 5837.0 rows/s\n",
      "2025-10-30 18:04:43,530 - INFO - Processing: AV.pkl\n",
      "2025-10-30 18:04:43,785 - INFO - Processing: BB.pkl\n",
      "2025-10-30 18:04:43,990 - INFO -  Processed 15,000 total rows | Written 24,126 segments | Rate: 5725.8 rows/s\n",
      "2025-10-30 18:04:44,044 - INFO - Processing: CG.pkl\n",
      "2025-10-30 18:04:45,861 - INFO -  Processed 20,000 total rows | Written 31,769 segments | Rate: 4453.8 rows/s\n",
      "2025-10-30 18:04:46,725 - INFO -  Processed 25,000 total rows | Written 39,321 segments | Rate: 4669.2 rows/s\n",
      "2025-10-30 18:04:47,610 - INFO -  Processed 30,000 total rows | Written 46,825 segments | Rate: 4808.2 rows/s\n",
      "2025-10-30 18:04:48,106 - INFO - Processing: CT.pkl\n",
      "2025-10-30 18:04:49,289 - INFO -  Processed 35,000 total rows | Written 54,157 segments | Rate: 4419.8 rows/s\n",
      "2025-10-30 18:04:49,902 - INFO -  Processed 40,000 total rows | Written 61,360 segments | Rate: 4688.4 rows/s\n",
      "2025-10-30 18:04:50,500 - INFO -  Processed 45,000 total rows | Written 68,442 segments | Rate: 4929.1 rows/s\n",
      "2025-10-30 18:04:51,108 - INFO -  Processed 50,000 total rows | Written 75,633 segments | Rate: 5134.7 rows/s\n",
      "2025-10-30 18:04:51,194 - INFO - Processing: DC.pkl\n",
      "2025-10-30 18:04:51,462 - INFO - Processing: FH.pkl\n",
      "2025-10-30 18:04:51,682 - INFO - Processing: FP.pkl\n",
      "2025-10-30 18:04:52,229 - INFO -  Processed 55,000 total rows | Written 81,627 segments | Rate: 5065.0 rows/s\n",
      "2025-10-30 18:04:52,780 - INFO -  Processed 60,000 total rows | Written 86,250 segments | Rate: 5258.7 rows/s\n",
      "2025-10-30 18:04:52,977 - INFO - Processing: GF.pkl\n",
      "2025-10-30 18:04:53,846 - INFO -  Processed 65,000 total rows | Written 92,058 segments | Rate: 5210.3 rows/s\n",
      "2025-10-30 18:04:54,531 - INFO -  Processed 70,000 total rows | Written 98,771 segments | Rate: 5319.0 rows/s\n",
      "2025-10-30 18:04:54,575 - INFO - Processing: HK.pkl\n",
      "2025-10-30 18:05:00,583 - INFO -  Processed 75,000 total rows | Written 106,353 segments | Rate: 3903.7 rows/s\n",
      "2025-10-30 18:05:02,404 - INFO -  Processed 80,000 total rows | Written 113,850 segments | Rate: 3803.4 rows/s\n",
      "2025-10-30 18:05:04,200 - INFO -  Processed 85,000 total rows | Written 121,334 segments | Rate: 3723.2 rows/s\n",
      "2025-10-30 18:05:06,016 - INFO -  Processed 90,000 total rows | Written 128,885 segments | Rate: 3651.7 rows/s\n",
      "2025-10-30 18:05:07,830 - INFO -  Processed 95,000 total rows | Written 136,431 segments | Rate: 3590.3 rows/s\n",
      "2025-10-30 18:05:09,643 - INFO -  Processed 100,000 total rows | Written 143,948 segments | Rate: 3537.0 rows/s\n",
      "2025-10-30 18:05:11,454 - INFO -  Processed 105,000 total rows | Written 151,427 segments | Rate: 3490.3 rows/s\n",
      "2025-10-30 18:05:13,316 - INFO -  Processed 110,000 total rows | Written 158,987 segments | Rate: 3443.4 rows/s\n",
      "2025-10-30 18:05:15,111 - INFO -  Processed 115,000 total rows | Written 166,497 segments | Rate: 3408.4 rows/s\n",
      "2025-10-30 18:05:16,448 - INFO - Processing: ID.pkl\n",
      "2025-10-30 18:05:18,024 - INFO - Processing: IM.pkl\n",
      "2025-10-30 18:05:18,201 - INFO - Processing: IT.pkl\n",
      "2025-10-30 18:05:18,251 - INFO -  Processed 120,000 total rows | Written 173,177 segments | Rate: 3253.8 rows/s\n",
      "2025-10-30 18:05:18,384 - INFO - Processing: JT.pkl\n",
      "2025-10-30 18:05:18,742 - INFO - Processing: KP.pkl\n",
      "2025-10-30 18:05:19,584 - INFO -  Processed 125,000 total rows | Written 180,369 segments | Rate: 3271.1 rows/s\n",
      "2025-10-30 18:05:21,113 - INFO -  Processed 130,000 total rows | Written 189,055 segments | Rate: 3271.0 rows/s\n",
      "2025-10-30 18:05:22,332 - INFO -  Processed 135,000 total rows | Written 197,762 segments | Rate: 3295.7 rows/s\n",
      "2025-10-30 18:05:22,479 - INFO - Processing: LN.pkl\n",
      "2025-10-30 18:05:23,808 - INFO -  Processed 140,000 total rows | Written 207,363 segments | Rate: 3299.0 rows/s\n",
      "2025-10-30 18:05:24,561 - INFO - Processing: LX.pkl\n",
      "2025-10-30 18:05:24,779 - INFO -  Processed 145,000 total rows | Written 217,013 segments | Rate: 3340.4 rows/s\n",
      "2025-10-30 18:05:24,788 - INFO - Processing: MF.pkl\n",
      "2025-10-30 18:05:24,916 - INFO - Processing: NA.pkl\n",
      "2025-10-30 18:05:25,208 - INFO - Processing: NO.pkl\n",
      "2025-10-30 18:05:25,452 - INFO - Processing: PL.pkl\n",
      "2025-10-30 18:05:25,622 - INFO - Processing: SN.pkl\n",
      "2025-10-30 18:05:25,918 - INFO -  Processed 150,000 total rows | Written 223,974 segments | Rate: 3367.2 rows/s\n",
      "2025-10-30 18:05:26,041 - INFO - Processing: SP.pkl\n",
      "2025-10-30 18:05:26,563 - INFO - Processing: SS.pkl\n",
      "2025-10-30 18:05:27,168 - INFO -  Processed 155,000 total rows | Written 232,735 segments | Rate: 3384.4 rows/s\n",
      "2025-10-30 18:05:27,807 - INFO - Processing: TT.pkl\n",
      "2025-10-30 18:05:29,171 - INFO -  Processed 160,000 total rows | Written 242,575 segments | Rate: 3347.2 rows/s\n",
      "2025-10-30 18:05:30,117 - INFO -  Processed 165,000 total rows | Written 252,100 segments | Rate: 3384.8 rows/s\n",
      "2025-10-30 18:05:31,046 - INFO -  Processed 170,000 total rows | Written 261,634 segments | Rate: 3422.2 rows/s\n",
      "2025-10-30 18:05:31,469 - INFO - Processing: XW.pkl\n",
      "2025-10-30 18:05:32,168 - INFO -  Processed 175,000 total rows | Written 269,065 segments | Rate: 3445.0 rows/s\n",
      "2025-10-30 18:05:32,301 - INFO - --- Processing Complete. Closing all files. ---\n",
      "2025-10-30 18:05:32,302 - INFO - Closed GERMANIC_MAINLAND file.\n",
      "2025-10-30 18:05:32,302 - INFO - Closed LATAM file.\n",
      "2025-10-30 18:05:32,303 - INFO - Closed MIDDLE_EAST file.\n",
      "2025-10-30 18:05:32,303 - INFO - Closed ASIA_PACIFIC file.\n",
      "2025-10-30 18:05:32,304 - INFO - Closed CANADA file.\n",
      "2025-10-30 18:05:32,304 - INFO - Closed ANGLOSPHERE_COMMONLAW file.\n",
      "2025-10-30 18:05:32,305 - INFO - Closed SOUTHERN_EUROPE file.\n",
      "2025-10-30 18:05:32,305 - INFO - Closed NORDICS file.\n",
      "2025-10-30 18:05:32,305 - INFO - Total rows scanned: 176,102\n",
      "2025-10-30 18:05:32,305 - INFO - Total rows skipped (unmapped country): 0\n",
      "2025-10-30 18:05:32,306 - INFO - Total text segments written: 270,294\n",
      "2025-10-30 18:05:32,306 - INFO - Total time: 50.93 seconds\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- Segments Written per Region ---\n",
      "ANGLOSPHERE_COMMONLAW: 40,243\n",
      "GERMANIC_MAINLAND: 20,166\n",
      "ASIA_PACIFIC: 153,581\n",
      "CANADA: 25,698\n",
      "NORDICS: 14,195\n",
      "SOUTHERN_EUROPE: 13,622\n",
      "MIDDLE_EAST: 2,347\n",
      "LATAM: 442\n",
      "---------------------------------\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "import glob\n",
    "import logging\n",
    "import time\n",
    "from collections import defaultdict\n",
    "\n",
    "# --- Configuration ---\n",
    "logging.basicConfig(level=logging.INFO, format='%(asctime)s - %(levelname)s - %(message)s')\n",
    "\n",
    "\n",
    "PICKLE_BASE_DIR = r'C:\\_Files\\School\\Competitions\\FIAM2025\\data\\global_text_data' \n",
    "\n",
    "\n",
    "OUTPUT_DIR = r'D:\\market_data\\text_data\\REGIONS'\n",
    "\n",
    "# --- !! IMPORTANT: DEFINE YOUR MAP !! ---\n",
    "# 3. Fill this map based on the output from script 1.\n",
    "#    Any country NOT in this map will be SKIPPED.\n",
    "COUNTRY_TO_REGION_MAP = {\n",
    "    # 'Country Name': 'REGION_NAME'\n",
    "    \n",
    "    # --- CANADA ---\n",
    "    'Canada': 'CANADA',\n",
    "    \n",
    "    # --- NORDICS ---\n",
    "    'Denmark': 'NORDICS',\n",
    "    'Finland': 'NORDICS',\n",
    "    'Norway': 'NORDICS',\n",
    "    'Sweden': 'NORDICS',\n",
    "    \n",
    "    # --- ASIA_PACIFIC ---\n",
    "    'China': 'ASIA_PACIFIC',\n",
    "    'Hong Kong': 'ASIA_PACIFIC',\n",
    "    'Japan': 'ASIA_PACIFIC',\n",
    "    'Singapore': 'ASIA_PACIFIC',\n",
    "    'South Korea': 'ASIA_PACIFIC',\n",
    "    'Taiwan': 'ASIA_PACIFIC',\n",
    "    \n",
    "    # --- GERMANIC MAINLAND ---\n",
    "    'Germany': 'GERMANIC_MAINLAND',\n",
    "    'Austria': 'GERMANIC_MAINLAND',\n",
    "    'Switzerland': 'GERMANIC_MAINLAND',\n",
    "    'Netherlands': 'GERMANIC_MAINLAND',\n",
    "    'Belgium': 'GERMANIC_MAINLAND',\n",
    "    'Luxembourg': 'GERMANIC_MAINLAND',\n",
    "\n",
    "    # --- SOUTHERN EUROPE ---\n",
    "    'France': 'SOUTHERN_EUROPE',\n",
    "    'Italy': 'SOUTHERN_EUROPE',\n",
    "    'Spain': 'SOUTHERN_EUROPE',\n",
    "    'Portugal': 'SOUTHERN_EUROPE',\n",
    "    \n",
    "    # --- ANGLOSPHERE / COMMON LAW ---\n",
    "    'United Kingdom': 'ANGLOSPHERE_COMMONLAW',\n",
    "    'Ireland': 'ANGLOSPHERE_COMMONLAW',\n",
    "    'Australia': 'ANGLOSPHERE_COMMONLAW',\n",
    "    \n",
    "    # --- LATIN AMERICA ---\n",
    "    'Mexico': 'LATAM',\n",
    "    \n",
    "    # --- MIDDLE EAST ---\n",
    "    'Israel': 'MIDDLE_EAST',\n",
    "}\n",
    "\n",
    "# --- Columns & Filters ---\n",
    "COUNTRY_COLUMN = 'country'\n",
    "TEXT_COLUMNS = ['section_7_risk_factors', 'section_5_management_discussion_and_analysis'] # Text columns to extract\n",
    "MIN_TEXT_LENGTH = 50 # Minimum characters for a text section to be included\n",
    "LOG_INTERVAL = 5000 # Log progress every N filings processed\n",
    "\n",
    "# --- Script ---\n",
    "\n",
    "def build_corpora(pickle_dir, output_dir, region_map):\n",
    "    \"\"\"\n",
    "    Scans all .pkl files, maps rows to regions, and appends text\n",
    "    to the correct regional corpus file.\n",
    "    \"\"\"\n",
    "    logging.info(\"--- Starting Part 2: Regional Corpus Build ---\")\n",
    "    if PICKLE_BASE_DIR == 'PLEASE_SET_THIS_PATH' or OUTPUT_DIR == 'PLEASE_SET_THIS_PATH':\n",
    "        logging.error(\"Please update the 'PICKLE_BASE_DIR' and 'OUTPUT_DIR' variables.\")\n",
    "        return\n",
    "    if not region_map:\n",
    "        logging.error(\"The 'COUNTRY_TO_REGION_MAP' is empty. Please define your regions.\")\n",
    "        return\n",
    "\n",
    "    os.makedirs(output_dir, exist_ok=True)\n",
    "    \n",
    "    # --- Open all output files ---\n",
    "    # Get all unique region names from your map\n",
    "    all_regions = set(region_map.values())\n",
    "    output_files = {} # Dictionary to hold the open file handles\n",
    "    \n",
    "    logging.info(f\"Opening {len(all_regions)} output files...\")\n",
    "    for region_name in all_regions:\n",
    "        try:\n",
    "            output_path = os.path.join(output_dir, f\"{region_name}_corpus.txt\")\n",
    "            # Open in 'append' mode to allow restarting\n",
    "            file_handle = open(output_path, 'a', encoding='utf-8')\n",
    "            output_files[region_name] = file_handle\n",
    "            logging.info(f\"Opened {output_path} for writing.\")\n",
    "        except Exception as e:\n",
    "            logging.error(f\"Failed to open output file for {region_name}: {e}\")\n",
    "            \n",
    "    if not output_files:\n",
    "        logging.error(\"No output files could be opened. Exiting.\")\n",
    "        return\n",
    "\n",
    "    # --- Scan all pickle files ---\n",
    "    logging.info(f\"Scanning for .pkl files in: {pickle_dir}\")\n",
    "    pickle_files = glob.glob(os.path.join(pickle_dir, '*.pkl'), recursive=False)\n",
    "    \n",
    "    if not pickle_files:\n",
    "        logging.warning(f\"No .pkl files found in {pickle_dir}.\")\n",
    "        return\n",
    "\n",
    "    logging.info(f\"Found {len(pickle_files)} pickle files to process.\")\n",
    "    \n",
    "    start_time = time.time()\n",
    "    total_rows_processed = 0\n",
    "    total_segments_written = 0\n",
    "    unmapped_rows = 0\n",
    "    stats = defaultdict(int) # Track segments per region\n",
    "\n",
    "    try:\n",
    "        for pkl_file in pickle_files:\n",
    "            logging.info(f\"Processing: {os.path.basename(pkl_file)}\")\n",
    "            try:\n",
    "                df = pd.read_pickle(pkl_file)\n",
    "                \n",
    "                # Check for required columns\n",
    "                required_cols = TEXT_COLUMNS + [COUNTRY_COLUMN]\n",
    "                missing_cols = [col for col in required_cols if col not in df.columns]\n",
    "                if missing_cols:\n",
    "                    logging.warning(f\" Skipping... Missing columns: {missing_cols}\")\n",
    "                    continue\n",
    "\n",
    "                # Iterate through rows\n",
    "                for index, row in df.iterrows():\n",
    "                    total_rows_processed += 1\n",
    "                    \n",
    "                    country = row[COUNTRY_COLUMN]\n",
    "                    # Find the region for this country from your map\n",
    "                    region = region_map.get(country)\n",
    "                    \n",
    "                    if not region:\n",
    "                        unmapped_rows += 1\n",
    "                        continue # Skip this row if country is not in our map\n",
    "                        \n",
    "                    # Get the correct output file handle\n",
    "                    outfile = output_files.get(region)\n",
    "                    if not outfile:\n",
    "                        logging.warning(f\"No output file handle for region '{region}'. Skipping.\")\n",
    "                        continue\n",
    "                        \n",
    "                    # Extract text from the text columns\n",
    "                    for col in TEXT_COLUMNS:\n",
    "                        text_content = row[col]\n",
    "                        if isinstance(text_content, str) and len(text_content.strip()) >= MIN_TEXT_LENGTH:\n",
    "                            cleaned_text = text_content.strip()\n",
    "                            outfile.write(cleaned_text + '\\n\\n')\n",
    "                            total_segments_written += 1\n",
    "                            stats[region] += 1\n",
    "                            \n",
    "                    if total_rows_processed % LOG_INTERVAL == 0:\n",
    "                        elapsed = time.time() - start_time\n",
    "                        rate = total_rows_processed / elapsed if elapsed > 0 else 0\n",
    "                        logging.info(f\" Processed {total_rows_processed:,} total rows | Written {total_segments_written:,} segments | Rate: {rate:.1f} rows/s\")\n",
    "                        \n",
    "            except Exception as e:\n",
    "                logging.error(f\" D-Error reading {pkl_file}: {e}\", exc_info=False)\n",
    "                \n",
    "    finally:\n",
    "        # --- Clean up ---\n",
    "        logging.info(\"--- Processing Complete. Closing all files. ---\")\n",
    "        for region, handle in output_files.items():\n",
    "            handle.close()\n",
    "            logging.info(f\"Closed {region} file.\")\n",
    "            \n",
    "    end_time = time.time()\n",
    "    total_time = end_time - start_time\n",
    "    logging.info(f\"Total rows scanned: {total_rows_processed:,}\")\n",
    "    logging.info(f\"Total rows skipped (unmapped country): {unmapped_rows:,}\")\n",
    "    logging.info(f\"Total text segments written: {total_segments_written:,}\")\n",
    "    logging.info(f\"Total time: {total_time:.2f} seconds\")\n",
    "    \n",
    "    print(\"\\n--- Segments Written per Region ---\")\n",
    "    for region, count in stats.items():\n",
    "        print(f\"{region}: {count:,}\")\n",
    "    print(\"---------------------------------\")\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    build_corpora(PICKLE_BASE_DIR, OUTPUT_DIR, COUNTRY_TO_REGION_MAP)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "bebc6eb2",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-10-27 08:42:05,815 - INFO - Attempting to read the last ~1000000 bytes from: D:\\market_data\\text_data\\USA\\corpus_cleaned.txt\n",
      "2025-10-27 08:42:05,817 - INFO - File size: 12,334,834,157 bytes\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "--- Last ~5000 Characters ---\n",
      "5 to Buy and 2 to Hold. Shares are priced at $28.16 and have an average target of $49.14, giving the stock a 46% upside for the year ahead. (See VMEO stock analysis on TipRanks)\n",
      "Boyd Gaming (BYD)\n",
      "Next up is Boyd Gaming, a major operator of casino gaming properties. The company got its start in 1975, in Las Vegas, and has since spread out of its hometown. Boyd is now active in 10 states (Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Nevada, Ohio, and Pennsylvania), and boasts 28 casino facilities.\n",
      "Like much of the leisure and entertainment industry, Boyd was badly hurt by the corona crisis in 2020. The company was forced to announce mass layoffs  25% of its workforce  in July of last year, and saw its 2Q20 revenues fall to just $209 million, approximately one-quarter normal levels. The company is experiencing better times this year, however, as the economy reopens and consumers begin spending on much-needed leisure.\n",
      "In its 2Q21 report, Boyd showed $893.6 million in revenue, some 14% above the analyst expectations and a whopping 325% up from the dreadful 2Q20. The 2Q21 revenue was the best in more than two years. EPS also turned around dramatically, from a 92-cent per share loss in the year-ago quarter to a $1 per share profit in this years second quarter.\n",
      "Along with these financial gains, BYD shares are also up. The stock has far outpaced the S&P 500s 32% one-year gain, increasing 99% over the same period.\n",
      "Nevertheless, Wells Fargos Daniel Politzer sees more gains on the horizon. The analyst rates BYD an Overweight (i.e. Buy) and has a $92 price target to suggest ~40% upside. (To watch Politzers track record, click here)\n",
      "Backing his stance, Politzer says, Our Overweight rating on BYD reflects our view that (1) at least 1,000 bps of BYDs recent margin expansion will prove sustainable; (2) it offers exposure to the highly attractive Las Vegas Locals market, which is ~30% of its EBITDAR and offers a low-/ mid-single-digit growth rate and 50%+ margins; (3) BYDs 5% stake in FanDuel is worth an estimated $1.3B, or $12 per share; and (4) BYDs 7x 2022E EV/EBITDA and current implied 11% free cash flow yield are attractive on both an historical and relative basis, and with a primed balance sheet at less than 3x net leverage forecast by year-end 2021, could set up for capital return to shareholders.\n",
      "Wall Street is unanimous on this one; The stock has a Strong Buy consensus rating, based on Buys only  6, in total. Shares in BYD are selling for $66.61 and their $86.67 average price target indicates room for ~30% growth over the next 12 months. (See BYD stock analysis on TipRanks)\n",
      "Zymeworks (ZYME)\n",
      "Lets wrap with Zymeworks, a clinical stage biotech firm based in Vancouver, Canada. Zymeworks is developing new medications for the treatment of cancer but also for autoimmune disorders and inflammatory diseases. The companys drug candidates are precision engineered biotherapeutics, based on protein modeling.\n",
      "Zymeworks leading drug candidate, zanidatamab, is currently undergoing multiple clinical trials. The drug is an HER2 specific antibody, and targets HER2-expressing cancers. Ongoing clinical trials include a Phase 1b/2 trial, testing zanidatamab and evorpacept in tandem against HER2-expressing breast cancer as well as other solid tumors. The first patient in this study was dosed earlier this month.\n",
      "A Phase 2 clinical trial of zanidatamab for the first-line treatment of HER2+ gastroesophageal adenocarcinoma (GEA) has shown promising early results, including a confirmed objective response rate of 75% overall. The results justify further testing, and Phase 3 study is planned to kick off during the current quarter.\n",
      "Other recent activity includes the dosing of the first patient in a new cohort of the Phase 1 trial of zanidatamab used in conjunction with tucatinib and traditional chemotherapy for the treatment of HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease.\n",
      "Wells Fargos Nick Abbott is impressed with the data available so far, writing: We believe that the recent 1st line gastroesophageal cancer data presented at ESMO demonstrates that zani is superior to HERCEPTIN and the combination of HERCEPTIN and PERJETA (HP) in patients with HER2+ve disease. Whilst HER2 expression in GEA is more heterogeneous than in breast cancer, and this may benefit zani's mechanism of action, we expect zani to be at least as effective as HP in1st line breast cancer. In our view, we believe that the totality of zani breast cancer data and the potential opportunity to expand into the HER2 low disease which for breast cancer is a market estimated to be 4-fold larger than the HER2+ve market, will enable ZYME to secure a high-value global partnership.\n",
      "To this end, Abbott rates ZYME an Overweight (i.e. Buy) and gives it a $56 price target, suggesting a huge 133% one-year upside potential. (To watch Abbotts track record, click here)\n",
      "With 6 reviews on record, including 4 Buys and 2 Holds, ZYME shares have a Moderate Buy consensus rating. The Street sees plenty of gains on the horizon here; the stocks average price target is $49.65, pointing to a 107% upside from the $24.01 trading price. (See ZYME stock analysis on TipRanks)\n",
      "To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.\n",
      "Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.\n",
      "\n",
      "Zymeworks Inc (ZYME) shares closed 0.9% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 44.1% year-to-date, down 41.4% over the past 12 months, and up 103.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.8%, and the S&P 500 rose 2.2%.\n",
      "Trading Activity\n",
      "Trading volume this week was 45.7% lower than the 20-day average.\n",
      "Beta, a measure of the stocks volatility relative to the overall market stands at 1.0.\n",
      "Technical Indicators\n",
      "The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.\n",
      "MACD, a trend-following momentum indicator, indicates a downward trend.\n",
      "The stock closed below its Bollinger band, indicating it may be oversold.\n",
      "The stock closed at 9.5% lower than its 5-day moving average, 18.8% lower than its 20-day moving average, and 26.6% lower than its 90-day moving average.\n",
      "Market Comparative Performance\n",
      "The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis\n",
      "The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis\n",
      "The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis\n",
      "Per Group Comparative Performance\n",
      "The company's stock price performance year-to-date lags the peer average by 28.9%\n",
      "The company's stock price performance over the past 12 months lags the peer average by 48.7%\n",
      "\n",
      "This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com.  2020 Kwhen Inc.\n",
      "\n",
      "4 Top Biotech Stocks To Watch This Upcoming Week\n",
      "As the broader stock market continues to show signs of caution, biotech stocks continue to offer their high-risk, high-reward potential. Biotech is a multi-billion industry with countless trials and FDA approvals involved. Each stage and interim progress along the way can become a catalyst for biotech stocks. A positive outcome or update can lead to a boost in shares. But a negative outcome or update can be detrimental to biotech stocks. Thus, careful due diligence could allow investors to manage their risk in this sector. Even now, biotech stocks such as BioNTech SE (NASDAQ: BNTX) and Johnson & Johnson (NYSE: JNJ) play important roles in combatting the pandemic. More and more countries are giving approvals to the vaccines that these biotech companies offer. For example, Irans new government has approved the use of JNJs COVID-19 vaccine in an attempt to fight off the fifth wave of infections. Given these circumstances, it is understandable why investors are eyeing some of the top biotech stocks in the stock market today. Best Biotech Stocks To Watch Right Now\n",
      "Moderna Inc (NASDAQ: MRNA)\n",
      "AbCellera Biologics Inc (NASDAQ: ABCL)\n",
      "Pfizer Inc. (NYSE: PFE)\n",
      "Zymeworks Inc (NYSE: ZYME)\n",
      "Moderna Inc\n",
      "First up, we will be looking at Moderna. Essentially, it is a biotech company that utilizes messenger RNA (mRNA) science to treat a broad spectrum of diseases across six modalities. A modality is a family of potential mRNA medicines that are consistent in both design and how and where they are delivered in the body. This would include cancer vaccines and prophylactic vaccines. For obvious reasons, MRNA stock has been on the top of many investors watchlists. On Thursday, Moderna announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX. This is the companys coronavirus vaccine for active immunization to prevent COVID-19 in individuals 12 years of age and older. The approval comes after the vaccine demonstrated an efficacy of 93% in the Phase 3 COVE study data. Well, this development is significant as it marks the first full approval for SPIKEVAX. Besides that, the company also recently highlighted a new analysis that suggests its vaccine is highly effective against circulating variants of concern. Furthermore, the company shared a new analysis of follow-up through 1 year in the Phase 3 COVE study suggesting a lower risk of breakthrough infection in participants vaccinated more recently compared to participants vaccinated last year. These are encouraging data for the company and would certainly play a role in combatting the pandemic. Given these exciting developments, would you add MRNA stock to your watchlist?\n",
      "Source: TD Ameritrade TOS\n",
      "Read More\n",
      "4 Semiconductor Stocks To Watch Right Now\n",
      "Good Stocks To Invest In Right Now? 4 IPO Stocks To Watch\n",
      "AbCellera Biologics Inc\n",
      "Following that, we have the tech company with a centralized operating system for next-generation antibody discovery, AbCellera. In detail, the company searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs. ABCL stock has risen approximately 20% during pre-market trading today. So let us see what is acting as the catalyst for this movement.\n",
      "For starters, the AbCellera announced today that the U.S. FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent symptomatic COVID-19. These antibodies have shown to be effective against the highly contagious Delta variant. So, we will now have more protection options for a significant number of people who may be still vulnerable to COVID-19. Not to mention, the company announced that it has acquired TetraGenetics, Inc earlier this week. TetraGenetics is a biotech company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins Together, it will provide an optimized protein source for AbCelleras antibody discovery. Hence giving rise to the potential to unlock the discovery of antibody therapies across a range of therapeutic areas. With all the buzz around the company now, would you jump on the ABCL stock bandwagon?\n",
      "Source: TD Ameritrade TOS\n",
      "[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know\n",
      "Pfizer Inc\n",
      "Another top biotech company that needs no introduction would be Pfizer. The company is a multinational pharmaceutical and biotechnology corporation with headquarters in New York City. Its portfolio of medicine spans many medical fields. Pfizer actively collaborates with health care providers, governments and local communities to support and provide access to health care. PFE stock has risen more than 25% over the past year. Last week, the company along with Myovant Sciences (NYSE: MYOV) announced that the U.S. FDA has accepted the review of its supplemental New Drug Application (sNDA) for MYFEMBREE. The drug is for the management of moderate to severe pain associated with endometriosis. Once approved, both companies believe that the drug will have the potential to redefine care for women with endometriosis. On top of that, Pfizer also announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO (abrocitinib). The drug is used for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and over. In fact, this is the first marketing authorization worldwide for this treatment. All things considered, do you still view PFE stock as an attractive opportunity?\n",
      "Source: TD Ameritrade TOS\n",
      "[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist\n",
      "Zymeworks Inc Zymeworks is a clinical-stage biopharmaceutical company that specializes in bio-therapeutics for the treatment of cancer in Canada. It operates through a number of platforms, including Azymetric, and ZymeLink. As of now, the companys lead product candidates are zanidatamab for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer, and ZW49 for the treatment of advanced HER2-expressing tumors. Yesterday, the company presented encouraging early data on zanidatamab at the European Society of Medical Oncology Congress 2021. The data was derived from a clinical study of 36 patients with HER2-expressing Gastroesophageal Adenocarcinoma (GEA). The drug in combination with chemotherapy showed a Confirmed objective response rate (cORR) of 75% overall and 93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP). Furthermore, the treatment is generally well-tolerated, with the majority of treatment-related adverse events considered mild to moderate. Despite the advancement in the health care industry, metastatic HER2-expressing GEA remains a difficult condition to treat. Therefore, the data presented demonstrate the potential of zanidatamab in the first-line setting and a new treatment option that is desperately needed. Given these considerations, would you say that ZYME stock is a top biotech stock to watch now?\n",
      "Source: TD Ameritrade TOS\n",
      "\n",
      "The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. To wit, the Zymeworks Inc. (NYSE:ZYME) share price has flown 117% in the last three years. Most would be happy with that. And in the last week the share price has popped 12%.\n",
      "The past week has proven to be lucrative for Zymeworks investors, so let's see if fundamentals drove the company's three-year performance.\n",
      "Zymeworks isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.\n",
      "Zymeworks actually saw its revenue drop by 38% per year over three years. So the share price gain of 30% per year is quite surprising. It's a good reminder that expectations about the future, not the past history, always impact share prices.\n",
      "The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).\n",
      "NYSE:ZYME Earnings and Revenue Growth September 17th 2021\n",
      "This free interactive report on Zymeworks' balance sheet strength is a great place to start, if you want to investigate the stock further.\n",
      "A Different Perspective\n",
      "Zymeworks shareholders are down 17% for the year, but the broader market is up 36%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Investors are up over three years, booking 30% per year, much better than the more recent returns. Sometimes when a good quality long term winner has a weak period, it's turns out to be an opportunity, but you really need to be sure that the quality is there. It's always interesting to track share price performance over the longer term. But to understand Zymeworks better, we need to consider many other factors. Case in point: We've spotted 2 warning signs for Zymeworks you should be aware of, and 1 of them can't be ignored.\n",
      "If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).\n",
      "Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Investors in Zymeworks Inc (Symbol: ZYME) saw new options begin trading this week, for the May 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYME options chain for the new May 21st contracts and identified one put and one call contract of particular interest.\n",
      "The put contract at the $30.00 strike price has a current bid of $2.20. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $27.80 (before broker commissions). To an investor already interested in purchasing shares of ZYME, that could represent an attractive alternative to paying $30.69/share today.\n",
      "Because the $30.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 7.33% return on the cash commitment, or 52.48% annualized  at Stock Options Channel we call this the YieldBoost.\n",
      "Below is a chart showing the trailing twelve month trading history for Zymeworks Inc, and highlighting in green where the $30.00 strike is located relative to that history:\n",
      "Turning to the calls side of the option chain, the call contract at the $35.00 strike price has a current bid of $1.80. If an investor was to purchase shares of ZYME stock at the current price level of $30.69/share, and then sell-to-open that call contract as a \"covered call,\" they are committing to sell the stock at $35.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 19.91% if the stock gets called away at the May 21st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ZYME shares really soar, which is why looking at the trailing twelve month trading history for Zymeworks Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ZYME's trailing twelve month trading history, with the $35.00 strike highlighted in red:\n",
      "Considering the fact that the $35.00 strike represents an approximate 14% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 68%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.87% boost of extra return to the investor, or 41.98% annualized, which we refer to as the YieldBoost.\n",
      "The implied volatility in the put contract example is 119%, while the implied volatility in the call contract example is 111%.\n",
      "Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $30.69) to be 61%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.\n",
      "Top YieldBoost Calls of the S&P 500 \n",
      "\n",
      "Fear of missing out -- also known as \"FOMO\" -- is a common yet dangerous emotion in the world of investing. It's completely understandable why an investor would want to hop onto a stock that has been skyrocketing, even if they're risking losses from a sharp reversal if that purchase is of an overvalued equity near its peak. On the other side of the coin, few people fear the prospect of avoiding a massive loss, but they still might hesitate to \"buy the dip\" on a stock if they suspect that the company's future could be other than bright.\n",
      "In this vein, shares of antibody developer Zymeworks (NYSE: ZYME) might seem like a questionable purchase. Over the last two years, the stock has careened wildly with every report of progress or failure in its clinical trials, and its late-stage pipeline is starting to look a bit sparse. Should investors take the plunge and bank on its upcoming clinical trial results to drive the stock back up?\n",
      "Image source: Getty Images.\n",
      "Why some investors might think they missed the boat\n",
      "Investors' current hesitations about this stock likely can be traced back to late January, when an unimpressive update on one of the company's phase 1 clinical trials -- for cancer treatment ZW49 -- led to a sharp sell-off. The stock has yet to recover, and it may take quite some time to do so, if it ever does. Even for investors who don't consider a major setback in an early-stage trial enough justification to drop a biotech stock, the issues with ZW49 were a major buzzkill.\n",
      "However, I'm of the opinion that it isn't too late to buy Zymeworks stock. The company still has plenty of growth potential -- assuming that it can get its headline therapy projects off the ground.\n",
      "Bispecific antibody therapeutics and antibody-drug conjugates are the heart of Zymeworks' pipeline. In English, that means the company is developing anti-cancer treatments that are designed to target two different sites on a cell. This, in theory, should make them safer and more effective than antibody treatments that bind to only one site.\n",
      "Zymeworks' lead candidate, zanidatamab, is currently in phase 3 testing as a treatment for biliary tract cancer. Beyond that, earlier-stage trials are ongoing to explore its efficacy against breast cancer and other solid tumors. The biologic could also be used in ovarian and salivary gland cancers, among others.\n",
      "Skeptical investors might posit that the potential value of the company's pipeline projects is already being factored into its stock price, meaning that there's no benefit to purchasing it at this point in the game. However, this argument doesn't fully appreciate Zymeworks' better-than-average ability to forge new revenue-bearing collaborations with larger competitors or start new projects with their help.\n",
      "Buying now is ill-advised\n",
      "Despite its recent setback with ZW49, Zymeworks is still strongly positioned to grow. In the first half of this year, it will initiate several new programs examining zanidatamab for breast cancer as a monotherapy or combination therapy, and it might announce others. It'll also report phase 2 data from existing projects. Each of these events will likely catalyze movement in the stock.\n",
      "From now until its pipeline projects come to fruition (assuming that they do), Zymeworks' partnerships will support the company lavishly. Its development collaborators are a who's who of big pharma power players, including the likes of Merck, Johnson & Johnson, Eli Lilly, and GlaxoSmithKline. These partnerships are worth more than just prestige: Management calculates that meeting the development milestones of its existing arrangements would deliver as much as $8.6 billion in revenue. That sum would be spread over at least a few years, but it's more than enough to keep its research and development budget of $168.5 million in 2020 fully funded.\n",
      "ZYME data by YCharts\n",
      "The right time may be approaching\n",
      "But, as useful as these collaborations have been in advancing the company's capabilities and supporting its operations with revenue, it's important to remember that they might not be enough to set shareholders up for success in the long term. Milestone payments and royalties are common sources of income for early-stage biotechs, but it's difficult for a maturing company to flourish without products of its own.\n",
      "Finishing the commercialization of a wholly internally developed project like zanidatamab will prove that Zymeworks is a credible drugmaker that doesn't need to rely on larger partners to survive. If everything goes as planned, it could commercialize zanidatamab in late 2022. Until then, there is plenty of time for would-be investors to find opportunities to buy in.\n",
      "10 stocks we like better than Zymeworks Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zymeworks Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of February 24, 2021\n",
      "Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.\n",
      "\n",
      "In trading on Monday, shares of Zymeworks Inc (Symbol: ZYME) crossed below their 200 day moving average of $40.61, changing hands as low as $40.11 per share. Zymeworks Inc shares are currently trading down about 1.2% on the day. The chart below shows the one year performance of ZYME shares, versus its 200 day moving average:\n",
      "Looking at the chart above, ZYME's low point in its 52 week range is $20.33 per share, with $59.03 as the 52 week high point  that compares with a last trade of $40.35.\n",
      "Click here to find out which 9 other stocks recently crossed below their 200 day moving average \n",
      "\n",
      "What happened\n",
      "Shares of Zymeworks (NYSE: ZYME) are crashing today, down by 23.7% as of 11:20 a.m. EST, after the company announced data late on Wednesday from the dose-escalation portion of a phase 1 study evaluating antibody-drug conjugate ZW49 in treating several types of HER2positive cancer.\n",
      "So what\n",
      "Zymeworks stated that there were \"multiple confirmed responses and stable disease observed in several tumor types\" in patients treated with ZW49. The company also said that the safety profile for the experimental therapy looked pretty good. While there were some adverse events, 90% of them were mild or moderate in severity.\n",
      "Image source: Getty Images.\n",
      "So why the big sell-off of the biotech stock today? Zymeworks' data was disappointing. As SVB Leerink analyst Andrew Berens wrote to clients, \"The results fell well short of investor expectations for a 40%-50% response rate.\"\n",
      "Unsurprisingly, Zymeworks executives had a more optimistic take. Chief Medical Officer Diana Hausman said, \"We are encouraged by the antitumor activity we are seeing so far with ZW49.\" CEO Ali Tehrani stated, \"I believe ZW49 is on track for becoming the HER2 ADC that delivers efficacy without compromising safety.\"\n",
      "At least one analyst also remained cautiously optimistic. Raymond James' David Novak acknowledged that Zymeworks' data fell short of expectations. However, he referred to the safety and tolerability profile of ZW49 as \"class-leading\" and said that it \"creates opportunity\" for the experimental drug.\n",
      "Now what\n",
      "The phase 1 dose-escalation study of ZW49 will continue. Zymeworks hasn't yet established the maximum tolerated dose for the therapeutic candidate. The biotech has also begun enrolling patients into the expansion cohort part of the ongoing study.\n",
      "10 stocks we like better than Zymeworks Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zymeworks Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of November 20, 2020\n",
      "Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Health care stocks were advancing premarket Thursday as the Health Care SPDR (XLV) was gaining 0.66% in value and the iShares NASDAQ Biotechnology Index (IBB) was recently up 0.41%.\n",
      "Zymeworks (ZYME) was slipping past 20% even after saying it has begun enrolling patients into the expansion cohort portion of its phase 1 clinical trial for the novel HER2-targeted antibody-drug conjugate.\n",
      "Danaher (DHR) was marginally declining even as it reported Q4 adjusted earnings of $2.08 per diluted share, up from $1.28 per share a year ago, beating the Capital IQ analyst consensus of $1.87 per share.\n",
      "BeiGene (BGNE) was over 1% higher after saying its Phase 3 trial in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) met its primary endpoint of overall survival.\n",
      "\n",
      "(RTTNews) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study.\n",
      "Read on\n",
      "1. Applied Genetic Throws Light on Achromatopsia Trials\n",
      "Applied Genetic Technologies Corp.'s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quantitative evidence of improvements in visual sensitivity.\n",
      "Achromatopsia (ACHM) is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. ACHM is associated with extremely poor visual acuity (most affected individuals are legally blind), extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. There is no specific treatment for ACHM, although deep red tinted glasses or contact lenses can reduce symptoms of light sensitivity and daytime blindness.\n",
      "The preliminary results of the ACHMB3 trial include 12-month data from 15 patients, 9month data from five patients, 6-month data from three patients and 3-month data from three patients, for a total of 26 patients across all dose groups. For ACHMA3, the new data analysis consists of 12-month data from 10 patients, 9-month data from four patients, 6-month data from one patient and 2 or 3-month data from three patients, for a total of 18 patients across all dose groups.\n",
      "In the ACHMB3 trial, 7 of the 16 patients in the three highest dose groups showed improvements in visual sensitivity, in the treated area, as measured by static perimetry while in the ACHMA3 trial, 3 of the 16 patients in the four highest dose groups showed improvements in visual sensitivity.\n",
      "The company expects to report 12-month data from the adult patients in the ACHMB3 and ACHMA3 trials in second quarter of calendar year 2021, and preliminary 3-month data from the pediatric patients in both trials is anticipated in the fourth quarter of calendar year 2021.\n",
      "AGTC closed Wednesday's trading at $4.45, down 5.72%. In after-hours, the stock was up 5.62% at $4.70.\n",
      "2. Deadlock on AstraZeneca Vaccine Supply Continues\n",
      "Stella Kyriakides, the European Commissioner for Health and Food Safety, on Wednesday, has urged AstraZeneca plc (AZN) to deliver on its commitments in the COVID-19 vaccine supply contract it had signed last August.\n",
      "AstraZeneca's COVID-19 vaccine was approved for emergency supply in the UK on Dec.30, 2020. In the EU, the drug regulator is scheduled to decide on the vaccine's approval tomorrow.\n",
      "The company had initially pledged to deliver 80 million doses of the vaccine to the 27 EU countries for February and March and more than 80 million doses in the second quarter. However, last week, AstraZeneca said that the initial supply of vaccine will be cut by 60% due to production issues.\n",
      "In a PR issued January 27, Kyriakides noted, \"Not being able to ensure manufacturing capacity is against the letter and the spirit of our agreement. I call on AstraZeneca to engage fully, to rebuild trust, to provide complete information and to live up to its contractual, societal and moral obligations\".\n",
      "As per the deal signed last August, the European Commission agreed to purchase 300 million doses of the AstraZeneca vaccine, with an option to purchase 100 million more, on behalf of EU Member States.\n",
      "3. CEL-SCI Catches Eye As it awaits head & neck cancer Trial Data\n",
      "Shares of CEL-SCI Corporation (CVM) closed at a five-year high of $25 on Wednesday, as the company continues to await the final results of its phase III study of Multikine in head and neck cancer.\n",
      "The phase III trial was started in late 2010 and the last patient was enrolled in the study in September 2016. With 928 patients having been enrolled, this study is said to be the largest ever in head and neck cancer.\n",
      "In a letter to shareholders early this month, Geert Kersten, the company's CEO, said that the database for the study was locked late last year (meaning it was ready to be analyzed) and experts are now analyzing the data according to a statistical analysis plan that was agreed to and finalized before database lock.\n",
      "CVM touched an intraday high of $40.91 Wednesday, before closing at $25, up 72.53%.\n",
      "4. Vir Biotech Continues To Rally\n",
      "Eli Lilly and Co. (LLY), Vir Biotechnology Inc. (VIR) and GlaxoSmithKline plc (GSK) have teamed up to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.\n",
      "As part of the collaboration, Lilly has expanded its ongoing phase II trial, dubbed BLAZE-4, to evaluate the administration of Bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg for COVID-19. The first patient has been dosed in the expanded BLAZE-4 trial as well.\n",
      "This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together to explore potential outcomes.\n",
      "The ongoing BLAZE 4 trial is evaluating the efficacy and safety of Bamlanivimab alone, and Bamlanivimab with other neutralizing antibodies including VIR-7831 (GSK4182136) versus placebo for the treatment of symptomatic COVID-19 in the outpatient setting.\n",
      "Bamlanivimab, a neutralizing antibody borne out of the collaboration between Lilly and AbCellera, is authorized for emergency use for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. VIR-7831 is a dual-action monoclonal antibody that was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells.\n",
      "On Tuesday, Vir announced encouraging initial topline data from its ongoing phase I trial of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection, sending the stock up over 70% to $77.\n",
      "VIR closed Wednesday's trading at $83.07, up 7.35%.\n",
      "5. Zymeworks Progresses with ZW49 Study\n",
      "Zymeworks Inc. (ZYME), on Wednesday, announced that it has begun enrolling patients into the expansion cohort portion of its ongoing phase I clinical trial for ZW49.\n",
      "ZW49, a HER2-targeted antibody drug conjugate (ADC), is being developed as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents.\n",
      "The expansion cohorts include HER2-positive breast cancer, HER2-positive gastroesophageal adenocarcinoma, and a basket cohort of other HER2-positive cancers and are actively enrolling at sites in U.S. and Canada, and are expected to open soon at additional sites in South Korea and Australia in collaboration with the company's partner, BeiGene.\n",
      "ZYME closed Wednesday's trading at $44.06, down 4.78%. In after-hours, the stock fell another 24% and was at $33.40.\n",
      "6. Stocks That Gained/Lost The Most\n",
      "Sorrento Therapeutics Inc. (SRNE) closed Wednesday's trading at $15.23, up 46.16%.\n",
      "Rubius Therapeutics Inc. (RUBY) closed at $14.69, up 43.88%.\n",
      "PetMed Express Inc. (PETS) closed at $51.80, up 33.64%.\n",
      "ENDRA Life Sciences Inc. (NDRA) closed at $2.20, down 22.81%.\n",
      "AIkido Pharma Inc. (AIKI) closed at $1.41, down 21.23%.\n",
      "\n",
      "The biotech sector has started the year with a bang. The industry benchmark, iShares NASDAQ Biotechnology ETF (IBB), is up ~11% so far in January -- far better than the S&P 500's 3% return.\n",
      "Covering the sector for Wells Fargo, 5-star analyst Jim Birchenough is upbeat about what he sees.\n",
      "Overall, we see roughly 20% to 30% additional upside for the sector by historical metrics and would argue that accelerating pace of innovation and greater pipeline de-risking should ultimately support higher returns on investment, Birchenough noted.\n",
      "An environment like that will be manna from heaven for any investor interested in pharmaceutical stocks; an improved political climate will just add some icing to this cake.\n",
      "While a split House and Senate supporting continued legislative inertia would have been best received, in terms of maintaining a positive status quo for biotechnology growth, we believe that value proposition for emerging biotechnology therapeutics should win-out under any administration and House/Senate mix, Birchenough added.\n",
      "With this in mind, we wanted to check out some of Wells Fargo's recent picks in the biotech space to see if the investment firm could steer us towards any game-changers. After running the tickers through TipRanks database, we found out that two recently scored Buy ratings from the rest of the Street, enough to earn a Strong Buy consensus rating.\n",
      "Karuna Therapeutics (KRTX)\n",
      "We will start with Karuna Therapeutics, a specialty pharma company whose focus is mental health. Specifically, Karuna works on the development of new drugs for the treatment of schizophrenia and dementia-related psychoses (DRP). With a potential patient base exceeding 2.7 million people, this is a large market. And the state of current treatment options is widely considered less than satisfactory. Medication side effects are severe, while therapeutic effects are less than desired. This leaves an opening for a company that can put a new, more effective, treatment on the market.\n",
      "Karuna is currently enrolling the pivotal Phase 3 EMERGENT-2 Study of its leading drug candidate, KarXT, for the treatment of acute psychosis in adults with schizophrenia. KarXT has showed a differentiated safety profile and efficacy in Phase 2 data. Furthermore, Phase 1b data in healthy elderly volunteers for DRP remain on track for 2Q21.\n",
      "This solid pipeline, with a new drug in multiple studies to treat several aspects of a serious disorder, has piqued Wells Fargo's interest.\n",
      "Covering KRTX for the firm, analyst Jacob Hughes writes, Karuna Therapeutics is our top idea in 2021. While KRTX shares have had an impressive run... we see a very attractive setup for the stock over the next couple years and several important catalysts in 2021 to drive the shares higher We think the pipeline has been de-risked and we like the risk/reward at these levels as the value of KarXT is proved out.\n",
      "To this end, Hughes rates the stock an Overweight (i.e. Buy), and his $163 price target implies an upside of ~59% for the coming year. (To watch Hughes track record, click here)\n",
      "Its not often that the analysts all agree on a stock, so when it does happen, take note. KRTX's Strong Buy consensus rating is based on a unanimous 6 Buys. The stocks $138.80 average price target suggests a 35% upside from the current share price of $102.80. (See KRTX stock analysis on TipRanks)\n",
      "Zymeworks, Inc. (ZYME)\n",
      "Vancouver-based Zymeworks is a clinical stage biotech involved in researching new drugs for the treatment of cancer, autoimmune disorders, and inflammatory diseases. The company focuses on biotherapeutics, drugs precisely engineered for their target diseases.\n",
      "The companys lead candidate, zanidatamab, has indications for biliary tract cancer, breast cancer, and gastroesophageal adenocarcinoma. The drug is in Phase 1/2 testing for these cancers. Zymeworks second clinical candidate, ZW49, like zanidatamab, is an HER2 bispecific antibody in early stage study as a solid tumor treatment. Initial data will be presented at an investor event on January 27.\n",
      "Based on Zymeworks recent study results, Wells Fargos Jim Birchenough writes, [We] expect zanidatamab to differentiate from current HER2 standards by virtue of depth of response in both refractory and frontline patients and to attract a prominent partner to pursue neoadjuvant and adjuvant breast cancer studies, and for ZW49 go-forward dose to demonstrate consistent responses to support further development, with upside potential from additional dose escalation.\n",
      "In line with his bullish stance, Birchenough rates ZYME an Overweight (i.e. Buy) and his price target, at $71, implies a ~47% growth ahead. (To watch Birchenoughs track record, click here)\n",
      "Turning now to the rest of the Street, it appears that other analysts are generally on the same page. With 4 Buys and 1 Hold assigned in the last three months, the consensus rating comes in as a Strong Buy. In addition, the $60.82 average price target implies ~26% upside from current levels. (See ZYME stock analysis on TipRanks)\n",
      "To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.\n",
      "Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.\n",
      "\n",
      "If you want sizzling returns, look no further than the biotech industry. The SPDR S&P Biotech ETF (NYSEMKT: XBI) -- a pretty good barometer for biotechs -- delivered a 48% gain last year. That marked the best performance for the ETF since 2013, when it soared by roughly the same amount. In six of the last 10 years, the biotech ETF generated a return of at least 30%.\n",
      "Investing in this ETF is a great way to profit from the momentum for biotech stocks. However, you can potentially come out even better by going with individual stocks with tremendous potential. Here are three top biotech picks for 2021 that especially stand out.\n",
      "Image source: Getty Images.\n",
      "1. Vertex Pharmaceuticals\n",
      "You'll be hard-pressed to find a stronger biotech than Vertex Pharmaceuticals (NASDAQ: VRTX). The company pretty much has it all, notably including a strong moat and multiple paths for growth.\n",
      "Let's start with Vertex's moat. The biotech practically owns the cystic fibrosis (CF) market with four approved drugs that treat the underlying cause of the genetic disease. Vertex expects that it will maintain a strong leadership position in the CF market at least through the late 2030s.\n",
      "What about growth? Vertex has just begun to market its newest CF drug, Trikafta/Kaftrio, in Europe. The drug became an almost instant blockbuster in the U.S. last year and is almost certain to do so across the Atlantic as well. Meanwhile, Vertex has also gained additional approvals for some of its other CF drugs that should boost sales.\n",
      "The biotech's pipeline also includes several potential huge winners. Despite a disappointing setback for one of its programs targeting genetic disease alpha-1 antitrypsin deficiency (AATD), Vertex will report phase 2 study results from another AATD candidate this year. The company's partnership with gene editing pioneer CRISPR Therapeutics could lead to a cure for rare blood disorders beta-thalassemia and sickle cell disease.\n",
      "Finally, Vertex has a massive cash stockpile that it can and likely will use to expand its pipeline. The company used nearly $1 billion in 2019 to buy Semma Therapeutics. The deal gave Vertex a promising gene therapy targeting type 1 diabetes that should advance to clinical testing this year.\n",
      "2. Exelixis\n",
      "I view Exelixis (NASDAQ: EXEL) as something of a diamond in the rough. The stock only rose 14% last year, well below the performance of the SPDR S&P Biotech ETF. However, 2021 could be a much better year for Exelixis.\n",
      "The company's crown jewel is Cabometyx, which has already been approved in the U.S. as a first-line treatment for kidney cancer and a second-line treatment for liver cancer. Cabometyx appears to be on track to generate sales of well over $650 million this year. However, the drug isn't close to achieving its full potential yet.\n",
      "Exelixis has a big opportunity with Cabometyx as part of combination therapies. A combo of the drug with Bristol Myers Squibb's Opdivo could win U.S. regulatory approval later this year. Cabometyx also has room to grow in international markets. That seems likely to happen, especially with a recent Japanese approval as a second-line treatment for liver cancer.\n",
      "Thanks to the commercial success of Cabometyx, Exelixis' cash position has improved significantly. And it's putting that cash to use in beefing up its pipeline. In December, the company licensed Iconic Therapeutics' lead antibody-drug conjugate program XB002 as well as experimental cancer drug XL102 from Aurigene, a subsidary of Dr. Reddy's.\n",
      "3. Novavax\n",
      "Interested in a really high-risk, high-reward biotech stock? Check out Novavax (NASDAQ: NVAX). It was one of the biggest winners in 2020 with shares skyrocketing 2,700%. I think Novavax can move even higher this year.\n",
      "Novavax's rise last year was fueled mainly by rapid progress for its COVID-19 vaccine candidate NVX-CoV2373. The company's early stage results for the experimental vaccine were so encouraging that some analysts called it potentially best-in-class. Along the way, Novavax picked up more than $2 billion in funding for its coronavirus program and supply deals with several countries.\n",
      "The biotech expects to announce interim results from a late-stage study of NVX-CoV2373 conducted in the U.K. early this year. Novavax initiated a late-stage study of the vaccine candidate in the U.S. and Mexico at the end of December. It's possible that the company could be in a position to file for U.S. emergency use authorization in the second quarter of 2021.\n",
      "Bernstein analyst Ronny Gal projects that Novavax could make $3.8 billion from NVX-CoV2373 this year. The company also has another potential blockbuster candidate that's headed for a regulatory approval filing with experimental flu vaccine NanoFlu. With its market cap still hovering around $8 billion, this high-risk biotech could deliver some big rewards if its clinical studies go well.\n",
      "10 stocks we like better than Novavax\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of November 20, 2020\n",
      "Keith Speights owns shares of Bristol Myers Squibb, SPDR S&P Biotech, and Vertex Pharmaceuticals. The Motley Fool owns shares of and recommends Bristol Myers Squibb and CRISPR Therapeutics. The Motley Fool recommends Exelixis and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Investors in Zymeworks Inc (Symbol: ZYME) saw new options begin trading this week, for the July 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYME options chain for the new July 2021 contracts and identified one put and one call contract of particular interest.\n",
      "The put contract at the $40.00 strike price has a current bid of $10.60. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $40.00, but will also collect the premium, putting the cost basis of the shares at $29.40 (before broker commissions). To an investor already interested in purchasing shares of ZYME, that could represent an attractive alternative to paying $45.01/share today.\n",
      "Because the $40.00 strike represents an approximate 11% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 69%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 26.50% return on the cash commitment, or 40.65% annualized  at Stock Options Channel we call this the YieldBoost.\n",
      "Below is a chart showing the trailing twelve month trading history for Zymeworks Inc, and highlighting in green where the $40.00 strike is located relative to that history:\n",
      "Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of $10.70. If an investor was to purchase shares of ZYME stock at the current price level of $45.01/share, and then sell-to-open that call contract as a \"covered call,\" they are committing to sell the stock at $50.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 34.86% if the stock gets called away at the July 2021 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ZYME shares really soar, which is why looking at the trailing twelve month trading history for Zymeworks Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ZYME's trailing twelve month trading history, with the $50.00 strike highlighted in red:\n",
      "Considering the fact that the $50.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 48%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 23.77% boost of extra return to the investor, or 36.46% annualized, which we refer to as the YieldBoost.\n",
      "The implied volatility in the put contract example is 124%, while the implied volatility in the call contract example is 117%.\n",
      "Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $45.01) to be 65%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.\n",
      "Top YieldBoost Calls of the S&P 500 \n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes were set to open sharply higher on Wednesday as the race for the White House went down to the wire, although investors remained worried about the prospect of a contested result. .N\n",
      "At 9:01 ET, Dow e-minis 1YMc1 were up 0.56% at 27,529. S&P 500 e-minis ESc1 were up 1.80% at 3,422, while Nasdaq 100 e-minis NQc1 were up 3.60% at 11,671.25. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Zymeworks ZYME.N, up 17.1% ** Uber Technologies UBER.N, up 12.5% ** Azek Company AZEK.N, up 11.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Everest Re Group RE.N, down 14.2% ** Clearwater Paper CLW.N, down 13.1% ** Nabors Industries NBR.N, down 8.1% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Digirad Corp DRAD.O, up 27.4% ** Lordstown Motors Equity Warrant RIDEW.O, up 19.1% ** Hall of Fame Resort & Entertainment Co HOFVW.O, up 19.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Infrastructure and Energy Alternatives IEAWW.O, down 23.1% ** Kura Oncology KURA.O, down 14.6% ** Allogene Therapeutics ALLO.O, down 13.4%\n",
      "** Alibaba BABA.N: up 1.5% premarket BUZZ-Remains top internet mega-cap pick\n",
      "** Digirad Corp DRAD.O: up 27.4% premarket BUZZ-Digirad gains on sale of mobile healthcare unit ** Goldman Sachs GS.N: down 0.6% premarket ** JPMorgan Chase & Co JPM.N: down 1.4% premarket ** Morgan Stanley MS.N: down 0.8% premarket BUZZ-U.S. big banks track Treasury yields lower on election uncertainty ** Enphase ENPH.O: down 3.1% premarket ** Sunpower SPWR.O: down 5.6% premarket ** First Solar FSLR.O: down 4.7% premarket ** Solaredge SEDG.O: down 2.8% premarket BUZZ-U.S. solar energy stocks fall as election race tightens ** Uber Technologies Inc UBER.N: up 12.5% premarket ** Lyft Inc LYFT.O: up 17.4% premarket BUZZ-Jumps after winning bid to keep California drivers as contractors ** Chevron Corp CVX.N: up 0.5% premarket ** Exxon Mobil Corp XOM.N: up 0.8% premarket ** Occidental Petroleum OXY.N: up 1.1% premarket BUZZ-Oil stocks up as crude rises after Trump falsely claims victory in U.S. election ** UnitedHealth UNH.N: up 6.9% premarket ** CVS Health Corp CVS.N: up 2.0% premarket BUZZ-Health insurers rise amid ongoing tight U.S. election race ** Apple Inc AAPL.O: up 3.5% premarket ** Amazon.com Inc AMZN.O: up 3.9% premarket ** Alphabet Inc GOOGL.O: up 3.9% premarket ** Netflix Inc NFLX.O: up 3.0% premarket BUZZ-Big Tech jumps amid tightening White House race\n",
      "** Supernus Pharma SUPN.O: up 16.8% premarket BUZZ-Jumps as seizure medication drives strong Q3 results ** Tabula Rasa HealthCare TRHC.O: down 8.5% premarket BUZZ-Tabula Rasa HealthCare down on revenue fall ** Mercury Systems MRCY.O: down 6.0% premarket BUZZ-Slips on lower Q1 profit as expenses rise ** Nabors Industries Ltd NBR.N: down 8.1% premarket BUZZ-Slips after Q3 revenue misses estimates ** Roku ROKU.O: up 3.2% premarket BUZZ-Rises as brokerage raises PT ahead of Q3 results ** Super Micro Computer SMCI.O: up 14.6% premarket BUZZ-Up on earnings beat for Q1 ** Fox Corp FOXA.O: up 1.7% premarket BUZZ-Fox Corp rises after brokerages turn bullish after upbeat Q1 ** Vertiv Holdings VRT.N: up 5.0% premarket BUZZ-Vertiv Holdings rises on Q3 revenue beat\n",
      "(Compiled by Arundhati Sarkar in Bengaluru)\n",
      "((Arundhati.Sarkar@thomsonreuters.com; twitter.com/Arundhati_05; +1 Ext: 2776;))\n",
      "\n",
      "When it comes to astronomical returns in investing, one of the most important factors -- aside from buying the right company -- is buying your shares early, when ordinary people have never heard of the stock. Of course, there is a danger in being too early. But you can guard against that danger by starting with just a small investment and adding more shares when you see more and more success.\n",
      "This sort of early-stage investing is very similar to the venture capital industry. Maybe one or two of three stocks will fail, but those small losses are irrelevant if and when the third stock has a 1,000% return. Here's why Ontrak (NASDAQ: OTRK), Nano-X Imaging (NASDAQ: NNOX), and Zymeworks (NYSE: ZYME) are all strong candidates for stratospheric outperformance by 2025. Image source: Getty Images.\n",
      "Will Ontrak overtake Livongo Health?\n",
      "Ontrak is competing with market leader Livongo Health (NASDAQ: LVGO) in a new virtual niche that marries the internet with healthcare knowledge. These companies send virtual text messages to people who have chronic medical conditions such as diabetes. Health insurance companies love such services because they help change patient behavior, which keeps a disease from getting more serious (and more expensive).\n",
      "Both of these stocks have been on fire in 2020. Livongo's stock has jumped almost 400% this year, thanks in part to the company's surprise acquisition by Teladoc Health. This merger has opened the door for Ontrak, which is now the largest pure play in this space. At the beginning of the year, Ontrak's shares sold for $16 -- now they are going for $62. As first-mover, Livongo has definite advantages and a big head start. Yet because of the merger, it's unclear whether the Livongo brand name will even exist in five years. Meanwhile, Ontrak is coming on fast. While Livongo is dominant right now in diabetes coaching, Ontrak is heading into new verticals like congestive heart failure and COPD. The future looks very bright for Ontrak. Image source: Nano-X.\n",
      "Is the X-ray market about to be disrupted?\n",
      "Nano-X Imaging is a newly public company using technology developed by Sony to disrupt the X-ray and other medical imaging systems. Nano-X offers a new, miniaturized system that's far simpler than the big, cumbersome X-ray machines and CAT scan machines hospitals use today. Your average CAT scan device weighs over 4,000 pounds. Nano-X's ARC weighs in at a little over 150 pounds.\n",
      "What's even nicer is that the new device is far cheaper, too. While traditional medical imaging systems cost $1 million to $3 million, Nano-X will be dramatically undercutting this market on price. It can manufacture its ARC device for $10,000.\n",
      "For stock investors, what's really exciting about this company is the business plan. Nano-X wants to sell its device at cost, or below cost, in order to make its system far more ubiquitous. The company will make its money by taking a small percentage every time the device is used. The near-term goal is to distribute 15,000 of these ARC devices around the world.\n",
      "At $10,000 a pop in manufacturing costs, the company will need about $150 million to execute its plan. (Nano-X raised approximately $153 million in its very recent initial public offering.) The stock had a huge run-up but suffered a nasty fall this week after short-selling outfit Citron Research called the company a \"fraud.\" Like most rule-breaking companies, it will likely be a highly volatile stock, with major price swings up and some scary drops. The major issue facing this company -- maybe the only serious worry -- is how well this device works. Is this nano-device good enough to outperform all those million-dollar CAT scan and X-ray machines?\n",
      "Recall that this technology was first developed by Sony, one of the world leaders in miniaturization. Sony spent over 15 years developing the ARC system. Also relevant: SK Telecom is a big investor in Nano-X. The Korean telecom giant has plans to distribute 2,500 of the company's systems in Korea and Vietnam next year, pending approval by regulatory authorities. The ARC device has yet to be approved by the FDA. But if it is approved, medical imaging might just get a lot simpler, easier, and cheaper. We might have to invent a new category for this one: hardware-as-a-service (HaaS).\n",
      "Why is big pharma so desperate to collaborate with Zymeworks?\n",
      "Zymeworks is a biotech company that has a trio of platform technologies that help with drug discovery. The company's Azymetric platform helps scientists find multifunctional therapeutics that can reach more than one target. The Effect platform helps researchers customize and optimize immune response. And Zymelink is the company's next-gen antibody drug conjugate (ADC) platform. While Zymeworks has its own pipeline of drug candidates, what really stands out about the company is the remarkable number of collaborators who have signed up to use its platform technology. This is a tiny biopharma company, with a market cap of less than $2 billion. And yet look at its client roster:\n",
      "COLLABORATOR MARKET CAP NUMBER OF DRUG CANDIDATES TO BE FOUND PLATFORM SUBSCRIPTION(S)\n",
      "Johnson & Johnson $390 billion Up to 6 Azymetric, Effect\n",
      "Merck $216 billion Up to 7 Azymetric, Effect\n",
      "Eli Lilly $144 billion 1 Azymetric\n",
      "Bristol Myers Squibb $134 billion Up to 10 Azymetric, Effect\n",
      "GlaxoSmithKline $98 billion Up to 6 Azymetric\n",
      "Daiichi Sankyo $61 billion Up to 3 Azymetric, Effect\n",
      "BeiGene $23 billion Up to 3 Azymetric, Effect\n",
      "That's a who's who of big pharma, all eager to use this tiny company's platforms in the development of 36 drug candidates. Of course, almost all of these drugs are still in preclinical trials. But it's rather shocking to imagine how big the Zymeworks pharmaceutical pipeline will be in five years. The company has revenue-sharing agreements in place with all of these companies. This is not only a validation of Zymeworks' science, but also a major source of future revenue streams.\n",
      "Not surprisingly, Zymeworks is also using its technology platforms to find its own drug candidates that it will keep in-house. The company's lead molecule, zanidatamab, is being evaluated as a best-in-class treatment for patients with HER2-expressing cancers, including breast cancer. The drug is currently being evaluated in phase 1 and phase 2 trials. The FDA has given the molecule two separate fast-track designations.\n",
      "Over the next five years, as many of these drug candidates move out of the lab and into clinical trials, the valuation of Zymeworks should increase dramatically. While it's early in this company's journey, its drug research platforms should unlock immense value in the years to come.\n",
      "10 stocks we like better than Ontrak, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Ontrak, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of August 1, 2020 Taylor Carmichael owns shares of Nano-X Imaging Ltd. and Ontrak, Inc. The Motley Fool owns shares of and recommends Bristol Myers Squibb, Livongo Health Inc, and Teladoc Health. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's major indexes climbed on Monday on a boost from technology stocks while signs of progress in developing a COVID-19 vaccine and a spurt of multi-billion dollar deals also brightened the mood. .N\n",
      "At 13:14 ET, the Dow Jones Industrial Average .DJI was up 1.30% at 28,025.03. The S&P 500 .SPX was up 1.45% at 3,389.48 and the Nasdaq Composite .IXIC was up 1.78% at 11,046.828. The top three S&P 500 .PG.INX percentage gainers: ** Tapestry Inc , up 9.7% ** Incyte Corp , up 7.4% ** Apartment Investment and Management Company , up 7.3% The top three S&P 500 .PL.INX percentage losers: ** Kroger Co , down 4% ** Coty Inc , down 3.8% ** J.B. Hunt Transport Services Inc , down 2.2% The top three NYSE .PG.N percentage gainers: ** Select Energy Services Inc , up 23.8% ** Nam Tai Property NTP.N, up 16% ** Zymeworks Inc , up 15.1% The top three NYSE .PL.N percentage losers: ** Graf Industrial Corp GRAF.N, down 10.7% ** Tortoise Acquisition Corp , down 10.9% ** Barnes & Noble Education Inc , down 6.4% The top three Nasdaq .PG.O percentage gainers: ** Immunomedics Inc , up 99.9% ** Cassava Sciences Inc , up 87.5% ** Vaxart Inc , up 46.9% The top three Nasdaq .PL.O percentage losers: ** Nano-X Imaging Ltd , down 14.9% ** Groupon Inc , down 11.8% ** Co-Diagnostics Inc , down 11.7% ** Kroger Co KR.N: down 4.0%\n",
      "BUZZ-Street View: Kroger's H2 looks strong, but COVID-19 risks remain ** Boeing Co BA.N: up 2.6%\n",
      "BUZZ-Rises ahead of key 737 MAX training review begins in London ** Oracle Corp ORCL.N: up 4.7%\n",
      "BUZZ-Oracle confirms being part of TikTok's proposal to govt, shares rise ** Nvidia Corp NVDA.O: up 4.7%\n",
      "BUZZ-Climbs on $40 bln deal for chip designer Arm ** J.Jill Inc JILL.N: up 26.1%\n",
      "BUZZ-Soars as lenders agree to out-of-court financial restructuring terms ** Gilead Sciences Inc GILD.O: up 3.7%\n",
      "BUZZ-Street View: Gilead's $21 bln deal should cement its foothold in cancer portfolio ** Merck & Co Inc MRK.N: up 1.0% ** Pfizer Inc PFE.N: up 3.5%\n",
      "BUZZ-No imminent threat to U.S. drugmakers from Trump drug pricing order - Evercore ** Town Sports International Inc CLUB.O: down 1.4%\n",
      "BUZZ-Drops on bankruptcy filing ** Seattle Genetics Inc SGEN.O: up 14.2%\n",
      "BUZZ-Jumps on Merck deal for cancer therapies ** Scientific Games Corp SGMS.O: up 13.1%\n",
      "BUZZ-surges as Caledonia-led group to take 34.9% stake ** Mallinckrodt Plc MNK.N: down 3.8%\n",
      "BUZZ-Falls after U.S. FDA declines to approve kidney treatment ** Sorrento Therapeutics Inc SRNE.O: up 14.7%\n",
      "BUZZ-Rises on license deal with Mayo Clinic for potential cancer treatments ** Nikola Corporation NKLA.O: up 14.4%\n",
      "BUZZ-Pares losses after strong rebuttal to short-seller report ** Incyte Corp INCY.O: up 7.4%\n",
      "BUZZ-Rises on positive data from potential COVID-19 drug combination trial ** Cassava Sciences Inc SAVA.O: up 87.5%\n",
      "BUZZ-Nearly doubles on positive data on lead Alzheimer's treatment ** Vaxart Inc VXRT.O: up 43.5%\n",
      "BUZZ-Rises on FDA nod for human study of potential COVID-19 vaccine ** Pfizer Inc PFE.N: up 3.5% ** BioNTech SE BNTX.O: up 4.7%\n",
      "BUZZ-Pfizer, Biontech rise on proposed expansion of COVID-19 vaccine trial enrollment ** Dynavax Technologies Corp DVAX.O: up 16.0%\n",
      "BUZZ-Rises on supply deal for COVID-19 vaccine development ** GameStop Corp GME.N: up 9.7%\n",
      "BUZZ-Jumps after brokerage upgrades on upcoming console launches ** InflaRx NV IFRX.O: up 14.7%\n",
      "BUZZ-Jumps on starting late-stage trial of potential COVID-19 treatment ** AutoZone Inc AZO.N: up 0.6%\n",
      "BUZZ-Wells Fargo likes risk/reward with stock 'stuck in the mud' ** Myovant Sciences Inc MYOV.N: up 7.0%\n",
      "BUZZ-Rises on positive study results in uterine fibroids treatment ** 89bio ETNB.O: up 7.7%\n",
      "BUZZ-Rises on positive results from liver disease treatment's early study ** Trevana Inc TRVN.O: up 20.5%\n",
      "BUZZ-Guggenheim bets on co's opioid painkiller, initiates with 'buy' ** Ziopharm Oncology Inc ZIOP.O: up 13.6%\n",
      "BUZZ-Up as rare brain tumor therapy gets FDA tag ** Verizon Communications Inc VZ.N: up 1.3%\n",
      "BUZZ-To buy Tracfone in $6.25 bln deal, shares rise ** Dow Inc DOW.N: up 0.5%\n",
      "BUZZ-Rises on plans to sell some U.S. Gulf Coast ops for $620 mln ** Delta Air Lines Inc DAL.N: up 2.6%\n",
      "BUZZ-Pledges loyalty program to raise $6.5 bln; shares rise ** Kala Pharmaceuticals Inc KALA.O: down 9.8%\n",
      "BUZZ-Slides as Jefferies downgrades on high cost of eye disease therapy ** Marinus Pharmaceuticals Inc MRNS.O: up 4.5%\n",
      "BUZZ-Gains on $84 mln contract for nerve agent-induced seizure drug ** Tempur Sealy International Inc TPX.N: up 8.1%\n",
      "BUZZ-Bounces on upbeat Q3 sales forecast ** Mogu Inc MOGU.N: up 13.2%\n",
      "BUZZ-Soars on $10 mln share buyback program ** CoreLogic Inc CLGX.N: up 1.2%\n",
      "BUZZ-Rises after Cannae Holdings, Senator Investment sweeten buyout bid ** OneWater Marine Inc ONEW.O: down 11.1%\n",
      "BUZZ-Slides on proposed equity offering ** Newmont Corp NEM.N: up 1.1% ** AngloGold Ashanti Ltd AU.N: up 3.3%\n",
      "BUZZ-Gold miners rise on weaker dollar, dovish U.S. Fed policy hopes USN ** Regeneron Pharmaceuticals Inc REGN.O: up 3.3%\n",
      "BUZZ-Up as co's treatment to be included in largest COVID-19 drug trial ** Adobe Systems Inc ADBE.O: up 2.4%\n",
      "BUZZ-Rises as Morgan Stanley lifts PT ahead of results ** DraftKings Inc DKNG.O: up 12.1%\n",
      "BUZZ-Rises on content integration agreement with ESPN ** Photronics Inc PLAB.O: up 6.5%\n",
      "BUZZ-Rises on $100 mln share buyback program\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "up 0.81%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "up 0.83%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 0.73%\n",
      "Energy\n",
      ".SPNY\n",
      "up 1.32%\n",
      "Financial\n",
      ".SPSY\n",
      "up 1.96%\n",
      "Health\n",
      ".SPXHC\n",
      "up 1.77%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 1.45%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "up 1.76%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 1.41%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 2.33%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "up 1.46%\n",
      "(Compiled by Shivani Kumaresan in Bengaluru)\n",
      "((Shivani.Kumaresan@thomsonreuters.com ; +1 ))\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks opened higher on Monday on signs of progress in developing a COVID-19 vaccine and a flurry of multi-billion dollar deals, including reports of Oracle winning the battle for the U.S. arm of TikTok. .N\n",
      "At 9:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.59% at 27,829.28. The S&P 500 .SPX was up 0.98% at 3,373.59 and the Nasdaq Composite .IXIC was up 1.42% at 11,007.598. The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp , up 7.7% ** Micron Technology Inc , up 6.1% ** Oracle Corp , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Kroger Co , down 3.3% ** Occidental Petroleum Corp , down 2.2% ** Apache Corp , down 1.9% The top three NYSE .PG.N percentage gainers: ** Zymeworks Inc , up 13.7% ** Adc Therapeutics SA ADCT.N, up 11.7% ** GameStop Corp , up 11.7% The top three NYSE .PL.N percentage losers: ** Scully Royalty Ltd , down 8% ** U.S. Silica Holdings Inc , down 5.2% ** Tortoise Acquisition Corp , down 6.4% The top three Nasdaq .PG.O percentage gainers: ** Cassava Sciences Inc , up 100.9% ** Immunomedics Inc , up 105.3% ** Scientific Games Corp , up 37.5% The top three Nasdaq .PL.O percentage losers: ** Nano-X Imaging Ltd , down 13.4% ** Origin Bancorp Inc , down 9.6% ** Kala Pharmaceuticals Inc , down 8.9% ** Kroger Co KR.N: down 3.3%\n",
      "BUZZ-Street View: Kroger's H2 looks strong, but COVID-19 risks remain ** Oracle Corp ORCL.N: up 4.3%\n",
      "BUZZ-Eyes record high on ByteDance partnership report; other bidders slip ** Nvidia Corp NVDA.O: up 7.8%\n",
      "BUZZ-Climbs on $40 bln deal for chip designer Arm ** J.Jill Inc JILL.N: up 54.2%\n",
      "BUZZ-Soars as lenders agree to out-of-court financial restructuring terms ** Merck & Co Inc MRK.N: up 0.3% ** Pfizer Inc PFE.N: up 1.2%\n",
      "BUZZ-No imminent threat to U.S. drugmakers from Trump drug pricing order - Evercore ** Town Sports International Inc CLUB.O: down 21.6%\n",
      "BUZZ-Drops on bankruptcy filing ** Seattle Genetics Inc SGEN.O: up 10.2%\n",
      "BUZZ-Jumps on Merck deal for cancer therapies ** Scientific Games Corp SGMS.O: up 36%\n",
      "BUZZ-surges as Caledonia-led group to take 34.9% stake ** Mallinckrodt Plc MNK.N: down 5.8%\n",
      "BUZZ-Falls after U.S. FDA declines to approve kidney treatment ** Sorrento Therapeutics Inc SRNE.O: up 5.2%\n",
      "BUZZ-Rises on license deal with Mayo Clinic for potential cancer treatments ** Incyte Corp INCY.O: up 3.3%\n",
      "BUZZ-Rises on positive data from potential COVID-19 drug combination trial ** Cassava Sciences Inc SAVA.O: up 100.9%\n",
      "BUZZ-Nearly doubles on positive data on lead Alzheimer's treatment ** Vaxart Inc VXRT.O:up 14%\n",
      "BUZZ-Rises on FDA nod for human study of potential COVID-19 vaccine ** Pfizer Inc PFE.N: up 1.2% ** BioNTech SE BNTX.O: up 6.3%\n",
      "BUZZ-Pfizer, BioNTech rise on proposed expansion of COVID-19 vaccine trial enrollment ** Dynavax Technologies Corp DVAX.O: up 8.9%\n",
      "BUZZ-Rises on supply deal for COVID-19 vaccine development ** GameStop Corp GME.N: up 10.8%\n",
      "BUZZ-Jumps after brokerage upgrades on upcoming console launches ** InflaRx NV IFRX.O: up 6.3%\n",
      "BUZZ-Jumps on starting late-stage trial of potential COVID-19 treatment ** AutoZone Inc AZO.N: up 0.4%\n",
      "BUZZ-Wells Fargo likes risk/reward with stock 'stuck in the mud'\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "up 0.83%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "up 1.11%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 0.20%\n",
      "Energy\n",
      ".SPNY\n",
      "down 0.49%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.57%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.85%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 0.50%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "up 1.77%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 0.67%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 0.79%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "up 0.53%\n",
      "(Compiled by Shivani Kumaresan in Bengaluru)\n",
      "((Shivani.Kumaresan@thomsonreuters.com ; +1 ))\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 was largely flat in afternoon trading on Friday towards the end of another volatile week as investors weighed Oracle's strong results against data that suggested a long and wobbly economic revival from a coronavirus-led downturn. .N\n",
      "At 13:30 p.m. ET, the Dow Jones Industrial Average .DJI was up 0.04% at 27,544.67. The S&P 500 .SPX was down 0.46% at 3,323.68 and the Nasdaq Composite .IXIC was down 1.23% at 10,785.08. The top three S&P 500 .PG.INX percentage gainers: ** Howmet Aerospace Ord , up 5.4% ** Under Armour Inc , up 5% ** Huntington Ingalls Industries Inc , up 4.8% The top three S&P 500 .PL.INX percentage losers: ** NortonLifeLock Inc , down 6.9% ** Darden Restaurants Inc , down 4.5% ** Expedia Group Inc , down 4.4% The top three NYSE .PG.N percentage gainers: ** Daqo New Energy Corp , up 17% ** Zymeworks Inc , up 13.7% ** Sachem Capital Corp , up 12.2% The top three NYSE .PL.N percentage losers: ** Brigham Minerals Inc , down 12.1% ** Revolve Group Inc , down 11.6% ** Cohen & Company Inc , down 10.7% The top three Nasdaq .PG.O percentage gainers: ** A-Mark Precious Metals Inc AMRK.O, up 22.7% ** Clearone Inc CLRO.O, up 20.9% ** Natural Health Trends Corp , up 20.9% The top three Nasdaq .PL.O percentage losers: ** Creatd Inc Ord , down 54.7% ** Amyris Inc , down 26.8% ** Evofem Biosciences Inc , down 21.5% ** Satsuma Pharmaceuticals Inc STSA.O: down 15.7%\n",
      "BUZZ-Credit Suisse double downgrades, lowest PT in Street ** Amyris Inc AMRS.O: down 26.8%\n",
      "BUZZ-Falls as LAVVAN files $881 mln lawsuit citing patent infringement ** Social Capital Hedosophia Holdings II Corp IPOB.N: up 0.3%\n",
      "BUZZ-Social Capital Hedosophia II looking to take Opendoor public, shares jump ** Northern Oil and Gas Inc NOG.A: up 7.6%\n",
      "BUZZ-Soars after buying producing assets in Delaware Basin ** Brigham Minerals Inc MNRL.N: down 12.1%\n",
      "BUZZ-Brigham Minerals slides as Warburg Pincus sells remaining stake ** LightPath Technologies Inc LTPH.O: up 3.3%\n",
      "BUZZ-Shines on strong Q4 results ** Chewy Inc CHWY.N: down 8.3%\n",
      "BUZZ-Falls on warning of higher H2 costs due to COVID-19 ** Daqo New Energy Corp DQ.N: up 16.6%\n",
      "BUZZ-Rises as unit submits IPO application on China's STAR market ** i3 Verticals Inc IIIV.O: down 6.9%\n",
      "BUZZ-Down after co prices stock offering ** Spero Therapeutics Inc SPRO.O: down 11.1%\n",
      "BUZZ-Drops after pricing stock offering ** Eastman Kodak Co KODK.N: up 5.2%\n",
      "BUZZ-Set for best day in two weeks ** BioTelemetry Inc BEAT.O: up 6.4%\n",
      "BUZZ-Needham begins with 'buy' on robust growth drivers ** Zumiez Inc ZUMZ.O: up 10.5%\n",
      "BUZZ-Rises as skateboard demand drives Q2 results beat ** Town Sports International Holdings Inc CLUB.O: down 18.4%\n",
      "BUZZ-Drops as report says co plans to file for bankruptcy ** Intra-Cellular Therapies Inc ITCI.O: down 12.6%\n",
      "BUZZ-Drops on $350 mln equity raise ** Nikola Corporation NKLA.O: down 16.0%\n",
      "BUZZ-Citron sides with Hindenburg on Nikola short, shares slump ** MediciNova Inc MNOV.O: up 1.7%\n",
      "BUZZ-Rises on positive data from partner's COVID-19 vaccine ** World Wrestling Entertainment Inc WWE.N: down 2.9%\n",
      "BUZZ-Wells Fargo cuts PT to Street low on higher costs ** Travelers Cos TRV.N: up 1.1%\n",
      "BUZZ-Wells Fargo upgrades, raises PT on lift from hard market dynamics ** Atara Biotherapeutics Inc ATRA.O: up 4.1%\n",
      "BUZZ-Rises on positive early-stage multiple sclerosis therapy study results ** VBL Therapeutics Ltd VBLT.O: up 11.4%\n",
      "BUZZ-Rises on positive data from multiple sclerosis treatment trial ** Muscle Maker Inc GRIL.O: down 14.1%\n",
      "BUZZ-Slides on discounted follow-on offer ** Laureate Education Inc LAUR.O: up 10.2%\n",
      "BUZZ-Jumps on $1.48 bln deal to sell Walden University ** Biofrontera AG BFRA.O: up 13.4%\n",
      "BUZZ-Jumps on plans to resolve legal disputes with shareholders ** Vroom Inc VRM.O: down 8.3%\n",
      "BUZZ-Vroom skids after equity raise ** Hologic Inc HOLX.O: up 3.1%\n",
      "BUZZ-Rises on increased demand for its COVID-19 tests ** Cinedigm Corp CIDM.O: up 29.1%\n",
      "BUZZ-Jumps on move to reduce total debt ** SAGE Therapeutics SAGE.O: up 2.9%\n",
      "BUZZ-Analysts see 'reason for optimism' in drug pipeline ** Tesla Inc TSLA.O: down 1.4%\n",
      "BUZZ-Reverses course to trade higher after Musk tweets about 'Battery Day' ** Forterra Inc FRTA.O: up 12.3%\n",
      "BUZZ-Jumps on favorable decision in arbitration proceeding ** Castor Maritime Inc CTRM.O: up 5.5%\n",
      "BUZZ-Rises on Q2 revenue jump ** Cognizant Technology Solutions Corp CTSH.O: up 3.4%\n",
      "BUZZ-Rises after BofA upgrades on digital push ** Thermo Fisher Scientific Inc TMO.N: up 2.7%\n",
      "BUZZ-Climbs a day after it boosts growth estimates\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "down 0.83%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "down 0.76%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 0.22%\n",
      "Energy\n",
      ".SPNY\n",
      "down 0.33%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.34%\n",
      "Health\n",
      ".SPXHC\n",
      "down 0.05%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 0.91%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "down 1.43%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 0.92%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "down 0.78%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "down 0.19%\n",
      "(Compiled by Shivani Kumaresan in Bengaluru)\n",
      "((Shivani.Kumaresan@thomsonreuters.com ; +1 ))\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Friday, after a pullback in the previous session, as Oracle's solid quarterly results underscored the resilience of tech-related companies during the coronavirus crisis. .N\n",
      "At 10:30 a.m. ET, the Dow Jones Industrial Average .DJI was up 0.55% at 27,686.84. The S&P 500 .SPX was up 0.44% at 3,353.94 and the Nasdaq Composite .IXIC was up 0.35% at 10,957.606. The top three S&P 500 .PG.INX percentage gainers: ** Cognizant Technology Solutions Corp , up 5.1% ** PerkinElmer Inc , up 4% ** Western Digital Corp , up 3.8% The top three S&P 500 .PL.INX percentage losers: ** NortonLifeLock Inc , down 6.5% ** Darden Restaurants Inc , down 3.3% ** Host Hotels & Resorts Inc , down 2.9% The top three NYSE .PG.N percentage gainers: ** Zymeworks Inc , up 12.5% ** Daqo New Energy Corp , up 11.8% ** Teck Resources Ltd , up 9.3% The top three NYSE .PL.N percentage losers: ** Brigham Minerals Inc , down 12.9% ** Blue Apron Holdings Inc , down 7.7% ** Revolve Group Inc , down 7% The top three Nasdaq .PG.O percentage gainers: ** BioFrontera AG , up 31% ** Wilhelmina International Inc , up 23.9% ** Checkpoint Therapeutics Inc , up 26.1% The top three Nasdaq .PL.O percentage losers: ** Jerrick Media Holdings Inc , down 51.3% ** Evofem Biosciences Inc , down 21.6% ** Amyris Inc , down 17.7% ** Satsuma Pharmaceuticals Inc STSA.O: down 10.3%\n",
      "BUZZ-Credit Suisse double downgrades, lowest PT in Street ** Peloton Interactive Inc PTON.O: up 3.3%\n",
      "BUZZ-Rises as strong revenue, outlook prompt PT hikes ** Amyris Inc AMRS.O: down 17.7%\n",
      "BUZZ-Falls as LAVVAN files $881 mln lawsuit citing patent infringement ** Northern Oil and Gas Inc NOG.A: up 4.9%\n",
      "BUZZ-Soars after buying producing assets in Delaware Basin ** Brigham Minerals Inc MNRL.N: down 12.7%\n",
      "BUZZ-Brigham Minerals slides as Warburg Pincus sells remaining stake ** LightPath Technologies Inc LTPH.O: up 3.5%\n",
      "BUZZ-Shines on strong Q4 results ** Chewy Inc CHWY.N: down 5.7%\n",
      "BUZZ-Falls on warning of higher H2 costs due to COVID-19 ** Daqo New Energy Corp DQ.N: up 11.5%\n",
      "BUZZ-Rises as unit submits IPO application on China's STAR market ** iRhythm Technologies Inc IRTC.O: up 0.7%\n",
      "BUZZ-Near-term revenue growth priced in, Needham says ** i3 Verticals Inc IIIV.O: down 7.6%\n",
      "BUZZ-Down after co prices stock offering ** Spero Therapeutics Inc SPRO.O: down 8.7%\n",
      "BUZZ-Drops after pricing stock offering ** Eastman Kodak Co KODK.N: up 3.9%\n",
      "BUZZ-Set for best day in two weeks ** Oracle Corp ORCL.N: up 3.3%\n",
      "BUZZ-Rises as brokerages raise PT after Q1 results beat ** BioTelemetry Inc BEAT.O: up 7.2%\n",
      "BUZZ-Needham begins with 'buy' on robust growth drivers ** Zumiez Inc ZUMZ.O: up 16.0%\n",
      "BUZZ-Rises as skateboard demand drives Q2 results beat ** Town Sports International Holdings Inc CLUB.O: down 12.1%\n",
      "BUZZ-Drops as report says co plans to file for bankruptcy ** Intra-Cellular Therapies Inc ITCI.O: down 7.6%\n",
      "BUZZ-Drops on $350 mln equity raise ** Nikola Corporation NKLA.O: down 15.3%\n",
      "BUZZ-Refutes short-seller's allegations, considers legal recourse ** MediciNova Inc MNOV.O: up 2.2%\n",
      "BUZZ-Rises on positive data from partner's COVID-19 vaccine ** World Wrestling Entertainment Inc WWE.N: down 1.4%\n",
      "BUZZ-Wells Fargo cuts PT to Street low on higher costs ** Travelers Cos TRV.N: up 0.9%\n",
      "BUZZ-Wells Fargo upgrades, raises PT on lift from hard market dynamics ** Atara Biotherapeutics Inc ATRA.O: up 10.7%\n",
      "BUZZ-Rises on positive early-stage multiple sclerosis therapy study results ** VBL Therapeutics Ltd VBLT.O: up 6.0%\n",
      "BUZZ-Rises on positive data from multiple sclerosis treatment trial ** Muscle Maker Inc GRIL.O: down 8.0%\n",
      "BUZZ-Slides on discounted follow-on offer\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "up 0.44%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "up 0.43%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 0.45%\n",
      "Energy\n",
      ".SPNY\n",
      "up 0.59%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.32%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.45%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 1.06%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "up 0.33%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 1.09%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 0.04%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "down 0.21%\n",
      "(Compiled by Shivani Kumaresan in Bengaluru)\n",
      "((Shivani.Kumaresan@thomsonreuters.com ; +1 ))\n",
      "\n",
      "InvestorPlace - Stock Market News, Stock Advice & Trading Tips\n",
      "Second-quarter results for Merck (NYSE:MRK) are in and Merck stockholders can breathe a sigh of relief. MRK stock gained 1.6% after announcing better than expected results on Friday, ending its 2-day negative streak at the stock market.\n",
      "Source: JHVEPhoto / Shutterstock.com\n",
      "The star was yet again the oncology division, which continues to prove the naysayers wrong.\n",
      "For the first decade of the new millennium, the company faced immense challenges with regards to settlements, loss of patents, and divestitures. It shed 47% of its value during that period.\n",
      "However, the opposite has transpired in this decade. Merck gained 118.6% led by the success of its hugely successful therapeutics business over the past five years. It has ambitious plans to invest over $19 billion to expand capacity over the next three years and restructuring its business to increase its profitability.\n",
      "Stellar Second-Quarter Results\n",
      "Merck investors have a lot to be cheerful about after the pharma giant reported beat Wall Street estimates for its second quarter and subsequently sending shares up 1.6% in early trading.\n",
      "8 5G Stocks to Get Rich Off Our Information Addiction\n",
      "The company reported second-quarter sales of $10.9 billion, beating analyst estimates by an impressive $0.5 billion. Additionally, its earnings per share of MRK stock were $1.37, which comfortably beat estimates of $1.06 per share.\n",
      "Perhaps the most encouraging sign is that Merck has raised yearly guidance, which it had previously lowered due to pressures exerted by the novel coronavirus pandemic. Earnings per share are expected to range from $5.63 to $5.78, which is again higher than analyst estimates of $5.31 per share.\n",
      "Keytrudas Impact Is Felt\n",
      "The stellar performance in the quarter is primarily driven by Mercks blockbuster cancer drug, Keytruda. It sold $3.4 billion in the quarter, up 29% from the same quarter last year. This is no surprise. Oncology is Mercks most successful division, growing more than 770% from 2015 to 2020.\n",
      "Mercks pharmaceutical division, though, took a hit and was down 7% compared to the same quarter last year. The slowdown was triggered by the pandemic, which caused a drop in routine vaccinations and acute care products. Pediatric vaccines, in particular, plummeted 44% while the Gardasil vaccine, which prevents papillomavirus, also dropped 26%.\n",
      "Mercks animal health division saw a modest decrease of 2% in sales.\n",
      "Animal healthcare is set to become one of the top divisions for the company in the future. The market is set to reach $47.31 billion by 2026 growing at a CAGR of 4.9%. Therefore, Merck has been aggressively expanding the division.\n",
      "MRK Stock and Dividends\n",
      "One of the primary concerns for any investor is a companys ability to pay and grow dividends consistently. Merck pays shareholders a quarterly dividend of 61 cents, which is roughly 3% of the MRK stock price.\n",
      "Mercks dividend payout ratio of 48.1% for its latest quarter is significantly lower than the previous three quarters. The ratio is surprising, considering how earning per share for its first quarter 2020 was the highest compared to the previous three quarters.\n",
      "Moreover, the company has generated positive cash flows for the past 10 years, which suggests the dividend is safe.\n",
      "The companys 5-year dividend growth is around 4.5%, which is lower than its competitor average of 6.5%.\n",
      "Merck is not precisely a dividend aristocrat, but it has been increasing dividends consistently since 2012.\n",
      "However, if youre looking for specifically a dividend stock within the sector, I would suggest investing in other companies. One alternative is Abbvie (NYSE: ABBV), which has a dividend growth of 20.7% in the past five years.\n",
      "Exciting Developments Ahead\n",
      "There are several exciting developments ahead for Merck. The first and most talked about topic in the pharma sector this year is a vaccine for Covid-19. Several companies are scrambling to develop vaccine candidates and be a step ahead of the competition.\n",
      "Merck recently made inroads in the race through agreements with Themis, IAVI, and Ridgeback Biotherapeutics.\n",
      "Merck signed an agreement to acquire Themis for an undisclosed amount. Themis focuses on developing vaccine candidates and immune-modulatory therapies using its measles virus vector platform.\n",
      "However, many believe Merck is a little late to the party after the company announced it would begin clinical studies of one of its Covid-19 vaccines by the end of September, and another by the end of this year.\n",
      "On Feb. 5, Merck announced that it was moving its biosimilars, womens health business and legacy brands into a new company. The remaining businesses will be centered around the companys core segments in vaccines, oncology, animal health and hospital segments. This focus is an effort to create more value.\n",
      "The company also posted significant successes in its animal health segment. The FDA has approved Bravecto 1-Month chews for puppies and dogs for the prevention of fleas and ticks.\n",
      "Additionally, Merck entered into an agreement with longtime partner in Zymeworks (NYSE: ZYME) for commercializing up to three specific antibodies in for animal healthcare. Zyme will receive an undisclosed upfront amount up to $411 million in option exercise fees and up to $480 million in milestones.\n",
      "Final Word on MRK Stock\n",
      "Merck is in a great spot heading into the second half of the year with an awesome second quarter. Theere are several projects in the pipeline, which will bear fruit from 2021 and beyond.\n",
      "Additionally, its oncology division  spearheaded by its Keytruda drug  continues to perform exceedingly well and will be a catalyst for the companys growth.\n",
      "Im bullish on MRK stocks prospects at this stage.\n",
      "Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelors of science degree in applied accounting from Oxford Brookes University. As of this writing, Muslim Farooque did not hold a position in any of the aforementioned securities.\n",
      "The post Keytruda Powers a Stellar Q2 for Merck appeared first on InvestorPlace.\n",
      "\n",
      "In trading on Friday, shares of Zymeworks Inc (Symbol: ZYME) crossed below their 200 day moving average of $37.21, changing hands as low as $36.25 per share. Zymeworks Inc shares are currently trading off about 5.1% on the day. The chart below shows the one year performance of ZYME shares, versus its 200 day moving average:\n",
      "Looking at the chart above, ZYME's low point in its 52 week range is $20.33 per share, with $52.75 as the 52 week high point  that compares with a last trade of $36.70.\n",
      "Click here to find out which 9 other stocks recently crossed below their 200 day moving average \n",
      "\n",
      "In trading on Friday, shares of Zymeworks Inc (Symbol: ZYME) crossed below their 200 day moving average of $34.88, changing hands as low as $34.74 per share. Zymeworks Inc shares are currently trading down about 3.9% on the day. The chart below shows the one year performance of ZYME shares, versus its 200 day moving average:\n",
      "Looking at the chart above, ZYME's low point in its 52 week range is $16.80 per share, with $52.75 as the 52 week high point  that compares with a last trade of $35.09.\n",
      "Click here to find out which 9 other stocks recently crossed below their 200 day moving average \n",
      "\n",
      "Keeping tabs on the quarterly activity of billionaire superinvestors can be a great way to unearth hidden gems, or perhaps avoid potential potholes. Billionaires, after all, are rich for a reason. When it comes to the complex but rewarding area of healthcare, Baker Brothers Advisors, a hedge fund run by billionaire brothers Felix and Julian Baker, is without question the best in the game at picking big winners in this volatile sector.\n",
      "While Felix and Julian Baker haven't always been spot on with their healthcare stock picks, they have hit the jackpot numerous times over the years. Some of their best picks to date include top growth stocks like Axsome Therapeutics, Exact Sciences, and GW Pharmaceuticals plc. So when the Baker Brothers start to pour money into a little known healthcare company, it's probably a good idea to take note. Which relatively unknown stocks have the Baker Brothers been quietly gobbling up in 2020? The fund recently disclosed massive buys in Aurinia Pharmaceuticals (NASDAQ: AUPH), Kodiak Sciences (NASDAQ: KOD), and Zymeworks (NYSE: ZYME). Are these biotech growth stocks suitable for everyday investors? Let's dig deeper to find out. Image source: Getty Images.\n",
      "Aurinia: A compelling growth story\n",
      "Aurinia's shares were up by nearly 200% before the COVID-19-induced sell-off. The company's stock has been blasting higher of late in response to the strong showing of its experimental lupus nephritis drug, voclosporin, in a pivotal stage trial. Lupus nephritis is characterized by swelling of the kidneys in patients, mostly women, afflicted with the autoimmune disorder systemic lupus erythematosus.\n",
      "By Aurinia's own estimates, voclosporin would target around 220,000 patients in the United States for this first indication. However, the company also has plans to eventually broaden the drug's label to include both dry eye syndrome and focal segmental glomerulosclerosis, another kidney ailment.\n",
      "The key info is that voclosporin could generate peak sales of approximately $770 million as a treatment for just lupus nephritis. But if Aurinia can successfully add on these two other indications, the drug's peak sales may even top $1.6 billion by the end of the decade. That's quite a haul for a company with a market cap of $1.7 billion at present. What's the opportunity? From an organic sales standpoint, Aurinia's growth story may take a few years to kick into high gear. Most early-commercial-stage biopharmas, after all, tend to struggle to generate sales right out of the gate because of a lack of infrastructure, networking experience, and limited financial resources.\n",
      "The good news is that Aurinia will probably never have to worry about the commercial side of the equation. Aurinia should either attract an eager marketing partner or a full-on takeover bid within the next 12 months, assuming voclosporin sails through its upcoming regulatory review in the United States.\n",
      "That's not a guaranteed outcome, to be sure. But voclosporin is exactly the type of well-differentiated, high-value asset that tends to attract buyers in the world of pharmaceuticals. So if you're comfortable with the risk associated with binary regulatory decisions, Aurinia's stock should definitely be on your radar right now. This stock could easily double by the end of the year, after all. Kodiak: More room to run\n",
      "Kodiak Sciences was one of the best-performing stocks last year, thanks to its experimental wet age-related macular degeneration drug KSI-301. In fact, KSI-301's early-stage results were so impressive that the Baker Brothers decided to strike up a $225 million capped royalty deal with Kodiak. That's certainly an unusual development for a drug that's still a few years away from reaching the market. But it does underscore KSI-301's enormous commercial potential. In short, this experimental eye medication could possibly rack up $3 billion to $4 billion in annual sales by 2030. What's the big deal? Most commercial-stage biopharma stocks trade at no less than three times the peak sales estimates of their flaghship products. So on the low end, Kodiak's shares appear more than capable of gaining another 300%, from current levels, within a few short years. Now, there is still quite a bit of clinical and regulatory risk on the table with this stock. But Kodiak's jaw-dropping upside potential should definitely appeal to the risk-tolerant crowd. Zymeworks: A top cancer play\n",
      "Zymeworks designs and trials cancer-fighting antibodies. The company's shares have been soaring over the past year because of a number of top-flight partnerships with several big pharmas, a large equity financing that shored up its balance sheet, and the steady progress of its lead HER2-positive cancer therapies called ZW25 and ZW49, respectively. Still, Zymework's shares may be an outright steal at current levels, even after the stock's recent run. Point blank: The company's market cap of $1.72 billion doesn't reflect the ginormous commercial potential of its clinical pipeline in any way. What's the risk? Zymeworks is targeting a number of hard-to-treat malginancies, and its pipeline won't produce a commercial-stage product anytime soon. That said, the company's robust pipeline of novel antibodies could attract a suitor in the not-so-distant future. Big pharma has already shown a strong interest in the company's anti-cancer platform, after all. Driving this point home, oncology companies with well-differentiated assets in early- to mid-stage development have consistently been some of the most attractive buyout targets for a number of years now.\n",
      "In all, Zymeworks is a risky biotech stock, to be sure, but the company does have a lot to offer growth-oriented investors. 10 stocks we like better than Aurinia Pharmaceuticals\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Aurinia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of March 18, 2020 George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.\n",
      "\n",
      "In trading on Monday, shares of Zymeworks Inc (Symbol: ZYME) crossed above their 200 day moving average of $33.24, changing hands as high as $35.96 per share. Zymeworks Inc shares are currently trading up about 9.6% on the day. The chart below shows the one year performance of ZYME shares, versus its 200 day moving average:\n",
      "Looking at the chart above, ZYME's low point in its 52 week range is $14.645 per share, with $52.75 as the 52 week high point  that compares with a last trade of $35.66.\n",
      "Click here to find out which 9 other stocks recently crossed above their 200 day moving average \n",
      "\n",
      "Investors in Zymeworks Inc (Symbol: ZYME) saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYME options chain for the new May 15th contracts and identified one put and one call contract of particular interest.\n",
      "The put contract at the $30.00 strike price has a current bid of $2.75. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $30.00, but will also collect the premium, putting the cost basis of the shares at $27.25 (before broker commissions). To an investor already interested in purchasing shares of ZYME, that could represent an attractive alternative to paying $31.79/share today.\n",
      "Because the $30.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 65%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 9.17% return on the cash commitment, or 68.28% annualized  at Stock Options Channel we call this the YieldBoost.\n",
      "Below is a chart showing the trailing twelve month trading history for Zymeworks Inc, and highlighting in green where the $30.00 strike is located relative to that history:\n",
      "Turning to the calls side of the option chain, the call contract at the $35.00 strike price has a current bid of $1.95. If an investor was to purchase shares of ZYME stock at the current price level of $31.79/share, and then sell-to-open that call contract as a \"covered call,\" they are committing to sell the stock at $35.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 16.23% if the stock gets called away at the May 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ZYME shares really soar, which is why looking at the trailing twelve month trading history for Zymeworks Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ZYME's trailing twelve month trading history, with the $35.00 strike highlighted in red:\n",
      "Considering the fact that the $35.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.13% boost of extra return to the investor, or 45.69% annualized, which we refer to as the YieldBoost.\n",
      "The implied volatility in the put contract example is 131%, while the implied volatility in the call contract example is 121%.\n",
      "Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $31.79) to be 58%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.\n",
      "Top YieldBoost Calls of the S&P 500 \n",
      "\n",
      "Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.\n",
      "On Monday, Cadence Bancorporation's Director, Marc J. Shapiro, made a $403,250 purchase of CADE, buying 25,000 shares at a cost of $16.13 a piece. Cadence Bancorporation is trading up about 1.3% on the day Wednesday. This buy marks the first one filed by Shapiro in the past twelve months.\n",
      "And at Zymeworks, there was insider buying on Monday, by Director Troy Cox who bought 7,500 shares for a cost of $46.50 each, for a trade totaling $348,750. Zymeworks is trading up about 6.4% on the day Wednesday.\n",
      "VIDEO: Wednesday 1/29 Insider Buying Report: CADE, ZYME\n",
      "\n",
      "Top Health Care Stocks:\n",
      "JNJ: -0.11%\n",
      "PFE: -0.17%\n",
      "ABT: +0.15%\n",
      "MRK: Flat\n",
      "AMGN: -0.32%\n",
      "Top health care stocks were mixed pre-bell Thursday.\n",
      "Moving stocks include:\n",
      "(+) Co-Diagnostics (CODX), which was surging by over 156% after the company said it has completed principle design work for a PCR screening test for new coronavirus 2019-nCoV, which has spread internationally in recent weeks after first being discovered in Wuhan, China.\n",
      "(-) Tetraphase Pharmaceuticals (TTPH) was down more than 21% after it launched a private placement and registered direct offering for gross proceeds of approximately $17.5 million.\n",
      "(-) Zymeworks (ZYME) was more than 3% lower after pricing its previously announced underwritten common share and pre-funded warrants offering for gross proceeds of approximately $279 million.\n",
      "\n",
      "(RTTNews) - Zymeworks Inc. (ZYME) said it has initiated a Phase 2 trial evaluating ZW25 combination therapy and reached an agreement with Pfizer which advances the study.\n",
      "Zymeworks' HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer's Ibrance, an oral CDK4/6 inhibitor, and the hormone therapy fulvestrant in patients with previously-treated locally advanced and/or metastatic HER2-positive, HR-positive breast cancer.\n",
      "Zymeworks will sponsor the study, and Pfizer will provide palbociclib.\n",
      "The Phase 2 clinical trial is a multicenter, open-label, two-part study. Part one of the study will evaluate the safety and tolerability of ZW25 in combination with palbociclib and fulvestrant and identify the recommended doses (RD) of ZW25 and palbociclib.\n",
      "Part two of the study will evaluate anti-tumor activity at the RD level. The trial will enroll up to 76 patients at sites in the United States and Canada, and expansion to Spain is planned.\n",
      "\n",
      "Looking for fresh investing ideas as we wrap up 2019? Youre not alone. Investors are hitting the Street, searching high and low for the most compelling opportunities to snap up this holiday season. Stocks worthy of a place in investors stockings are the names not only poised to outperform but also backed by the Streets analysts.\n",
      "As investors hunt for stock market deals, they are also looking to the pros for some guidance as to what the economic landscape looks like going into 2020. Deutsche Bank Group Chief Economist, David Folkerts-Landau, tells clients that he expects the S&P 500 to climb higher through the first quarter of 2020.\n",
      "We believe that after a globally synchronized slow down over the past 18 months global growth is now bottoming out well short of recession territory and will get back on track early next year. While activity may slow a bit further from its current levels in the near term, we are optimistic when looking forward several quarters. Uncertainty about trade policy and national politics are getting resolved, there is limited inventory overhang, and the still unprecedented monetary easing is feeding through into the global economy, he stated.\n",
      "Deutsche Banks analysts are some of the best-performing on Wall Street, with their selections offering plenty of investing inspiration. Not to mention the firm ranks within the top 10 of TipRanks Top Performing Research Firms. With this in mind, we wanted to check out 3 of Deutsche Banks stock picks. Upon closer inspection with the use of TipRanks' Stock Screener tool, we found out that the rest of the Street is also in favor of these names, as each has earned a Strong Buy consensus rating.\n",
      "Uber Technologies (UBER)\n",
      "The popular ride sharing platform has found itself in hot water recently over its operations in London. That being said, Deutsche Bank analyst Lloyd Walmsley actually sees the stock clawing its way back after bad news as a positive.\n",
      "The trouble for Uber started when it lost its license to operate in London thanks to a few key issues brought up by the Transport for London (TfL). The company had been letting unauthorized drivers upload pictures to other Uber accounts as well as allowed suspended or dismissed drivers to create accounts. Adding fuel to the fire, the TfL found several insurance-related issues including drivers working without proper insurance. Uber can appeal the decision, with the Wall Street Journal stating that the appeal process could take eight months, during which time the company would still be allowed to operate.\n",
      "As Walmsley estimates that London accounts for 5% of Ubers bookings, or about $2.5 billion in 2019, its no wonder some investors are worried. Nonetheless, the five-star analyst tells clients that based on conversations with industry sources, he thinks Uber will most likely continue to operate.\n",
      "We think Uber will get a license given (1) the new leadership at the company under Dara Khosrowshahi has been making bona fide efforts to improve the safety of the app, work with regulators, and generally improve the culture (e.g. \"Do the right thing, period\") (2) it is working transparently with regulators, including in London, and the Transport for London (TfL) itself acknowledged such in its press release, and (3) while channel feedback was (not surprisingly) mixed here, one competitor noted Uber's safety processes are as good, if not better than, the other players in the market, the analyst explained.\n",
      "With Walmsley adding that the CEOs recent insider buying, the passing of the lockup expiration, improving competitive and profitability trends in the U.S. and Latin America, tighter private capital markets and improving disclosure point to shares gaining in the long-run, he kept the Buy recommendation. At the $50 price target, the upside potential is 69%. (To watch Walmsleys track record, click here)\n",
      "All in all, other analysts agree that Uber still looks like a long-term winner. With 21 Buy ratings vs 5 Holds, the stock is a Strong Buy. While slightly below Walmsleys forecast, the $45.52 average price target suggests solid upside potential of 60%. (See Uber stock analysis on TipRanks)\n",
      "Zymeworks (ZYME)\n",
      "Zymeworks wants to help bring patients home disease free, developing treatments for various forms of cancer as well as tumors. After gaining 187% year-to-date, the biotech company is definitely on the Streets radar.\n",
      "During the ESMO Asia 2019, the company provided an update on the first part of the Phase 1 trial evaluating single-agent ZW25 in HER2+ cancers, not including breast cancer. The data demonstrated that response rates improved for colorectal cancer and gastroesophageal adenocarcinoma, with ZW25's safety profile still looking promising. Most noteworthy, however, was that one pancreatic cancer patient experienced a 100% decrease in target lesions.\n",
      "Overall, we view the ESMO Asia update as continuing to support the broad activity of ZW25 monotherapy in HER2+ cancers, especially in HER2-high cancers, with a safety profile that appears highly amenable to combination approaches. Further, first responses in duodenal and pancreatic tumors expand the breadth of that clinical activity and provide more reasons for us to be enthusiastic with regard to the company, Deutsche Banks Konstantinos Aprilakis commented.\n",
      "As the analyst also highlights the potential opportunity for accelerated approval given the lack of any targeted HER2 therapies approved in this setting, he keep his Buy recommendation. Adding to the good news, Aprilakis bumped up the price target by $10 to $49, implying shares could surge 16% in the next twelve months. (To watch Aprilakis track record, click here)\n",
      "When it comes to the rest of the Street, lets just say theyve been pretty impressed with ZYME. Out of 6 analysts that have issued ratings in the last three months, 5 Buys were given compared to 1 Hold. Additionally, the $51 average price target brings the upside potential to 21%. (See Zymeworks stock analysis on TipRanks)\n",
      "PTC Inc. (PTC)\n",
      "In terms of digital transformation, PTC is leading the way. With its innovative software solutions, the company provides customers with the capabilities they need to succeed. While PTC has struggled year-to-date, Deutsche Banks Alex Tout believes the current share price represents an attractive entry point.\n",
      "At its investor event in Boston, Massachusetts, the company restated its goal of $850 million free cash flow by full year 2024, or 31% full year 2019 through 2024 CAGR.\n",
      "Tout argues that this target appears attainable as the prediction is in line with its blended end markets, noting, While we think investors may still need some convincing that PTCs ARR growth outlook to FY24 is realistic given the performance in FY19, fundamentally we believe that some acceleration from FY19's level of ARR growth is likely, not least as PTCs high-growth IoT/AR business (as well as, now, Onshape) becomes an ever larger part of the mix and the headwind from the Productivity Zone/FSG reduces.\n",
      "According to the analyst, PTCs acquisition of Onshape could lift its historical growth rate as the addition helps PTC cater to SMB companies that were previously out of its reach. On top of this, the company has partnerships with Microsoft, Ansys and Rockwell Automation that are still being developed.\n",
      "Taking all this into consideration, Tout maintained the bullish call. While he did lower the price target from $105 to $95, he still sees 24% upside potential in store. (To watch Touts track record, click here)\n",
      "Similarly, the rest of the Street is getting onboard. 5 Buys and 1 Hold assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $87 average price target puts the potential twelve-month gain at 15%. (See PTC stock analysis on TipRanks)\n",
      "\n",
      "(RTTNews) - The stocks on the move...\n",
      "1. Zymeworks Inc. (ZYME)\n",
      "Zymeworks is a clinical-stage biopharmaceutical company developing biotherapeutics, with a focus on immuno-oncology and other therapeutic areas.\n",
      "The Company's lead asset is ZW25, which is under a:\n",
      "-- Phase I trial as a monotherapy in patients with HER2-expressing solid tumors, including biliary tract cancer, colorectal cancer, gynecological cancers, and gastroesophageal adenocarcinoma. -- Phase II study in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.\n",
      "Another product in the pipeline is ZW49, under a phase I trial in patients with locally advanced (unresectable) or metastatic HER2-expressing cancers.\n",
      "Zymeworks has licensed its technology platform to leading pharmaceutical and biotechnology companies to bring innovative therapies into clinical development.\n",
      "In July of this year, Celgene Corp. selected a lead therapeutic candidate built using Zymeworks' proprietary Azymetric platform and exercised its option to a commercial license for which Zymeworks received a US$7.5 million payment.\n",
      "Recent event:\n",
      "On November 5, 2019, the Company reported financial results for the third quarter ended September 30, 2019.\n",
      "The net loss for the three months ended September 30, 2019, widened to $30.5 million or $0.70 per share from $18.8 million or $0.59 per share in the same period of 2018. Revenue from partnerships for the recent third quarter was $7.9 million compared to $2.1 million in the same period of 2018.\n",
      "The Company ended September 30, 2019, with cash of $335.1 million.\n",
      "ZYME touched an all-time high of $38.30 in intraday trading on Tuesday, before closing at $38.29, up 2.93%.\n",
      "2. Invitae Corporation (NVTA)\n",
      "Invitae is a medical genetics company.\n",
      "Early this month, the Company announced financial and operating results for the third quarter ended September 30, 2019.\n",
      "For the third quarter of 2019, Invitae reported a net loss of $78.7 million or $0.82 per share compared to a net loss of $31.7 million or $0.45 per share in the third quarter of 2018. Non-GAAP net loss was $65.8 million in the third quarter of 2019, or a $0.69 non-GAAP net loss per share.\n",
      "The Company derives revenue from test reports generated from its assays. Revenue in the third quarter of 2019 was $56.5 million compared to $37.4 million in the year-ago quarter.\n",
      "Over 129,000 samples were accessioned in the third quarter of 2019, representing a 65% increase over the 78,000 samples in the third quarter of 2018. Gross profit in the third quarter of 2019 was $24.4 million compared to $16.9 million in the third quarter of 2018.\n",
      "The Company ended September 30, 2019, with cash of $473.5 million.\n",
      "NVTA closed Tuesday's trading at $19.40, up 6.24%. The stock is off 32% from its 52-week high of $28.75 recorded on August 7, 2019.\n",
      "\n",
      "One out of every eight women in the United States will develop breast cancer, according to Breastcancer.org. Of those, about 25% will have an aggressive type called \"HER2-positive,\" which also recurs at higher rates.\n",
      "The human epidermal growth factor receptor 2 (HER2) gene produces proteins that control breast cell division, growth, and repairs. Too many copies of the gene, or too many receptor proteins, lead to excessive growth of cancer cells.\n",
      "Image Source: Getty Images\n",
      "Here we'll explore four biotech companies developing new therapies aimed at HER2-positive breast cancers.\n",
      "Seattle Genetics: Positive trial results for tucatinib\n",
      "Shares of Seattle Genetics (NASDAQ: SGEN) jumped 15% this week following the announcement of positive clinical trial results for its oral HER2-targeted breast cancer drug tucatinib. Patients in the trial received either trastuzumab and capecitabine, or those two drugs plus tucatinib. The patients had received three prior therapies before entering the trial. Of note: The cancer had spread to the brain in 47% of patients in the trial.\n",
      "Seattle Genetics highlighted that the trial reached the primary endpoint of progression-free survival. The tucatinib-treated patients had a 46% reduction in risk of disease progression or death. For patients whose cancer had spread to the brain, the drug demonstrated a 52% reduction in disease progression or death. Additional trial endpoints, including overall survival, favored tucatinib treatment.\n",
      "Seattle Genetics plans to unveil more detailed results from the trial at the San Antonio Breast Cancer Symposium (SABCS) in December. Until then, the company has begun work to gain approval globally, starting with a New Drug Application filing to be submitted to the Food and Drug Administration (FDA) in the first quarter of 2020.\n",
      "MacroGenics: Investors sell on bad news\n",
      "This week did not go so well for MacroGenics (NASDAQ: MGNX). Following a planned interim update on its pivotal phase 3 clinical trial, the stock lost 20% of its value. To add insult to injury, dozens of class-action law firms are lining up to get investors to sue the company based on the results.\n",
      "MacroGenics set out to test whether its drug margetuximab, given with chemotherapy, is superior to trastuzumab with chemotherapy in metastatic HER2-positive breast cancer patients who have had at least two prior therapies. Both margetuximab and trastuzumab are monoclonal antibodies targeting HER2.\n",
      "The Sophia trial, as it's dubbed, plans to have full results in 2020. The data release this month included a preplanned interim analysis to determine the survival benefit between the treatment arms. Patients receiving margetuximab showed a 1.8-month benefit, increasing survival to 21.6 months compared to 19.8 months. The market's reaction indicates that investors clearly expected to see a greater improvement.\n",
      "MacroGenics further highlighted that 85% of the patients in the trial had a specific genetic profile. Margetuximab's overall survival benefit in these patients increased to 4.3 months better than the comparator arm. MacroGenics also analyzed smaller subgroups with different genetic signatures. Detailed results from the Sophia trial will be presented during an oral session at the SABCS meeting.\n",
      "Merus and Zymeworks: Additional treatments in the pipeline\n",
      "Looking beyond Seattle Genetics' tucatinib, an oral small-molecule tyrosine kinase inhibitor, and Macrogenics' monoclonal antibody margetuximab: Merus (NASDAQ: MRUS) and Zymeworks (NYSE: ZYME) are developing novel therapies that work by different mechanisms.\n",
      "Merus created MCLA-128, a bispecific antibody that binds to HER2 as well as HER3; this dual mechanism will allow MCLA-128 to overcome resistance to cancers that develop in response to other HER2 treatments. Merus is conducting a phase 2 clinical trial of MCLA-128 in patients with metastatic HER2-positive breast cancer, and a phase 1 clinical trial in patients with a specific protein fusion known to activate HER2.\n",
      "Merus' stock jumped 13% Friday morning, on news that it would present data on MCLA-128 and another pipeline compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held over the weekend in Boston. The presentations focus on the phase 1 trial and the ability to target cancers with the fusion protein.\n",
      "Like Merus, Zymeworks seeks to fight HER2-positive cancers with a bispecific antibody named ZW25, which binds to two distinct areas on that receptor. The company believes this approach increases the drug's ability to enter and destroy the cancer cell. Currently ZW25 is in a phase 2 clinical trial in HER2-expressing cancers.\n",
      "Zymeworks did not stop there. Piggybacking on ZW25 and its ability to enter cancer cells, Zymeworks created ZW49, which attaches highly potent anticancer warheads to the original ZW25. This antibody-drug conjugate can potentially kill HER2-positive cancer cells more effectively. ZW49 is in a phase 1 clinical trial, so it will take time before its cancer-fighting ability is known.\n",
      "Zymeworks' stock has risen 20% since a data presentation on SW25 in late September at the European Society for Medical Oncology's annual meeting; year to date, shareholders have doubled their money. With half its shares in the hands of institutions, Zymeworks appears to be a consistent gainer, but it needs to show some meaningful midstage trial results.\n",
      "Breast cancer patients with the aggressive HER2-positive form need better treatment options. It appears that Seattle Genetics' tucatinib will provide one next year, if approved; importantly, it appears to benefit patients with brain metastases.\n",
      "As for MacroGenics, investors may want to hold off until margetuximab's full overall survival data are known in 2020. Finally, Merus and Zymeworks look interesting for those willing to take riskier, long-term bets.\n",
      "10 stocks we like better than Seattle Genetics\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Seattle Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 1, 2019 David Haen owns shares of Seattle Genetics. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Top Health Care Stocks:\n",
      "JNJ: +0.26%\n",
      "PFE: +0.36%\n",
      "ABT: +0.27%\n",
      "MRK: +0.25%\n",
      "AMGN: -0.85%\n",
      "Most health care giants were gaining pre-market Monday.\n",
      "Stocks moving on news include:\n",
      "(+) Dova Pharmaceuticals (DOVA), which was jumping by more than 38% after the drug maker said it has agreed to be acquired by Swedish Orphan Biovitrum AB for $29.00 per share, or up to $915 million.\n",
      "(+) Zymeworks (ZYME) was up more than 5% amid results from the ongoing multi-center phase 1 clinical study evaluating the company's HER2-targeted bispecific antibody ZW25 in solid tumor patients. According to the biopharmaceutical firm, results affirmed the ability of ZW25 to provide durable disease control in patients with a variety of HER2-expressing solid tumors, including biliary tract cancer, colorectal cancer gynecological cancers, and gastroesophageal adenocarcinoma.\n",
      "(+) Mallinckrodt (MNK) was over 5% higher after saying it has finalized an agreement announced early this month to settle opioid lawsuits with Cuyahoga and Summit Counties in Ohio.\n",
      "\n",
      "Top Health Care Stocks:\n",
      "JNJ: -0.24%\n",
      "PFE: -0.39%\n",
      "ABT: -1.95%\n",
      "MRK: -0.38%\n",
      "AMGN: -1.03%\n",
      "Health care giants were retreating pre-bell Monday.\n",
      "Stocks moving on news include:\n",
      "(-) GlycoMimetics (GLYC), which was plunging more than 55% after the biopharmaceutical firm said a phase 3 study of its lead compound failed to meet primary or secondary efficacy endpoints, putting at risk a license agreement of up to $285 million with Pfizer (PFE) for the development and commercialization of rivipansel.\n",
      "(+) Provention Bio (PRVB) was up nearly 4% after saying the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease.\n",
      "In other sector news:\n",
      "(=) Zymeworks (ZYME) was unchanged after it reported a Q2 adjusted loss of $0.61 per share compared with a $0.05 loss per share in the prior-year period. Analysts polled by Capital IQ were expecting an adjusted loss of $0.60 per share.\n",
      "\n",
      "Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.65 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 6.35%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.22, delivering a surprise of 37.14%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates two times.\n",
      "Zymeworks Inc.Which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.05 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 2.70%. This compares to year-ago revenues of $0.12 million. The company has topped consensus revenue estimates just once over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zymeworks Inc. Shares have added about 82.4% since the beginning of the year versus the S&P 500's gain of 2.4%.\n",
      "What's Next for Zymeworks Inc.\n",
      "While Zymeworks Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zymeworks Inc. Was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.59 on $5 million in revenues for the coming quarter and -$2.37 on $25.50 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "Zymeworks Inc. (ZYME): Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Zymeworks, a early-stage biotech developing bispecific antibodies that target HER2 tumors, raised $59 million by offering 4.5 million shares at $13, the low end of the range of $13 to $16. Zymeworks plans to list on the NYSE under the symbol ZYME. Citi, Barclays and Wells Fargo Securities acted as lead managers on the deal.\n",
      "The article Zymeworks prices IPO at $13, the low end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.\n",
      "Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.\n",
      "\n",
      "Zymeworks, an early-stage biotech developing antibodies that target HER2 tumors, announced terms for its IPO on Monday.\n",
      "The Vancouver, Canada-based company plans to raise $65 million by offering 4.5 million shares at a price range of $13 to $16. Insiders intend to purchase $42 million worth of shares in the offering (64% of the IPO). At the midpoint of the proposed range, Zymeworks would command a fully diluted market value of $361 million.\n",
      "The company is backed by Eli Lilly ( LLY ) and Celgene (Nasdaq: CELG).\n",
      "Zymeworks was founded in 2003 and booked $11 million in revenue for the 12 months ended December 31, 2016. It plans to dual list on the NYSE and Toronto Stock Exchange under the symbol ZYME. Citi, Barclays and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of April 24, 2017.\n",
      "The article Cancer biotech Zymeworks sets terms for $65 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.\n",
      "Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.\n",
      "\n",
      "Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Triumph Financial Inc (Symbol: TFIN), where a total volume of 6,724 contracts has been traded thus far today, a contract volume which is representative of approximately 672,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 428.9% of TFIN's average daily trading volume over the past month, of 156,785 shares. Especially high volume was seen for the $75 strike call option expiring February 16, 2024, with 6,600 contracts trading so far today, representing approximately 660,000 underlying shares of TFIN. Below is a chart showing TFIN's trailing twelve month trading history, with the $75 strike highlighted in orange:\n",
      "Zynex Inc (Symbol: ZYXI) saw options trading volume of 10,030 contracts, representing approximately 1.0 million underlying shares or approximately 323.8% of ZYXI's average daily trading volume over the past month, of 309,765 shares. Especially high volume was seen for the $5 strike put option expiring February 16, 2024, with 5,000 contracts trading so far today, representing approximately 500,000 underlying shares of ZYXI. Below is a chart showing ZYXI's trailing twelve month trading history, with the $5 strike highlighted in orange:\n",
      "And CorMedix Inc (Symbol: CRMD) options are showing a volume of 16,184 contracts thus far today. That number of contracts represents approximately 1.6 million underlying shares, working out to a sizeable 256.1% of CRMD's average daily trading volume over the past month, of 631,880 shares. Especially high volume was seen for the $5 strike call option expiring December 15, 2023, with 3,316 contracts trading so far today, representing approximately 331,600 underlying shares of CRMD. Below is a chart showing CRMD's trailing twelve month trading history, with the $5 strike highlighted in orange:\n",
      "For the various different available expirations for TFIN options, ZYXI options, or CRMD options, visit StockOptionsChannel.com.\n",
      "Today's Most Active Call & Put Options of the S&P 500 \n",
      "Also see:\n",
      " Funds Holding CNX\n",
      " SOND YTD Return\n",
      " Funds Holding OBIL\n",
      "\n",
      "(RTTNews) - Zynex, Inc. (ZYXI), a medical device company, on Wednesday announced that it will repurchase up to $20 million of its common stock in a share repurchase program commencing on November 1.\n",
      "The company will purchase the common stock from the open market in negotiated transactions from time to time. The program will be terminated on November 1, 2024 or when the limit of $20 million is reached.\n",
      "The buyback will be funded with existing cash balances.\n",
      "Currently, Zynex shares are trading at $8.83, down 0.56% on Nasdaq.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.09, delivering a surprise of 125%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $49.92 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 0.84%. This compares to year-ago revenues of $41.52 million. The company has topped consensus revenue estimates three times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 49% since the beginning of the year versus the S&P 500's gain of 9%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.18 on $55.8 million in revenues for the coming quarter and $0.41 on $192.4 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 46% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "One other stock from the same industry, Maravai LifeSciences Holdings, Inc. (MRVI), is yet to report results for the quarter ended September 2023. The results are expected to be released on November 7.\n",
      "This company is expected to post break-even quarterly earnings per share in its upcoming report, which represents a year-over-year change of -100%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Maravai LifeSciences Holdings, Inc.'s revenues are expected to be $75.23 million, down 60.7% from the year-ago quarter.\n",
      "Infrastructure Stock Boom to Sweep America\n",
      "A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. Its bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.\n",
      "The only question is Will you get into the right stocks early when their growth potential is greatest?\n",
      "Zacks has released a Special Report to help you do just that, and today its free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.\n",
      "Download FREE: How To Profit From Trillions On Spending For Infrastructure >>\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "Zynex Inc. (ZYXI) : Free Stock Analysis Report\n",
      "Maravai LifeSciences Holdings, Inc. (MRVI) : Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Fintel reports that on October 16, 2023, RBC Capital initiated coverage of Zynex (NASDAQ:ZYXI) with a Outperform recommendation.\n",
      "Analyst Price Forecast Suggests 201.48% Upside\n",
      "As of October 5, 2023, the average one-year price target for Zynex is 24.48. The forecasts range from a low of 20.20 to a high of $29.40. The average price target represents an increase of 201.48% from its latest reported closing price of 8.12.\n",
      "See our leaderboard of companies with the largest price target upside.\n",
      "The projected annual revenue for Zynex is 201MM, an increase of 13.46%. The projected annual non-GAAP EPS is 0.61.\n",
      "What is the Fund Sentiment?\n",
      "There are 313 funds or institutions reporting positions in Zynex. This is an increase of 14 owner(s) or 4.68% in the last quarter. Average portfolio weight of all funds dedicated to ZYXI is 0.04%, a decrease of 21.74%. Total shares owned by institutions increased in the last three months by 12.50% to 14,218K shares.\n",
      "The put/call ratio of ZYXI is 9.53, indicating a bearish outlook.\n",
      "What are Other Shareholders Doing?\n",
      "IJR - iShares Core S&P Small-Cap ETF holds 1,499K shares representing 4.27% ownership of the company. In it's prior filing, the firm reported owning 1,625K shares, representing a decrease of 8.40%. The firm decreased its portfolio allocation in ZYXI by 28.61% over the last quarter.\n",
      "VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 733K shares representing 2.09% ownership of the company. No change in the last quarter.\n",
      "Millennium Management holds 446K shares representing 1.27% ownership of the company. In it's prior filing, the firm reported owning 376K shares, representing an increase of 15.73%. The firm decreased its portfolio allocation in ZYXI by 18.45% over the last quarter.\n",
      "IWM - iShares Russell 2000 ETF holds 445K shares representing 1.27% ownership of the company. In it's prior filing, the firm reported owning 466K shares, representing a decrease of 4.59%. The firm decreased its portfolio allocation in ZYXI by 29.56% over the last quarter.\n",
      "Geode Capital Management holds 433K shares representing 1.23% ownership of the company. In it's prior filing, the firm reported owning 438K shares, representing a decrease of 1.03%. The firm decreased its portfolio allocation in ZYXI by 28.42% over the last quarter.\n",
      "Zynex Background Information\n",
      "(This description is provided by the company.)\n",
      "Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.\n",
      "Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.\n",
      "Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.\n",
      "Click to Learn More\n",
      "This story originally appeared on Fintel.\n",
      "\n",
      "Health care stocks were rising late Monday afternoon, with the NYSE Health Care Index adding 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%.\n",
      "The iShares Biotechnology ETF (IBB) was climbing 0.7%.\n",
      "In corporate news, Pfizer (PFE) and BioNTech (BNTX) said Monday the US Food and Drug Administration has approved its supplemental biologics license application for their updated COVID-19 vaccine targeting the Omicron XBB.1.5 sublineage for individuals 12 years of age and older. Pfizer shares were down 0.9% while BioNTech was shedding 1.9%.\n",
      "Crinetics Pharmaceuticals (CRNX) shares jumped almost 62% after the company said a phase 3 trial of its paltusotine drug candidate for acromegaly, a hormonal disorder that causes swelling of the hands and feet, met its primary and secondary endpoints.\n",
      "Zynex (ZYXI) said Monday that its boar approved a $10 million stock-repurchase program that will begin Wednesday and end on Sept. 12, 2024, or when the $10 million limit is reached. Its shares added more than 8%.\n",
      "Tenon Medical (TNON) was down almost 40% after the company said it kicked off a public offering of its shares.\n",
      "\n",
      "Health care stocks were rising Monday afternoon, with the NYSE Health Care Index adding about 1% and the Health Care Select Sector SPDR Fund (XLV) up 0.8%.\n",
      "The iShares Biotechnology ETF (IBB) was climbing 0.7%.\n",
      "In corporate news, Crinetics Pharmaceuticals (CRNX) shares jumped 64% after the company said a phase 3 trial of its paltusotine drug candidate for acromegaly, a hormonal disorder that causes swelling of the hands and feet, met its primary and secondary endpoints.\n",
      "Zynex (ZYXI) said Monday that its board of directors approved a $10 million stock repurchase program that will begin Wednesday and end on Sept. 12, 2024, or when the $10 million limit is reached. The shares added more than 9%.\n",
      "Day One Biopharmaceuticals (DAWN) said Monday it has completed the rolling submission of the new drug application to the US Food and Drug Administration for tovorafenib to treat relapsed or progressive pediatric low-grade glioma, a common brain tumor in children. Its shares were higher by 0.5%\n",
      "\n",
      "(RTTNews) - Zynex, Inc. (ZYXI), a medical device maker, said on Monday that it has approved a share repurchase drive to buy back its $10 million of its shares.\n",
      "Following the news, ZYXI was trading up by 6.36 percent at $7.85 per share on the Nasdaq.\n",
      "The repurchase program will begin on September 13, 2023, and is scheduled to end on September 12, 2024, or when the $10 million limit is reached.\n",
      "Thomas Sandgaard, CEO of Zynex, said: \"We are focused on continuing to deliver strong returns for our shareholders, and continuing the repurchase program shows our confidence in the company's outlook and future cash flow. Our consistent operating performance allows us an opportunity to invest in Zynex and return value to our shareholders simultaneously.\"\n",
      "Zynex expects to finance the purchases with cash on hand, which is not expected to have a material impact on capital levels.\n",
      "The company had around 41.7 million shares issued and 35.1 million shares outstanding as of September 8.\n",
      "\n",
      "The average one-year price target for Zynex (NASDAQ:ZYXI) has been revised to 24.48 / share. This is an increase of 9.09% from the prior estimate of 22.44 dated July 5, 2023.\n",
      "The price target is an average of many targets provided by analysts. The latest targets range from a low of 20.20 to a high of 29.40 / share. The average price target represents an increase of 150.82% from the latest reported closing price of 9.76 / share.\n",
      "What is the Fund Sentiment?\n",
      "There are 306 funds or institutions reporting positions in Zynex. This is an increase of 15 owner(s) or 5.15% in the last quarter. Average portfolio weight of all funds dedicated to ZYXI is 0.05%, a decrease of 18.22%. Total shares owned by institutions increased in the last three months by 9.49% to 13,006K shares.\n",
      "The put/call ratio of ZYXI is 6.45, indicating a bearish outlook.\n",
      "What are Other Shareholders Doing?\n",
      "IJR - iShares Core S&P Small-Cap ETF holds 1,625K shares representing 4.52% ownership of the company. In it's prior filing, the firm reported owning 1,610K shares, representing an increase of 0.90%. The firm decreased its portfolio allocation in ZYXI by 15.41% over the last quarter.\n",
      "VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 733K shares representing 2.04% ownership of the company. No change in the last quarter.\n",
      "IWM - iShares Russell 2000 ETF holds 466K shares representing 1.30% ownership of the company. In it's prior filing, the firm reported owning 495K shares, representing a decrease of 6.35%. The firm decreased its portfolio allocation in ZYXI by 15.25% over the last quarter.\n",
      "Geode Capital Management holds 438K shares representing 1.22% ownership of the company. In it's prior filing, the firm reported owning 429K shares, representing an increase of 1.95%. The firm decreased its portfolio allocation in ZYXI by 18.59% over the last quarter.\n",
      "Millennium Management holds 376K shares representing 1.05% ownership of the company. In it's prior filing, the firm reported owning 139K shares, representing an increase of 63.08%. The firm increased its portfolio allocation in ZYXI by 142.15% over the last quarter.\n",
      "Zynex Background Information\n",
      "(This description is provided by the company.)\n",
      "Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.\n",
      "Additional reading:\n",
      "AMENDMENT TO STOCK PURCHASE AGREEMENT\n",
      "Zynex Reports Second Quarter 2023 Financial Results Q2 2023 Revenue increased 22% to $45.0 Million; EPS $0.09\n",
      "Zynex Reports Preliminary Second Quarter 2023 Results\n",
      "Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management\n",
      "Zynex Announces Share Buyback Program\n",
      "This story originally appeared on Fintel.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 125%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of 300%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates four times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $44.95 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 1.02%. This compares to year-ago revenues of $36.76 million. The company has topped consensus revenue estimates three times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 31.2% since the beginning of the year versus the S&P 500's gain of 18.9%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.13 on $49.5 million in revenues for the coming quarter and $0.45 on $192.3 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "Zevia (ZVIA), another stock in the same industry, has yet to report results for the quarter ended June 2023.\n",
      "This stevia-sweetened soda maker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of +46.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Zevia's revenues are expected to be $42 million, down 7.8% from the year-ago quarter.\n",
      "Free Report: Top EV Battery Stocks to Buy Now\n",
      "Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to \"insane levels,\" and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid.\n",
      "Download free today.\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "Zynex Inc. (ZYXI) : Free Stock Analysis Report\n",
      "Zevia PBC (ZVIA) : Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Health care stocks were mostly lower on Wednesday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.1%.\n",
      "The iShares Biotechnology ETF (IBB) was climbing 1.3%.\n",
      "In company news, Recursion Pharmaceuticals (RXRX) shares soared 84% after it said Wednesday that NVIDIA (NVDA) invested $50 million into the pharmaceutical company through a private investment in public equity deal.\n",
      "Avrobio (AVRO) shares jumped 43% after the company said it is launching a \"comprehensive exploration of strategic alternatives\" to boost shareholder value.\n",
      "Zynex (ZYXI) rose 1.9% after it affirmed previous guidance for Q2 earnings per share of $0.03 to $0.07 and revenue of $43.5 million to $45.5 million.\n",
      "\n",
      "Below is Validea's guru fundamental report for ZYNEX INC. (ZYXI). Of the 22 guru strategies we follow, ZYXI rates highest using our Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 82% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E RATIO: PASS\n",
      "REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS\n",
      "SALES GROWTH RATE: PASS\n",
      "CURRENT QUARTER EARNINGS: PASS\n",
      "QUARTERLY EARNINGS ONE YEAR AGO: PASS\n",
      "POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS\n",
      "EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL\n",
      "EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS\n",
      "EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS\n",
      "EARNINGS PERSISTENCE: FAIL\n",
      "LONG-TERM EPS GROWTH: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "INSIDER TRANSACTIONS: PASS\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "ZYXI Guru Analysis\n",
      "ZYXI Fundamental Analysis\n",
      "More Information on Martin Zweig\n",
      "Martin Zweig Portfolio\n",
      "About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in \"Dirty Harry\", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.\n",
      "Additional Research Links\n",
      "Top Healthcare Stocks\n",
      "Dividend Aristocrats2023\n",
      "Wide Moat Stocks2023\n",
      "High Insider Ownership Stocks\n",
      "Factor-Based Stock Portfolios\n",
      "Excess Returns Investing Podcast\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "What happened\n",
      "Shares of Zynex (NASDAQ: ZYXI) are up more than 9% early Wednesday afternoon after the medical equipment company announced it planned to do a stock repurchase. That said, the stock is down more than 32% so far this year.\n",
      "So what\n",
      "Zynex makes electrotherapy medical devices for pain management and rehabilitation and a blood volume monitor for use in healthcare settings. The company announced on Wednesday morning that its board of directors had approved a $10 million stock buyback program that would begin Wednesday and run until next June. The buyback should be accretive to the stock's earnings per share (EPS), and will be financed with the company's cash reserves, so investors were happy.\n",
      "The move is meant to show confidence in the company, especially with its shares down to start the year. Last year, the company did $30 million in stock buybacks.\n",
      "Now what\n",
      "The latest move may be warranted, as the company's shares have fallen despite strong numbers. The drop was likely mainly to the company agreeing in May to pursue a stock sale offering of $50 million in convertible senior notes, due in 2026, for financing.\n",
      "In the first quarter, Zynex reported revenue of $42.2 million, up 36% year over year, and net income listed as $1.6 million, up 17% over the same period last year. The company's guidance points to annual revenue between $180 million and $200 million, compared to $158.2 million in 2022, and yearly EPS of between $0.40 and $0.50, compared to EPS of $0.44 last year. The EPS would likely be higher, but the company said it is expecting higher labor costs and increased expenses for anticipated product launches.\n",
      "10 stocks we like better than Zynex\n",
      "When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "They just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of June 12, 2023\n",
      "Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Health care stocks were lower late Wednesday with the NYSE Health Care Index falling 1.1% and the Health Care Select Sector SPDR Fund (XLV) down 1%.\n",
      "The iShares Biotechnology ETF (IBB) was decreasing 0.8%.\n",
      "In company news, Blue Water Biotech (BWV) shares jumped 62% after the company agreed to buy six drugs with prior approvals for multiple indications in the US from WraSer and parent Xspire Pharma for $8.5 million in cash and 1 million restricted shares of common stock.\n",
      "UnitedHealth (UNH) shares fell 6.4% after a company executive said non-urgent surgeries for seniors increased more than projected in the past two months as COVID-delayed procedures were rescheduled.\n",
      "Zynex (ZYXI) jumped 10% after the company's board approved a $10 million share repurchase plan effective immediately.\n",
      "Eagle Pharmaceuticals (EGRX) said the US Food and Drug Administration granted qualified infectious disease product and fast-track designations for CAL02, which is under development to treat severe community-acquired bacterial pneumonia. The company's shares fell 5%.\n",
      "\n",
      "Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index falling 0.9% and the Health Care Select Sector SPDR Fund (XLV) down 1%.\n",
      "The iShares Biotechnology ETF (IBB) was decreasing 0.9%.\n",
      "In company news, UnitedHealth (UNH) shares were down past 7% after a company executive said non-urgent surgeries for seniors increased more than projected in the past two months as COVID-delayed procedures were rescheduled.\n",
      "Zynex (ZYXI) was rising past 10% after saying its board approved a $10 million share repurchase plan effective immediately.\n",
      "Eagle Pharmaceuticals (EGRX) said the US Food and Drug Administration has granted qualified infectious disease product and fast-track designations for CAL02, which is under development to treat severe community-acquired bacterial pneumonia. The company's shares were down about 4%.\n",
      "\n",
      "The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.\n",
      "INSULET CORPORATION (PODD) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and wirelessly monitors the Pod's operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SECTOR: PASS\n",
      "SALES: PASS\n",
      "CURRENT RATIO: PASS\n",
      "LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL\n",
      "LONG-TERM EPS GROWTH: FAIL\n",
      "P/E RATIO: FAIL\n",
      "PRICE/BOOK RATIO: FAIL\n",
      "Detailed Analysis of INSULET CORPORATION\n",
      "PODD Guru Analysis\n",
      "PODD Fundamental Analysis\n",
      "STRYKER CORP (SYK) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. The Company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. Its products are sold in over 75 countries through Company-owned subsidiaries and branches, as well as through third-party dealers and distributors. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Its geographical segments include United States and International.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SECTOR: PASS\n",
      "SALES: PASS\n",
      "CURRENT RATIO: FAIL\n",
      "LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL\n",
      "LONG-TERM EPS GROWTH: PASS\n",
      "P/E RATIO: FAIL\n",
      "PRICE/BOOK RATIO: FAIL\n",
      "Detailed Analysis of STRYKER CORP\n",
      "SYK Guru Analysis\n",
      "SYK Fundamental Analysis\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. The Company's devices are intended for pain management and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SECTOR: PASS\n",
      "SALES: FAIL\n",
      "CURRENT RATIO: PASS\n",
      "LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS\n",
      "LONG-TERM EPS GROWTH: FAIL\n",
      "P/E RATIO: FAIL\n",
      "PRICE/BOOK RATIO: FAIL\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "ZYXI Guru Analysis\n",
      "ZYXI Fundamental Analysis\n",
      "LIGAND PHARMACEUTICALS INC (LGND) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. The Company's Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. The Company's products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and Other. Kyprolis is formulated with Ligand's Captisol technology. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. Its other products include Pneumosil, Rylaze, Nexterone, Veklury, Zulresso, and Noxafil-IV.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SECTOR: PASS\n",
      "SALES: FAIL\n",
      "CURRENT RATIO: PASS\n",
      "LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS\n",
      "LONG-TERM EPS GROWTH: FAIL\n",
      "P/E RATIO: FAIL\n",
      "PRICE/BOOK RATIO: FAIL\n",
      "Detailed Analysis of LIGAND PHARMACEUTICALS INC\n",
      "LGND Guru Analysis\n",
      "LGND Fundamental Analysis\n",
      "INTERCEPT PHARMACEUTICALS INC (ICPT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company's marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SECTOR: PASS\n",
      "SALES: FAIL\n",
      "CURRENT RATIO: PASS\n",
      "LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS\n",
      "LONG-TERM EPS GROWTH: FAIL\n",
      "P/E RATIO: FAIL\n",
      "PRICE/BOOK RATIO: FAIL\n",
      "Detailed Analysis of INTERCEPT PHARMACEUTICALS INC\n",
      "ICPT Guru Analysis\n",
      "ICPT Fundamental Analysis\n",
      "Benjamin Graham Portfolio\n",
      "Top Benjamin Graham Stocks\n",
      "About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the \"Father of Value Investing\" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Zynex (NASDAQ:ZYXI) with a Buy recommendation.\n",
      "Analyst Price Forecast Suggests 96.15% Upside\n",
      "As of April 24, 2023, the average one-year price target for Zynex is 22.44. The forecasts range from a low of 18.18 to a high of $29.40. The average price target represents an increase of 96.15% from its latest reported closing price of 11.44.\n",
      "See our leaderboard of companies with the largest price target upside.\n",
      "The projected annual revenue for Zynex is 201MM, an increase of 18.95%. The projected annual non-GAAP EPS is 0.61.\n",
      "What is the Fund Sentiment?\n",
      "There are 289 funds or institutions reporting positions in Zynex. This is an increase of 14 owner(s) or 5.09% in the last quarter. Average portfolio weight of all funds dedicated to ZYXI is 0.06%, an increase of 49.31%. Total shares owned by institutions decreased in the last three months by 1.76% to 11,896K shares.\n",
      "The put/call ratio of ZYXI is 6.03, indicating a bearish outlook.\n",
      "What are Other Shareholders Doing?\n",
      "IJR - iShares Core S&P Small-Cap ETF holds 1,610K shares representing 4.39% ownership of the company. In it's prior filing, the firm reported owning 1,660K shares, representing a decrease of 3.10%. The firm increased its portfolio allocation in ZYXI by 35.33% over the last quarter.\n",
      "VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 733K shares representing 2.00% ownership of the company. No change in the last quarter.\n",
      "IWM - iShares Russell 2000 ETF holds 495K shares representing 1.35% ownership of the company. In it's prior filing, the firm reported owning 508K shares, representing a decrease of 2.60%. The firm increased its portfolio allocation in ZYXI by 35.37% over the last quarter.\n",
      "Geode Capital Management holds 429K shares representing 1.17% ownership of the company. In it's prior filing, the firm reported owning 425K shares, representing an increase of 0.93%. The firm increased its portfolio allocation in ZYXI by 43.25% over the last quarter.\n",
      "Invesco holds 314K shares representing 0.86% ownership of the company. In it's prior filing, the firm reported owning 155K shares, representing an increase of 50.55%. The firm increased its portfolio allocation in ZYXI by 182.30% over the last quarter.\n",
      "Zynex Background Information\n",
      "(This description is provided by the company.)\n",
      "Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.\n",
      "See all Zynex regulatory filings.\n",
      "This story originally appeared on Fintel.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this company would post earnings of $0.19 per share when it actually produced earnings of $0.20, delivering a surprise of 5.26%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates four times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $42.17 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 6.30%. This compares to year-ago revenues of $31.08 million. The company has topped consensus revenue estimates three times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 19.8% since the beginning of the year versus the S&P 500's gain of 5.6%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.08 on $44.42 million in revenues for the coming quarter and $0.47 on $190.04 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "One other stock from the same industry, Veru Inc. (VERU), is yet to report results for the quarter ended March 2023.\n",
      "This company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of -83.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Veru Inc.'s revenues are expected to be $4.03 million, down 69.1% from the year-ago quarter.\n",
      "Top 5 ChatGPT Stocks Revealed\n",
      "Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.\n",
      "Today you can invest in the wave of the future, an automation that answers follow-up questions  admits mistakes  challenges incorrect premises  rejects inappropriate requests. As one of the selected companies puts it, Automation frees people from the mundane so they can accomplish the miraculous.\n",
      "Download Free ChatGPT Stock Report Right Now >>\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "Zynex Inc. (ZYXI) : Free Stock Analysis Report\n",
      "Veru Inc. (VERU) : Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Fintel reports that on April 12, 2023, HC Wainwright & Co. reiterated coverage of Zynex (NASDAQ:ZYXI) with a Buy recommendation.\n",
      "Analyst Price Forecast Suggests 92.95% Upside\n",
      "As of April 6, 2023, the average one-year price target for Zynex is $22.44. The forecasts range from a low of $18.18 to a high of $29.40. The average price target represents an increase of 92.95% from its latest reported closing price of $11.63.\n",
      "See our leaderboard of companies with the largest price target upside.\n",
      "The projected annual revenue for Zynex is $201MM, an increase of 27.29%. The projected annual non-GAAP EPS is $0.61.\n",
      "What are Other Shareholders Doing?\n",
      "State Board Of Administration Of Florida Retirement System holds 20K shares representing 0.05% ownership of the company. In it's prior filing, the firm reported owning 11K shares, representing an increase of 43.18%. The firm increased its portfolio allocation in ZYXI by 156.96% over the last quarter.\n",
      "QCSTRX - Stock Account Class R1 holds 3K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 5K shares, representing a decrease of 61.79%. The firm decreased its portfolio allocation in ZYXI by 23.38% over the last quarter.\n",
      "TISBX - TIAA-CREF Small-Cap Blend Index Fund Institutional Class holds 28K shares representing 0.08% ownership of the company. In it's prior filing, the firm reported owning 32K shares, representing a decrease of 12.76%. The firm increased its portfolio allocation in ZYXI by 6.38% over the last quarter.\n",
      "Farmers & Merchants Investments holds 0K shares representing 0.00% ownership of the company. No change in the last quarter.\n",
      "Gladius Capital Management holds 3K shares representing 0.01% ownership of the company. In it's prior filing, the firm reported owning 4K shares, representing a decrease of 56.20%. The firm decreased its portfolio allocation in ZYXI by 99.84% over the last quarter.\n",
      "What is the Fund Sentiment?\n",
      "There are 286 funds or institutions reporting positions in Zynex. This is an increase of 12 owner(s) or 4.38% in the last quarter. Average portfolio weight of all funds dedicated to ZYXI is 0.07%, an increase of 53.04%. Total shares owned by institutions decreased in the last three months by 3.10% to 11,821K shares.\n",
      "The put/call ratio of ZYXI is 11.15, indicating a bearish outlook.\n",
      "Zynex Background Information\n",
      "(This description is provided by the company.)\n",
      "Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.\n",
      "See all Zynex regulatory filings.\n",
      "This story originally appeared on Fintel.\n",
      "\n",
      "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.\n",
      "BROOKLINE BANCORP, INC. (BRKL) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Brookline Bancorp, Inc. is a bank holding company for Brookline Bank, Bank Rhode Island (BankRI), and PCSB Bank (Bank's). The Company is also the parent of Brookline Securities Corp. (BSC) and Clarendon Private, LLC. The Bank's activities include acceptance of commercial, municipal and retail deposits, origination of mortgage loans on commercial and residential real estate located principally in New England, origination of commercial loans and leases to small and mid-sized businesses, investment in debt and equity securities, and the offering of cash management and investment advisory services. Brookline Bank includes its wholly owned subsidiaries, Longwood Securities Corp. (LSC), Eastern Funding LLC (Eastern Funding) and First Ipswich Insurance Agency. BankRI includes its wholly owned subsidiaries, Acorn Insurance Agency, BRI Realty Corp., BRI Investment Corp. and its wholly owned subsidiary, BRI MSC Corp. PCSB Bank operates as a separate bank subsidiary of the Company.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of BROOKLINE BANCORP, INC.\n",
      "BRKL Guru Analysis\n",
      "BRKL Fundamental Analysis\n",
      "PROSPERITY BANCSHARES, INC. (PB) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Prosperity Bancshares, Inc. is a financial holding company. The Company operates through its Prosperity Bank (the Bank). The Bank provides a range of financial products and services to businesses and consumers throughout Texas and Oklahoma. The Bank operates approximately 272 full-service banking locations: 65 in the Houston area, including The Woodlands; 30 in the South Texas area including Corpus Christi and Victoria; 62 in the Dallas/Fort Worth, Texas area; 22 in the East Texas area; 29 in the Central Texas area, including Austin and San Antonio; 34 in the West Texas area, including Lubbock, Midland-Odessa and Abilene; 16 in the Bryan/College Station area; 6 in the Central Oklahoma area; and 8 in the Tulsa, Oklahoma area.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of PROSPERITY BANCSHARES, INC.\n",
      "PB Guru Analysis\n",
      "PB Fundamental Analysis\n",
      "GILDAN ACTIVEWEAR INC (USA) (GIL) is a mid-cap value stock in the Apparel/Accessories industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Gildan Activewear Inc. is a Canada-based, vertically integrated manufacturer of everyday basic apparel, including activewear, underwear, and hosiery products. The Company's primary product categories include activewear tops and bottoms (activewear), socks (hosiery), underwear tops and bottoms (underwear) and intimates. Its activewear product lines include T-shirts, fleece tops and bottoms, and sports shirts. Its hosiery product lines include athletic, dress, casual and workwear socks, liner socks, socks for therapeutic purposes, sheer panty hose, tights, and leggings. Its underwear product lines include men's and boy's underwear (tops and bottoms) and ladies panties. The Company's intimates product lines include ladies shapewear, intimates, and accessories. The products it manufactures, and sells are marketed under Company brands, including Gildan, American Apparel, Comfort Colors, Gildan Hammer, Alstyle and GoldToe. It also sells socks under the Under Armour brand.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: FAIL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of GILDAN ACTIVEWEAR INC (USA)\n",
      "GIL Guru Analysis\n",
      "GIL Fundamental Analysis\n",
      "NEDBANK GROUP LTD. (ADR) (NDBKY) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Nedbank Group Limited is a digital financial services provider. The Company's principal banking subsidiary is Nedbank Limited. It offers wholesale and retail banking, as well as insurance, asset management and wealth management services and solutions. The Company offers the solutions through its frontline clusters; Nedbank Corporate and Investment Banking, which includes investment banking, global markets and treasury, commercial property finance, deposit-taking and transactional banking; Nedbank Retail and Business Banking, which includes transactional banking, card and payment solutions, lending and deposit-taking and investment products; Nedbank Wealth, which includes high-net-worth banking, wealth management, asset management and insurance, and Nedbank Africa Regions, which includes transactional banking, lending, deposit-taking and card products, and wealth management. The Company's primary market is South Africa and it also operates in five countries outside South Africa.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of NEDBANK GROUP LTD. (ADR)\n",
      "NDBKY Guru Analysis\n",
      "NDBKY Fundamental Analysis\n",
      "PLUMAS BANCORP (PLBC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Plumas Bancorp is a bank holding company of Plumas Bank (the Bank). The Bank primarily is engaged in providing loans and investment securities. The Bank provides multi-community independent bank services to the financial needs of individuals and businesses within the Bank's geographic footprint. The Bank's principal commercial lending services include term real estate, commercial and industrial term loans. In addition, the Bank provides government-guaranteed and agricultural loans, as well as credit lines. The Bank's principal retail lending services include consumer, automobile and home equity loans. The Bank provides land development and construction loans on a limited basis. The Bank provides small business administration loans to qualified borrowers through its government-guaranteed lending center. The Bank's primary service area covers the Northeastern portion of California, with Lake Tahoe to the south and the Oregon border to the north, and the Northwestern portion of Nevada.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "Detailed Analysis of PLUMAS BANCORP\n",
      "PLBC Guru Analysis\n",
      "PLBC Fundamental Analysis\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 0% to 87% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "ZYXI Guru Analysis\n",
      "ZYXI Fundamental Analysis\n",
      "UFP TECHNOLOGIES, INC. (UFPT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 72% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: UFP Technologies, Inc. is a designer and custom manufacturer of components, subassemblies, products and packaging utilizing foams, films and plastics primarily for the medical market. The Company's single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods and orthopedic implant packaging. The Company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics, and industrial markets. The applications of its products include military uniform and gear components, automotive interior trim, athletic padding, environmentally friendly protective packaging, air filtration, abrasive nail files, and protective cases and inserts. Its wholly owned subsidiaries include Simco Industries, Inc., Dielectrics, Inc., Contech Medical, Inc. and UFP Realty LLC.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "Detailed Analysis of UFP TECHNOLOGIES, INC.\n",
      "UFPT Guru Analysis\n",
      "UFPT Fundamental Analysis\n",
      "BRITISH AMERICAN TOBACCO PLC (ADR) (BTI) is a large-cap value stock in the Tobacco industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: British American Tobacco p.l.c. is a United Kingdom-based, multi-category consumer goods company that provides tobacco and nicotine products. The Company invests in building a portfolio of tobacco and nicotine products alongside its traditional tobacco business, including vapour products, tobacco heating products (THPs) and modern oral products. It manages a globally integrated supply chain, and its products are distributed to retail outlets across the world. The Company's segments include the United States, Asia-Pacific and Middle East, Americas and Sub-Saharan Africa, and Europe and North Africa. The Company's products as sold in the United States, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus. Its vapour products are hand-held, battery-powered devices that heat a liquid and creates a vapor to be inhaled. Its THP products do not burn tobacco and no smoke is produced. Its modern oral products are white in color and contain nicotine, water, and other food-grade ingredients.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of BRITISH AMERICAN TOBACCO PLC (ADR)\n",
      "BTI Guru Analysis\n",
      "BTI Fundamental Analysis\n",
      "DUCOMMUN INC (DCO) is a small-cap growth stock in the Aerospace & Defense industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Ducommun Incorporated is a provider of engineering and manufacturing services for various products and applications used in the aerospace and defense, industrial, medical, and other industries. The Company offers value-added products and manufacturing solutions to its customers in its primary businesses of electronics, structures, and integrated solutions. It operates through two segments: Electronic Systems and Structural Systems. The Electronic Systems segment designs, engineers and manufactures electronic and electromechanical products used in technology-driven markets, including aerospace and defense and industrial end-use markets. It has multiple product offerings in electronics manufacturing for diverse applications, such as complex cable assemblies and interconnect systems, printed circuit board assemblies, and lighting diversion systems. The Structural Systems segment designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of DUCOMMUN INC\n",
      "DCO Guru Analysis\n",
      "DCO Fundamental Analysis\n",
      "FIFTH THIRD BANCORP (FITB) is a large-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Fifth Third Bancorp (the Bancorp) is a bank holding company for Fifth Third Bank, National Association. The Bancorp conducts its principal lending, deposit gathering, transaction processing and service advisory activities through its banking and non-banking subsidiaries from banking centers located throughout the Midwestern and Southeastern regions of the United States. The Bancorp operates through three segments: Commercial Banking, which offers credit intermediation, cash management and financial services to large and middle-market businesses and government and professional customers; Consumer and Small Business Banking provides a full range of deposit and loan products to individuals and small businesses through a network of full-service banking centers and relationships with indirect and correspondent loan originators, and Wealth and Asset Management, which provides a range of wealth management services for individuals, companies and nonprofit organizations.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of FIFTH THIRD BANCORP\n",
      "FITB Guru Analysis\n",
      "FITB Fundamental Analysis\n",
      "360 DIGITECH INC - ADR (QFIN) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: 360 DigiTech Inc is a China-based company mainly engaged in credit technology services. The services provided by the Company are divided into credit-driven services and platform services according to the nature of the service and the level of related credit risk. The credit-driven services match potential borrowers with financial institutions, enabling financial institutions to obtain borrowers, conduct credit evaluation, fund matching and post-loan services. The platform services include a full range of loan assistance and post-loan services under the capital-light model, intelligent marketing services, referral services, and risk management software as services (SaaS) for financial institution partners under the Intelligent Credit Engine (ICE) model.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "EPS GROWTH RATE: FAIL\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of 360 DIGITECH INC - ADR\n",
      "QFIN Guru Analysis\n",
      "QFIN Fundamental Analysis\n",
      "LANDSEA HOMES CORP (LSEA) is a small-cap value stock in the Construction Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Landsea Homes Corporation is a residential homebuilder company. It is engaged in designing, constructing, marketing and sale of suburban and urban single-family detached and attached homes in California, Arizona, Florida, Texas, and Metro New York. It offers a range of housing options. The Arizona market consists of entry-level, single-family homes in Avondale, Buckeye, Chandler, Goodyear, Mesa, Phoenix, Queen Creek, Surprise, and Tolleson. The California market consists of single-family detached and attached homes in Alameda, Contra Costa, Marin, San Joaquin, and Santa Clara counties in Northern California and Los Angeles, Orange, and San Bernardino counties in Southern California. The Florida market consists of entry-level single-family homes and attached homes in metro Orlando and Palm Bay in Florida. The New York Metro market consists of two condominium projects: Chelsea neighborhood in New York City, New York and Port Imperial in Weehawken, New Jersey along the gold cost.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: FAIL\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of LANDSEA HOMES CORP\n",
      "LSEA Guru Analysis\n",
      "LSEA Fundamental Analysis\n",
      "INTERNATIONAL GENERAL INSURANC HLDGS LTD (IGIC) is a small-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on Peter Lynch changed from 63% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: International General Insurance Holdings Ltd is a Jordan-based commercial insurance and reinsurance company. It has a worldwide portfolio of energy, property, general aviation, construction and engineering, ports and terminals, marine cargo, marine trades, contingency, political violence, financial institutions, general third-party liability, legal expenses, reinsurance treaty business, among others. Its segments include Specialty Long-tail, Specialty Short-tail and Reinsurance. Its Specialty Long-tail segment includes casualty business, financial institutions line of business, marine liability line of business, and inherent defects insurance line of business. Its Specialty Short-tail segment includes energy, property, construction and engineering, political violence, ports and terminals, marine cargo, contingency and general aviation lines of business. Reinsurance segment includes inward reinsurance treaty business.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "Detailed Analysis of INTERNATIONAL GENERAL INSURANC HLDGS LTD\n",
      "IGIC Guru Analysis\n",
      "IGIC Fundamental Analysis\n",
      "INTREPID POTASH INC (IPI) is a small-cap value stock in the Non-Metallic Mining industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Intrepid Potash, Inc. is a diversified mineral company. The Company delivers potassium, magnesium, sulfur, salt, and water products to agriculture, animal feed and the oil and gas industry. The Company's segments include potash, Trio, and oilfield solutions. It sells potash into three primary markets: the agricultural market as a fertilizer input, the industrial market as a component in drilling and fracturing fluids for oil and gas wells and an input to other industrial processes, and the animal feed market as a nutrient supplement. Trio is its specialty fertilizer that delivers potassium, sulfate, and magnesium in a single particle. It produces Trio in premium, granular, standard, and fine standard sizes. It also offers potassium chloride (KCl) real-time mixing services on location for hydraulic fracturing operations and trucking services. The Company also sells salt, magnesium chloride, metal recovery salts, brines, and water that are derived as part of its mining processes.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of INTREPID POTASH INC\n",
      "IPI Guru Analysis\n",
      "IPI Fundamental Analysis\n",
      "PACTIV EVERGREEN INC (PTVE) is a small-cap value stock in the Paper & Paper Products industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Pactiv Evergreen Inc. is a manufacturer of fresh food and beverage packaging in North America. The Company produces a range of on-trend and feature-rich products that protect, package and display food and beverages for consumers. Its products, many of which are made with recycled, recyclable, or renewable materials, are supplied to a diversified mix of customers, including restaurants, foodservice distributors, retailers, food and beverage producers, packers, and processors. The Company operates through three segments, foodservice, food merchandising and beverage merchandising. The Foodservice segment manufactures food containers, drinkware (hot and cold cups and lids), tableware, service ware and other products. The Food Merchandising segment manufactures clear rigid-display containers, containers for prepared and ready-to-eat food, trays for meat and poultry and egg cartons. The Beverage Merchandising segment manufactures cartons for fresh refrigerated beverage products.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "INVENTORY TO SALES: PASS\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: FAIL\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of PACTIV EVERGREEN INC\n",
      "PTVE Guru Analysis\n",
      "PTVE Fundamental Analysis\n",
      "BANKWELL FINANCIAL GROUP INC (BWFG) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 89% to 100% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Bankwell Financial Group, Inc. is a bank holding company. The Company offers a range of financial services through its banking subsidiary, Bankwell Bank (the Bank). The Bank is a Connecticut state non-member bank. The Bank's commercial lending products include owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans (such as business term loans, equipment financing and lines of credit) to small and mid-sized businesses, and real estate construction and development loans. Its depository products include checking, savings, money market and certificates of deposit. The Bank operates branches in New Canaan, Stamford, Fairfield, Westport, Darien, Norwalk, and Hamden, Connecticut. The Bank provides a range of services to clients in its market, an area encompassing approximately a 100-mile radius around its branch network.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of BANKWELL FINANCIAL GROUP INC\n",
      "BWFG Guru Analysis\n",
      "BWFG Fundamental Analysis\n",
      "INVESTAR HOLDING CORP (ISTR) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Investar Holding Corporation is a financial holding company that conducts its operations primarily through its subsidiary, Investar Bank, National Association (the Bank). The Bank offers a range of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses as well as loans to individuals. The Bank's business lending products include owner-occupied commercial real estate loans, construction loans and commercial and industrial loans, such as term loans, equipment financing and lines of credit, while its loans to individuals include first and second mortgage loans, instalment loans, and lines of credit. For business customers, it targets small to medium-sized businesses and professional organizations, such as law firms, accounting firms and medical practices. Its primary areas of operation are south Louisiana, and its surrounding areas; southeast Texas, and its surrounding areas; and Alabama, and its surrounding areas.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of INVESTAR HOLDING CORP\n",
      "ISTR Guru Analysis\n",
      "ISTR Fundamental Analysis\n",
      "NATURAL RESOURCE PARTNERS LP (NRP) is a small-cap value stock in the Coal industry. The rating according to our strategy based on Peter Lynch changed from 56% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Natural Resource Partners L.P. is engaged in the business of owning, managing, and leasing a diversified portfolio of mineral properties in the United States, including interests in coal and other natural resources. The Company operates through two segments: Mineral Rights and Soda Ash. The Mineral Rights segment consists of approximately 13 million acres of mineral interests and other subsurface rights across the United States. Its ownership provides critical inputs for the manufacturing of steel, electricity and basic building materials, as well as opportunities for carbon sequestration and renewable energy. Its Soda Ash segment consists of approximately 49% non-controlling equity interest in Sisecam Wyoming, a trona ore mining and soda ash production business located in the Green River Basin of Wyoming. Sisecam Wyoming mines trona and processes it into soda ash that is sold both domestically and internationally into the glass and chemicals industries.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: FAIL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of NATURAL RESOURCE PARTNERS LP\n",
      "NRP Guru Analysis\n",
      "NRP Fundamental Analysis\n",
      "RAMACO RESOURCES INC (METC) is a small-cap value stock in the Coal industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Ramaco Resources, Inc. is a metallurgical coal company. The Company operates and develops metallurgical coal in southern West Virginia, southwestern Virginia, and southwestern Pennsylvania. Its development portfolio primarily includes four properties: Elk Creek, Berwind, RAM Mine and Knox Creek. The Elk Creek property consists of approximately 20,200 acres of controlled mineral rights and contains 16 seams that it has targeted for production. It operates three deep mines and a surface mine at its Elk Creek mining complex. The Berwind property consists of approximately 41,300 acres of controlled mineral rights and is located on the border of West Virginia and Virginia. The Knox Creek property consists of approximately 62,100 acres of controlled mineral rights. Its RAM Mine property is located in southwestern Pennsylvania, consists of approximately 1,567 acres of controlled mineral rights. Its subsidiaries include Ramaco Development, LLC; RAM Mining, LLC; and RAMACO Coal Sales, LLC.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: FAIL\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of RAMACO RESOURCES INC\n",
      "METC Guru Analysis\n",
      "METC Fundamental Analysis\n",
      "LUTHER BURBANK CORP (LBC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Luther Burbank Corporation is a bank holding company. The Company operates primarily through its subsidiary, Luther Burbank Savings (the Bank). It also owns Burbank Financial Inc., a real estate investment company, and Luther Burbank Statutory Trusts I and II, entities created to issue trust-preferred securities. Its principal business is accepting deposits from the public and investing those funds in a range of loans, including permanent mortgage loans and construction loans secured by residential, multifamily, and commercial real estate. It specializes in real estate secured lending in metropolitan areas in the western United States, including Colorado, Utah and Arizona, and has developed multifamily residential, jumbo nonconforming single family residential and commercial real estate lending. It has approximately 10 full service branches in California, located in Sonoma, Marin, Santa Clara, and Los Angeles Counties, and one full service branch in Washington, located in King County.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: FAIL\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of LUTHER BURBANK CORP\n",
      "LBC Guru Analysis\n",
      "LBC Fundamental Analysis\n",
      "VICTORY CAPITAL HOLDINGS INC (VCTR) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 74% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Victory Capital Holdings, Inc. is a diversified asset management firm. The Company is focused on providing investment management services and products to institutional, intermediary, retirement platforms and individual investors. It has approximately 12 autonomous investment franchises and a solutions platform. It offers a range of investment products, including actively and passively managed mutual funds, rules-based and active exchange traded funds (ETFs), institutional separate accounts, variable insurance products (VIPs), environmental, social, and governance and impact investment strategies, alternative investments, private closed end funds, and a 529 Education Savings Plan. Its franchises and solutions platform collectively manages a diversified set of approximately 130 investment strategies for a range of institutional and retail clients and direct investors. The Company's investment adviser is Victory Capital Management Inc.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of VICTORY CAPITAL HOLDINGS INC\n",
      "VCTR Guru Analysis\n",
      "VCTR Fundamental Analysis\n",
      "CANADIAN IMPERIAL BANK OF COMMERCE (USA) (CM) is a large-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 85% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Canadian Imperial Bank of Commerce is a Canada-based financial institution. The Company offers a full range of advice, solutions and services through its digital banking network across personal and business banking, commercial banking and wealth management, and capital markets businesses. Its personal banking offers products and services, including personal checking, health savings account, personal lending, EasyPath banking, personal savings, retirement, traditions club and mortgage. Its private wealth offers investment management, corporate and institutional services, wealth planning and trustee services and private banking. The Company's commercial banking includes commercial lending, capital markets, commercial real estate and treasury management. It also includes small business banking and agility digital banking. The Company has over 13 million personal banking, business, public sector and institutional clients.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: FAIL\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of CANADIAN IMPERIAL BANK OF COMMERCE (USA)\n",
      "CM Guru Analysis\n",
      "CM Fundamental Analysis\n",
      "Peter Lynch Portfolio\n",
      "Top Peter Lynch Stocks\n",
      "About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. (\"Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it,\" is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a \"stocks for the everyman/everywoman\", breaking his approach down into easy-to-understand concepts.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this company would post earnings of $0.12 per share when it actually produced earnings of $0.13, delivering a surprise of 8.33%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $48.81 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.69%. This compares to year-ago revenues of $40.37 million. The company has topped consensus revenue estimates three times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 31.5% since the beginning of the year versus the S&P 500's gain of 0.6%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.06 on $38.83 million in revenues for the coming quarter and $0.52 on $195.82 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "One other stock from the same industry, High Tide Inc. (HITI), is yet to report results for the quarter ended January 2023. The results are expected to be released on March 17.\n",
      "This company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +36.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "High Tide Inc.'s revenues are expected to be $82.62 million, up 44.9% from the year-ago quarter.\n",
      "Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry\n",
      "Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you  and its FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.\n",
      ">>Send me my free report on the top 5 EV stocks\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "Zynex Inc. (ZYXI) : Free Stock Analysis Report\n",
      "High Tide Inc. (HITI) : Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Health care stocks were falling this afternoon, with the NYSE Health Care Index down 1.3% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.6%.\n",
      "The iShares Biotechnology ETF (IBB) declined 1.5%.\n",
      "In company news, Coherus BioSciences (CHRS) rose 7.6% after the company said it expects significant topline growth during 2023 and beyond and reported a smaller-than-expected Q4 net loss.\n",
      "Protagonist Therapeutics (PTGX) jumped 52% after the company said its JNJ-2113 drug candidate met its primary endpoint during phase 2b testing in patients with moderate to severe plaque psoriasis.\n",
      "Zynex (ZYXI) slumped 20% after the medical device company postponed the release of its Q4 financial results, needing more time \"to complete its year-end closing procedures.\"\n",
      "Cara Therapeutics (CARA) declined 34% after the specialty drug maker reported a Q4 net loss of $0.56 per share on $3.3 million in revenue, missing the Capital IQ consensus expecting a $0.36 per loss on $14.5 million in revenue.\n",
      "\n",
      "Health care stocks were falling this afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both posting 1.6% declines.\n",
      "The iShares Biotechnology ETF (IBB) also was sinking 1.1%.\n",
      "In company news, Cara Therapeutics (CARA) declined over 31% after the specialty drug maker reported a Q4 net loss of $0.56 per share on $3.3 million in revenue, missing the Capital IQ consensus expecting a $0.36 per loss during the three months ended Dec. 31 on $14.5 million in Q4 revenue.\n",
      "Zynex (ZYXI) sank 19% after the medical device company postponed the release of its Q4 financial results, explaining it needed more time \"to complete its year-end closing procedures.\"\n",
      "Protagonist Therapeutics (PTGX) jumped over 39% after saying its JNJ-2113 drug candidate met its primary endpoint during phase 2b testing in patients with moderate to severe plaque psoriasis.\n",
      "\n",
      "Health care stocks were advancing pre-bell Tuesday. The Health Care Select Sector SPDR Fund (XLV) was 0.07% higher and the iShares Biotechnology ETF (IBB) was climbing past 1% recently.\n",
      "Cara Therapeutics (CARA) was down more than 25% after reporting a Q4 net loss of $0.56 per diluted share, narrower than a per-share loss of $0.63 a year earlier but still wider than the per-share loss of $0.36 estimated by analysts polled by Capital IQ.\n",
      "Zynex (ZYXI) was retreating by more than 11% after it postponed the release of its Q4 and full-year financial results and the conference call initially scheduled for the same day.\n",
      "IDEAYA Biosciences (IDYA) was more than 2% lower after it reported a Q4 diluted loss of $0.50 per share, compared with a loss of $0.47 a year earlier. Analysts polled by Capital IQ expected a loss of $0.56.\n",
      "\n",
      "(RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.30 A.M. ET).\n",
      "In the Green\n",
      "WW International, Inc. (WW) is up over 16% at $4.49. Squarespace, Inc. (SQSP) is up over 14% at $27.55. Southland Holdings, Inc. (SLND) is up over 14% at $10.55. Nyxoah S.A. (NYXH) is up over 14% at $6.10. Semantix, Inc. (STIX) is up over 14% at $4.99. ZyVersa Therapeutics, Inc. (ZVSA) is up over 12% at $2.44. Biomea Fusion, Inc. (BMEA) is up over 11% at $14.77. MariaDB plc (MRDB) is up over 11% at $2.78. American Well Corporation (AMWL) is up over 9% at $2.92. Anghami Inc. (ANGH) is up over 8% at $1.99.\n",
      "In the Red\n",
      "Cara Therapeutics, Inc. (CARA) is down over 27% at $7.28. Appreciate Holdings, Inc. (SFR) is down over 20% at $2.43. Harbor Custom Development, Inc. (HCDI) is down over 14% at $7.00. Tremor International Ltd (TRMR) is down over 13% at $6.52. Zynex, Inc. (ZYXI) is down over 11% at $11.00. Orchestra BioMed Holdings, Inc. (OBIO) is down over 9% at $16.50. Ambrx Biopharma Inc. (AMAM) is down over 9% at $11.33. Yiren Digital Ltd. (YRD) is down over 9% at $2.50. ProPetro Holding Corp. (PUMP) is down over 6% at $9.01. Nutanix, Inc. (NTNX) is down over 5% at $27.09. BioRestorative Therapies, Inc. (BRTX) is down over 5% at $3.39.\n",
      "\n",
      "By Jorgelina do Rosario and Rachel Savage\n",
      "LONDON/JOHANNESBURG, Jan 24 (Reuters) - Loans committed by China's two main trade policy banks fell to a 13-year low of $3.7 billion in 2021 due to Beijing curtailing funding for large-scale oil projects, a study from Boston University Global Development Policy Center showed.\n",
      "Commitments made to 100 developing nations by the Export-Import Bank of China (China EximBank) and the China Development Bank (CDB) have fallen every year since hitting a record in 2016 as the lenders scaled back financing even before the COVID-19 pandemic hit in 2020.\n",
      "\"We expect an overall shift toward lower volume, higher quality investment from China,\" Kevin Gallagher, director of the university's Global Development Policy Center, told Reuters.\n",
      "\"China's domestic priorities beyond COVID-19 are still significant, given the large amounts of debt and the swings in renminbi that may necessitate the need to be conservative with dollar holdings so they can serve as insurance on the home front.\"\n",
      "China is the world's largest bilateral lender, according to the World Bank data. Western countries such as the United States and multilateral lenders are pressing Beijing to offer debt relief to emerging economies in distress, such as Zambia and Sri Lanka. China tends to disclose little on lending conditions and how it renegotiates with borrowers.\n",
      "China EximBank and CBD made $498 billion in loan commitments globally between 2008-2021 as part of Beijing's \"Belt and Road\" infrastructure initiative.\n",
      "General purpose lending to state-owned oil companies, for example in Angola, Brazil, Ecuador, Russia and Venezuela, reached $60 billion between 2009 and 2017.\n",
      "Since then, lending has been less focused on petroleum producers, with Bangladesh and Sri Lanka among top recipients. The average size of loan pledges has also fallen, from $534 million between 2013-2017, to $378 million from 2018-2021.\n",
      "Russia was the top recipient, with $58 billion in loans in the 2008-2021 period, followed by Venezuela with $55 billion mostly for extraction and pipelines projects, but lending to the South American oil giant halted in 2015, two years before it defaulted on its overseas debt.\n",
      "Angola was the third largest recipient with $33 billion for projects in transport, agriculture, water and oil, with Kenya, Ethiopia and Egypt being other top African borrowers.\n",
      "WORLD BANK STEPS IN\n",
      "While Chinese lending has been waning, World Bank lending has ramped up, the study found.\n",
      "The Washington-based lender financed projects in developing countries worth an average of $40 billion annually between 2016-2019, before scaling up its response to the pandemic in 2020 when it stepped in with $67 billion, its largest annual commitment since 2008. The following year, commitments were almost $62 billion - 17 times more than Chinese financing.\n",
      "\"The World Bank had a fixed amount of lending capacity, but this was accelerated as part of the COVID-19 response,\" Gallagher said, adding this might return to trend post-pandemic.\n",
      "Overall, China's commitments were 83% of the $601 billion lent by the World Bank from 2008-2021.\n",
      "Reuters reported this month that the World Bank was seeking to vastly expand its lending capacity to address climate change and other global crises and would negotiate with shareholders ahead of April meetings on proposals including a capital increase and new lending tools.\n",
      "Looking into 2022, the general trend away from supporting finance for large-scale hydrocarbon projects continues, the study added.\n",
      "\"It is telling that Chinese development finance institutions opted not to support Russias recent Arctic LNG 2 mega-project, even though they lent over $11 billion to a similar Russian project (Yamal LNG) just a few years ago,\" said Rebecca Ray, senior academic researcher for the policy center.\n",
      "\"Given this change of heart, it seems unlikely that China returns to major Russian lending in the near-term,\" she added.\n",
      "World Bank tops China in loans for development projects\n",
      "China's top borrowers (Reporting by Rachel Savage and Jorgelina do Rosario, editing by Karin Strohecker, Alex Richardson and Kevin Liffey)\n",
      "((Rachel.Savage@thomsonreuters.com;))\n",
      "\n",
      "By Jorgelina do Rosario and Rachel Savage\n",
      "LONDON/JOHANNESBURG, Jan 24 (Reuters) - Loans committed by China's two main trade policy banks fell to a 13-year low of $3.7 billion in 2021 due to Beijing curtailing funding for large-scale oil projects, a study from Boston University Global Development Policy Center showed.\n",
      "Commitments made to 100 developing nations by the Export-Import Bank of China (China EximBank) and the China Development Bank (CDB) have fallen every year since hitting a record in 2016 as the lenders scaled back financing even before the COVID-19 pandemic hit in 2020.\n",
      "\"We expect an overall shift toward lower volume, higher quality investment from China,\" Kevin Gallagher, director of the university's Global Development Policy Center, told Reuters.\n",
      "\"China's domestic priorities beyond COVID-19 are still significant, given the large amounts of debt and the swings in renminbi that may necessitate the need to be conservative with dollar holdings so they can serve as insurance on the home front.\"\n",
      "China is the world's largest bilateral lender, according to the World Bank data. Western countries such as the United States and multilateral lenders are pressing Beijing to offer debt relief to emerging economies in distress, such as Zambia and Sri Lanka. China tends to disclose little on lending conditions and how it renegotiates with borrowers.\n",
      "China EximBank and CBD made $498 billion in loan commitments globally between 2008-2021 as part of Beijing's \"Belt and Road\" infrastructure initiative.\n",
      "General purpose lending to state-owned oil companies, for example in Angola, Brazil, Ecuador, Russia and Venezuela, reached $60 billion between 2009 and 2017.\n",
      "Since then, lending has been less focused on petroleum producers, with Bangladesh and Sri Lanka among top recipients. The average size of loan pledges has also fallen, from $534 million between 2013-2017, to $378 million from 2018-2021.\n",
      "Russia was the top recipient, with $58 billion in loans in the 2008-2021 period, followed by Venezuela with $55 billion mostly for extraction and pipelines projects, but lending to the South American oil giant halted in 2015, two years before it defaulted on its overseas debt.\n",
      "Angola was the third largest recipient with $33 billion for projects in transport, agriculture, water and oil, with Kenya, Ethiopia and Egypt being other top African borrowers.\n",
      "WORLD BANK STEPS IN\n",
      "While Chinese lending has been waning, World Bank lending has ramped up, the study found.\n",
      "The Washington-based lender financed projects in developing countries worth an average of $40 billion annually between 2016-2019, before scaling up its response to the pandemic in 2020 when it stepped in with $67 billion, its largest annual commitment since 2008. The following year, commitments were almost $62 billion - 17 times more than Chinese financing.\n",
      "\"The World Bank had a fixed amount of lending capacity, but this was accelerated as part of the COVID-19 response,\" Gallagher said, adding this might return to trend post-pandemic.\n",
      "Overall, China's commitments were 83% of the $601 billion lent by the World Bank from 2008-2021.\n",
      "Reuters reported this month that the World Bank was seeking to vastly expand its lending capacity to address climate change and other global crises and would negotiate with shareholders ahead of April meetings on proposals including a capital increase and new lending tools.\n",
      "World Bank tops China in loans for development projects\n",
      "China's top borrowers (Reporting by Rachel Savage and Jorgelina do Rosario, editing by Karin Strohecker and Alex Richardson)\n",
      "((Rachel.Savage@thomsonreuters.com;))\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: FAIL\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "Detailed Analysis of AMERISOURCEBERGEN CORP.\n",
      "ABC Guru Analysis\n",
      "ABC Fundamental Analysis\n",
      "HCA HEALTHCARE INC (HCA) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Motley Fool is 75% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: HCA Healthcare, Inc. is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. It owns and operates approximately 182 hospitals, comprised of 175 general, acute care hospitals; five psychiatric hospitals; and two rehabilitation hospitals. The Company also operates around 125 freestanding surgery centers and over 21 freestanding endoscopy centers. The Company operates in two geographically organized groups: The National and American Groups. The National Group includes 96 hospitals located in Alaska, California, Florida, Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, North Carolina, South Carolina, Utah and Virginia. The American Group includes approximately 79 hospitals located in Colorado, Kansas, southern Kentucky, Louisiana, Missouri, Tennessee and Texas. The Company also operates seven hospitals in England. Its facilities are located in over 20 states and England.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of HCA HEALTHCARE INC\n",
      "HCA Guru Analysis\n",
      "HCA Fundamental Analysis\n",
      "AMPHASTAR PHARMACEUTICALS INC (AMPH) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 73% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: FAIL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "Detailed Analysis of AMPHASTAR PHARMACEUTICALS INC\n",
      "AMPH Guru Analysis\n",
      "AMPH Fundamental Analysis\n",
      "SHOCKWAVE MEDICAL INC (SWAV) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Shockwave Medical, Inc. is a medical device company. The Company is engaged in medical device treatment of atherosclerotic cardiovascular disease (atherosclerosis) through its differentiated local delivery of sonic pressure waves for the treatment of calcified plaque, which refer to as intravascular lithotripsy (IVL). Its products for the treatment of peripheral artery disease (PAD) includes Shockwave M5 IVL catheter (M5 catheter) and Shockwave S4 IVL catheter (S4 catheter). Its product for the treatment of coronary artery disease (CAD) is Shockwave C2 IVL catheter (C2 catheter). M5 catheter is a five-emitter catheter for use in its IVL System in medium vessels for the treatment of above-the-knee PAD. S4 catheter is a four-emitter catheter for use in its IVL System in small vessels for the treatment of below-the-knee PAD. C2 catheter is a two-emitter catheter for use in its IVL System for the treatment of CAD.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of SHOCKWAVE MEDICAL INC\n",
      "SWAV Guru Analysis\n",
      "SWAV Fundamental Analysis\n",
      "CELLDEX THERAPEUTICS, INC. (CLDX) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. It operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The Company's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: FAIL\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: FAIL\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: FAIL\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of CELLDEX THERAPEUTICS, INC.\n",
      "CLDX Guru Analysis\n",
      "CLDX Fundamental Analysis\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "ZYXI Guru Analysis\n",
      "ZYXI Fundamental Analysis\n",
      "MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 68% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of MEDPACE HOLDINGS INC\n",
      "MEDP Guru Analysis\n",
      "MEDP Fundamental Analysis\n",
      "NEUROCRINE BIOSCIENCES, INC. (NBIX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 68% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: FAIL\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: FAIL\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of NEUROCRINE BIOSCIENCES, INC.\n",
      "NBIX Guru Analysis\n",
      "NBIX Fundamental Analysis\n",
      "VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 68% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company's other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of VERTEX PHARMACEUTICALS INCORPORATED\n",
      "VRTX Guru Analysis\n",
      "VRTX Fundamental Analysis\n",
      "MERIDIAN BIOSCIENCE INC (VIVO) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 67% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "Detailed Analysis of MERIDIAN BIOSCIENCE INC\n",
      "VIVO Guru Analysis\n",
      "VIVO Fundamental Analysis\n",
      "Motley Fool Portfolio\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Shares of Zynex Inc. (ZYXI) have gained 16% over the past four weeks to close the last trading session at $10.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.39 indicates a potential upside of 65.3%.\n",
      "The average comprises five short-term price targets ranging from a low of $7 to a high of $28.50, with a standard deviation of $8.49. While the lowest estimate indicates a decline of 33.5% from the current price level, the most optimistic estimate points to a 170.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.\n",
      "While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.\n",
      "However, an impressive consensus price target is not the only factor that indicates a potential upside in ZYXI. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.\n",
      "Here's What You Should Know About Analysts' Price Targets\n",
      "According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.\n",
      "While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?\n",
      "They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.\n",
      "However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.\n",
      "That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.\n",
      "Why ZYXI Could Witness a Solid Upside\n",
      "There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.\n",
      "Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 1.7%, as two estimates have moved higher compared to no negative revision.\n",
      "Moreover, ZYXI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\n",
      "Therefore, while the consensus price target may not be a reliable indicator of how much ZYXI could gain, the direction of price movement it implies does appear to be a good guide.\n",
      "\n",
      "7 Best Stocks for the Next 30 Days\n",
      "Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers \"Most Likely for Early Price Pops.\"\n",
      "Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>\n",
      "\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "\n",
      "(RTTNews) - The following are some of the companies belonging to the healthcare sector that reported quarterly financial results on Thursday.\n",
      "Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), which reported lower-than-expected financial results for the third quarter, has reiterated FY 2022 net product revenue guidance.\n",
      "Revenue grew to $264.3 million in Q3 2022, from $187.6 million in Q3 2021, but fell short ofanalysts' estimate of $291.75 million.\n",
      "On a GAAP basis, net loss for the third quarter of 2022 widened to $405.9 million or $3.32 per share, from last year's $204.5 million or $1.72 per share. Analysts polled by Thomson Reuters expected a loss of $1.77 million.\n",
      "On a non-GAAP basis, the net loss was $193.6 million or $1.58 per share in Q3 2022 compared to a net loss of $189.8 million or $1.59 per share in Q3 2021.\n",
      "The company has four marketed products ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.\n",
      "Alnylam reiterated its previous net product revenue guidance for the fiscal year 2022, to be in the range of $870-$930 million.\n",
      "The company has a couple of clinical trial catalysts to watch in the coming months.\n",
      "A phase 1 study of ALN-XDH in patients with gout is ongoing, with preliminary results expected in late 2022.\n",
      "In early 2023, Alnylam expects initial data from a phase I study of ALN-APP in patients with early-onset Alzheimer's Disease.\n",
      "The company does not plan to conduct the optional interim analysis for the HELIOS-B phase III study in patients with ATTR amyloidosis with cardiomyopathy. The study remains on track for topline results in early 2024.\n",
      "On Sep.30, 2022, cash, cash equivalents, and marketable securities totaled $2.27 billion.\n",
      "ALNY has traded in a range of $117.58 to $236.8 in the last 52 weeks. The stock closed Thursday's trading at $194, down 3.49%.\n",
      "DexCom Inc. (DXCM), reported better-than-expected earnings for the third quarter ended Sep.30, 2022 and raised its revenue outlook for the full year.\n",
      "In Q3 2022, revenue grew 18% to $769.6 million from $650.2 million in the same quarter of the prior year.\n",
      "On GAAP basis, net income grew to $101.2 million, or $0.24 per share, in the third quarter of 2022, from $87.3 million, or $0.21 per diluted share, in the same quarter of 2021.\n",
      "On a non-GAAP basis, the net income improved to $111.9 million, or $0.28 per share in the third quarter of 2022 from $89.3 million or $0.22 per share in the same quarter of 2021. Wall Street analysts were expecting earnings of $0.24 per share.\n",
      "The company raised its revenue outlook for the fiscal year 2022, to be in the range of $2.88 - 2.91 billion from the previous range of $2.86 - 2.91 billion. Analysts estimate the revenue for FY 2022 to be $2.89 billion. Revenue was $2.45 billion last year.\n",
      "Dexcom ended Q3 2022, with $2.37 billion in cash, cash equivalents, marketable securities, and undrawn credit facility.\n",
      "DXCM has traded in a range of $66.89 to $164.86 in the last 52 weeks. The stock closed Thursday's trading at $101.25, down 1.33%.\n",
      "Travere Therapeutics Inc. (TVTX) has reported a wider loss and lower revenue for the third quarter ended September 30, 2022. This biopharmaceutical company is developing therapies for rare kidney, liver, and metabolic diseases Revenue is generated from the following approved products. -- Chenodal indicated for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. -- Cholbam for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. -- Thiola and Thiola EC prescribed for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.\n",
      "Revenue for the third quarter of 2022 declined to $50.8 million, from $54.2 million in the same period in 2021.\n",
      "In Q3 2022, the net loss widened to $69.7 million, or $1.09 per share from $35.6 million, or $0.59 per share in Q3 2021. Wall Street analysts expected the company to incur a loss of $0.86 per share.\n",
      "The most advanced product in Travere's pipeline is Sparsentan, an investigational dual-acting angiotensin, and endothelin receptor antagonist proposed for the treatment of IgA nephropathy (IgAN).\n",
      "Sparsentan is under FDA review, with a decision expected on February 17, 2023. In the European Union also, this product is under the European Medicines Agency (EMA) review for conditional marketing authorization, with a decision expected in the second half of 2023.\n",
      "The company is also exploring Sparsentan in Focal Segmental Glomerulosclerosis and a phase III trial in this indication, dubbed DUPLEX, is underway. Topline data from this study is expected in the first half of 2023.\n",
      "As of September 30, 2022, the company had $506.3 million in cash, cash equivalents, and marketable securities.\n",
      "TVTX has traded in a range of $20.49 to $31.65 in the last 52 weeks. The stock is trading at $24.65, up 9.65% in Thursday's after-hours session.\n",
      "Zynex, Inc. (ZYXI), which reported revenue growth of 19% for the third quarter of 2022, expects revenue to grow 23% in the fourth quarter.\n",
      "In the third quarter of 2022, the company's revenue increased to $41.5 million from $34.7 million in the third quarter of 2021.\n",
      "Net income declined to $4.9 million or $0.13 per share in Q3 2022, from $6.1 million or $0.16 per share in the third quarter of 2021, but came in just above analysts' consensus estimate of $0.12 per share.\n",
      "The company provided revenue guidance for the fourth quarter of 2022 along with FY 2022.\n",
      "For the fourth quarter, the company expects revenue to be in the range of $48 million to $51 million, with the analysts' consensus estimate being $49.18 million. Revenue was $40.37 million in the fourth quarter of 2021.\n",
      "For FY 2022, the company anticipates revenue to be in the range of $157.4 million to $160.4 million, in line with Wall Street analysts' estimate of $158.45 million. Revenue was $130.3 million in FY 21.\n",
      "The company ended the third quarter of 2022 with $23.5 million in cash reserves.\n",
      "ZYXI has traded in a range of $4.97 to $15.66 in the last 52 weeks. The stock closed Thursday's trading at $9.21, up 0.66%.\n",
      "Insmed Incorporated (INSM) has reported a wider loss for the third quarter of 2022 even as revenue climbed nearly 45% .\n",
      "In the third quarter of 2022, revenue grew to $67.7 million, from for the third quarter of 2021.\n",
      "In Q3 2022, Insmed's net loss widened to $131.1 million, or $1.09 per share on revenue of $67.7 million. This compared with a net loss of $112.7 million or $0.96 per share and revenue of $46.8 million in the year-ago period.\n",
      "Wall Street analysts' expected the earnings to be $0.89 per share.\n",
      "Anticipated events:\n",
      "By the end of 2022, the company expects to report topline data from the phase II pharmacokinetic/pharmacodynamic study of Brensocatib in patients with cystic fibrosis. The company intends to share data from the ARISE post-marketing confirmatory trial of ARIKAYCE in patients with nontuberculous mycobacterial lung disease caused by Mycobacterium Avium Complex (MAC), over the course of 2023. In the second quarter of 2024, the company expects topline data from the phase III ASPEN Trial of Brensocatib for the treatment on-Cystic Fibrosis Bronchiectasis.\n",
      "Insmed ended the third quarter of 2022, with $513.3 million in cash, cash equivalents, and marketable securities.\n",
      "INSM has traded in a range of $16.41 to $34.44 in the last 52 weeks. The stock closed Thursday's trading at $16.98, down 4.12%.\n",
      "Aargenx SE's (ARGX), Vyvgart, which was approved last December for Myasthenia Gravis, a rare, chronic, autoimmune, neuromuscular disease, has generated net product sales of $131.3 million for the third quarter ended Sep.30, 2022.\n",
      "Efgartigimod, the active ingredient in Vyvgart, is also being explored in a couple of indications. A registrational trial of SC efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy, dubbed ADHERE, is underway, with topline data expected in the first quarter of 2023.\n",
      "The company expects topline data from the second registrational ADVANCE-SC trial of SC efgartigimod for primary immune thrombocytopenia (ITP) in the second half of 2023.\n",
      "In the second half of 2023, the company expects topline data from the registrational ADDRESS trial of SC efgartigimod for Pemphigus Vulgaris and Foliaceus.\n",
      "ARGX has traded in a range of $249.5 to $403.77 in the last 52 weeks. The stock closed Thursday's trading at $372.24, down 2.97%.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 8.33%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.08, delivering a surprise of 14.29%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $41.52 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 0.66%. This compares to year-ago revenues of $34.79 million. The company has topped consensus revenue estimates three times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have added about 1% since the beginning of the year versus the S&P 500's decline of -19.6%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.19 on $49.02 million in revenues for the coming quarter and $0.43 on $158.11 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "Another stock from the same industry, Quanterix Corporation (QTRX), has yet to report results for the quarter ended September 2022.\n",
      "This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Quanterix Corporation's revenues are expected to be $22.56 million, down 15.4% from the year-ago quarter.\n",
      "\n",
      "This Little-Known Semiconductor Stock Could Be Your Portfolios Hedge Against Inflation\n",
      "Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and thats just the tip of the iceberg), you have a need for semiconductors. Thats why their importance cant be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.\n",
      ">>Yes, I Want to Help Protect My Portfolio During the Recession\n",
      "\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "\n",
      "The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. Importantly, Zynex, Inc. (NASDAQ:ZYXI) does carry debt. But the real question is whether this debt is making the company risky.\n",
      "When Is Debt A Problem?\n",
      "Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.\n",
      "How Much Debt Does Zynex Carry?\n",
      "As you can see below, at the end of June 2022, Zynex had US$13.3m of debt, up from none a year ago. Click the image for more detail. However, its balance sheet shows it holds US$26.9m in cash, so it actually has US$13.6m net cash.\n",
      "NasdaqGS:ZYXI Debt to Equity History October 6th 2022\n",
      "How Healthy Is Zynex's Balance Sheet?\n",
      "We can see from the most recent balance sheet that Zynex had liabilities of US$18.8m falling due within a year, and liabilities of US$31.7m due beyond that. Offsetting these obligations, it had cash of US$26.9m as well as receivables valued at US$27.8m due within 12 months. So it actually has US$4.14m more liquid assets than total liabilities.\n",
      "Having regard to Zynex's size, it seems that its liquid assets are well balanced with its total liabilities. So while it's hard to imagine that the US$365.2m company is struggling for cash, we still think it's worth monitoring its balance sheet. Succinctly put, Zynex boasts net cash, so it's fair to say it does not have a heavy debt load!\n",
      "Even more impressive was the fact that Zynex grew its EBIT by 302% over twelve months. That boost will make it even easier to pay down debt going forward. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Zynex's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.\n",
      "Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. While Zynex has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. In the last three years, Zynex's free cash flow amounted to 25% of its EBIT, less than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.\n",
      "Summing Up\n",
      "While we empathize with investors who find debt concerning, you should keep in mind that Zynex has net cash of US$13.6m, as well as more liquid assets than liabilities. And it impressed us with its EBIT growth of 302% over the last year. So we don't think Zynex's use of debt is risky. Above most other metrics, we think its important to track how fast earnings per share is growing, if at all. If you've also come to that realization, you're in luck, because today you can view this interactive graph of Zynex's earnings per share history for free.\n",
      "If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.\n",
      "Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n",
      "\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.\n",
      "In contrast to all that, many investors prefer to focus on companies like Zynex (NASDAQ:ZYXI), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Zynex with the means to add long-term value to shareholders.\n",
      "How Fast Is Zynex Growing?\n",
      "The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Shareholders will be happy to know that Zynex's EPS has grown 23% each year, compound, over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.\n",
      "One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Zynex shareholders can take confidence from the fact that EBIT margins are up from 6.4% to 18%, and revenue is growing. Ticking those two boxes is a good sign of growth, in our book.\n",
      "In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.\n",
      "NasdaqGS:ZYXI Earnings and Revenue History September 6th 2022\n",
      "In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of Zynex's forecast profits?\n",
      "Are Zynex Insiders Aligned With All Shareholders?\n",
      "Many consider high insider ownership to be a strong sign of alignment between the leaders of a company and the ordinary shareholders. So we're pleased to report that Zynex insiders own a meaningful share of the business. In fact, they own 43% of the shares, making insiders a very influential shareholder group. Those who are comforted by solid insider ownership like this should be happy, as it implies that those running the business are genuinely motivated to create shareholder value. With that sort of holding, insiders have about US$144m riding on the stock, at current prices. That should be more than enough to keep them focussed on creating shareholder value!\n",
      "It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. Our analysis has discovered that the median total compensation for the CEOs of companies like Zynex with market caps between US$200m and US$800m is about US$2.7m.\n",
      "Zynex's CEO took home a total compensation package of US$988k in the year prior to December 2021. That's clearly well below average, so at a glance that arrangement seems generous to shareholders and points to a modest remuneration culture. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. Generally, arguments can be made that reasonable pay levels attest to good decision-making.\n",
      "Should You Add Zynex To Your Watchlist?\n",
      "For growth investors, Zynex's raw rate of earnings growth is a beacon in the night. If you need more convincing beyond that EPS growth rate, don't forget about the reasonable remuneration and the high insider ownership. Everyone has their own preferences when it comes to investing but it definitely makes Zynex look rather interesting indeed. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if Zynex is trading on a high P/E or a low P/E, relative to its industry.\n",
      "The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.\n",
      "Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.\n",
      "Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n",
      "\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "InvestorPlace - Stock Market News, Stock Advice & Trading Tips\n",
      "In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion. They also tend to be riskier than large-cap names.\n",
      "Revenue and profits of small-cap stocks tend to be much lower than those of their large-cap peers, while the small caps debt-revenue ratios tend to be higher.\n",
      "As a result, small-cap companies are more likely to go bankrupt, but there still are small-cap stocks to buy that can really run.\n",
      "Its much easier to make huge profits with small-cap stocks than with large-cap ones, and history shows that the best small-cap stocks to buy can indeed make huge fortunes for investors.\n",
      "For example, Amazon (NASDAQ:AMZN), Tesla (NASDAQ:TSLA) and ServiceNow (NYSE:NOW) were once small-cap stocks.\n",
      "And some professional money managers who believe in momentum investing would say that the best small-cap stocks to buy are those whose values have been climbing in recent weeks. That increases the chances of making a great deal of money in the market.\n",
      "That said, consider these seven small-cap stocks to buy as we enter September.\n",
      "ZYXI Zynex $8.92\n",
      "YTRA Yatra Online $2.76\n",
      "TSRI TSR $7.95\n",
      "APM Aptorums $1.47\n",
      "JOB GEE $0.72\n",
      "VTVT vTv Therapeutics $1.04\n",
      "ZAIRF Zinc8 $0.24\n",
      "Zynex (ZYXI)\n",
      "Source: ArtemisDiana/Shutterstock\n",
      "Zynex (NASDAQ:ZYXI) sells its own medical devices and those of other companies. Many of the products that Zynex sells are pain-relievers. Its leading product NextWave  uses electrical currents to relieve pain.\n",
      "Given increased fears of opioid addiction, the demand for Zynexs pain-relieving products is likely to be very strong. The companys orders reached record levels in Q2, as its orders increased 19% quarter over quarter and 10% year over year, and the company preliminarily reported that its sales had jumped 18% year over year in Q2.\n",
      "For the full year, Zynex expects its EBITDA, excluding certain items, to come in between $25 million and $35 million. Zynexs forward price-earnings ratio is a reasonable 21.5, making in one of the better small-cap stocks to buy right now.\n",
      "Yatra Online (YTRA)\n",
      "Source: Shutterstock\n",
      "As in the U.S., India is experiencing a huge travel rebound as fears of the coronavirus subside and as lockdowns are terminated.\n",
      "Indian online travel agency Yatra Online (NASDAQ:YTRA) is clearly benefiting from that trend.\n",
      "Yatras revenue jumped 141% year-over-year in the second quarter to $15.9 million, excluding certain items. Its adjusted EBITDA in Q2 came in at $1.6 million.\n",
      "The shares are trading at a very attractive forward price-sales ratio of just 1.7 ($173 million market cap/$106 million analysts mean estimate for next year).\n",
      "TSR (TSRI)\n",
      "Source: GaudiLab / Shutterstock\n",
      "TSR (NASDAQ:TSRI) should be reporting very strong financial results in the current macro environment. The U.S. labor market remains tight while many IT companies are still generating huge profits. Those IT firms are more likely than in past years to use recruiters like TSR and to pay them high commissions.\n",
      "For its fiscal Q4 that ended in May, TSRs sales jumped 24% to a record $26.2 million, while its EPS came in at 15 cents, versus a per-share loss of 2 cents during the same period a year earlier. For the full fiscal year, TSRs EPS jumped to $3.30, versus a per share loss of 31 cents during the previous year.\n",
      "The stock has climbed 12% in the last three months, and its P/E ratio is a tiny 2.4. With the IT labor market likely to remain very tight for a long time, TSR stock is one of the better small-cap stocks worth considering. Aptorum (APM)\n",
      "Source: Pavel Kapysh / Shutterstock.com\n",
      "In January, the FDA granted orphan drug designation to Aptorums (NASDAQ:APM) SACT-1 cancer treatment, as InvestorPlace writer Joel Baglole reported.\n",
      "A recent clinical trial indicated that the drug does not adversely affect electrical currents in the heart. The Phase 1 clinical data also suggested that any QT interval after oral administration of SACT-1 at 150 mg was well within clinically acceptable limits.\n",
      "Despite the recent slump of stocks, Aptorum has climbed 4% in August. Moreover, the shares have jumped 53% since May.\n",
      "These gains indicate that the Street is very excited about SACT-1 . That, in turn, suggests that APT stock may continue to climb going further and that the drug could become a big moneymaker for the company. Indeed, orphan drugs are often very lucrative for pharmaceutical firms.\n",
      "GEE Group (JOB)\n",
      "Source: Shutterstock\n",
      "Rrecruiting company GEE (NYSE:JOB) focuses on placing skilled professionals in positions. In addition to IT workers, Gee also recruits across the white-collar spectrum.\n",
      "Gee should continue to benefit from the tight labor market for some time, as more companies that have difficulty hiring skilled employees turn to recruiters.\n",
      "In its fiscal Q3 that ended in June, Gees operating income came in at $3.2 million, up from $1.8 million during the same period a year earlier. And the firms revenue increased to $41.1 million from $38.1 million during the same period a year earlier.\n",
      "In the last month, JOB stock has soared 30%, while its P/E ratio is a tiny 3.56 making it among the more attractive small-cap stocks out there.\n",
      "vTv Therapeutics (VTVT)\n",
      "Source: Gorodenkoff / Shutterstock.com\n",
      "vTv Therapeutics (NASDAQ:VTVT) has a diabetes treatment, TTP399, thats getting a lot of attention.\n",
      "In May, G42 Healthcare agreed to purchase $25 million of VTVT for about $2.41 per share, well above the stocks current level of $1.\n",
      "Whats more, last month, another investment company, CinPax, agreed to acquire $10 million in VTVT stock for $2.41 per share. CinRx also obtained a warrant to buy another 1.2 million shares for about 72 cents per share. The warrants will become exercisable upon agreed vesting triggers.\n",
      "vTv intends to begin two Phase 3 studies of its drug next quarter. In the last three months, VTVT stock has shot up 47%.\n",
      "Zinc8 (ZAIRF)\n",
      "Source: Shutterstock\n",
      "Zinc8 (OTC:ZAIRF) is developing an energy storage system to store energy significantly longer than lithium-ion batteries and is much cheaper.\n",
      "Based on Zinc8s recently released Q2 earnings press release, it appears that the system met all of an unnamed cloud service providers requirements, including demonstrating discharges of 6+ hours.\n",
      "It sounds as though Zinc8s system passed its test with flying colors and that the cloud service provider remains quite interested in using the system.\n",
      "Zinc8 is looking to build a factory in Ulster, N.Y. and has received support for that initiative from the Senate Majority Leader, Charles Schumer. Given Schumers support for the firm, I think its likely that Zinc8 will benefit from the Democrats climate bill.\n",
      "ZAIRF stock has soared 50% in the last three months.\n",
      "On the date of publication, Larry Ramer held long positions in VTVT and ZAIRF. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\n",
      "Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israels largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been GE, solar stocks, and Snap. You can reach him on StockTwits at @larryramer.\n",
      "The post 7 Hot Small-Cap Stocks to Buy in September appeared first on InvestorPlace.\n",
      "\n",
      "If you want to know who really controls Zynex, Inc. (NASDAQ:ZYXI), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Dont tell me what you think, tell me what you have in your portfolio.\n",
      "With a market capitalization of US$374m, Zynex is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Zynex.\n",
      "NasdaqGS:ZYXI Ownership Breakdown August 9th 2022\n",
      "What Does The Institutional Ownership Tell Us About Zynex?\n",
      "Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.\n",
      "We can see that Zynex does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zynex's historic earnings and revenue below, but keep in mind there's always more to the story.\n",
      "NasdaqGS:ZYXI Earnings and Revenue Growth August 9th 2022\n",
      "We note that hedge funds don't have a meaningful investment in Zynex. Looking at our data, we can see that the largest shareholder is the CEO Thomas Sandgaard with 42% of shares outstanding. For context, the second largest shareholder holds about 8.9% of the shares outstanding, followed by an ownership of 3.7% by the third-largest shareholder.\n",
      "A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 51% stake.\n",
      "Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.\n",
      "Insider Ownership Of Zynex\n",
      "While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.\n",
      "I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.\n",
      "Our information suggests that insiders maintain a significant holding in Zynex, Inc.. Insiders own US$160m worth of shares in the US$374m company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.\n",
      "General Public Ownership\n",
      "With a 22% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Zynex. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.\n",
      "Next Steps:\n",
      "It's always worth thinking about the different groups who own shares in a company. But to understand Zynex better, we need to consider many other factors. For example, we've discovered 1 warning sign for Zynex that you should be aware of before investing here.\n",
      "Ultimately the future is most important. You can access this free report on analyst forecasts for the company.\n",
      "NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.\n",
      "Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n",
      "\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 14.29%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.03, delivering a surprise of -40%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $36.76 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 0.92%. This compares to year-ago revenues of $31.02 million. The company has topped consensus revenue estimates two times over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 16.5% since the beginning of the year versus the S&P 500's decline of -15.6%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.12 on $41.61 million in revenues for the coming quarter and $0.43 on $158.57 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "Cardiovascular Systems (CSII), another stock in the same industry, has yet to report results for the quarter ended June 2022. The results are expected to be released on August 2.\n",
      "This medical device developer is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of -57.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Cardiovascular Systems' revenues are expected to be $62.88 million, down 11.4% from the year-ago quarter.\n",
      "\n",
      "Zacks Names \"Single Best Pick to Double\"\n",
      "From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.\n",
      "Its a little-known chemical company thats up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.\n",
      "This company could rival or surpass other recent Zacks Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.\n",
      "Free: See Our Top Stock and 4 Runners Up >>\n",
      "\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "\n",
      "(RTTNews) - The following are some of the biotech companies that posted quarterly earnings and provided a business update on Thursday.\n",
      "1. ABIOMED Inc. (ABMD) expects its revenue for fiscal year 2023 to grow 11% to 15% on a reported basis compared to fiscal year 2022.\n",
      "Revenue is expected to range between $1.14 billion and $1.18 billion in fiscal year 2023 compared to $1.03 billion reported in fiscal year 2022. Analysts, on average, are expecting revenue of $1.17 billion for fiscal 2023.\n",
      "The company posted a non-GAAP net income of $203.53 million or $4.44 per share for fiscal year ended March 31, 2022 compared to $175.07 million or $3.84 per share in the prior year.\n",
      "Wall Street analysts were looking for earnings of $4.35 per share and revenue of $1.03 billion.\n",
      "ABMD closed Thursday's trading at $287.22, up 3.63%.\n",
      "2. Accolade Inc. (ACCD) has reported a wider-than-expected loss for the fiscal fourth quarter and full year ended February 28, 2022 while revenue for the periods topped analysts' estimates.\n",
      "However, the revenue forecast provided by the company for fiscal first quarter ending May 31, 2022, and fiscal year ending February 28, 2023, are well below analysts' expectations.\n",
      "For the fiscal first quarter ending May 31, 2022, the company expects revenue between $81 million and $83 million while the consensus analysts' estimate is $85.91 million. The company's revenue was $59.5 million for the fiscal first quarter ended May 31, 2021.\n",
      "For the fiscal year ending February 28, 2023, Accolade anticipates revenue between $350 million and $365 million - well below the consensus analysts' estimate of $387.39 million. Revenue was $310.0 million for fiscal year 2022.\n",
      "ACCD closed Thursday's trading at $11.06, down 9.93%. In after-hours, the stock fell over 30% to $7.74.\n",
      "3. AC Immune SA (ACIU) has a couple of clinical trial events to watch out for this year.\n",
      "-- A phase 1b/2 trial of ACI-24 anti-Abeta vaccine in patients with Alzheimer's disease is expected to be initiated in the first half of this year. Data from the phase Ib portion of the trial is anticipated in the second half of this year. -- Top line results from a phase II trial of Crenezumab anti-Abeta antibody in patients with autosomal dominant Alzheimer's disease are expected in the first half of this year. -- Additional fluid biomarker data from a phase II study of Semorinemab anti-Tau antibody in mild-to-moderate Alzheimer's disease, dubbed Lauriet, is anticipated in the second half of this year. -- Results from phase II and phase I trials of PI-2620 Tau-PET tracer in AD and progressive supranuclear palsy respectively, are expected in the second half of 2022. -- The company expects to initiate a phase II trial of ACI-7104 anti-a-syn vaccine in early Parkinson's disease in the second half of this year.\n",
      "Cash position:\n",
      "As of March 31, 2022, cash on hand totaled CHF 173.8 million.\n",
      "ACIU closed Thursday's trading at $3.42, down 0.87%.\n",
      "4. Alnylam Pharmaceuticals Inc. (ALNY) has lowered its 2022 guidance range for combined net product revenues based on the first quarter results.\n",
      "For full year 2022 the company now expects combined net product revenues to range between $870 million and $930 million, down from its prior guidance of $900 million to $1 billion.\n",
      "Vutrisiran, the company's investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, is under FDA review, with a decision expected on July 14, 2022.\n",
      "The following events are expected in early and mid-2022.\n",
      "-- Topline results from phase III trial of Patisiran in ATTR amyloidosis patients with cardiomyopathy, dubbed APOLLO-B. -- Results from phase II monotherapy study of Cemdisiran in patients with IgA nephropathy. -- Novartis plans to report results from its ORION-3 phase II study of Inclisiran in patients with heterozygous familial hypercholesterolemia or pre-existing atherosclerotic cardiovascular disease on background statin +/- ezetimibe therapy. Inclisiran is being developed by Novartis under a license from Alnylam Pharma. -- Topline results from Part B of a phase I study of ALN-HSD in patients with NASH.\n",
      "ALNY closed Thursday's trading at $143.16, down 7.59%.\n",
      "5. Baxter International Inc. (BAX) expects sales to grow approximately 26% for the second quarter and 23%-24% for full-year 2022, on a reported basis.\n",
      "The company had reported sales of $3.1 billion for the second quarter of 2021 and $12.8 billion for full-year 2021.\n",
      "Wall Street analysts, on average, expect the company to report sales of $3.88 billion for the second quarter and $15.9 billion for full-year 2022.\n",
      "BAX closed Thursday's trading at $70.80, down 0.38%.\n",
      "6. GlycoMimetics Inc. (GLYC) has a couple of clinical trial events to watch in the coming months.\n",
      "The company expects to submit an IND, seeking FDA clearance to initiate a phase I trial for GMI-1687 in sickle cell disease in the first half of 2022.\n",
      "The lead drug candidate Uproleselan is under a phase III trial in relapsed/refractory AML. GlycoMimetics now anticipates mid-year 2023 for the overall survival events trigger, with top line data disclosure shortly thereafter.\n",
      "Cash position:\n",
      "As of March 31, 2022, GlycoMimetics had cash of $76.5 million.\n",
      "GLYC closed Thursday's trading at $0.77, down 7.98%.\n",
      "7. LeMaitre (LMAT), a provider of vascular devices, implants and services, has lowered its sales outlook for full-year 2022 due to a negative impact from the stronger U.S. dollar.\n",
      "For full-year 2022, the company now expects sales to range between $160.0 million and $164.0 million, down from its prior forecast of $162 million to $166 million. The company had reported sales of $154.4 million in 2021.\n",
      "Wall Street analysts, on average, expect the company to report sales of $164.75 million for the year.\n",
      "LMAT closed Thursday's trading at $45.81, up 2.97%.\n",
      "8. Novocure (NVCR) expects 2022 to be a transformational period, with a couple of clinical milestones to be achieved.\n",
      "The following data readouts and events are anticipated this year.\n",
      "-- Data from phase 2 pilot trial evaluating the safety and efficacy of Tumor Treating Fields concomitant with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma, dubbed EF-31. -- Data from phase pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma, dubbed EF-33. -- Last patient enrollment in phase 3 pivotal trial studying radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer, dubbed METIS. -- Data from LUNAR study, a phase III pivotal trial testing the effectiveness of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage 4 non-small cell lung cancer who progressed during or after platinum-based therapy.\n",
      "Cash position:\n",
      "The company's cash on hand totaled $932.3 million as of March 31, 2022.\n",
      "NVCR closed Thursday's trading at $77.18, up 0.30%.\n",
      "9. Zynex Inc. (ZYXI) an innovative medical technology company, which reported strong Q1 results, expects continued growth during this year.\n",
      "For the second quarter 2022, revenue is expected to be between $35.0 and $38.0 million, an increase of approximately 18% from the year-ago period.\n",
      "Looking ahead to full year 2022, the company anticipates revenue to be in the range of $150 million to $170 million. Revenue reported in 2021 was $130.3 million.\n",
      "Analysts polled by Thomson Reuters are looking for revenue of $37.14 million for Q2, and $159.82 million for full-year 2022.\n",
      "Cash on hand was $39.2 million as of March 31, 2022.\n",
      "ZYXI closed Thursday's trading at $7.14, up 2.44%.\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of -40%. A quarter ago, it was expected that this company would post earnings of $0.19 per share when it actually produced earnings of $0.23, delivering a surprise of 21.05%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $31.08 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 0.66%. This compares to year-ago revenues of $24.13 million. The company has topped consensus revenue estimates just once over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 23.1% since the beginning of the year versus the S&P 500's decline of -12.2%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.11 on $37.58 million in revenues for the coming quarter and $0.50 on $159.91 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "Evolus, Inc. (EOLS), another stock in the same industry, has yet to report results for the quarter ended March 2022. The results are expected to be released on May 10.\n",
      "This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -315.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "Evolus, Inc.'s revenues are expected to be $30.27 million, up 147.3% from the year-ago quarter.\n",
      "\n",
      "5 Stocks Set to Double\n",
      "Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.\n",
      "Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.\n",
      "Today, See These 5 Potential Home Runs >>\n",
      "\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "\n",
      "Trending Health Care Stocks To Watch In The Stock Market This Week\n",
      "As talks of a possible recession by the end of the year arise, investors could be thinking of rotating towards more defensive positions. As such, they could consider investing in health care stocks. This comes as health care stocks encompass a broad range of companies that are normally more resilient to a volatile market. These include drug retailers, insurance providers, hospitals, and biotech companies as well. Given the fact that health care is a necessity, there will always be a demand for the products and services that these companies provide. Hence, investing in health care stocks could make for a viable play during an uncertain market.\n",
      "Investors could consider the likes of Pfizer (NYSE: PFE). Being at the forefront of the pandemic, most would be familiar with the company that brought the Covid-19 vaccine to billions. Its antiviral Covid-19 pill, Paxlovid, is also in high demand. As a matter of fact, Taiwan just placed an order of 700,000 units of the companys Paxlovid antiviral Covid-19 pill. Apart from Pfizer, investors could also consider Lyra Therapeutics (NASDAQ: LYRA). Last week, the company announced that it has entered into a securities purchase agreement to sell securities in a private placement. The gross proceeds from the placement are expected to be approximately $100.5 million, which would help fund the companys plans. And on that note, check out these four health care stocks in the stock market today.\n",
      "Health Care Stocks To Watch Right Now Veru Inc. (NASDAQ: VERU)\n",
      "Zynex Inc. (NASDAQ: ZYXI) Eli Lilly And Company (NYSE: LLY) BioNTech SE (NASDAQ: BNTX) Veru Starting us off today is Veru, a biopharmaceutical company that engages itself primarily in oncology. Verus strategy mainly focuses on the clinical development and commercialization of oncology drugs. Particularly, it focuses on breast cancer and prostate cancer, two of the most prevalent cancers globally.Products in its breast cancer development portfolio include Enobosarm and Sabizabulin. As for its prostate cancer portfolio, it includes Sabizulin, VERU-100, and Zuclomiphene citrate. This week, VERU stock skyrocketed over 130% as its Sabizulin drug made headlines. Cutting to the chase, Veru proudly announced yesterday the positive efficacy and safety results of its Phase 3 Covid-19 clinical trial evaluating sabizabulin. In detail, the trial evaluates oral sabizabulin against placebo in 150 hospitalized Covid-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS). As such, sabizabulin is now the first drug to demonstrate a clinically and statistically meaningful reduction in deaths of hospitalized patients with Covid-19. Mitchell Steiner, CEO of Veru, added We strongly believe that sabizabulin, with its dual anti-viral and anti-inflammatory properties which demonstrated positive efficacy and safety results in the Phase 3 COVID-19 study, can be that greatly needed oral therapy for hospitalized moderate to severe COVID-19 patients. With this in mind, would VERU stock make your list of top health care stocks to buy today?\n",
      "Source: TD Ameritrade TOS\n",
      "[Read More] Stock Market Today: Dow Jones, S&P 500 Up On Key Inflation Data; Beyond Meat Expands Its Chicken Tenders To Over 8,000 Retailers\n",
      "Zynex\n",
      "Following that, we have Zynex. Through its subsidiaries, Zynex markets electrotherapy products that help improve the lives of patients who have functional disabilities. The Companys offerings include devices for pain management, neurological diagnosis and cardiac monitoring. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications. Over the past month, ZYXI stock has seen an impressive rise of over 30%.\n",
      "Last Friday, the company announced preliminary results for its first-quarter 2022 financials. The medical device company sees $30.5 to $31.5 million in unaudited revenue, signaling an estimated 26% year-over-year increase. Next to that, the company is looking at $3 to $4 million in EBITDA. Apart from this, Zynex also reaffirmed its guidance for the full fiscal year of 2022. Namely, it forecasts revenue to range between $150 million to $170 million. Earnings, on the other hand, is expected to be between $25 million to $35 million. Given the upbeat preliminary results, should investors be keeping an eye on ZYXI stock?\n",
      "Source: TD Ameritrade TOS\n",
      "[Read More] Metaverse Stocks To Buy Today? 4 For Your April Watchlist\n",
      "Eli Lilly and Company\n",
      "Another top health care stock to watch is Eli Lilly and Company (LLY). It is a leading pharmaceutical firm that has operations that span across the globe. For a sense of scale, the company has offices in 18 countries while its products are sold in approximately 125 countries. In brief, the companys portfolio includes treatments for various diseases including diabetes, cancer, endocrine-related illnesses, and Covid-19 to name a few. In the past year, LLY stock has seen gains of over 65% which would likely make many investors happy.\n",
      "Last Wednesday, Morgan Stanley (NYSE: MS) analyst Terence Flynn raised the price target on MS stock from $265 to $364. At the same time, the analyst also maintained an Overweight rating on the company. Flynn cites LLY as having the most robust new product cycle and growth outlook in the pharmaceutical industry. This is because the company could be launching five new drugs over the next two years. On top of that, two of the aforementioned five drugs are forecasted to hit 2030 sales above $5 billion. With LLYs prospects looking up, is LLY stock a buy?\n",
      "Source: TD Ameritrade TOS\n",
      "[Read More] Top Stock Market News For Today April 12, 2022\n",
      "BioNTech BioNTech is a biopharmaceutical company that has pioneered novel therapies for cancer and other serious diseases. Accordingly, the company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Thanks to its deep expertise in mRNA vaccine development and its in-house manufacturing capabilities, the company created one of the first mRNA vaccines in the world to treat Covid-19. Earlier in the month, the company reported its fourth-quarter and full-year financials. Diving in, revenues for the quarter grew by over 1,000% year-over-year to $6.16 billion on strong vaccine sales. In fact, BioNTech has sold over 2.6 billion doses of its vaccine to more than 165 countries and regions worldwide in 2021. This also includes more than 1 billion doses to low- and middle-income countries. It also says that it has signed orders for 2022 delivery of up to 2.4 billion vaccine doses. Its net profit for the quarter also rose by over 700% to $3.53 billion. Also, BioNTech announced that its global Covid-19 supply chain and manufacturing network now includes 20 manufacturing facilities that span across four continents. With this strong quarter in mind, should investors be on the lookout for BNTX stock?\n",
      "Source: TD Ameritrade TOS\n",
      "If you enjoyed this article and youre interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel.\n",
      "CLICK HERE RIGHT NOW!!\n",
      "\n",
      "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.\n",
      "ZYNEX INC. (ZYXI) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. designs, manufactures and markets medical devices, which treats chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation. The Company's medical devices are small, portable, battery operated and include an electrical pulse generator, which is connected to the body via electrodes. Its primary product is the NexWave device. The NexWave is marketed to physicians and therapists by its field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "Full Guru Analysis for ZYXI\n",
      "Full Factor Report for ZYXI\n",
      "GENIE ENERGY LTD (GNE) is a small-cap value stock in the Electric Utilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 100% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Genie Energy Ltd. is a global provider of energy services that operates through its subsidiaries. The Company's segments include Genie Retail Energy (GRE), GRE International and Genie Energy Services (GES). The GRE segment consists of retail energy providers (REPs) and related businesses. GRE's REP businesses purchase electricity and natural gas on the wholesale markets and resell its commodities to its residential and business customers in the United States. The GRE International segment consists of REPs and operates under a range of brand names, including Lumo Energia, Genie Energy Japan and Orbit Energy. The GES segment consists of businesses that market and provide energy solutions and also includes controlling interests in Prism, Diversegy and Genie Solar Energy. Its subsidiaries include Genie Energy International Corporation (GEIC), Genie Retail Energy (GRE), Genie Retail Energy International LLC (GREI), Genie Energy Services (GES) and Genie Oil and Gas, Inc. (GOGAS).\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of GENIE ENERGY LTD\n",
      "Full Guru Analysis for GNE\n",
      "Full Factor Report for GNE\n",
      "TILLY'S INC (TLYS) is a small-cap value stock in the Retail (Apparel) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 100% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Tilly's, Inc. is a destination specialty retailer of casual apparel, footwear and accessories for young men, young women, boys and girls. The Company operates approximately 244 stores, in 33 states. Its stores are located in malls, lifestyle centers, power centers, community centers, outlet centers and street-front locations. The Company also offers online shopping, where it offers same products as offers in stores, supplemented by additional online-only styles. The Company's third-party brands include Adidas, BDG, Billabong, Birkenstock, Brixton, Champion, Converse, Diamond Supply, Dickies, Dr. Martens, Ethika, Free People, G-Shock, Herschel Supply Co., HUF, Hurley, Hydro Flask, Jansport, Levi's, Neff, Nike SB, O'Neill, Obey, Primitive, RayBan, Riot Society, Rip Curl, Roxy, RVCA, Salty Crew, Santa Cruz, Spy, Stance, The North Face, Vans and Volcom.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of TILLY'S INC\n",
      "Full Guru Analysis for TLYS\n",
      "Full Factor Report for TLYS\n",
      "FIDUS INVESTMENT CORP (FDUS) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Fidus Investment Corporation is a closed-end, non-diversified investment company. The Company provides customized debt and equity financing solutions to lower middle-market companies. The Company's investment objective is to provide attractive risk-adjusted returns by generating both current income from its debt investments and capital appreciation from its equity-related investments. The Company typically invests in mezzanine debt, which includes senior subordinated notes and junior secured loans. The Company structures some of its debt investments as senior secured or unitranche loans. The Company's equity securities typically consist of either a direct minority equity investment in common or preferred stock or membership/partnership interests of a portfolio company, or it may receive warrants to buy a minority equity interest in a portfolio company in connection with a debt investment. Its investment activities are managed by Fidus Investment Advisors, LLC, its investment advisor.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of FIDUS INVESTMENT CORP\n",
      "Full Guru Analysis for FDUS\n",
      "Full Factor Report for FDUS\n",
      "MONROE CAPITAL CORP (MRCC) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Monroe Capital Corporation is a closed-end, non-diversified management investment company. The Company is a specialty finance company focused on providing financing primarily to lower middle-market companies in the United States and Canada. The Company's investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation primarily through investments in senior, unitranche and junior secured debt, and unsecured subordinated debt and equity. The Company provides customized financing solutions focused primarily on senior secured, junior secured and unitranche (a combination of senior secured and junior secured debt in the same facility) debt, and subordinated debt and equity, including equity co-investments in preferred and common stock and warrants. The Company's investment activities are managed by its investment advisor, Monroe Capital BDC Advisors, LLC (MC Advisors).\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of MONROE CAPITAL CORP\n",
      "Full Guru Analysis for MRCC\n",
      "Full Factor Report for MRCC\n",
      "MADISON COVERED CALL & EQUITY STRTGY FD (MCN) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Madison Covered Call & Equity Strategy Fund (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Fund will pursue its investment objectives by investing primarily in large and mid-capitalization common stocks. Under normal market conditions, the Fund will seek to generate current earnings from option premiums by writing (selling) covered call options on a substantial portion of its portfolio securities. The Fund's portfolio of investment includes communication services, health care, consumer discretionary, industrials, consumer staples, information technology, energy, materials, exchange traded funds, short-term investments, financial and utilities. The Fund's investment advisor is Madison Asset Management, LLC.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "Detailed Analysis of MADISON COVERED CALL & EQUITY STRTGY FD\n",
      "Full Guru Analysis for MCN\n",
      "Full Factor Report for MCN\n",
      "BANKWELL FINANCIAL GROUP INC (BWFG) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 89% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Bankwell Financial Group, Inc. is a bank holding company. The Company offers a range of financial services through its banking subsidiary, Bankwell Bank (the Bank). The Bank is a Connecticut state non-member bank. The Bank provides a range of banking services to commercial and consumer customers, concentrated in the New York metropolitan area and throughout Connecticut. The Bank's commercial lending products include owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans (such as business term loans, equipment financing and lines of credit) to small and mid-sized businesses, and real estate construction and development loans. Its depository products include checking, savings, money market and certificates of deposit. Its branch offices are located in New Canaan, Stamford, Norwalk, Fairfield, Darien and Westport, Connecticut.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of BANKWELL FINANCIAL GROUP INC\n",
      "Full Guru Analysis for BWFG\n",
      "Full Factor Report for BWFG\n",
      "AMPHASTAR PHARMACEUTICALS INC (AMPH) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. It manufactures and sells over 20 products. It operates through two segments: finished pharmaceutical products and API products. It marketed products include Primatene Mist, Enoxaparin, Glucagon for Injection Emergency Kit, Naloxone and Other finished pharmaceutical products. Primatene Mist, an over-the-counter epinephrine inhalation product, is indicated for the temporary relief of mild symptoms of intermittent asthma. Enoxaparin is an injectable form of low molecular weight heparin that is used as an anticoagulant, which is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis. Glucagon for injection is a difficult to manufacture injectable product.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: FAIL\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "Detailed Analysis of AMPHASTAR PHARMACEUTICALS INC\n",
      "Full Guru Analysis for AMPH\n",
      "Full Factor Report for AMPH\n",
      "GRANITE REAL ESTATE INVESTMENT TRUST (GRP.U) is a mid-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 72% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Granite Real Estate Investment Trust is a Canada-based real estate investment trust (REIT) engaged in the acquisition, development, ownership and management of logistics, warehouse and industrial properties in North America and Europe. The Company owns approximately 114 investment properties in seven countries having approximately 49.4 million square feet of gross leasable area. It has a team of approximately 53 real estate professionals, which is engaged in operations, leasing, development, investment and asset management. The Company's investment properties consist of income-producing properties, properties under development and land held for development. The income-producing properties are for industrial use and can be categorized as modern logistics/distribution warehouse facilities, multi-purpose facilities, which are tenantable by a variety of users, or special purpose properties designed and built with specialized features and leased to Magna.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of GRANITE REAL ESTATE INVESTMENT TRUST\n",
      "Full Guru Analysis for GRP.U\n",
      "Full Factor Report for GRP.U\n",
      "UBIQUITI INC (UI) is a large-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Ubiquiti Inc. is engaged in selling equipment, and providing related software platforms, through a network of over distributors, online retailers and direct to customers through its webstores. The Company develops technology platforms for high-capacity distributed Internet access, unified information technology, and consumer electronics for professional, home and personal use. The Company categorizes its solutions in to three main categories: service providers, enterprises and consumers. Its service provider product platforms provide carrier-class network infrastructure for fixed wireless broadband, wireless backhaul systems and routing. Its enterprise product platforms provide wireless local area network (WLAN) infrastructure, video surveillance products, switching and routing solutions, security gateways, and other complimentary WLAN products. Its consumer products, sold under the Ubiquiti Labs brand name, are targeted at smart home and connected consumers.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of UBIQUITI INC\n",
      "Full Guru Analysis for UI\n",
      "Full Factor Report for UI\n",
      "VALHI, INC. (VHI) is a small-cap value stock in the Chemical Manufacturing industry. The rating according to our strategy based on Peter Lynch changed from 74% to 96% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Valhi, Inc. is a holding company. The Company operates through its wholly owned and majority owned subsidiaries, including NL Industries, Inc., Kronos Worldwide, Inc. (Kronos), CompX International, Inc. (CompX), Tremont LLC, Basic Management, Inc. (BMI) and the LandWell Company (LandWell). Its Chemicals Segment is operated through Kronos. Kronos is a producer and marketer of titanium dioxide pigments (TiO2). Its Component Products segment is operated through CompX. CompX is a manufacturer of security products used in the recreational transportation, postal, office and institutional furniture, cabinetry, tool storage and healthcare applications. Its Real Estate Management and Development segment is operated through BMI and LandWell. BMI provides utility services to certain industrial and municipal customers and owns real property in Henderson, Nevada. LandWell is engaged in the development of certain land holdings for commercial, industrial and residential purposes in Henderson, Nevada.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "INVENTORY TO SALES: PASS\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of VALHI, INC.\n",
      "Full Guru Analysis for VHI\n",
      "Full Factor Report for VHI\n",
      "TCG BDC INC (CGBD) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: TCG BDC, Inc. is an externally managed, non-diversified closed-end investment company. The Company's investment objective is to generate current income and capital appreciation primarily through debt investments. The Company's core investment strategy focuses on lending to the United States and middle-market companies. The Company seeks to achieve its investment objective primarily through direct origination of secured debt instruments. The Company's first lien senior secured loans, including stand-alone first lien loans, first lien/last out loans and unitranche loans. Its Second lien senior secured loans, including Middle market senior loans with the balance of its assets invested in higher-yielding investments, including unsecured debt, mezzanine debt and investments in equities. The Company is managed by its investment adviser, Carlyle Global Credit Investment Management L.L.C.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of TCG BDC INC\n",
      "Full Guru Analysis for CGBD\n",
      "Full Factor Report for CGBD\n",
      "LOMA NEGRA COMPANIA INDL ARGNTNA SA-ADR (LOMA) is a small-cap value stock in the Construction - Raw Materials industry. The rating according to our strategy based on Peter Lynch changed from 72% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Loma Negra Compania Industrial Argentina SA is an Argentina-based vertically integrated company active in the cement industry. It produces and distribute cement, masonry cement, aggregates, concrete, and lime, primarily used in private and public construction, to wholesale distributors, concrete producers, and industrial customers, among others. The Company operates five segments: Cement, masonry cement and lime Argentina, Cement Paraguay, Concrete, Aggregates, Railroad and Others. Cement, masonry cement and lime Argentina includes the cement, masonry cement and lime business in Argentina. Cement Paraguay includes the cement business in Paraguay. Concrete includes principally the production and sale of ready-mix concrete. Aggregates includes the production and sale of granitic aggregates. Railroad includes the provision of the railroad transportation service. Others includes the industrial waste treatment and recycling business to produce materials for use as fuel o raw material.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of LOMA NEGRA COMPANIA INDL ARGNTNA SA-ADR\n",
      "Full Guru Analysis for LOMA\n",
      "Full Factor Report for LOMA\n",
      "ALPHA METALLURGICAL RESOURCES INC (AMR) is a mid-cap value stock in the Coal industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Alpha Metallurgical Resources, Inc., formerly Contura Energy, Inc., is a mining company with operations across Virginia and West Virginia. The Company is principally engaged in supplying metallurgical products to the steel industry. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities. The Company operates in one reportable segment: Met, which consists of five active mines and two preparation plants in Virginia, fourteen active mines and five preparation plants in West Virginia, as well as expenses associated with certain closed mines. The Met segment operations consist of met coal mines, including Deep Mine 41, Road Fork 52, Black Eagle, and Lynn Branch. The coal produced by its Met segment operations is predominantly met coal with some amounts of thermal coal being produced as a byproduct of mining.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: FAIL\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of ALPHA METALLURGICAL RESOURCES INC\n",
      "Full Guru Analysis for AMR\n",
      "Full Factor Report for AMR\n",
      "ZIM INTEGRATED SHIPPING SERVICES LTD (ZIM) is a mid-cap value stock in the Water Transportation industry. The rating according to our strategy based on Peter Lynch changed from 0% to 78% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zim Integrated Shipping Services Ltd is an Israel-based company. It operates as fleet and a network of shipping lines offering cargo transportation services on all major global trade routes, it also offers multi-modal, cargo handling, tariff management, schedule information, and other related services supported by the company's local offices and representatives around the world.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: FAIL\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of ZIM INTEGRATED SHIPPING SERVICES LTD\n",
      "Full Guru Analysis for ZIM\n",
      "Full Factor Report for ZIM\n",
      "ALIGN TECHNOLOGY, INC. (ALGN) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 69% to 87% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Align Technology, Inc. designs, manufactures and markets Invisalign clear aligners and iTero intraoral scanners and services for dentistry, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for dental laboratories and dental practitioners. It operates through two segments: Clear Aligner segment and Imaging Systems and CAD/CAM services (Systems and Services) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Invisalign Moderate, Lite and Express packages and Invisalign Go (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Systems and Services segment consists of its iTero intraoral scanning systems, which includes a hardware platform and restorative or orthodontic software options, OrthoCAD services and ancillary products, as well as exocad's CAD/CAM software solution.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of ALIGN TECHNOLOGY, INC.\n",
      "Full Guru Analysis for ALGN\n",
      "Full Factor Report for ALGN\n",
      "COHEN & STEERS TOTAL RETURN REAL. FD INC (RFI) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Cohen & Steers Total Return Realty Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The investment objective of the Fund is to achieve a high total return through investment in real estate securities. Real estate securities include common stocks, preferred stocks and other equity securities of any market capitalization issued by real estate companies, including real estate investment trusts (REITs) and similar REIT-like entities. The Fund invests in sectors, including industrials, office, residential, healthcare, shopping centers, specialty, diversified and self-storage. Cohen & Steers Capital Management, Inc. is the Fund's investment advisor.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "Detailed Analysis of COHEN & STEERS TOTAL RETURN REAL. FD INC\n",
      "Full Guru Analysis for RFI\n",
      "Full Factor Report for RFI\n",
      "MERCEDES-BENZ GROUP AG (DDAIF) is a large-cap value stock in the Auto & Truck Manufacturers industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Mercedes-Benz Group AG, formerly Daimler AG (Daimler), is a Germany-based automotive engineering company. The Company engages in the development, production and distribution of cars and vans in Germany, and the management of the Daimler Group. The segments include Mercedes-Benz Cars, Mercedes-Benz Vans and Daimler Financial Services. The Mercedes-Benz Cars segment includes vehicles of the Mercedes-Benz brand, including the brands, Mercedes-AMG and Mercedes-Maybach, and small cars under the smart brand, as well as the Mercedes me brand. The Mercedes-Benz Vans sells vans under the brand name Mercedes-Benz and the Freightliner brand. The Daimler Mobility AG offers e.g. financing, leasing, car subscription and car rental, fleet management, digital services, as well as mobility services. The Daimler financial services also supports the sales of its automotive brands worldwide.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: FAIL\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of MERCEDES-BENZ GROUP AG\n",
      "Full Guru Analysis for DDAIF\n",
      "Full Factor Report for DDAIF\n",
      "SOUTHERN FIRST BANCSHARES, INC. (SFST) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Southern First Bancshares, Inc. is a bank holding company. The Company's primary business is to serve as the holding company for Southern First Bank (the Bank), a South Carolina state bank. The Bank is a commercial bank with approximately eight retail offices located in the Greenville, Columbia, Charleston, Raleigh, Greensboro and Atlanta. The Bank is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC) and providing commercial, consumer and mortgage loans to the general public. In addition to deposit and loan services, it offers other bank services, such as Internet banking, cash management services, safe deposit boxes, direct deposit and automatic drafts for various accounts. The Bank offers a range of lending services, including real estate, commercial, equity-line consumer loans to individuals and small- to medium-sized businesses, and professional firms.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: NEUTRAL\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: PASS\n",
      "RETURN ON ASSETS: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of SOUTHERN FIRST BANCSHARES, INC.\n",
      "Full Guru Analysis for SFST\n",
      "Full Factor Report for SFST\n",
      "FERRO CORPORATION (FOE) is a small-cap growth stock in the Chemical Manufacturing industry. The rating according to our strategy based on Peter Lynch changed from 0% to 87% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Ferro Corporation (Ferro), is a supplier of technology-based functional coatings and color solutions. The Company's segments include Functional Coatings and Color Solutions. Ferro supplies Functional Coatings for glass, metal, ceramic and other substrates and Color Solutions in the form of specialty pigments and colorants for a range of industries and applications. Ferro products are used in the building and construction, automotive, electronics, industrial products, household furnishings, sanitary, packaging and appliance markets. Ferro's products fall into two general categories: Functional Coatings, which perform specific functions in the manufacturing processes and end products of its customers; and Color Solutions, which provide aesthetic and performance characteristics to its customers' products. The Company produces its products primarily in the Europe, Middle East and Africa region, the United States, the Asia Pacific region, and Latin America.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of FERRO CORPORATION\n",
      "Full Guru Analysis for FOE\n",
      "Full Factor Report for FOE\n",
      "GENESCO INC. (GCO) is a small-cap value stock in the Retail (Apparel) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Genesco Inc. is a specialty retailer engaged in sourcing and design, marketing and distribution of footwear and accessories. The Company operates through four segments, Journeys Group, Schuh Group, Johnston & Murphy Group, and Licensed Brands. The Journeys Group segment comprises of the Journeys, Journeys Kidz and Little Burgundy retail footwear chains and e-commerce operations. The Schuh Group segment comprises of the Schuh retail footwear chain and e-commerce operations. The Johnston & Murphy Group segment comprises of Johnston & Murphy retail operations, e-commerce operations and wholesale distribution of products under the Johnston & Murphy brand. The Licensed Brands segment comprises of the licensed Dockers, Levi's, and G.H. Bass brands, as well as other brands it licenses for footwear. The Company operates approximately 1,439 retail stores in the United States, Puerto Rico, Canada, the United Kingdom and the Republic of Ireland.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "Detailed Analysis of GENESCO INC.\n",
      "Full Guru Analysis for GCO\n",
      "Full Factor Report for GCO\n",
      "NL INDUSTRIES INC (NL) is a small-cap value stock in the Personal & Household Prods. industry. The rating according to our strategy based on Peter Lynch changed from 0% to 81% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: NL Industries, Inc. is a manufacturer of engineered components utilized in a variety of applications and industries. It operates in the component products industry through its subsidiary CompX International Inc. It also operates in the chemicals industry through its non-controlling interest in Kronos Worldwide, Inc. (Kronos). The Company through its security products operations, manufactures mechanical and electronic cabinet locks and other locking mechanisms used in recreational transportation, postal, office and institutional furniture, cabinetry, tool storage and healthcare applications. It also manufactures stainless steel exhaust systems, gauges, throttle controls, wake enhancement systems, trim tabs and related hardware and accessories for the recreational marine and other industries through its Marine Components operations. Its products include National Cabinet Loc, Fort Lock, Lockview and RegulatoR. Its marine components products include Custom Marine and Livorsi Marine.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "SALES: FAIL\n",
      "INVENTORY TO SALES: PASS\n",
      "YIELD COMPARED TO THE S&P 500: PASS\n",
      "YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: PASS\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: BONUS PASS\n",
      "Detailed Analysis of NL INDUSTRIES INC\n",
      "Full Guru Analysis for NL\n",
      "Full Factor Report for NL\n",
      "CHILDREN'S PLACE INC (PLCE) is a small-cap value stock in the Retail (Apparel) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: The Children's Place, Inc. is a children's specialty apparel retailer in North America. The Company provides apparel, footwear, accessories, and other items for children. It designs, contracts to manufacture and licenses to sell merchandise under brand names, such as The Children's Place, Place, Baby Place and Gymboree. The Company operates through two segments: the Children's Place U.S. and the Children's Place International. The Children's Place U.S. segment includes the United States and Puerto Rico-based stores. The Children's Place International segment includes its Canadian-based stores, wholesale customers, as well as international franchisees. The Company has various departments and serves the wardrobe needs of girls and boys (sizes 4-18), toddler girls and boys (sizes 6 months-5T), and baby (sizes 0-24 months). Its merchandise is also available online at and The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS\n",
      "EARNINGS PER SHARE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: FAIL\n",
      "FREE CASH FLOW: NEUTRAL\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of CHILDREN'S PLACE INC\n",
      "Full Guru Analysis for PLCE\n",
      "Full Factor Report for PLCE\n",
      "JACKSON FINANCIAL INC (JXN) is a mid-cap value stock in the Insurance (Life) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 78% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Jackson Financial Inc. is a holding company. The Company offers a suite of annuities to retail investors in the United States. It also offers fixed index annuities and fixed annuities. The Company helps to clarify the complexity of retirement planning for financial professionals and their clients. The Company operates through three segments: Retail Annuities, Institutional Products and Closed Life and Annuity Blocks. The Retail Annuities segment includes variable, fixed index and fixed annuities, The Institutional Products segment includes traditional guaranteed investment contracts, Federal Home Loan Bank funding agreements and medium-term funding agreement-backed notes and The Closed Life and Annuity Blocks segment includes various protection products, primarily including whole life, universal life, variable universal life and term life insurance products.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "P/E/GROWTH RATIO: PASS\n",
      "SALES AND P/E RATIO: PASS\n",
      "EPS GROWTH RATE: PASS\n",
      "TOTAL DEBT/EQUITY RATIO: NEUTRAL\n",
      "EQUITY/ASSETS RATIO: FAIL\n",
      "RETURN ON ASSETS: FAIL\n",
      "FREE CASH FLOW: BONUS PASS\n",
      "NET CASH POSITION: NEUTRAL\n",
      "Detailed Analysis of JACKSON FINANCIAL INC\n",
      "Full Guru Analysis for JXN\n",
      "Full Factor Report for JXN\n",
      "More details on Validea's Peter Lynch strategy\n",
      "Peter Lynch Stock Ideas\n",
      "About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. (\"Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it,\" is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a \"stocks for the everyman/everywoman\", breaking his approach down into easy-to-understand concepts.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.\n",
      "BUILD-A-BEAR WORKSHOP, INC (BBW) is a small-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Joel Greenblatt changed from 60% to 80% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Build-A-Bear Workshop, Inc. primarily operates specialty stores that provide a make your own stuffed animal interactive entertainment experience in which guests, with the help of the Company's associates, visit a variety of stations to assemble and customize a stuffed animal. It has three segments. Direct-to-consumer segment includes the operations of corporately managed locations and other retail delivery operations in the United States, Canada, China, Ireland and the United Kingdom, including its e-commerce sites. Commercial segment includes the Company's transactions with other businesses, mainly consisting of licensing the Company's intellectual properties for third-party use and wholesale activities. International franchising segment includes the licensing activities of the Company's franchise agreements with store locations in Asia, Australia, the Middle East, Africa and South America. It has approximately 355 corporately managed stores and 72 internationally franchised stores.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "EARNINGS YIELD: NEUTRAL\n",
      "RETURN ON TANGIBLE CAPITAL: NEUTRAL\n",
      "FINAL RANKING: FAIL\n",
      "Detailed Analysis of BUILD-A-BEAR WORKSHOP, INC\n",
      "Full Guru Analysis for BBW\n",
      "Full Factor Report for BBW\n",
      "ZYNEX INC. (ZYXI) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joel Greenblatt changed from 70% to 80% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. designs, manufactures and markets medical devices, which treats chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation. The Company's medical devices are small, portable, battery operated and include an electrical pulse generator, which is connected to the body via electrodes. Its primary product is the NexWave device. The NexWave is marketed to physicians and therapists by its field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "EARNINGS YIELD: NEUTRAL\n",
      "RETURN ON TANGIBLE CAPITAL: NEUTRAL\n",
      "FINAL RANKING: FAIL\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "Full Guru Analysis for ZYXI\n",
      "Full Factor Report for ZYXI\n",
      "MATSON INC (MATX) is a mid-cap value stock in the Water Transportation industry. The rating according to our strategy based on Joel Greenblatt changed from 0% to 90% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Matson, Inc. is a holding company, which provides ocean transportation and logistics services. The Company operates through two segments: Ocean Transportation and Logistics. The Ocean Transportation business is conducted through the Company's subsidiary, Matson Navigation Company, Inc. (MatNav), which provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska and Guam, and to other island economies in Micronesia. MatNav also operates two expedited services from China to Long Beach, California, and provides services to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Dutch Harbor to Asia. The Logistics business is conducted through MatNav's subsidiary, Matson Logistics, Inc. (Matson Logistics), which provides multimodal transportation brokerage of domestic and international rail intermodal services, long-haul and regional highway trucking services, and flat-bed and project services.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "EARNINGS YIELD: NEUTRAL\n",
      "RETURN ON TANGIBLE CAPITAL: NEUTRAL\n",
      "FINAL RANKING: PASS\n",
      "Detailed Analysis of MATSON INC\n",
      "Full Guru Analysis for MATX\n",
      "Full Factor Report for MATX\n",
      "More details on Validea's Joel Greenblatt strategy\n",
      "Joel Greenblatt Stock Ideas\n",
      "About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The \"Magic Formula,\" as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Zynex Inc. (ZYXI) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.\n",
      "This quarterly report represents an earnings surprise of 21.05%. A quarter ago, it was expected that this company would post earnings of $0.12 per share when it actually produced earnings of $0.15, delivering a surprise of 25%.\n",
      "Over the last four quarters, the company has surpassed consensus EPS estimates three times.\n",
      "Zynex Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $40.37 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 1.69%. This compares to year-ago revenues of $25.61 million. The company has topped consensus revenue estimates just once over the last four quarters.\n",
      "The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\n",
      "Zynex Inc. Shares have lost about 26.5% since the beginning of the year versus the S&P 500's decline of -11.3%.\n",
      "What's Next for Zynex Inc.\n",
      "While Zynex Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\n",
      "There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\n",
      "Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\n",
      "Ahead of this earnings release, the estimate revisions trend for Zynex Inc. Unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\n",
      "It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.08 on $36.67 million in revenues for the coming quarter and $0.57 on $172.47 million in revenues for the current fiscal year.\n",
      "Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\n",
      "National Vision (EYE), another stock in the same industry, has yet to report results for the quarter ended December 2021. The results are expected to be released on February 28.\n",
      "This discount optical retailer and eye care provider is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of -104.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.\n",
      "National Vision's revenues are expected to be $463.4 million, down 6.7% from the year-ago quarter.\n",
      "\n",
      "Zacks Names \"Single Best Pick to Double\"\n",
      "From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.\n",
      "Its a little-known chemical company thats up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.\n",
      "This company could rival or surpass other recent Zacks Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.\n",
      "Free: See Our Top Stock and 4 Runners Up >>\n",
      "\n",
      "Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\n",
      "\n",
      "The big shareholder groups in Zynex, Inc. (NASDAQ:ZYXI) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes \"a business with enduring competitive advantages that is run by able and owner-oriented people.\" So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.\n",
      "Zynex is a smaller company with a market capitalization of US$285m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Zynex.\n",
      "NasdaqGS:ZYXI Ownership Breakdown February 9th 2022\n",
      "What Does The Institutional Ownership Tell Us About Zynex?\n",
      "Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.\n",
      "We can see that Zynex does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zynex's historic earnings and revenue below, but keep in mind there's always more to the story.\n",
      "NasdaqGS:ZYXI Earnings and Revenue Growth February 9th 2022\n",
      "We note that hedge funds don't have a meaningful investment in Zynex. With a 42% stake, CEO Thomas Sandgaard is the largest shareholder. In comparison, the second and third largest shareholders hold about 8.6% and 3.8% of the stock.\n",
      "A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 50% stake.\n",
      "While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.\n",
      "Insider Ownership Of Zynex\n",
      "While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.\n",
      "Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.\n",
      "Our most recent data indicates that insiders own a reasonable proportion of Zynex, Inc.. It has a market capitalization of just US$285m, and insiders have US$121m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.\n",
      "General Public Ownership\n",
      "The general public-- including retail investors -- own 27% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.\n",
      "Next Steps:\n",
      "It's always worth thinking about the different groups who own shares in a company. But to understand Zynex better, we need to consider many other factors. Be aware that Zynex is showing 3 warning signs in our investment analysis , and 1 of those is a bit concerning...\n",
      "But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.\n",
      "NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.\n",
      "Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n",
      "\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Zynex Inc (ZYXI) shares closed today at 1.2% above its 52 week low of $8.37, giving the company a market cap of $294M. The stock is currently down 5.6% year-to-date, down 35.3% over the past 12 months, and up 4379.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%.\n",
      "Trading Activity\n",
      "Trading volume this week was 32.3% lower than the 20-day average.\n",
      "Beta, a measure of the stocks volatility relative to the overall market stands at 0.8.\n",
      "Technical Indicators\n",
      "The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.\n",
      "MACD, a trend-following momentum indicator, indicates a downward trend.\n",
      "The stock closed above its Bollinger band, indicating it may be overbought.\n",
      "Market Comparative Performance\n",
      "The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis\n",
      "The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis\n",
      "The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis\n",
      "Per Group Comparative Performance\n",
      "The company's stock price performance year-to-date lags the peer average by -339.6%\n",
      "The company's stock price performance over the past 12 months lags the peer average by 17.0%\n",
      "\n",
      "This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com.  2020 Kwhen Inc.\n",
      "\n",
      "Zynex, Inc. (NASDAQ:ZYXI), is not the largest company out there, but it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$15.15 and falling to the lows of US$9.88. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Zynex's current trading price of US$9.88 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Lets take a look at Zynexs outlook and value based on the most recent financial data to see if there are any catalysts for a price change.\n",
      "What's the opportunity in Zynex?\n",
      "Great news for investors  Zynex is still trading at a fairly cheap price according to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average. In this instance, Ive used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stocks cash flows. I find that Zynexs ratio of 34.38x is below its peer average of 47.31x, which indicates the stock is trading at a lower price compared to the Medical Equipment industry. Zynexs share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its industry peers, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once its there, it may be hard to fall back down into an attractive buying range.\n",
      "Can we expect growth from Zynex?\n",
      "NasdaqGS:ZYXI Earnings and Revenue Growth December 14th 2021\n",
      "Future outlook is an important aspect when youre looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so lets also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for Zynex. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.\n",
      "What this means for you:\n",
      "Are you a shareholder? Since ZYXI is currently below the industry PE ratio, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current price multiple.\n",
      "Are you a potential investor? If youve been keeping an eye on ZYXI for a while, now might be the time to enter the stock. Its prosperous future profit outlook isnt fully reflected in the current share price yet, which means its not too late to buy ZYXI. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment.\n",
      "So while earnings quality is important, it's equally important to consider the risks facing Zynex at this point in time. Our analysis shows 3 warning signs for Zynex (1 is a bit concerning!) and we strongly recommend you look at these before investing.\n",
      "If you are no longer interested in Zynex, you can use our free platform to see our list of over 50 other stocks with a high growth potential.\n",
      "Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n",
      "\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P 600 Small Cap Growth ETF (Symbol: SLYG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $107.22 per unit.\n",
      "With SLYG trading at a recent price near $94.02 per unit, that means that analysts see 14.04% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SLYG's underlying holdings with notable upside to their analyst target prices are eHealth Inc (Symbol: EHTH), Zynex Inc (Symbol: ZYXI), and Brinker International, Inc. (Symbol: EAT). Although EHTH has traded at a recent price of $24.34/share, the average analyst target is 119.39% higher at $53.40/share. Similarly, ZYXI has 57.75% upside from the recent share price of $14.58 if the average analyst target price of $23.00/share is reached, and analysts on average are expecting EAT to reach a target price of $58.40/share, which is 51.49% above the recent price of $38.55. Below is a twelve month price history chart comparing the stock performance of EHTH, ZYXI, and EAT:\n",
      "Below is a summary table of the current analyst target prices discussed above:\n",
      "NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET\n",
      "SPDR S&P 600 Small Cap Growth ETF SLYG $94.02 $107.22 14.04%\n",
      "eHealth Inc EHTH $24.34 $53.40 119.39%\n",
      "Zynex Inc ZYXI $14.58 $23.00 57.75%\n",
      "Brinker International, Inc. EAT $38.55 $58.40 51.49%\n",
      "Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.\n",
      "10 ETFs With Most Upside To Analyst Targets \n",
      "\n",
      "Zynex, Inc. (NASDAQ:ZYXI) shareholders are no doubt pleased to see that the share price has bounced 29% in the last month, although it is still struggling to make up recently lost ground. Unfortunately, despite the strong performance over the last month, the full year gain of 4.7% isn't as attractive.\n",
      "After such a large jump in price, Zynex may be sending very bearish signals at the moment with a price-to-earnings (or \"P/E\") ratio of 49.4x, since almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 10x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.\n",
      "While the market has experienced earnings growth lately, Zynex's earnings have gone into reverse gear, which is not great. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.\n",
      "NasdaqGS:ZYXI Price Based on Past Earnings November 5th 2021\n",
      "If you'd like to see what analysts are forecasting going forward, you should check out our free report on Zynex.\n",
      "Does Growth Match The High P/E?\n",
      "The only time you'd be truly comfortable seeing a P/E as steep as Zynex's is when the company's growth is on track to outshine the market decidedly.\n",
      "Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 6.4%. This means it has also seen a slide in earnings over the longer-term as EPS is down 8.4% in total over the last three years. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.\n",
      "Turning to the outlook, the next three years should generate growth of 85% per annum as estimated by the five analysts watching the company. Meanwhile, the rest of the market is forecast to only expand by 11% per year, which is noticeably less attractive.\n",
      "With this information, we can see why Zynex is trading at such a high P/E compared to the market. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.\n",
      "What We Can Learn From Zynex's P/E?\n",
      "Zynex's P/E is flying high just like its stock has during the last month. We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.\n",
      "We've established that Zynex maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. It's hard to see the share price falling strongly in the near future under these circumstances.\n",
      "Don't forget that there may be other risks. For instance, we've identified 3 warning signs for Zynex (1 doesn't sit too well with us) you should be aware of.\n",
      "It's important to make sure you look for a great company, not just the first idea you come across. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20x).\n",
      "This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "(RTTNews) - Medical technology company Zynex, Inc. (ZYXI) shares are up more than 7% Wednesday morning following significantly higher earnings, better than the consensus estimate.\n",
      "Net income in the third quarter increased significantly to $6.11 million or $0.17 per share from $1.33 million or $0.04 per share in the same quarter a year ago. Analysts surveyed by Thomson Reuters expected the company to report earnings of $0.12 per share.\n",
      "Revenue for the quarter increased 74% year over year to $34.79 million, driven by growth in orders.\n",
      "For the fourth quarter, the company expects revenue to be between $40 million and $43 million. The consensus estimate stands at $41.22 million.\n",
      "Full-year revenue is expected in the range of $130 million- $133 million. Analysts see revenue of $131.52 million for the period.\n",
      "ZYXI, currently at $13.39, has traded in the range of $10.66- $22.89 in the last one year.\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, inc (NASDAQ: ZYXI)\n",
      "Q3 2021 Earnings Call\n",
      "Nov 2, 2021, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good day, and welcome to the Zynex Q3 2021 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. Certain statements in this release are forward-looking and, as such, are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that can cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our annual report on Form 10-K for the year ended December 31 of 2020, as well as Forms 10-Q and 8-K, press releases and the company's website.\n",
      "I would now like to turn the conference over to Thomas Sandgaard, President, CEO. Please go ahead.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "They just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of October 20, 2021\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our 2021 third quarterearnings call Today, we will be covering activities in both of our divisions at Zynex Medical, where we focus on pain management and Zynex Monitoring Solutions. Before we get into the details of our financial performance and operations, I'd like to mention that this week is the 25-year anniversary of Zynex being incepted and me starting the business in a one bedroom with just a couple of thousand on a credit card, having just moved to Colorado from Denmark. It has been a long road of bootstrapping but looking at our results, the past four to five years, certainly worth it.\n",
      "I want to express my gratitude to all of our employees for working so hard to make this a success, as well as our public shareholders for being loyal and believing in the company and our business model. In that context, I'm excited to announce yet another quarter of record revenue and net income. Net income increased 118% sequentially compared to the second quarter, which demonstrates the operating leverage we're achieving from the investments we made in our sales organization. Our third quarter revenue of $34.8 million is the highest quarterly revenue in the company's history and increased 74% compared to the same quarter last year.\n",
      "We continue to see good order flow and third quarter orders came in 70% higher than the third quarter of last year. In the second-half of 2021, we're seeing the job market continue the trend we saw emerge in the second quarter, in that how unemployment has been dealt with politically still keeps a big chunk of the workforce at home, leading to a shortage of workers, including sales reps. This significantly impacts our ability to hire employees for our cohort headquarter. Specifically order entry, patient enrollment and insurance billing, these positions are important to keep up with our overall growth.\n",
      "We are also seeing the same dynamics as most of the businesses especially medical, where there's a lot of movement and significantly inflating pay for sales representative. We are currently competing in that space and have increased incentives such as sign-on bonuses, etc, to keep a decent hiring rate. Rather than slacking on our minimum criteria for hire we have instead adjusted our growth plans to focus on more productivity growth per sales rep and improving the quality of our entire sales force, which has also led to increased trimming of non-productive reps. During the third quarter, we focused on the productivity of our sales reps and trimmed our less productive reps.\n",
      "The trimming of sales reps in the highly competitive job market resulted in a decrease in active sales reps to approximately 430 reps at the end of the third quarter. The average revenue per rep during the third quarter therefore grew to approximately $325,000, up $50,000 compared to the second quarter, almost $100,000 compared to Q3 of last year. The sales reps number is less than previously anticipated which has obviously led to higher near-term profits than expected earlier in this year. As we've discussed previously regarding our inventory, we took a more conservative position in response to COVID and any possible supply chain issues which resulted in increased inventory levels during this year.\n",
      "In the third quarter, our inventory levels moved back toward more normal levels, and we have to report that to-date, we have had no supply chain issues in our business. The opioid epidemic continues to be a serious issue in this country, and we increasingly are working to get patients off opioids and for physicians to use our prescription strength technology as the first line of defense when treating pain. Currently, the devastating impact has reached the level where nearly 100,000 die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects.\n",
      "Our products for pain management and rehabilitation still stand out as some of the best products in the industry. The NexWave for pain management and our NeuroMove device for stroke rehabilitation, as well as the InWave for incontinence treatment, puts us in a very strong product position in these rehabilitation markets. We continue to see great potential in both our product divisions, our existing revenue generating area for pain management, as well as the huge unmet potential for our blood volume monitor. In the past five to six months, we have significantly increased activity in our monitoring solutions division.\n",
      "We are more than triple staffing and consultants while we also have increased our clinical research, capabilities and initiating several more studies across the country looking at different aspects of the clinical value that our technology can provide hospitals and surgical centers. As most of you probably know, we managed to get FDA clearance for our CM-1500 blood and fluid monitor over a year ago and have the product ready in production. The CM-1500 is a non-invasive monitor intended to monitor patient's fluid balance in hospitals and surgical centers. We expect to initially target ORs and surgeries that typically display substantial blood loss, as well as recovery rooms and ICUs where internal bleedings today are common and difficult to detect until serious complications occur.\n",
      "We believe this product will lead to safer surgeries, fewer complications and less mortality, one of the biggest unmet needs in hospitals today. We continue to see solid preliminary results from a clinical study at Wake Forest, and we're preparing to commence more studies on the device shortly. We're seeing interest in purchasing the device from hospitals that have a device on [Indecipherable]. Our engineering team is well underway with building prototypes of the next generation CM-1600 device that'll be easier to use in surgical settings.\n",
      "And today we have, with us our Vice President of our Zynex Monitoring Division, Donald Gregg, that'll fill you in with more details as to his background, what we've been doing and short as well as long-term plans.\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "Thanks, Thomas. Good afternoon, everyone. Let me start with some background on myself. I've spent about 15 years in the high tech and consumer industries and a bit over a decade in medical device, leading infusion pumps, respiratory and health informatics products and businesses for start-up multinational global corporations and various executive leadership roles. As most of you probably already know, as Thomas mentioned, the FDA cleared the CM-1500 fluid volume monitor a year ago. Our focus in 2021 has been on this, cementing the wireless version our CM-1600 to the FDA by the end of the calendar year.\n",
      "The current CM-1500 is a non-invasive monitor intended to monitor patients fluid balance in hospitals and surgical centers. We expect to initially target operating rooms, surgeries and clinical care, critical care settings, where fluid responsiveness is a known challenge. In this space, there are two primary areas that need to be addressed. Number one is overall fluid volume. The question is, is the patient losing too much blood or fluid or being overloaded with fluid. The second one, and perhaps is probably the most important is understanding fluid status and being able to know if the patient should receive more fluid or not.\n",
      "Incorrect fluid therapy can lead to severe negative outcomes including increased morbidity and mortality. Patients die postoperatively and more frequently than intraoperatively, largely due to hemodynamic instability. Therefore, we are very focused on hemodynamic stability perioperatively and postoperatively. We believe this product will lead to safer surgeries, fewer complications and of course less mortality as Thomas had mentioned. This is one of the biggest unmet needs in hospitals today. We continue to see promising preliminary results, as Thomas mentioned from a clinical study at Wake Forest.\n",
      "We've commenced additional studies on that device as well. Wake Forest is planning to publish in the results of the study in Q1, and we started a very specific apheresis blood donation study with [Indecipherable] that continues to refine our patented relative index algorithm for fluid prediction and blood components, fluid loss and re infusion of blood into the body. Additionally, we are starting a dialysis observational study this calendar year that continues to characterize the relative index for change with specific values of fluid loss.\n",
      "We plan to expand our clinical footprint and are heavily investing in a robust cadence of clinical evidence to enable us to expand into other care areas where fluid monitoring is a priority for patients. We had a very successful trade show at Anesthesiology 2021 in San Diego. You also might know this as the ASA conference. There was significant excitement from our key opinion leaders or our KOLs in both the U.S. and internationally.\n",
      "They are very interested in validating the need to focus on hemodynamic stability, drain and post-surgery. We have several leading anesthesiologists in their field that approached us to work closely on the predictive algorithm to solve the question of should I give my patient fluid or not? We are seeing significant interest in placing and purchasing the device from hospitals, and we continue to develop our pipeline focused on commercializing the wireless CM-1600 version of the monitor post FDA clearance in the first half of 2022.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Thank you, Don. I'll now turn the call over to Dan Moorhead, our CFO.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First I'll review our 2021 third quarter results. Orders grew 70% year-over-year and net revenue grew 74% to $34.8 million from $20 million in 2020. It's also worth noting that Q3 revenue increased 12% sequentially compared to Q2. Device revenue increased 71% to $9.1 million, compared to $5.3 million last year. Supplies revenue increased 75% year-over-year to $25.7 million from $14.7 million. Gross margins were 80% in the third quarter of 2021, compared to 77% in Q2. As we mentioned previously, we transitioned our production and warehouse to a new facility during Q1 which put some pressure on gross margins during the first half of the year. But as we continue to increase volumes and get better pricing we've been able to increase margins throughout the year.\n",
      "We still expect margins to range between 75% and 80% going forward. Sales and marketing expenses increased 39% year-over-year due to our sales force growth. G&A expense grew 39% year-over-year. Much of that increase is related to facilities and increased headcount in our reimbursement and patient support functions related to our order growth. Third quarter net income was $6.1 million a 358% increase year-over-year and $0.17 per diluted share. Both net income and earnings per share were company records.\n",
      "Adjusted EBITDA which is a standard EBITDA calculation plus an exclusion of non-cash stock-based comp, severance, non-cash lease expense, and other income expense and as reconciled in our press release was $9.3 million in the third quarter and was also the highest in company's history. I'll now review our 2021 nine month results. Orders grew 134% year-over-year, which increased net revenue 65% to $89.9 million from $55.4 million in 2020. Device revenue increased 79% to $23.3 million, compared to $13 million last year. Supplies revenue increased 61% year-over-year to $66.7 million from $41.5 million.\n",
      "Gross margins were 78% during the first nine months of 2021. Sales and marketing expenses increased 86% year-over-year and G&A expense grew 42% year-over-year. 2021 nine month net income was $8.2 million, or $0.23 per diluted share compared to net income of $7.3 million or $0.21 per diluted share in 2020. Adjusted EBITDA was $13.7 million for the first nine months of 2021. On the balance sheet as of September 30, 2021 our cash balance was $35.4 million and grew just under 10% during the quarter due to our record profitability. And that also includes spending $0.5 million on our stock buyback, which expired during the quarter. Our working capital was $59.6 million at September 30, up 13% compared to Q2.\n",
      "With that, I'll turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Thank you, Dan. I'm pleased with the third quarter order growth of 70% in a record revenue and profitability. It clearly justifies the investments in our sales personnel, sales management and insight support functions. Our focus for the remainder of the year is continuing to increase sales rep productivity as our sales force gets more experience, continuing to leverage the investments we made within sales and G&A to further improve profitability and most importantly, helping our patients in pain.\n",
      "We will continue our sales force growth in Q4 and into 2022, but due to the current tight labor market, it'll be at a slower but more profitable pace than prior years. We continue -- we estimate our fourth quarter revenue to come in between $40 million and $43 million with an adjusted EBITDA between $9 million and $10 million. The fourth quarter revenue range is 54% to 65% than 2020's fourth quarter revenue. And full year 2021 revenue is estimated between $130 million and $133 million, with adjusted EBITDA between $22.7 million and $23.7 million.\n",
      "We are also expecting significant positive cash flow in Q4 due to the seasonality of deductibles and continued profitability. The full year revenue estimate is approximately 62% to 66% above 2020's full year revenue of $80.1 million. My long-term goal for electrotherapy and rehab division is to continue to grow our share of the huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing our domestic sales force as well as potential acquisitions of complementary technologies.\n",
      "Our long term goal is still to fill all 800 territories, of which we have felt well over half in the U.S. and get sales reps fully productive. We see that it takes up to two years to make a sales rep fully productive. We are extremely encouraged by the progress we made in our Monitoring Solutions division and the positive feedback from the market. We're pleased with what that distribution has accomplished so far during this year and the more recent increase in staffing and activity. In summary, we announced strong growth in orders and revenue and profitability. And we expect a strong growth in order to drive continued growth in revenue and profit in the remainder of the year and during the next year too.\n",
      "We will now answer questions from our listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "Thank you. [Operator Instructions] Our first question comes from Jeffrey Cohen with Ladenburg Thalmann. Please go ahead.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Hi, Thomas, Donald and Dan, how are you?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "We are doing well. How are you doing, Jeff?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Just fine. Staying well. So thanks for the commentary and thanks for your commentary, Donald as well. I wondered if Thomas, maybe you could talk a little bit about the CMS business and your comment about complementary acquisitions for the CM-1600 in the fluid monitor and how should we think about that as far as the business growing and also as far as the commercial channels, as far as your plans for dealing with the various channels out there as they approach?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "That's right. So I'm thinking it in about it in regards to both divisions. We are looking at opportunities that could fit into the pain management and rehab division as well as opportunities that could fit into the monitoring solutions product range and the type of products we see could be complementary there. It's a little different as to how we're looking at those opportunities that are out there. We're looking at products that are fully developed and typically already have reimbursement codes and long, long history of being reimbursed well by insurance companies and something that would also fit well into the core point that our huge sales force have across the country.\n",
      "So we're looking at that kind of opportunities. And while we're looking at that, we obviously distribute products from other manufacturers such as cervical traction, low back support devices. We will soon be introducing knee braces and also cold and hot therapy used to post-operatively. So those are products we already distribute from other manufacturers, so we just -- we keep looking at potential opportunities to strengthen that product line. And in terms of monitoring solutions that there are so many great technologies that that have been invented out there and could potentially fit well with our blood and fluid monitor and sepsis monitoring that we are also looking at fit into that space. So we keep looking at those opportunities. But as you know, I'm pretty stubborn about those things and nothing has materialized yet.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Okay. So more multi-functional with your current sales organization with pain and a little bit beyond. And then would you be going kind of a B2B model in-house direct when you're talking about the hospital environment or ASC environment or clinic environment?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Well, the -- we obviously -- our sales force and pain management is that they all have a fairly small radios, that's a total of 800 territories across the country. So they sell the right thing. They go to primarily physicians and especially in orthopedic surgery. And they get a prescription that is then send in to us here and with that and with the patient demographics, we are able to build the patient's health insurance and that's how we get paid.\n",
      "So it's a direct sales force where pretty much all of them have a base salary and commission on top of that In our Monitoring Solutions division we expect to see a direct -- a very separate but direct sales force, as well as working with larger companies, either as distributors or private labeling as an OEM arrangement, that could potentially be some licensing that could come. But we, as I mentioned before, we expect in that division to apply a multi-faceted strategy to hit to hit the market of hospitals and surgical centers.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Okay, got it. And then lastly, a quick one for you Dan on the margin side. Very strong for the quarter, but should we be thinking of the next year or two similarly to how we were thinking of it yesterday or is it Q3 representing some trend or it's a bit of an outlier?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "No, I think we still expect that 75% to 80%, sometimes we're on the higher and sometimes it's on the floor and we're always pretty close to that range. So I don't know the basis of change that. I still think that's kind of the modeling formula going forward is that 75% to 80%.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Perfect. Okay. Thanks for taking our questions.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thank you.\n",
      "Operator\n",
      "Our next question comes from Matthew O'Brien with Piper Jaffray. Please go ahead.\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Good afternoon. Thanks for taking the questions. So I guess just for starters, maybe, Dan, can you give us the numbers as far as sales reps at the end of Q3 and then how many you expect to exit Q4 with?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "We had -- I think we had it in one of the stories, it was about 430 is what we were showing at the end of the quarter. I think end of the year is going to be around there. I don't think you're going to see anything materially up or down. Like Thomas said, we are trimming some of the less productives and we'll add some new people as well, but the net change should be pretty minimal\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah. There is some limit to how much we can add to the sales force now compared to a year ago where it was a lot easier. So therefore that limitation on what we are adding will barely just keep up with or maybe exceed a little bit how many people that are not making it in our current sales force.\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Okay. Thank you. And then, as I look at the sequential bump from Q3 to Q4 in terms of the guidance, it's about $7 million at the midpoints, roughly. That's a little bit higher than what you guys did last year. I know it was a COVID year, but even the year before that and the year before that. So I'm just wondering if there is the expectation of some ramp in productivity or there's a bolus of people that haven't been able to get access that you're expecting in Q4 that give you comfort in getting up to kind of the midpoint of the range here in Q4.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah. That's a good question, Matt. I would say because the numbers keep getting bigger, so the relative increase is not as big as the absolute increase you see there. So this is more of a reflection of the orders that are, have already been shipped, maybe in prior periods and it just keep accumulating in terms of the revenue we generate from them in supplies and monthly rentals, etc. So it's just, it's still just more of a compounding effect and the numbers are getting bigger. So therefore you're right, you're looking at something like a $7 million increase, but it's more an effect of more, more and more of, we're firing on all cylinders than any significant boost.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Very good. I think Matt if you look at as a percentage too it's similar to what we've done in the past like you said the RON numbers are a little bigger, but last year, actually sequentially, we were up more as a percentage. And in '19, we were up a little bit more as well. So this year, obviously the range is a little wider, but we're generally in the same spot and I would say it's even down a little bit compared to last year.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah, but we have the seasonality of Q1 always being by far the weakest quarter and Q4 was being the strongest definitely boosted by patients, insurance deductibles being met.\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Okay. Okay. Thanks for that. Last one for me is just on the blood monitoring side, you're there's a lot of commentary on that product and in the script today and just overall. So I'm just curious as far as what kind of impact you anticipate that category will have on the business as we head into 2022. And then, as I look at numbers for next year, it's still a pretty healthy increase, even though it seems like the sales force number is going to be a little bit flatter coming out of this year. I mean are you comfortable with where The Street's at as far as '22 revenues go? Thank you.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Well, maybe I should I should answer that one obviously. We are internally very bullish on what we can, what we can squeeze out of the sales force and the internal infrastructure of the organization. We have to support that in terms of how much cash we can collect. And obviously we're beginning to get well into the at least to the $100 million to $200 million in annual revenue. And so relatively speaking of growth might be big in dollars. But percentage wise, it'll naturally start slowing down. So yeah, we at this point we haven't really finalized our planning for next year in terms of where we'll be in terms of orders and revenue and expenses. We have some rough ideas. And just here early on, we might be very optimistic as to these -- the amount of growth we'll be able to achieve next year, even at these revenue levels. So -- but I think we'll be -- we'll have to wait until our nextearnings callbefore we can really comment on where we at compared to the analysts.\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Okay. And blood monitoring side?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah. Maybe Don can speak to the potential revenue in that.\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "Yeah. So we've been really focused currently on our FDA submission for our wireless CM-1600. We've been thinking through what the strategy looks like of the design of the sales force. As I mentioned earlier in the commentary that our submission to the FDA will be this year. We're expecting that it'll be a very traditional 90 days, maybe 90 plus days and we'll see revenue in the back half of 2022. We will be preparing our commercialization plans in Q1 and Q2. We will start executing with a small direct and some indirect sales force in probably late Q2, early Q3 of the 2022 specifically for that. I'm not so sure I have exact numbers for you, but this will be certainly a very important execution phase in the first half of 2022.\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Great. Thank you.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "You're welcome.\n",
      "Operator\n",
      "The next question comes from Yi Chen with H.C. Wainwright. Please go ahead.\n",
      "Yi Chen -- H.C. Wainwright & Co. LLC -- Analyst\n",
      "Thank you for taking my question. The first question is, could you comment on the number of sales reps you aim to achieve by the end of 2022? And also, you mentioned that the average revenue generated per rep has been improving. Can you tell us what is your target average revenue per rep and how soon do you expect to achieve that?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah. Hello. This is Thomas. In terms of revenue per rep, if I take your question sort of in backwards order, we know from our more -- well-seasoned and better producing sales reps that they can produce up toward $2 million a year in revenue within their territory. And therefore, we are still planning on long term, but we might be half a decade out, hopefully a little sooner than that, but at long term that the average sales reps and there will be some, some brand new ones in that mix so that the average will be right around $1 million per sales rep. So that target hasn't changed.\n",
      "In terms of how many reps we expect to have by the end of next year? There's obviously, as we can see right now, the shortage of potential employees, whether they are sales reps or people that want to come work at our corporate headquarters is playing a very, very significant role right now. If we assume that things start normalizing and get back to the supply demand levels we saw a couple of years ago here in Colorado and across United States in supply demand in terms of the workforce, then I would expect us to get very close to 600 by the end of next year. But if the first and the second quarter demonstrate the same type of challenges we're seeing right now that would obviously put a damper on it. But I'm sure no matter how bad that goes we'll be well over 500 again by the end of next year.\n",
      "Yi Chen -- H.C. Wainwright & Co. LLC -- Analyst\n",
      "Got it. Thank you. And my next question is do you expect CM-1600 when commercialized will have a similar gross margin to the next wave margin?\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "So, This is Don. I can take that question. When you look at the CM-1600, it's a networked device and this network device has a piece of capital equipment. It has software and it has disposables. Traditionally in this business, in the monitoring space, you have a strategy that you'll have margins on the hardware, you'll have margins on the disposables, you'll have margins on the on the software. Very high margins on software and high margins on the disposables because it's a razor, razor blade type business. And so, I'm expecting that margins will be a bit higher on the disposables on the software and will be on par if not a little bit better on the capital side. We've focused significantly on cost production in our wireless and what I would call design for manufacturing so we can manufacture this in high volume.\n",
      "Yi Chen -- H.C. Wainwright & Co. LLC -- Analyst\n",
      "Got it. Thank you.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "You're welcome.\n",
      "Operator\n",
      "Our next question comes from Marc Wiesenberger with B. Riley Securities. Please go ahead.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Thank you. Good afternoon. You've talked about it becoming difficult to onboard new reps and maybe that's lowering the potential growth rate for generating new orders. Have you thought of working with any telehealth companies to provide direct access to doctors who can prescribe the next wave to generate orders maybe in a non-traditional route than you historically done?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Oh, yes, we have. We've certainly thought about it. We also are looking at how successful we have been in terms of growing revenues and filling up the territories across the country. We know with high certainty how well a good relationship between a physician and a sales representative from our company works in terms of developing orders and subsequent revenue. And we have we have seen incredibly high growth rates as a result of that. So if we look at that question specifically, you could say we could potentially try to add another way of growing the business. And as a result of that, potentially if not as successful be distracting our efforts internally and also externally versus the more traditional knocking on doors and building relationships.\n",
      "The extent to which the building relationships, the direct sales force, how successful that that is right now that make us stick to that for now. And maybe when we get to the point of having sales reps in all 800 territories and then being reasonably profitable, that would be 800 sales reps and hopefully approaching the million per the average sales rep. And as we're looking at strategies to develop the market further, the potential unlocking the potential there really is in the pain management area that would definitely be one of those ways we could potentially grow more revenue on top of what 800 sales reps can provide for us. So right now we're looking at it as one of the many options we could apply. But I want to make sure we get all 800 territories filled with eventually very productive sales force and then grow further from there.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Got it, OK. Sticking on the tight labor conditions theme for a little bit longer. Could you quantify maybe any potential drag on the results either in the current quarter or potentially maybe what you're seeing in the fourth quarter, not necessarily from slower sales rep growth, but maybe kind of more from the back office labor constraints in the billing department that you highlighted?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah, true, throughout the corporate office we have approximately I would say between 80 and 100 unfilled open positions so that obviously means that we're still processing the orders. We are severely understaffed in every department, nearly every department I would say. However, we do get the work done. But there are many things you do as an organization where you build structures for the future. We may not necessarily build them to the same extent, but an organization that doesn't grow as fast and doesn't have a difficult job market against them might see.\n",
      "There's obviously activities that are not specifically geared toward reaching this month's goal of processing that many orders or whatever the task may be like that are more social in nature and just part of building a good, good work environment to get to know your co-workers and all that. They are less of that in a period like that versus let's hopefully in a year from now being be in a better position, we will be eventually focused more and maybe team building and things like that. So those are some of the more intangible things we get the work done. And that's really what matters now while we are we, we are staffing up. We have a net addition in contrast to our sales force we have, we are every week we are adding net more than we are losing. So we are. We're not losing. We're not losing ground here, corporate. But it could definitely be better. This is still quite a few empty seats there.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Got it. Got it. Thanks. It seems, maybe, that you have an elevated level of cash right now, I'm wondering if you could talk about the capital allocation priorities, balancing pain management and monitoring and kind of the split there. And then I think Dan noted that the pain management and monitoring it, and kind of the split there. And then, I think Dan noted that the buyback ended in September, based on where the stock is right now. Is there any plans to reinstate that in the near-term?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "I'll start with the buyback. Everything's on the table. We got to look and see current business activities where we need capital allocated and those types of things. So but I don't know that we have any intention to reinstate it immediately, but I think it's definitely on the table. Sorry. Can you repeat your other question, Marc?\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Yeah. In terms of capital allocation kind of split between monitoring and pain management going forward?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "If you just talk to normal operating activities, I would say, pain managements is running, we're running between, what $25 million and $30 million an expense per quarter, monitoring even though we're making a significant investment in it, is still, probably 10% to 15% of that. So it's still by far, a small piece of the pie but it's, it's definitely grown this year. Last year we were probably close to a million. This year, we're probably between $2 million and $2.5 million if you look at the full year and next year is probably, another $1 million and $1.5 million on top of that. So there's definitely, with all the activities that Thomas and Don talked about, there's definitely some P&L expenses sitting there. So but that's -- it's always in the plan.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Got it. Very helpful. Don, can you provide more detail on the difference between overall fluid volume versus understanding the fluid status?\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "Yeah, so overall, fluid volume and fluid status is slightly different, but very related. What's important is fluid responsiveness and fluid responsiveness is about asking yourself, if you're an anesthesiologist, if you should give your patient fluid. And the reason that is, is because you can put your patient into some challenges around cardiac conditions. Today there are many organizations that are kind of focused on are they losing fluid or are they somewhat getting overloaded? We have to address that question as well. But one of the things that's most important is predictably figuring out if you need to give your patient fluid or not, because clinically, that's the most important -- that's most important for -- in a surgical setting because of you want to ensure stability from a hemodynamic standpoint.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Got it. Very helpful, and then just a final one for me, as we think of the business and kind of the long tail of the consumable revenue that's generated off the initial order. If you were to stop all device sales, let's say at the end of the fourth quarter, what kind of runway do you see for consumables revenue? I mean, how long would you be able to still generate consumables revenue? Thank you.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Well, for the next decade obviously, it would be on a declining scale, but it's obviously as you see in our reporting a very significant part of our revenue and even more significant part of our profitability. So the first quarter as an example, you wouldn't barely see much of a dip and then it'll just slide down so that it'll be somewhat insignificant compared to today's numbers one year, more than five years out. So there wouldn't -- if a patient has a device and even if we got absolutely no prescription in scripts and we will still get revenue from the monthly rentals and the supplies, they're consuming. As insurances approve and disapprove it and forget to pay or forget to tell us about it and all the stuff that goes on in between.\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "Great. Very helpful. Thank you very much. Congrats on a good quarter.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Thank you.\n",
      "Operator\n",
      "Our next question comes from James Terwilliger with Northland Securities. Please go ahead.\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "Hey, Thomas. Can you hear me?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yeah. I can hear you. How are you doing?\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "I'm doing well. I hope you guys are all doing well. A couple of quick questions. First of all, congrats on a nice quarter. This is good revenue growth numbers. It's a great EPS number. My first question is how many reps have you guys had that had to trim? I think it's terrible when anyone loses a job, but clearly I understand that. And then maybe a turnover percentage, a percentage of reps first what you've been able to keep?\n",
      "And then how much time do you give a rep before you kind of make that call that, hey, they're just not getting it done? We know its 6 months, 12 months for a sales rep, depending on the territory and medical devices, if it's brand new or an existing territory for them to become productive. Those are my days at Johnson & Johnson. But again how much turnover do you have and how many reps have you lost or have you trimmed, maybe a turnover percentage and then how much time do you give them before you make that decision?\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Well, I don't have all those, I don't have enough numbers with me to give you specific answers to all of it, but I can, you can obviously imagine when, when our net number of sales reps went from 500 down to 430 at the end of the last quarter that we, we got rid of more than that, quite a few and we, we added about 300 reps, nearly all of those in the second half of last year. And that was we, we obviously especially those that had been, 6 months to 12 months, 6 months to 9 months, that was quite a few among those that that just never really made it.\n",
      "And I would say because we, we added so many, we get, we gave them more time or I should say, we gave our regional sales managers more time than usual to eventually get them up and running because they had a lot to work with. We only have 15 regional sales managers. So we gave them a lot to work with and a lot of that. This is not only dealing with the existing sales reps, but also holding the hands of brand new reps to get them, get them up and running. And so we normally, we normally see right after the 90 days that the sales rep either will make it or not.\n",
      "But I would say in the last, the last couple of quarters, we have given them longer than normal simply because the, our managers had to have more to work with them than normal and therefore gave them, gave the reps a chance beyond what we normally would do. So here recently we have cleaned up a lot because it's not worth carrying people that are not going to make it. Now we definitely know, let's put it that way at who couldn't make it. And we just keep building the sales force at a slower than before cadence. I don't have the calculations about specific churn rates really, but it's obviously a lot of people we have talked about when the net has gone down by 70.\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "Thank you. My second question is really on the gross margins, I wonder if there's anything you guys could add. I thought I heard you say earlier in the call maybe a price increase. A lot of the companies I'm talking to are having pressure on the gross margins with the supply chain issues that are everywhere. And then you guys actually came in I think at about 80% and it was actually real nice gross margin numbers. Anything else that you can add there in terms of did you get a price increase during the quarter or is it a trend or I know the range is at 75%, 76% to 80%. But is there anything else you can add on how the gross margins did so well here in Q3?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "No, it's really just normal operating like I said we have gotten better on the pricing side from the suppliers, we -- our volumes have increased significantly over the last couple of years. And so obviously that helps from a pricing perspective\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "On our cost prices.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Yes.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Not on our.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Our retail, our MSRP or whatever you want to -- the revenue pricing hasn't changed at all. So it's really just improvements there and then -- it's absorbing, like I said, the investment we've made in the production facility and those things, as revenues get higher and higher those -- that absorption percentage gets lower and lower. So it's really those two factors that have continued to drive margins. And again, I think 75 to 80 going forward is reasonable. So it may not always be 80, it may be 77 or 78, but that's all within the expected range.\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "No, it's a very, very good number, I think I'm at 76 going forward trying to be conservative, so the 80 is a great number, especially with the conditions everyone's operating under. My next question is how big is the current patient monitoring division? I know you're looking for strategic partnerships and maybe some independent distributors. How big is the patient monitoring division as it sits today?\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "So this is Don, I'll take that question. Today, we have a mix of engineering focused on both the CM-1500 and the wireless version, the CM-1600. In addition to that, I have people focused on running clinical trials. And there's -- we've kind of quadrupled the size of the team to be very strategic and focused. You'll see additional commercial team that will be built in Q1, Q2 timeframe of 2022. And so we're staffed somewhere around 20 to 25 with contractors and things like that.\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "Okay, fantastic. Thank you. And that's a very important product as we move into next year. My last question is I had a lot of concern coming in and like I said, I think your numbers are very good. I'm concerned with maybe what happened down in Florida with COVID, with dental procedures have been delayed. Sometimes it's hard to catch the patient coming out of the hospital, the same thing with Texas. Do you think that had any impact on your on your numbers? I know they're going to impact other medical device companies. Do you think that have any impact on your numbers or you guys kind of sailed right through that.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yes. We haven't really seen COVID, except for the second quarter last year where there was a lot of uncertainty in clinics sets, so how to deal with us and sales reps and in general. Since then, we haven't really seen any impact. It's still lurking a little bit, but all it does, it's more the individual performance by those 430 sales reps that dictates and how they eventually get the relationships built. And I think I noticed this morning you mentioned Florida which is a big state. That's also the state that has the second biggest decline in incidence of COVID or infections of COVID right now. So I think very quickly, they will probably be back to another level of being able to do medical procedures, etc.\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "Okay, great. Well, I'll jump back in queue, but thanks, guys for taking my questions and nice job on the quarter. Thanks, guys.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Thank you.\n",
      "Operator\n",
      "This concludes our question-and-answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Yes. Thank you. I hope today'searnings callhas been informative for everyone and I appreciate the interest in Zynex and listening in to this call. Thank you and a great day to all.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 55 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Chairman Of The Board, President & Chief Executive Officer\n",
      "Donald Gregg -- Vice President, Zynex Monitoring Solutions\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Jeffrey Cohen -- Ladenburg Thalmann & Co., Inc. -- Analyst\n",
      "Matthew O'Brien -- Piper Jaffray -- Analyst\n",
      "Yi Chen -- H.C. Wainwright & Co. LLC -- Analyst\n",
      "Marc Wiesenberger -- B. Riley Securities, Inc. -- Analyst\n",
      "James Terwilliger -- Northland Securities, Inc. -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Zynex Inc (ZYXI) shares closed 1.4% lower than its previous 52 week low, giving the company a market cap of $402M. The stock is currently down 14.0% year-to-date, down 32.1% over the past 12 months, and up 5411.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 fell 0.8%.\n",
      "Trading Activity\n",
      "Trading volume this week was 23.4% lower than the 20-day average.\n",
      "Beta, a measure of the stocks volatility relative to the overall market stands at 0.5.\n",
      "Technical Indicators\n",
      "The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.\n",
      "MACD, a trend-following momentum indicator, indicates a downward trend.\n",
      "The stock closed below its Bollinger band, indicating it may be oversold.\n",
      "Market Comparative Performance\n",
      "The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis\n",
      "The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis\n",
      "The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis\n",
      "Per Group Comparative Performance\n",
      "The company's stock price performance year-to-date beats the peer average by -1.0%\n",
      "The company's stock price performance over the past 12 months lags the peer average by 101.9%\n",
      "\n",
      "This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com.  2020 Kwhen Inc.\n",
      "\n",
      "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P 600 Small Cap ETF (Symbol: SLY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $108.89 per unit.\n",
      "With SLY trading at a recent price near $92.52 per unit, that means that analysts see 17.70% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of SLY's underlying holdings with notable upside to their analyst target prices are Zynex Inc (Symbol: ZYXI), NeoGenomics Inc (Symbol: NEO), and Global Net Lease Inc (Symbol: GNL). Although ZYXI has traded at a recent price of $12.96/share, the average analyst target is 80.56% higher at $23.40/share. Similarly, NEO has 31.90% upside from the recent share price of $42.74 if the average analyst target price of $56.38/share is reached, and analysts on average are expecting GNL to reach a target price of $22.50/share, which is 30.59% above the recent price of $17.23. Below is a twelve month price history chart comparing the stock performance of ZYXI, NEO, and GNL:\n",
      "Below is a summary table of the current analyst target prices discussed above:\n",
      "NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET\n",
      "SPDR S&P 600 Small Cap ETF SLY $92.52 $108.89 17.70%\n",
      "Zynex Inc ZYXI $12.96 $23.40 80.56%\n",
      "NeoGenomics Inc NEO $42.74 $56.38 31.90%\n",
      "Global Net Lease Inc GNL $17.23 $22.50 30.59%\n",
      "Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.\n",
      "10 ETFs With Most Upside To Analyst Targets \n",
      "\n",
      "There's been a notable change in appetite for Zynex, Inc. (NASDAQ:ZYXI) shares in the week since its quarterly report, with the stock down 17% to US$13.89. Revenues were US$31m, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$0.08, an impressive 21% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Zynex after the latest results.\n",
      "NasdaqGS:ZYXI Earnings and Revenue Growth July 31st 2021\n",
      "Following the latest results, Zynex's four analysts are now forecasting revenues of US$133.8m in 2021. This would be a huge 33% improvement in sales compared to the last 12 months. Per-share earnings are expected to jump 118% to US$0.33. Before this earnings report, the analysts had been forecasting revenues of US$138.7m and earnings per share (EPS) of US$0.37 in 2021. From this we can that sentiment has definitely become more bearish after the latest results, leading to lower revenue forecasts and a real cut to earnings per share estimates.\n",
      "Despite the cuts to forecast earnings, there was no real change to the US$23.40 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Zynex, with the most bullish analyst valuing it at US$38.00 and the most bearish at US$15.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.\n",
      "Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Zynex's growth to accelerate, with the forecast 76% annualised growth to the end of 2021 ranking favourably alongside historical growth of 40% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 8.3% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Zynex to grow faster than the wider industry.\n",
      "The Bottom Line\n",
      "The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. The consensus price target held steady at US$23.40, with the latest estimates not enough to have an impact on their price targets.\n",
      "Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Zynex going out to 2023, and you can see them free on our platform here..\n",
      "It is also worth noting that we have found 3 warning signs for Zynex (1 is significant!) that you need to take into consideration.\n",
      "This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, inc (NASDAQ: ZYXI)\n",
      "Q2 2021 Earnings Call\n",
      "Jul 29, 2021, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good day, and welcome to the Zynex 2021 Second Quarter Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]\n",
      "Certain statements in this release are forward-looking and, as such, are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2020, as well as Forms 10-Q and 8-K, press releases in the Company's website. Please note this event is being recorded.\n",
      "I would now like to turn the conference over to Thomas Sandgaard, Founder, Chairman and Chief Executive Officer. Please go ahead, sir.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "They just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of June 7, 2021\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "Good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our 2021 second quarterearnings call I'm excited to announce yet another quarter of revenue growth and positive net income.\n",
      "Our second quarter revenue of $31 million is the highest quarterly revenue in this Company's history and increased 61% compared to the same quarter last year. We continue to see good auto flow as the economy returns to normal, and second quarter orders came in 247% higher than Q2 of last year and 11% sequentially compared to the first quarter of this year. The continued strength in orders speeds volumes to the relationships that our sales force has been main prescribers and the need for them to prescribe non-opioid [Phonetic] solutions for their patients in pain. As a reminder, the majority of cash and revenue related to order comes in over the year and following years, following the receipt of the order as the patient use the device and related supplies, which should lead to expanding revenue and profitability further throughout 2021 and beyond.\n",
      "During the second quarter, we continued to focus on the productivity of our sales reps and trimmed our less productive reps. Determining of sales reps and the high competitive job market resulted in not hiring as many reps as we said goodbye to. And therefore also a decrease in active sales reps now ass throughout the second quarter to approximately 450 reps at the end of the second quarter. The decrease in sales reps now slightly decreased the forecasted revenue, but also in term, which I think is very important boost profitability in the near-term. It is obviously very difficult to grow as fast as we have been growing for a while and invest in the Salesforce was a very high expense and, and post a significant profit. We now saw the beginning of Q2 and expect to see that throughout the rest of the year that will be slightly more profitable than we originally expected. We still expect to have approximately 550 sales reps by year end.\n",
      "The addition of a net of 50 sales reps compared to the beginning of this year, compared to a net of over 300 that we added in 2020, most of those in the second half of 2020. The additional sales force growth is now happening at a much slower pace, which will directly help our bottom line. I also want to mention that our operations still continue without issues and our supply chain remains uninterrupted. As we discussed previously, we are taking a very conservative position in response to COVID and any possible supplier supply chain issues which resulted in an increased inventory at the end of Q1 of approximately three million inaccessible normal levels in Q2 our inventory level started moving back to more normal levels, which will continue during the second half of 2021.\n",
      "As announced earlier this year, we moved into a new corporate headquarters during the quarter. The new building has additional square footage and expansion rights to support our continued growth. The opioid epidemic continues to be a serious issue in this country. And we are increasingly working to get patients off opioids and for physicians to use our prescription space technology as the first line of defense when treating pain.\n",
      "Currently, the devastating impact has reached the level where 10s of 1000s die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technologies that literally has no side effects. Our product for pain management and rehabilitation still stand out as some of the best in the industry. The next wave for pain management on [indecipherable] devices for stroke rehabilitation, and the contents treatment puts us in a very strong product position and the rehabilitation. We continue to see great potential in both our product division, our existing revenue generating area for pain management, as well as a huge unmet potential for blood volume monitor. As most of you probably already know, we managed to get FDA clearance for our CM-1500 blood volume monitor a year ago, we recently also filed a patent on top of the three patents that have now been issued for the blood volume monitor, but also for a non-invasive method to detect the early detection of sepsis.\n",
      "The CM-1500 is a non-invasive monitor intended to monitor patients fluid balance in the hospitals and surgical centers. We expect to easily target ORs and surgeries that typically display substantial problems as well as recovery rooms and ICUs where internal bleeding so they are common and difficult to detect until serious complications occur. We believe this product will lead to safer surgeries fewer complications and less mortality, one of the biggest unmet needs in hospitals today. We continue to see solid preliminary results from a clinical study of Wake Forest, we have now had the device monitor more than more than 120 patients. And the device so far has been solid in terms of not providing a false positive or when there has been bleeding and or other fluid loss showing a significant change. So, this is obviously very encouraging.\n",
      "And we are gearing up to commence those studies on the device shortly. Our engineering team is also expanding pretty significantly and well underway the building prototypes of the next generation CM-1600, that will be easy to use in settings compared to CM-1500. And we are also adding personnel and other resources to conduct more clinical research.\n",
      "I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First I will review our 2021 second quarter results.\n",
      "Orders grew 247% year-over-year and net revenue grew 61% to $31 million from $19.3 million in 2020. It is also worth noting the Q2 revenue increased 29% sequentially, compared to Q1. Device revenue increased 83% to $7.8 million, compared to $4.3 million last year. Supplies revenue increased 55% year-over-year to $23.2 million from $15 million. Gross margins were 77% in the quarter. As we have mentioned previously, we transitioned our production and warehouse to a new facility during Q1. This has greatly enhanced our efficiency, but in the short-term, it has put some pressure on gross margins. Sales and marketing expenses increased 102% year-over-year, due to our Salesforce growth.\n",
      "G&A expense grew 43% year-over-year. Much of the increase was related to increase headcount in our reimbursement and patient support functions related to our order growth. Second quarter net income was $2.8 million or $0.08 per diluted share. Adjusted EBITDA, which is a standard EBITDA calculation plus an exclusion of non-cash, stock-based compensation, severance non-cash lease expense and other income expense and is reconciled in our press release was $4.8 million in the second quarter of 2021. I will now review our 2021 six month results.\n",
      "Orders grew 186% year-over-year, which increased net revenue 60% to $55.1 million from $34.5 million in 2020. Device revenue increased 84% to $14.2 million, compared to $7.7 million last year. Supplies revenue increased 53% year-over-year to $41 million from $26.8 million. Gross margins were 76% in the first half of 2021. Sales and marketing expenses increased 123% year-over-year and G&A expense grew 44% year-over-year. 2021 six months net income was $2.1 million or $0.06 per diluted share, compared to net income of $6 million or $0.17 per diluted share last year.\n",
      "Adjusted EBITDA was $4.4 million in the first half of 2021. On the balance sheet as of June 30th, cash was $32.3 million, which is down slightly from Q1, but mainly related to the $2 million in purchases in our stock buyback program. Our working capital was $52.9 million at June 30.\n",
      "With that, I will turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "I'm sorry. I will be right back. And I'm pleased with the second quarter, order growth of 247% and revenue our growth of 61%. It really justifies the investments in our sales personnel, sales management, and insight support functions.\n",
      "Our focus for 2021 is increasing sales rep for productivity as selling resumes to normal course, continuing to leverage the investments we have made within sales and DNA to improve profitability, and most importantly, helping patients in pain. We will continue our Salesforce growth in the second half of 2021, but a slower pace than in 2020. We have made the investments in growing out of Salesforce, primarily in the second half of 2020. This investment is showing all the right signs that the first quarter always grew at 140% year-over-year and again, in the second quarter of 247% year-over-year. These orders converting to revenue over the next several quarters, I should say several years and further out. And therefore, we continued to build profitability in the second half of 2021 and 2022. We estimate our third quarter revenue to come in between $34.5 million and $36 million with an adjusted EBITDA of between five million and six million. The third quarter revenue range is now at 72% to 80% higher than 2020s third quarter revenue.\n",
      "We have now our full year 2021 revenue estimated from to now be between 130 million and 137.5 million with adjusted EBITDA expected to come in between 16.5 million and 21.5 million. The full year 2021 revenue estimate is in the lower end of previously provided guidance due to fewer than expected field and sales reps, which is partly due to how hot it is to hire sales reps side. But the good part about it is that is having a positive effect on our near-term profitability.\n",
      "The full year revenue estimate is approximately 62% to 72% of 2020 revenue of 80.1 million. My long-term goal for our electro therapy and rehab division is to continue to grow our share of a huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing domestic Salesforce, as well as potential acquisitions of complementary technologies. Our long-term goal is to fill all 800 territories in the U.S. and eventually our sales reps all become fully productive. We see that it takes up to two years to make a sales rep fully productive.\n",
      "In summary, we have announced strong growth in orders and we see those will drive revenue growth and profitability growth in the second half of 2021.\n",
      "We will now answer questions from all the listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "Thank you. [Operator Instructions] The first question will come from Matthew O'Brian with Piper Sandler.\n",
      "Unidentified Participant\n",
      "Hi guys. This is Simran [Phonetic] on for Matt. Thank you for taking the question. So, I wanted to speak on the sales force, as you guys are looking to onboard more reps, I think you mentioned 550 was the target by year end, what does that mean for the spend here in the back half of the year in order to hit that target, and then can you also speak on the attrition you are seeing in the sales force, which seem to impact this quarters total rep number more so than in previous quarters?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes, I would say it impacts the bottom line more than anything, relatively new reps that got added, maybe at the very end of last year, would not have provided a whole lot of orders that have contributed to revenue yet. So, the fact that we-in the first quarter we are very conservative about adding a whole lot of reps and are more focused on trimming those that were not so productive and continue that trend here through the second quarter as well contributed to a better bottom line than we originally estimated. Not really contributing so much to any change in revenue. And we will see, as we ramp-up to sales force again, although it will be at a much slower pace, we will see that the rest of the year looks pretty solid in terms of the bottom line. And we will be coming in at approximately the same revenue that we were expecting going into the year.\n",
      "Unidentified Participant\n",
      "Okay, sorry, I think what I meant was would you have to spend more in order to hit that target in order to onboard those reps, the 550 that you are trying to hit by your end?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "There is not a whole lot of additional expense. I think the fact that we will end up at 550, a while back six months ago, seven months ago, we were thinking more like 600 reps at the end of the year. So as a result of that we will end up spending less and therefore we are very optimistic about the EBITDA and the EBITDA margin. And then if you look at it a percent of-just real quick, if you look at it as a percent of revenue, Q2 sales and expenses, were about 44%. It should be similar to that in Q3 as a percentage as the revenue goes up. And then we will continue to gain more leverage on it. So, it should be approaching, 40% to 41% of revenue by Q4.\n",
      "Unidentified Participant\n",
      "Okay, thank you guys. And then just a follow-up, could you maybe provide some color of what that means for the outlook in 2022?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes, since we have seen several quarters with order growth well over 100%, which is a doubling of revenue. Of course, it is yet to be seen how well our first sales force will continue to ramp up on how the new reps we add in globe will be ramping up in the early days, to see if we can get the same kind of order growth in the next quarter too. Obviously, as our numbers -- the top line continue to go up, and we feel more and more territories and they become more mature the percentage growth will eventually start dropping. But, revenue for next year compared to the revenue for this year could well be approaching a 100%. But again, that would be pretty significant. That is a significant tolerance on that. It is always easier to predict when a company grows 5% or 6% a year, and when we are talking about this kind of growth, there is a pretty good tolerance on the revenue growth and order growth we will see next year.\n",
      "Unidentified Participant\n",
      "Okay, perfect. Thank you guys for taking the question.\n",
      "Operator\n",
      "The next question will come from Jeffrey Cohen with Ladenburg Thalmann. Please go ahead.\n",
      "Unidentified Participant\n",
      "Hi, Dan and Thomas, this is actually Destiny [Phonetic] on for Jeff. Thank you for taking my question. I was just wondering if you could first maybe talk about some of the progress you have made around securing an additional supplier or additional supply sources. I know that you mentioned that you are taking precautions and being conservative. So, I'm wondering if there is any additional information you could give us around that?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "No. Not really any material, significant information. It just shows quarter-after-quarter that this guidance here we applied or started applying about two years ago, it is working really well. Having so many sites and sources in place, and also being very conservative about placing orders far in the future has put us in a strong position, and we are just obviously trimming the inventory levels a little bit, just so that as we see that long-term supply chains will be more stable, that we don't carry too much inventory. But, so-our cash position a little bit on the other hand, as we were able to afford it, I think that money was well spent.\n",
      "Unidentified Participant\n",
      "Understood. Thank you. Perhaps I will transition over to some Salesforce questions. Could you remind me how many sales reps one call center or backend individual support, can typically manage in terms of patient volume?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes. We change this all the time because in terms of the infrastructure, the back office supporting our sales reps. We have here the last couple of years, we probably restructured that over two years, probably four or five times as we continue to grow as-the issues we are dealing with on the Salesforce keeps changing. But probably more importantly, as we, in the middle of last year or the second half of last year expanded our regional sales manager from five up to 15 to manage how many sales reps we have we have now. So, as a result of that, we have actually been able to make it a little lighter, on the inside and move people over to processing orders, making sure that the prescriptions we get the background information to demographics, etcetera, that is almost complete. So it just kept changing. But typically, we have had one support person, if you want to put it that way, of per region and a couple of support people per region as well that helps the reps getting-filling the paperwork in complete, etcetera. So depending on how you create the structure, but it takes about three, maybe four people per region to support them, and you multiply that by 15. So that tells you about the support organization.\n",
      "Unidentified Participant\n",
      "Okay. Thank you. Got it. Alright. Thank you. And I have to ask your progress around the blood volume monitor. How, what kind of feedback are you getting internally from your VP of sales and off as well as some of the initial customers and placements. And then you mentioned some clinical work, and I was wondering if you could provide a little more detail on that as well?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes. I don't have the list with me-that is more than half a dozen to 10 sites research, hospitals, etcetera. That we were working on, I don't remember the names right here. And then more kind of in hop with that deal we talking to, obviously he is really excited, very excited about the kind of edit you are getting from wake forest. I believe that, it is better than we would expect. But we also trying to, especially with the new studies signed we are deciding I have tried to stress test it. So that is the more extreme situations we put the device in and therefore potentially learn more about how to train and optimize some of the parameters we use that into the index. But so far, it looks like a very, very solid product.\n",
      "Unidentified Participant\n",
      "Okay, that is very interesting. Great, thank you. I think I'll take the rest of my questions offline and let someone else jump in. Thank you.\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Okay, thanks.\n",
      "Operator\n",
      "The next question will come from Yi Chen with HC Wainwright. Please go ahead.\n",
      "Yi Chen -- HC Wainwright -- Analyst\n",
      "Thank you for taking my question. I think your original go for the sales rep number by the end of this year was 600. Now that is a bit lower. So would you say the overall timeframe for to reach your ultimate goal up for the number of sales reps has shifted little bit later, due to the difficulty of funding experienced and protective sales reps?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes. I would say, yes. I'm not sure we have been specific about an endpoint for that. But we should be able to add from here on up to 100 rep a year. And we could probably push it or because we saw what we could do last year. We can probably push it to get to 600 by year. But at this point, because it is not as easy as it was a year ago. I think it is better that we also picky about who we hire. So we have a highest success rate. I think that is important too, obviously, is that it is going to, as we continue to grow over the next several years has been the-it gave us a slightly better EBITDA margin or profitability, by not growing as fast. So, technically you are right; yes.\n",
      "Yi Chen -- HC Wainwright -- Analyst\n",
      "Okay, got it. At this point, would you be able to provide some clarification regarding the potential launch or the launch of the blood body monitor potentially in 2022 and whether that is going to be the original model or the newest model?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "That is a good question. Personally, I think the features including being wireless, instead of having a cable over to the patient is one of those things, that is going to make it a much easier sell and there is a few things in the [indecipherable] concept, the algorithms and all that still the same. So, that is something we are definitely looking at. I think it is probably more about having have a little more substance in terms of the clinical support. So, that when we do approach at a broader scale, hospitals in general, surgical centers, etcetera, that we may get a an easy sell for the sales force and all the medical device companies we might be working with. In the future to get, but it is yes, there is definitely building the clinical evidence.\n",
      "And we are also debating internally, where we should put the biggest push, whether it should be the existing model, or a one of the two next models that we have in the pipeline, and literally prototyping now.\n",
      "Yi Chen -- HC Wainwright -- Analyst\n",
      "So by the end of this year, we will have better clarity as to the launch?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes, probably. I think there is so much happening in that division now that there'll be a lot more to talk about in the next in a couple of quarters. Definitely, yes.\n",
      "Yi Chen -- HC Wainwright -- Analyst\n",
      "Okay. Thank you, Thomas.\n",
      "Operator\n",
      "The next question will come from Marc Wiesenberger with B. Riley. Please go ahead.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Thanks. Good afternoon. The updated guide contemplates any potential disruptions from the Delta variants in the second half of the year or is it based essentially on an unchanged environment in the second quarter?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "I would say no. And to be more specific, unchanged environment. Yes. That what we estimate.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Got it. And then a little more commentary on the calling of the sales force. Was there a change in any quota levels or what kind of went into the decision to trim now was it that you just kind of your tolerance for some wider performance was no longer acceptable or kind of maybe just help us understand your thought process on trimming now?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "I think it is a combination of things. But one of the primary driving factors was obviously considering the 300 net additions last year where the majority was toward the end of the year. We did have quite a few people that were not performing to use the term quota to sort of the minimum requirements that tell us that we will have a solid performer long-term. So, that is been quite a bit of turnover in that. And deliberately, early in the year, we were hiring at a much lower rate, probably about a fifth of what we did in the second half of last year. And that obviously made it out to be a deduction in sales force. It is not something that we would look at as a negative, of course, I will take the, the increased bottom line anyway while we serve silver reorder significantly, but as we looking at it, it is now becoming easier to manage the sales force for regional sales managers because they have fuel and as you said, less dysfunctional reps that you need to attend to.\n",
      "So, that is a lot of benefits, as we didn't has that leaning into the Salesforce, during that period. We have now doubled, tripled that effort, so that we will be adding in public, probably you might have 20 every month throughout the rest of the year.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Got it. Thank you. Can you talk about the Top 10 reps and what percentage of sales they represent as well as the Top 50 sales reps and how have those percentages changed since end of last year?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Paul, I don't have the numbers in front of me, so I'd have to guess a little bit. But our Top 10 reps would probably be producing something like 4% or 5% of all orders. And there is also, let me think, and there is not necessarily a correlation between who are the Top 10 order producers and who are the better revenue producers. But we still have some reps that are, that if you were upset, produce maybe two million or close to two million a year and quite a few more of a dozen that produced well over a million a year. And a lot of reps that are slowly creeping up there, but they obviously need to have been employed here for quite a while before the accumulator revenue, as he comes in month after month or after the order comes in before that revenue slowly stops moving the average revenue per sales number.\n",
      "And to your question of Top 50, approx 10% of our Salesforce, we probably get something like 15% of all orders from those. It is very widespread as you can think. They all are fortunately just concentrated to a few reps, but that is been spread out through the entire country.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Sure. Yep. Just two final questions from me. With regards to the next wave, do you have any plans to kind of update it at all, maybe make it wireless or add additional functionality and just not, how do you, how long do you think the current iteration can sustain its reception in the market as we do see some early entrance having maybe a more kind of updated team management devices?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Currently, we don't have any plans. So, we got really great engineers so that we relatively quickly can bring you a new versions of that technology or all the products to the market if need be. And as we see new technologies come to the market all the time, we saw that, 30-years ago, we saw that, 20-years ago, 10-years ago, etcetera. It is still a very strong in terms of market at that the ability and holds a very strong position. And what we have seen is, most what is more important is obviously that, pretty much all insurance cover it. We also see that obviously prescribers are familiar with it and becoming more and more familiar with it. And one of the most important things that drives when prescriptions are waiting to lot of extent. The relationship between the sales rep and the prescriber, as well as how well we as an organization, not just the device, but how well we take care of the patients. We help them with insurance questions.\n",
      "We helped them with technical questions. And we literally follow up with the patient same day, or did they ask for more phase? We get the prescriptive. We follow up with a patient same day or the day after the procedure, the device, and we have a very extensive customer service department. We tried to keep as well-staffed, I should say, in some cases, almost half so that we can answer all calls that come in at 90% at a time. So no one gets to leave voice mails or anything. It is part of the overall experience and also makes the prescriber want to continue to prescribe the device because we take good care of the patient. So it is not just having a great device. It is seeing time to experience and having a strong sales force with the strong relationships. That is important for attenuating the prescription.\n",
      "And then, the future of revenue as you were alluding to. So the pressure on just having essentially new technology, it is really the whole package and being able to with prescription slings. I like to say, if you would be able to have patients with pain. So I don't see a competitive product, from a product point of view, competitive pressure at all.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Understood, thanks. And then, just a final one for me, have you added any sales reps in the monitoring division at all?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "We are about to add a few people who are developing people that you can call them go inside sales reps, then spending a lot of the time of developing key opinion leaders more than just knocking on doors and try to move some box. So, that is when they believe the strategy here early on, it is about getting for research, also building key opinion leaders and, and part of the staff steps that you have to take in this type of medical device sales.\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "Understood. Thank you very much.\n",
      "Operator\n",
      "The next question will come from James Terwilliger of Northland Securities. Please go ahead.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Excellent, thank you. First of all, thanks for taking my question and a nice job on the quarter. Very quickly and I apologize, Thomas. I have been kind of flipping between different earnings calls and fortunately. On the pain management side and I have heard this from some other companies. Are you getting hit by any type of wage pressure? It is hard to find employees out there, let alone good employees. Are you seeing any type of increase in wage pressure or what you have to pay these particular, sales reps that you are trying to hire?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "We lost Thomas there, but we are seeing, It is just general hiring pressure, one finding them, and then it becomes wage pressure because they may have offers from a lot of different places to work. And it is just very competitive in this industry period, sales, med device or med tech, I would say generally, it is really competitive. So yes, that that ends up putting some pressure on, wages and how that wage package is structured for sure.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Yes, no, I'm hearing that from other companies as well. And again, I apologize. I have been jumping around on a couple calls. How many people are moving on to the to the monitor division? How many people were in that? I know, we talked about business development and working with KOLs [Phonetic]? Is it a five to 10 person team in there? I know it is pretty lean and mean, but I mean, is that still kind of or how many people were in that monitoring division at this time?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Yes, I think it is been a handful in that kind of five to 10 range. But we have definitely seen some new hires here. So, we have bumped over 10. And then the hiring plan for the rest of the year. Thomas, you can comment more, but I think it is going to push us close to 15 to 20 by the end of the year.\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "Yes, absolutely. We are now investing heavily in it. And we have a great guy, John Gray that is running that division. And it is very encouraging to see how we now see a lot of activity in that that division.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "So, I got two more questions on the monitor. I thought I heard Wake Forest earlier in the call. And again, I apologize again, how many clinical test sites or how many beta sites are you in right now? I know it is early, but I know it is going to be a tough sell a piece of capital equipment going into a hospital after the hospital shut down with COVID. But how many different hospital clients are you kind of working through with this monitor at this time?\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "I will be talking to a lot of hopefully, we will get started very, very soon. But technically, we just in that one right now.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Okay. And then, lastly, Thomas, this is for you. If you are looking to, 2022 and how you would launch this monitor. And I don't want to get into the numbers because it is too early. Would your preference be to go with an internal sales force or strategic partner or maybe monitor with your business development people? So, maybe some independent distributors, I could call on those hospitals or any what is your thought on ideally, I know, you may not have the answer yet, what you would want to do in terms of distribution for this monitor?\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "I think, as a small medical device company, and this is a fairly new area for us, relatively speaking, I think the best thing we can do is explore all options. And fortunately, we do have the financial ability to take the time to do it right. And also to develop on all fronts, whether it is private labeling, whether it is strategic partnerships, whether it is like licensing, whether it is a direct sales force, and it could also from a geographic perspective, be different. applying different distribution strategies, depending on the part of the globe that we are addressing.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Now that makes complete sense. Once again, nice job on the quarter and I will jump back in the queue. Thanks for taking my question guys. Take care of yourself.\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Thanks, James.\n",
      "Operator\n",
      "And this will conclude our question-and-answer session. I would like to turn the conference back over to Mr. Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "Thank you. I hope today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening in on this call. Thank you and a great day to all.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 44 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- President & Chief Executive Officer\n",
      "Daniel Moorhead -- Chief Financial Officer\n",
      "Unidentified Participant\n",
      "Yi Chen -- HC Wainwright -- Analyst\n",
      "Marc Wiesenberger -- BRiley FBR -- Analyst\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "If you want to know who really controls Zynex, Inc. (NASDAQ:ZYXI), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Warren Buffett said that he likes \"a business with enduring competitive advantages that is run by able and owner-oriented people.\" So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.\n",
      "Zynex is not a large company by global standards. It has a market capitalization of US$581m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Zynex.\n",
      "NasdaqGS:ZYXI Ownership Breakdown July 22nd 2021\n",
      "What Does The Institutional Ownership Tell Us About Zynex?\n",
      "Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.\n",
      "As you can see, institutional investors have a fair amount of stake in Zynex. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Zynex, (below). Of course, keep in mind that there are other factors to consider, too.\n",
      "NasdaqGS:ZYXI Earnings and Revenue Growth July 22nd 2021\n",
      "We note that hedge funds don't have a meaningful investment in Zynex. Looking at our data, we can see that the largest shareholder is the CEO Thomas Sandgaard with 43% of shares outstanding. In comparison, the second and third largest shareholders hold about 8.9% and 3.6% of the stock.\n",
      "After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.\n",
      "While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.\n",
      "Insider Ownership Of Zynex\n",
      "The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.\n",
      "Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.\n",
      "Our information suggests that insiders maintain a significant holding in Zynex, Inc.. It has a market capitalization of just US$581m, and insiders have US$251m worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.\n",
      "General Public Ownership\n",
      "The general public, with a 24% stake in the company, will not easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.\n",
      "Next Steps:\n",
      "I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with Zynex (including 1 which is a bit unpleasant) .\n",
      "Ultimately the future is most important. You can access this free report on analyst forecasts for the company.\n",
      "NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.\n",
      "This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "In trading on Friday, the Invesco S&P SmallCap Health Care ETF is outperforming other ETFs, up about 1.7% on the day. Components of that ETF showing particular strength include shares of Zynex, up about 7.1% and shares of Apollo Medical Holdings, up about 7% on the day.\n",
      "And underperforming other ETFs today is the Junior Gold Miners ETF, off about 2.9% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of Sulliden Mining Capital, lower by about 9.1%, and shares of Gold Resource, lower by about 6.1% on the day.\n",
      "VIDEO: Friday's ETF Movers: PSCH, GDXJ\n",
      "\n",
      "Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vicor Corp (Symbol: VICR), where a total of 552 contracts have traded so far, representing approximately 55,200 underlying shares. That amounts to about 44.4% of VICR's average daily trading volume over the past month of 124,305 shares. Particularly high volume was seen for the $80 strike call option expiring January 21, 2022, with 278 contracts trading so far today, representing approximately 27,800 underlying shares of VICR. Below is a chart showing VICR's trailing twelve month trading history, with the $80 strike highlighted in orange:\n",
      "Zynex Inc (Symbol: ZYXI) saw options trading volume of 781 contracts, representing approximately 78,100 underlying shares or approximately 44.3% of ZYXI's average daily trading volume over the past month, of 176,415 shares. Especially high volume was seen for the $17.50 strike call option expiring July 16, 2021, with 465 contracts trading so far today, representing approximately 46,500 underlying shares of ZYXI. Below is a chart showing ZYXI's trailing twelve month trading history, with the $17.50 strike highlighted in orange:\n",
      "And General Electric Co (Symbol: GE) options are showing a volume of 225,804 contracts thus far today. That number of contracts represents approximately 22.6 million underlying shares, working out to a sizeable 43.5% of GE's average daily trading volume over the past month, of 52.0 million shares. Especially high volume was seen for the $13 strike call option expiring July 02, 2021, with 28,162 contracts trading so far today, representing approximately 2.8 million underlying shares of GE. Below is a chart showing GE's trailing twelve month trading history, with the $13 strike highlighted in orange:\n",
      "For the various different available expirations for VICR options, ZYXI options, or GE options, visit StockOptionsChannel.com.\n",
      "Today's Most Active Call & Put Options of the S&P 500 \n",
      "\n",
      "It is hard to get excited after looking at Zynex's (NASDAQ:ZYXI) recent performance, when its stock has declined 17% over the past three months. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. In this article, we decided to focus on Zynex's ROE.\n",
      "Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.\n",
      "How To Calculate Return On Equity?\n",
      "ROE can be calculated by using the formula:\n",
      "Return on Equity = Net Profit (from continuing operations)  Shareholders' Equity\n",
      "So, based on the above formula, the ROE for Zynex is:\n",
      "9.7% = US$5.4m  US$56m (Based on the trailing twelve months to March 2021).\n",
      "The 'return' refers to a company's earnings over the last year. That means that for every $1 worth of shareholders' equity, the company generated $0.10 in profit.\n",
      "What Is The Relationship Between ROE And Earnings Growth?\n",
      "We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or \"retains\" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.\n",
      "Zynex's Earnings Growth And 9.7% ROE\n",
      "When you first look at it, Zynex's ROE doesn't look that attractive. However, given that the company's ROE is similar to the average industry ROE of 10%, we may spare it some thought. Particularly, the exceptional 35% net income growth seen by Zynex over the past five years is pretty remarkable. Considering the moderately low ROE, it is quite possible that there might be some other aspects that are positively influencing the company's earnings growth. Such as - high earnings retention or an efficient management in place.\n",
      "As a next step, we compared Zynex's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 15%.\n",
      "NasdaqCM:ZYXI Past Earnings Growth May 19th 2021\n",
      "The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Zynex's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.\n",
      "Is Zynex Using Its Retained Earnings Effectively?\n",
      "Conclusion\n",
      "Overall, we feel that Zynex certainly does have some positive factors to consider. Despite its low rate of return, the fact that the company reinvests a very high portion of its profits into its business, no doubt contributed to its high earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.\n",
      "This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\n",
      "\n",
      "Shares of Zynex closed 10.1% higher on Monday after the medical device manufacturer announced its plans to repurchase $10 million worth of shares.\n",
      "Zynex (ZYXI) said that the repurchase program will commence immediately and is set to expire on Sep. 8, or before the buyback limit of $10 million is reached.\n",
      "The companys CEO Thomas Sandgaard said, this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy. He added that, the buyback program represents an attractive opportunity to deploy capital in a way that will benefit stockholders.\n",
      "Last month, Zynex reported lower-than-expected 4Q results. The company reported 4Q earnings of $0.05 per share, which missed consensus estimates by a cent and fell 44.4% year-over-year. Revenues of $25.6 million grew 81% year-over-year but missed analysts expectations of $25.8 million. (See Zynex stock analysis on TipRanks)\n",
      "Following the 4Q miss, B.Riley Financial analyst Marc Wiesenberger downgraded the stock to Hold from Buy and lowered the price target to $19 (17% upside potential) from $23. In a note to investors, the analyst said that the company provided a wider than normal FY21 guidance range. The analyst further lowered his FY21 estimates, given deteriorating profitability and increased uncertainty.\n",
      "Overall, the Street has a Moderate Buy consensus rating based on 1 Buy and 3 Holds. The average analyst price target of $21.63 implies upside potential of over 33% to current levels. Shares have gained about 14.6% in one year.\n",
      "Related News:\n",
      "Dycom Plans $150M Share Buyback After 4Q Sales Beat; Stock Jumps 12.4%\n",
      "CMC Materials Bumps Up Quarterly Dividend By 5%, Boosts Share Buyback Plan\n",
      "Henry Schein Reinstates Share Buyback Plan; Street Sees 30% Upside\n",
      "\n",
      "Health care stocks were ending moderately higher this afternoon, with the NYSE Health Care Index rising 0.6% while the SPDR Health Care Select Sector ETF also was up 0.1%.\n",
      "The Nasdaq Biotechnology index, however, was slipping 1.5%, giving back an earlier gain.\n",
      "In company news, Dentsply Sirona (XRAY) climbed 3.5% after the dental products supplier Monday said it was expanding its partnership with the North American Dental Group through a new agreement providing network-affiliated dentists with added access to Dentsply scanning and imaging tools. Financial details and other terms of the new contract were not disclosed.\n",
      "NantKwest (NK) rose 4% after the immunotherapy company and merger partner ImmunityBio said they have dosed the first cohorts of their hAd5 T-cell-based COVID-19 vaccine candidate in the US and South Africa to determine which route combination provides the best efficacy against mutated variants of the coronavirus.\n",
      "XpresSpa Group (XSPA) climbed 9.7% after saying it was collaborating with United Airlines (UAL) to open a COVID-19 testing facility at George HW Bush Intercontinental Airport in Houston.\n",
      "Zynex (ZYXI) climbed 12% after the medical device company authorized a new, $10 million stock repurchase program running through Sept. 8.\n",
      "\n",
      "Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 1.2% while the SPDR Health Care Select Sector ETF also was 1.3%.\n",
      "The Nasdaq Biotechnology Index was climbing 0.3%.\n",
      "In company news, XpresSpa Group (XSPA) climbed about 15% after saying it was collaborating with United Airlines (UAL) to open a COVID-19 testing facility at George HW Bush Intercontinental Airport in Houston.\n",
      "NantKwest (NK) rose 10.5% after the immunotherapy company and merger partner ImmunityBio said they have dosed the first cohorts of their hAd5 T-cell-based COVID-19 vaccine candidate in the US and South Africa to determine which route combination provides the best efficacy against mutated variants of the coronavirus.\n",
      "Zynex (ZYXI) climbed 8.5% after the medical device company authorized a new, $10 million stock repurchase program running through Sept. 8.\n",
      "\n",
      "Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioMarin Pharmaceutical Inc (Symbol: BMRN), where a total of 4,955 contracts have traded so far, representing approximately 495,500 underlying shares. That amounts to about 47.1% of BMRN's average daily trading volume over the past month of 1.1 million shares. Particularly high volume was seen for the $75 strike put option expiring April 16, 2021, with 599 contracts trading so far today, representing approximately 59,900 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $75 strike highlighted in orange:\n",
      "Zynga Inc (Symbol: ZNGA) saw options trading volume of 118,153 contracts, representing approximately 11.8 million underlying shares or approximately 46% of ZNGA's average daily trading volume over the past month, of 25.7 million shares. Particularly high volume was seen for the $11.50 strike call option expiring March 12, 2021, with 51,178 contracts trading so far today, representing approximately 5.1 million underlying shares of ZNGA. Below is a chart showing ZNGA's trailing twelve month trading history, with the $11.50 strike highlighted in orange:\n",
      "And Zynex Inc (Symbol: ZYXI) saw options trading volume of 2,303 contracts, representing approximately 230,300 underlying shares or approximately 45.8% of ZYXI's average daily trading volume over the past month, of 502,350 shares. Particularly high volume was seen for the $12.50 strike call option expiring May 21, 2021, with 660 contracts trading so far today, representing approximately 66,000 underlying shares of ZYXI. Below is a chart showing ZYXI's trailing twelve month trading history, with the $12.50 strike highlighted in orange:\n",
      "For the various different available expirations for BMRN options, ZNGA options, or ZYXI options, visit StockOptionsChannel.com.\n",
      "Today's Most Active Call & Put Options of the S&P 500 \n",
      "\n",
      "What happened\n",
      "Shares of Zynex (NASDAQ: ZYXI) were crashing 17.8% lower as of 11:21 a.m. EST on Friday. The steep drop came after the medical technology company announced its fourth-quarter results following the market close on Thursday.\n",
      "So what\n",
      "It wasn't that Zynex's Q4 results were bad. The company reported that revenue soared 81% year over year to an all-time high of $25.6 million. It generated earnings in the fourth quarter of $1.8 million, or $0.05 per diluted share. The problem was that those numbers didn't quite meet Wall Street's expectations.\n",
      "An even bigger issue, though, was that Zynex's 2021 Q1 forecast fell short of analysts' views. The company projects Q1 revenue between $23 million and $24.5 million. This midpoint of that range is well below the average analyst estimate of $27.4 million. And while Wall Street was looking for earnings of $0.07 per share in the first quarter, Zynex anticipates a \"small loss.\"\n",
      "Image source: Getty Images.\n",
      "However, it's important for investors to keep the big picture in mind. The first quarter is historically weaker due to the seasonal impact of deductibles resetting. But Zynex expects its sales and bottom line to improve throughout 2021. The healthcare stock should rebound if it delivers stronger growth than expected.\n",
      "Now what\n",
      "The main thing to watch with Zynex now is what impact the expansion of its sales force has on order growth. The company thinks that it should see an uptick in orders in the first half of 2021, with revenue increasing in the second half of the year and beyond.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of February 24, 2021\n",
      "Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, Inc (NASDAQ: ZYXI)\n",
      "Q4 2020 Earnings Call\n",
      "Feb 25, 2021, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good afternoon, and welcome to the Zynex Fourth Quarter and Full Year 2020 Earnings Call. [Operator Instructions] Certain statements in this release are forward-looking and as such, are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2020, and as well as forms 10-Q, 8-K and 8-K/A, press releases and the company's website. Please note, this event is being recorded.\n",
      "I would now like to turn the conference over to Thomas Sandgaard, Founder, Chairman and Chief Executive Officer. Please go ahead.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of February 24, 2021\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our 2020 fourth quarter and full yearearnings call I'm excited to announce yet another quarter of revenue growth and positive net income. Our fourth quarter revenue of $25.6 million increased 81% compared to the same quarter last year. It was also the highest quarterly revenue in the history of the company. It was our 18th straight quarter with positive net income and fully diluted earnings per share was $0.05. Adjusted EBITDA for the fourth quarter was $3.4 million, as we continue to invest in growing our sales force. We continue to see good order flow as we push through obstacles related to COVID-19 pandemic. Fourth quarter orders came in 117% higher than the fourth quarter of last year and 45% sequentially compared to Q3. For the full year, orders grew 96% compared to 2019, a solid result in the middle of the pandemic.\n",
      "The continued strength in orders and growth of those orders speaks volumes to the relationships that our sales force has with many prescribers and the need for them to prescribe non-opioid, nonaddictive prescriptions solutions for the patients in pain. As selling gets back to normal later in 2021, we see an upside in sales order growth as the over 300 sales reps we added net during 2020, they haven't been able to get access to many of the clinics in the territories due to COVID restrictions. As a reminder, the majority of cash and revenue related to an order comes in over the year following the receipt of the order as the patient uses the device and related supplies, which should lead to expanding revenue and profitability in the second half of 2021 and beyond. In Q4, we continued to aggressively add sales reps and exceeded 500 total reps by the end of the fourth quarter. Our recruiting efforts continue to be supported by a surge in candidates due to increased unemployment-related rates related to COVID-19.\n",
      "We expect these new hires to provide significant productivity increases in 2021 and beyond. We expect to have over 600 sales reps by year-end. I should also mention that our operations continue without any issues, and our supply chain remains uninterrupted. It's our practice to keep several months of finished products on the shelf, have four months of components on hand for internal assembly and 12 to 18 months of orders placed with our vendors on top of the in-house materials. During 2020, we took an even more conservative approach in response to COVID and any possible supply chain issues, which resulted in an increased inventory of approximately $3 million higher than our normal levels. We should be back to a more normal inventory level when we get through Q2 and Q3. The opioid epidemic continues to be a serious issue in this country, and we are increasingly working to get patients off opioids and for physicians to use our prescription strength technology as the first line of defense when treating pain.\n",
      "Currently, the devastating impact has reached a level where tens of thousands die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects. Our products for pain management and still stand out as some of the best products in the industry. The NextWave for pain management, our NeuroMove device for store rehabilitation and InWave treatment puts us in a very strong product position in the rehabilitation markets. We continue to see great potential in both our product divisions, our existing revenue-generating area for pain management as well as a huge unmet potential for our Blood Volume Monitor. As most of you probably already know, we managed to get the FDA clearance for our CM-1500 blood and fluid monitor nearly a year ago. The CM-1500 is a non-basin monitor intended to monitor patients load balance in hospitals and surgical centers. We expect to initially target ORs and surgeries that typically display substantial blood loss as well as recovery rooms and ICUs where internal bleedings today are common and difficult to detect until the point where serious complications occur.\n",
      "We believe this product will lead to safer surgeries, fewer complications at less mortality, one of the biggest unmet needs in hospitals today. We're still recruiting to add more personnel to this division. We're seeing good solid preliminary results from a clinical study at and we're preparing to commence more studies on the device shortly. We are seeing interest in purchasing the device from hospitals that have -- now have the device and demo, and our engineering team are well under way with building prototypes of our next-generation CM-1600 device that will be easier to use in certain settings. Recently, a file a patent application for a technology that is somewhat similar in nature, but will be used for noninvasively early detecting sepsis and another huge unmet problem in hospitals today.\n",
      "I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First, I'll review our 2020 fourth quarter results. Orders grew 117% year-over-year, and net revenue grew 81% to $25.6 million from $14.2 million in 2019. Device revenue increased 118% to $8.2 million compared to $3.8 million last year. Supplies revenue increased 67% year-over-year to $17.4 million from $10.4 million. Gross margins were 78% in the fourth quarter. Sales and marketing expenses increased 156% year-over-year, as we continue to aggressively grow our sales force, and G&A expense grew 91% year-over-year. Much of the increase was related to increased headcount in our reimbursement and patient support functions related to our order growth. Fourth quarter net income was $1.8 million or $0.05 per diluted share. Adjusted EBITDA, which is a standard EBITDA calculation plus an exclusion of noncash stock-based compensation and other income expense and is reconciled in our press release, was $3.4 million in the fourth quarter of 2020. I'll now review the 2020 full year results. Orders grew 96% year-over-year, which increased net revenue 76% to $80.1 million from $45.5 million in 2019.\n",
      "Device revenue increased 99% to $21.3 million compared to $10.7 million last year. Supplies revenue increased 69% year-over-year to $58.9 million from $34.8 million. Gross margins were 78%. Sales and marketing expenses increased 130% year-over-year, and G&A expense grew 71% year-over-year. 2020 net income was $9.1 million or $0.26 per diluted share compared to net income of $9.5 million or $0.28 per diluted share in 2019. Adjusted EBITDA increased 13% to $13.7 million in 2020. On the balance sheet, as of December 31, 2020, our cash balance was $39.2 million, up from $14 million at year-end. As many of you know, we completed an equity transaction during July, which added $25 million to the balance sheet. Cash was down slightly from Q3 as we increased our inventory to protect against any supply chain issues. Our working capital grew 205% to $52.9 million at December 31 and compared to $17.4 million as of December 31, 2019.\n",
      "With that, I'll turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Thank you, Dan. I'm pleased with our full year growth -- full year-over-year growth in orders of 96%, and our revenue growth of 76% in the midst of a COVID-19 pandemic. It's a huge testament to our efforts to grow our sales force and clearly justifies the investments in our sales personnel, sales management and inside support functions. Our focus for 2021 is on increasing sales productivity as selling resumes to its normal course, continuing to leverage the investments we have made within sales and also G&A to improve profitability and most importantly, help our patients in pain. We will continue to grow our sales force during 2021, except it will be at a much slower pace than last year.\n",
      "We have made the investments in growing our sales force primarily in the second half of last year. This investment is showing all the right signs as Q4 orders grew an impressive 117% year-over-year. January of this year grew 98% over last January, and February is currently trending above 120%, while March looks a growth over -- well over 150% at this point. Eventually, over the next one year or 2, these orders will turn into revenue, and therefore, we expect to return to a healthier relationship between top line revenue and sales expenses, as we get into the third and fourth quarters of 2021. As always, with the beginning of the year, we see insurance deductibles impacting revenues. So this seasonality that we see every year means a flat or slightly lower revenue in the first quarter compared to the fourth quarter of the previous year. That's been the case for many years. We estimate our first quarter revenue to come in between $23 million and $24.5 million with an adjusted EBITDA loss between $0.5 million and $1.5 million. As a reminder, first quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year.\n",
      "This revenue seasonality, along with the sales force investments we made in the second half of 2020, is causing a small loss in Q1. With our current order growth, we expect revenue and profitability to ramp up significantly throughout the year. The Q1 revenue range is 51% to 61% higher than in 2020, and full year 2021 revenue is estimated to come in between $135 million and $150 million with adjusted EBITDA between $15 million and $25 million. The full year revenue estimate is approximately 68% to 87% above 2020 revenue of $80.1 million. My goal for our electrotherapy and rehab division is to continue to grow our share of the huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors, this includes growing our domestic sales force as well as potential acquisitions of complementary technologies.\n",
      "The very large expense line in our financials is, therefore, part of a very deliberate effort to grow our top line revenue long-term and therefore leverage the healthy margins in our industry to maximize long-term profitability and earnings per share. We will see the effects of that in the third quarter of this year and going forward. In the meantime, our revenue is still impacted by the slowdown in orders in Q2 last year due to COVID and our bottom line impacted by adding a net of 300 sales reps during last year, primarily during the second half. Our long-term goal is still to fill all 800 territories in the U.S. and get sales reps fully productive. We see that it takes up to about two years to make a sales rep fully productive. In summary, we announced yet another great quarter with strong growth in orders, growth in revenue and profit.\n",
      "We will now answer questions from our listeners.\n",
      "Questions and Answers:\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "[Operator Instructions] We'll take our first question today from Yi Chen with H.C. Wainwright. Please go ahead.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Thank you for taking my questions. My first question is, how much impact from COVID-19 have you incorporated into the 2021 revenue guidance?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Relatively little. The biggest impact was a -- came from a significant dip in orders in April and May, to some degree, the first half of June of last year. So we saw a significant dip in orders in that second quarter, that impacted revenue in the third and fourth quarter of last year. So we came out a little less than what else we could have. We definitely still see the impact of that dip in orders here in this first quarter. There will be a little bit in the second. I think once we get to the third quarter of this year, the impact from that dip is very little. All of our webs are obviously not having full access to the same type of access that they used to have before COVID. But just the fact that we have added so many sales reps has more than mitigated those marginal difficulties we see for the individual web. So therefore, we still see order growth in the range of, at least, double over last year, except for that second quarter of last year. And eventually, we'll see revenue growth catching up to that kind of order growth.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "And second question, does the -- does your revenue projection include any potential revenue from the Blood Volume Monitor? And if not, can we still expect the device to be commercialized sometime later this year?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Well, it's definitely commercialized. It's already sitting in a few hospitals where people are looking at and testing it and have indicated that they're certainly interested in acquiring it. We have not put any of those numbers in the forecast for this year. We have so much growth in the pain management division alone that it wasn't necessary to put that in. So that buys us a little or puts some of the pressure -- take some of the pressure off in terms of certainly the public markets and the perception of how much revenue should come this year, but there might be a little that will trickle in before the end of the year. Most of the activity is obviously on getting more clinical data, but we do have some sales reps.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "So currently, you do not have a dedicated sales team for the Blood Volume Monitoring yet, is that correct?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "We do have one person it's business development director business development, but we might expand with more people to basically undertake a sales of up just one person.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Okay. And finally, can you provide an update on the development of the sepsis monitoring?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Yes. We are still in the very early stages of figuring out the prototyping of that device. So there's not a whole lot yet other than the concept is the patent has been filed. And while the patent application has been filed, and we will be looking at how we can develop a prototype for it. We just added one more engineer to the engineering team. So we should have the resources to take that on as soon as he starts.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay, thank you.\n",
      "Operator\n",
      "We'll take our next question from Jeffrey Cohen with Ladenburg Thalmann. Please go ahead.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Hi. Thomas there every year. And then. Great. Are you doing. Pretty good. No complaints. A few questions. So firstly, can you remind us on the sepsis monitor, what you anticipate the input is?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Well, it's -- the principle is the same, which is multiple parameters that have a correlation with the onset of sepsis. Individually, they don't mean much. But when you put them together in an index then it becomes a very strong indication, just like the Blood Volume Monitor. In this case, we're looking at heart rate, temperature, respiratory rate and one or two more parameters to eventually add into that index that could give us an alarm that. So the end result of that is -- a medical professional that you should probably take a blood same so that you can analyze to see, if you actually half sets is coming on. And that would be earlier than when it gets into a very serious situation, where it's more obvious that So if we can take -- have medical professionals take that sample early on and with a decent degree of probability will then be able to say, yes, we can start treatment now rather than later. We will be able to save some lives and obviously reduce a lot of complications.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "And similar to the Blood Volume Monitor, you would be applying this to the forum or the hand as far as a click?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "That would be -- this product here will have the ability to have the sensors applied -- the more flexibility as to where that can be applied than the Blood Volume Monitor. But that is definitely an option to place it there, and the sensors could -- would, for the most, be somewhat similar.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Got it. And then on first time I've heard you really talk about or mention acquisitions or complementary products, are you thinking about that in the pain/opioid arena or are you thinking about that as far as analysis in the hospital patient population or all in, any?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Yes. We're looking at both. We have somewhat close or very close, in some cases, actually for both divisions. As of now, what's on the table right now, those things that are more imminent potential acquisitions, they would be in the pain management space. I mean we already distributed products from other companies. If we add more products in that space, it would have an immediate sales channel, and we're only looking at products that would be able to leverage that we have -- that they would have the same call point. So that's what we're looking at, but it's going to be the right opportunity for us to pull the trigger.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And then lastly, as far as the guidance on both sides with the range as well as the EBITDA numbers, it looked like 2020 was a fairly methodical and orderly ramp-up of revenues. It sounds like what you're saying is a little bit of a reset in Q1 similar to Q4 with probably another equal and orderly ramp up throughout the year to get to that midpoint. And with the midpoint in the, call it, 76% or 77% range, are we OK in thinking about, generally speaking, the sales and marketing line being driven by the, say, 80% to 85%, and then the G&A line increasing in the 60% to 65%?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "I would say for the full year, the sales side -- this year, sales comes in at a little over 40%, and that's going to be similar next year, but it's going to decrease significantly over the course of the year. With the guidance we gave in Q1, the sales and marketing line is over 50% because of the flatness in revenue in Q1 that we see every year. And then you should see a decrease down toward 40% by the end of the year.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "As far as -- its margin. And on the growth side then, the sales and marketing could be 70%, 75% range for the year?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "I don't have that calculation in front of me. I typically look at it as a percent of revenue, and you'll definitely -- I'd have to go back and look at it that way. But again, if you're trending down toward about 40% as a percent of revenue by the end of the year, that's about right.\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Are you talk about gross profit margin or you talking about our sales expense line?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Yes. I was thinking of just trying to get a better hand on the expense lines. So with that midpoint in guidance, I think, we're at, call it, 60% and 30% first being sales and marketing for the year in that general range?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "Yes. Yes, that's pretty close.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And I think I got it. And lastly, on the sales front. So you increased dramatically last year by 300-plus reps getting over 500. It sounds like this year, perhaps another 100-ish get added. Any commentary on retention or selection or qualification or training of note, and how that's been going?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "It's about the same. As we've seen before, we continue to get better and better at training new reps. It's going to be a little easier this year because training about 500 new reps last year -- maybe not that much, 400 or something like that. And then 300 of them are still with us was obviously a big task on top of the reps that were already on board. So this year, by only adding 100 net, is going to enable us to make sure we pay more attention, not only during training, but in the first few days when our regional sales managers hold their hands out in the field after they get their initial training. It will be a much easier task, and we could probably achieve even better results in terms of early on productivity and retention rate.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay, perfect. Thanks for taking the questions.\n",
      "Operator\n",
      "[Operator Instructions] We'll take our next question from Marc Wiesenberger with B. Riley Securities. Please go ahead.\n",
      "Aman [Phonetic] -- B. Riley Securities -- Analyst\n",
      "Hey, thanks for taking my question. This is actually Aman jumping in for Marc. So I wanted to ask, can you talk about the demand and prescriptions associated with rehabbing from surgical procedures and where are you relative to normalized levels? And how has that trended over the last couple of quarters?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Well, the demand is -- some people describe the demand for professional or medical pain management to be in the $500 billion range, well wide and half of it being here in the U.S. And what we see -- so that's a pretty good way of illustrating that any rep we have in the 800 territories that already mapped out barely scratch the surface of the demand that exists in their territories, whether it's the amount of patients that they are or it's the amount of clinics that they can even possibly get to during a day or during the time that they work force. So we see the long-term revenue potential be an average of $1 million per sale reps for long term. Obviously, it takes a couple of years for most reps to get to that kind of productivity. That's order productivity then the revenue comes even lighter than that because of our business model. But right now, because of how many new reps they are and they're just beginning to send in the first few orders, that obviously means that our average is way lower than that something we've covered many times previously.\n",
      "But obviously, if you say that the average revenue program long-term is $1 million a year, and we'll eventually have filled up 800 territories that should be equating to a revenue of $800 million in theory. We currently see that we have a few reps that are producing over $2 million a year in annual revenue, and our top 20 reps produce an average of -- you got to be below the top 20 to be producing in the neighborhood of maybe $1 million in annual revenue. So it's absolutely attainable, but we have so many reps that are just slowly working up to that. So it a very slow, slow-moving machine that we have built here, but there's also a lot of sustainability to it because the revenue is generated for a couple of years after we get those orders. So it's slowly getting on the books. And eventually, in the future quarters, we'll see the accumulated effect of those orders turning into revenue.\n",
      "Aman [Phonetic] -- B. Riley Securities -- Analyst\n",
      "Okay. And then I wanted to ask about your supply chain. Are you seeing any input inflation there? And do you have any ability to pass that on to your customers?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "We're fortunate enough to be growing so fast and also now having pretty much second sources on everything we do, and that puts us in a very strong negotiating position. So if the worldwide is trend to see increased prices, we still see decreasing prices on our raw material and components, simply because our volumes are increasing so much, and we've been good at creating second sources. So we have competition and pricing as a result of that. So we see the opposite trend, but that's not obviously a macro trend. That's something that's self inflected, just the fact that we're doing better.\n",
      "Aman [Phonetic] -- B. Riley Securities -- Analyst\n",
      "Got it. Good to know. And then last question for me, and I'll jump back in the queue. Can you talk about any traction you're getting with other products like NeuroMove and InWave? And do you have any plans to make more aggressive efforts to monetize these products besides the NextWave?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Right now, our focus is to primarily increase revenue of the NextWave. That is where the most obvious demand is. And you can say, where you get the most bank to the buy, adding more sales webs, providing them with better training, better promotional and material and better support. So our investments have been more in the sales force. Also, we added from going -- last year, we added 10 more regional sales managers. We went from five to 15 regional sales managers, that's also an investment way that primarily fits that space. And the other products that we distribute from other companies and potentially will acquire that fit into that sales force is where our focus is. Long term, you're right. We've got some great products. Our InWave for treatment is a great product, and there's really good reimbursement for it as well. So as we penetrate those markets better, that's certainly something we could take up and do more of.\n",
      "That's probably an item we can -- that -- where we can utilize at least part of our sales force. The NeuroMove will probably the way things are reimbursement wise right now, require more effort, more of an investment long-term and potentially securing better reimbursement and/or educating the end users more than necessarily the physicians to drive more revenue on that. So that is more longer term. We also need to consider expansion internationally in terms of diversifying and expanding our revenue base that way. So that will be part of the mix as well. But again, we're probably a couple of years out before we look at and be looking at expanding into those areas. The demand is so big and any effort we put in, in pain management and that area right now pays off so quickly that it's an obvious one to put most of our entity on short-term intent.\n",
      "Aman [Phonetic] -- B. Riley Securities -- Analyst\n",
      "Thank you. I'll pass it on.\n",
      "Operator\n",
      "Next question comes from Matt O'Brien with Piper Sandler. Please go ahead.\n",
      "Crean [Phonetic] -- Piper Sandler -- Analyst\n",
      "Hi, thank you. This is Crean on for Matt, and thanks for taking the questions. So first, could you talk a little bit about the revenue mix shift we're seeing with supplies decreasing a bit? And what are the drivers of that? And also, where do you see mix going over the coming years?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "I would say, overall, that is pretty meaningless, how that flows because it's very constant. It just -- well, maybe Dan can give the more technical explanation of it. Every patient has a total revenue stream that comes from device and supplies. The only thing is that when we have a huge uptick in orders, obviously, initially, there would be an uptick in the device revenue versus the supplies, but long term, then the supplies revenue catch up to it. But overall, it's flat. It's technicalities, and that makes it looks like there are fluctuations. But maybe you?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "Yes. Typically, like he said, it's typically pretty flat. We're usually around 75% supplies. Q4 is always a little bit of an anomaly because we see a -- at the end of the year, we always see a bump in device we had the same thing last year. It didn't quantify quite as much as it did this year, but the customer base is a lot bigger this year. So again, I agree with Thomas, I think it's going to be pretty flat, and you're typically in that 25% to 75% device supplies as a percentage of revenue.\n",
      "Crean [Phonetic] -- Piper Sandler -- Analyst\n",
      "Great. That's super helpful. And second, can you just provide a little more color on the gross margin pressures we're seeing and where you see that going throughout '21 and into 2022?\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "We've been pretty confident. We've been in that 78% range for the last several quarters. In prior years, we might have been a little higher than that. But coming out of '15, '16, '17, when the company really didn't have a huge staff, we were lacking in a lot of areas. And so to get staffing where it needed, we had to make those investments and sacrifice the margin a little bit. Going into '21, as many people know, we did open up a new facility that is our production facility stand-alone. Prior, it was on the first floor of our corporate headquarters. So that investment, obviously, we took a space that we needed to grow into a little bit. So I think that will put a little margin pressure in '21. And so instead of maybe that 78% to 82%, maybe we're 75% to 80% going into next year, but the product margins themselves have been pretty constant.\n",
      "Crean [Phonetic] -- Piper Sandler -- Analyst\n",
      "Awesome. And last one for me. I know you touched on this earlier, but could you just expand a little bit more on the retention and turnover you're seeing of your reps? And since you've onboarded a bunch of new folks, so quickly we'd be interested in hearing how those metrics have been trending versus historical levels?\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Yes. We -- those that we hired during last year, we -- most of them were came on board in the second half, and therefore, a lot of them has still been with us less than a quarter. We typically give them 90 days, sometimes a little extra to prove that they can actually sell more than just the initial interviewing. And yes, right at here, we had a little bit of cleanup. So we are probably still in the 10% -- a little lower 10%, maybe 10%, 15% attrition rate. So it's probably -- if you look at other medical device companies, probably a little better than you see in other medical device companies. And I expect we will be doing even better here this year because we're only going to be hiring at a rate that is less than 1/3 of what we did last year and much less probably 1/4 of what we did in the second half of last year. And that gives us the ability to be even pick here when we recruit, we can pay more attention to the individuals during training. And our regional sales managers will be able to follow-up and hold the hands of the new sales reps better than they were able to last year. So I expect to see a significant improvement in the retention -- in sales force going forward.\n",
      "Crean [Phonetic] -- Piper Sandler -- Analyst\n",
      "Thank you.\n",
      "Operator\n",
      "And this concludes our question-and-answer session. I'd like to turn the conference back over to Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Yes. Thank you. First of all, I just wanted to apologize for the technical difficulties in dialing in today. But other than that, I hope that today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening into this call. Thank you, and a great day to all.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 47 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Chairman of the Board, President, and Chief Executive Officer\n",
      "Daniel J. Moorhead -- Chief Financial Officer\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Aman [Phonetic] -- B. Riley Securities -- Analyst\n",
      "Crean [Phonetic] -- Piper Sandler -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: The Dow and the Nasdaq hit record highs on Thursday in anticipation of President-elect Joe Biden's pandemic aid proposal to jump-start a struggling economy after data highlighted weakening labor market conditions. .N\n",
      "At 12:10 ET, the Dow Jones Industrial Average .DJI was up 0.37% at 31,174.28. The S&P 500 .SPX was up 0.15% at 3,815.72 and the Nasdaq Composite .IXIC was up 0.41% at 13,182.579. The top three S&P 500 .PG.INX percentage gainers: ** KLA Corporation , up 8.3% ** Applied Materials Inc , up 8% ** Occidental Petroleum Corp , up 7.8% The top three S&P 500 .PL.INX percentage losers: ** Viatris Inc , down 6.1% ** Rollins Inc , down 3.5% ** BlackRock Inc , down 3.4% The top three NYSE .PG.N percentage gainers: ** Dpw Holdings Inc , up 39.5% ** Maxar Technologies Inc , up 28.3% ** 3D Systems Corporation , up 22% The top three NYSE .PL.N percentage losers: ** Kuke Music Holding Ltd , down 11.4% ** Bank of Montreal , down 9.4% ** Direxion Daily Semiconductor Bear 3X Shares , down 9.4% The top three Nasdaq .PG.O percentage gainers: ** Poshmark Inc , up 119.7% ** Datasea Inc , up 80.9% ** Lexicon Pharmaceuticals , up 71.6% The top three Nasdaq .PL.O percentage losers: ** Eos Energy Enterprises Inc , down 27.8% ** Viveve Medical Inc , down 20.6% ** Eos Energy Enterprises , down 18.2% ** Bionano Genomics BNGO.O : up 23.6%\n",
      "BUZZ-Rises on regaining Nasdaq listing compliance ** Affirm Holdings Inc AFRM.O : up 29.4%\n",
      "BUZZ-Affirm soars after debut double ** Poshmark Inc POSH.O : up 119.7%\n",
      "BUZZ-Poshmark shares more than double in Nasdaq debut ** PFSweb Inc PFSW.O : up 17.9%\n",
      "BUZZ-PFSweb surges on order fulfillment numbers ** Nordstrom JWN.N : down 1.6%\n",
      "BUZZ-Drops as holiday-period sales fall ** Johnson & Johnson JNJ.N : up 2.1%\n",
      "BUZZ-Rises on positive interim results from COVID-19 vaccine trial ** Fuelcell Energy FCEL.O : down 10.4%\n",
      "BUZZ-JPM downgrades to 'neutral' on valuation ** Organogenesis ORGO.O : up 36.5%\n",
      "BUZZ-Jumps as Q4 prelim revenue beat estimates ** Take-Two Interactive TTWO.O : down 0.4%\n",
      "BUZZ-MKM Partners downgrades on lack of growth catalysts ** Vipshop Holdings VIPS.N : down 1.3%\n",
      "BUZZ-Falls as China probes into possible unfair competition ** NantKwest NK.O : up 20.4%\n",
      "BUZZ-Rises on positive interim survival rate data from cancer trials ** Tesla TSLA.O : down 0.2%\n",
      "BUZZ-Falls after agency asks for recall of 158,000 vehicles ** Chembio Diagnostics CEMI.O : up 13.7%\n",
      "BUZZ-Rises after COVID-19 test gets CE mark ** Express EXPR.N : up 26.2%\n",
      "BUZZ-Surges after announcing $140 million in new financing ** Orchard Therapeutics ORTX.O : up 9.4%\n",
      "BUZZ-Rises after FDA grants 'special' status to gene therapy ** Kaleido Biosciences KLDO.O : up 3.1%\n",
      "BUZZ-Rises on positive data from COVID-19 treatment trial ** Virgin Galactic Holdings SPCE.N : up 14.9%\n",
      "BUZZ-Virgin Galactic soars after ARK files space exploration ETF ** Lexicon Pharma LXRX.O : up 71.6%\n",
      "BUZZ-Up on positive FDA feedback for diabetes drug ** Apache Corp APA.O : up 3.4%\n",
      "BUZZ-Gains on Q2 profit vs year-ago loss ** Beyond Meat BYND.O : up 9.3%\n",
      "BUZZ-Beyond Meat gains on Taco Bell partnership ** Super League Gaming SLGG.O : up 7.0%\n",
      "BUZZ-Up as co gains more video views, registered users ** Lemonade Inc LMND.N : down 3.8%\n",
      "BUZZ-Lemonade slips after pricing share offering ** Gilead Sciences Inc GILD.O : up 2.0%\n",
      "BUZZ-Gilead on track for growth in 2021 ** Twist Bioscience TWST.O : up 7.9%\n",
      "BUZZ-Twist Bioscience up on shipping new RNA sequences for COVID-19 testing ** Align Technology Inc ALGN.O : up 1.4% ** Zimmer Biomet Holdings Inc ZBH.N : up 0.5% ** Insulet Corp PODD.O : up 4.1% ** Inmode Ltd INMD.O : up 3.2%\n",
      "BUZZ-MedTech: Baird says year-end demand recovery bodes well for sector ** Walt Disney Co DIS.N : up 0.1%\n",
      "BUZZ-Citi expects Disney to surpass Netflix in subscriber growth in 3 years ** Intel Corp INTC.O : up 4.5% ** VMware Inc VMW.N : up 1.3%\n",
      "BUZZ-Street View: Pat Gelsinger as CEO is VMware's loss, Intel's gain ** Bally's Corp BALY.N : up 0.1% ** Boyd Gaming Corp BYD.N : up 1.6% ** Caesars Entertainment CZR.O : up 2.6% ** Churchill Downs Inc CHDN.O : up 1.9% ** Red Rock Resorts RRR.O : up 1.9%\n",
      "BUZZ-U.S. gaming: KeyBanc starts coverage on promising outlook ** Alibaba Group Holding BABA.N: up 3.7% ** Baidu Inc BIDU.O : up 7.5%\n",
      "BUZZ-China tech giants rise on report of U.S. shelving planned investment ban ** Alaska Air ALK.N : up 6.2%\n",
      "BUZZ-Up as quarterly cash burn slows on improving bookings ** Acacia Communications ACIA.O : up 32.4%\n",
      "BUZZ-Soars after agreeing to Cisco's raised buyout offer ** Signet Jewelers SIG.N : up 7.7%\n",
      "BUZZ-Rises on holiday sales bump, upbeat Q4 forecast ** Alteryx Inc AYX.N : up 10.7% ** Snowflake SNOW.N : up 3.6%\n",
      "BUZZ-Alteryx Inc, Snowflake gain on data processing deal ** Venus Concept Inc VERO.O : up 5.5%\n",
      "BUZZ-Rises after prelim Q4 sales beat estimates ** Dogness International Corp DOGZ.O : up 2.8%\n",
      "BUZZ-Rises on pet feeders order from Petco ** Square Inc SQ.N : up 1.9%\n",
      "BUZZ-Square Inc gains as brokerages raise PT on Cash App growth ** Delta Air Lines DAL.N : up 3.1%\n",
      "BUZZ-Rises on upbeat comments on recovery in 2021 ** Zynex ZYXI.O : up 7.6%\n",
      "BUZZ-Rises on filing patent for sepsis monitor ** Ethan Allen Interiors ETH.N : up 5.4%\n",
      "BUZZ-Rises on higher furniture orders in Q2\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "down 0.47%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "down 0.09%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "down 0.35%\n",
      "Energy\n",
      ".SPNY\n",
      "up 2.49%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.62%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.22%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 0.73%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "down 0.17%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 0.10%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 0.60%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "down 0.30%\n",
      "(Compiled by Lasya Priya M in Bengaluru)\n",
      "((LasyaPriya.M@thomsonreuters.com))\n",
      "\n",
      "It's easier to find bargains in the stock market if you look at high-quality small-cap stocks because not many investors have an appetite for these lesser known names. For perspective, the Russell 2000, an index tracking small-cap stocks, rose 18.4% in 2020, outperforming the S&P 500 by more than two percentage points.\n",
      "You may not be that familiar with Zynex Medical (NASDAQ: ZYXI), Regenxbio (NASDAQ: RGNX), and Koppers Holdings (NYSE: KOP), but all three present solid investment opportunities.\n",
      "Image source: Getty Images.\n",
      "1. Zynex Medical has plenty of growth ahead\n",
      "There's one really good reason to like Zynex Medical -- strong revenue growth. From 2016 to 2019, the medical devices company increased revenue 242%, or 51% annually. For 2020, management expects sales ranging between $80 million and $81 million, a rise somewhere in the neighborhood of 77% over the $45.5 million the company posted in 2019.\n",
      "Zynex manufactures electrotherapy devices for pain management, rehabilitative purposes, neurological diagnoses, and cardiac monitoring. While the stock is up more than 71% over the past 12 months, it has dropped 25% in the last three months and wasn't helped by a third-quarter earnings miss by 23%.\n",
      "With a price-to-earnings (P/E) ratio of 46, it's easy to see how some may think the stock is overpriced, but I think that's shortsighted. It's not just a growth stock, but one that has been profitable for 17 consecutive quarters. A few months ago, the stock may have been overpriced, but now it's much more in line with the typical P/E of a medical devices company.\n",
      "I think a lot of people panicked and sold the stock when its third-quarter net income came in at $1.3 million, down 34% from the year-ago quarter. As clinics remained shut due to the COVID-19 pandemic, the company increased its sales force headcount drastically, and that drove up marketing costs in order to maintain revenue growth. This strategy, however, seems like a temporary fix, and sales and marketing costs should go down as clinics resume normal operations.\n",
      "Nearly all medical device companies faced headwinds last year during the pandemic because fewer medical procedures were performed. I think the company's focus on nonopioid, nonaddictive pain management will serve it well in the future.\n",
      "\n",
      "Data source: YCharts.\n",
      "2. Breakthrough procedures have the market excited about Regenxbio\n",
      "Shares in Regenxbio, a clinical-stage biotech company specializing in gene therapies, nearly 11% over the past year and almost 60% in the past three months. The company has a strong pipeline, and its proprietary gene delivery platform -- the NAV technology platform -- has already helped bring one major drug to market, Novartis' Zolgensma. The one-time gene therapy treats pediatric spinal muscular atrophy and goes for $2.1 million a dose, making it the most expensive drug in the world.\n",
      "In the third quarter, Regenxbio reported revenue of $98.6 million, an increase of 572% year over year, but that's a misleading -- $80 million of that was from a one-time milestone payment from Novartis regarding Zolgensma. Still, Regenxbio is a rarity in that it is a clinical-stage biotech company that reported a profit of $9 million last quarter.\n",
      "What's exciting about the company is it has a great late-stage eye disease candidate. RGX-314 is in phase 2 trials to treat wet age-related macular degeneration and diabetic retinopathy, the leading cause of vision loss for diabetics. RGX-314 uses an adeno-associated virus as a vector, or delivery method, to send a protein that fights a key link to both diseases, excessive vascular endothelial growth factor.\n",
      "Another potential factor pushing up the price of Regenxbio stock is the possibility that it could be bought by a larger pharmaceutical company looking to diversify its portfolio in the burgeoning gene therapy space. Late last month, for example, Eli Lilly announced it had a nearly $1 billion deal in place to purchase Prevail Therapeutics, which, like Regenxbio, specializes in gene therapies.\n",
      "3. Koppers Holdings is building a solid foundation\n",
      "Shares in Koppers Holdings are down more than 20% over the past year, but they've climbed more than 36% over the past three months. The company produces treated wood products, wood treatment chemicals, and carbon compounds. Some of the company's products represent the backbone of the country's infrastructure, such as pressure-treated railroad ties and utility poles, pressure-treated wood for home repairs, and chemicals for the production of concrete, rubber, and plasticizers.\n",
      "While business slowed during 2020 because of the pandemic, it did so only slightly. Management expects sales of $1.6 billion for 2020, compared to $1.65 billion in 2019, and earnings before interest, taxes, depreciation, and amortization (EBITDA) to be between $204 million and $210 million, compared to $201.1 million in 2019.\n",
      "In November, the company said it had sales of $121.7 million, a rise of 1.8% over the same month in 2019. Much of that was driven by the company's performance chemicals segment, which saw a 28.9% sales rise because of increased demand for residential treated lumber. That helped make up for lowered sales in the company's other segments of railroad products and services, and its carbon materials and chemicals segment.\n",
      "There's a lot to like about Koppers Holdings. It has increased cash from operations the past three quarters, boosted EBITDA growth, and trimmed $125 million of debt in 2020. The stock seems relatively cheap with a price-to-earnings ratio (trailing 12 months) of 5.2, compared to the typical ratio of around 23 for a chemical company.\n",
      "\n",
      "Data source: YCharts.\n",
      "Making the right choice for you\n",
      "I like all three companies, though they don't have that much in common other than being small-cap stocks that are profitable and have potential.\n",
      "I like Zynex Medical the most after its breakout year. It still has great fundamentals and its recent slide has made its price reasonable. Koppers Holdings has the slowest growth of the three, but is the best priced. Looking at its earnings and stable cash flows, it may be the best choice for risk-adverse investors.\n",
      "Regenxbio is probably the riskiest of the three but its gene therapy solutions make it an attractive buyout candidate, and the stock could soar this year.\n",
      "10 stocks we like better than Koppers Holdings\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Koppers Holdings wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of November 20, 2020\n",
      "Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, Inc (NASDAQ: ZYXI)\n",
      "Q3 2020 Earnings Call\n",
      "Oct 27, 2020, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good afternoon, everyone, and welcome to the Zynex Q3 2020 Earnings Call. [Operator Instructions] Certain statements in this release are forward-looking and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the risk factors section of our annual report on Form 10-K for the year ended December 31, 2019, as well as Forms 10-Q, 8-K and 8-K/A, press releases in the company's website. Please also note, today's event is being recorded.\n",
      "And at this time, I'd like to turn the conference call over to Thomas Sandgaard, Founder, Chairman and Chief Executive Officer. Sir, please go ahead.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you, and good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our 2020 third quarterearnings call I'm excited to announce yet another quarter of revenue growth and positive net income. Our third quarter revenue of $20 million increased 69% compared to the same quarter last year. It was also the highest quarterly revenue in the history of the company. It was actually our 17th straight quarter with positive net income and fully diluted earnings per share was $0.04. Adjusted EBITDA for the third quarter was $2.4 million as we continue to invest in growing our sales force.\n",
      "Similar to many companies, we've seen the impact of COVID-19 pandemic and Q3 orders came in at 96%, higher than Q3 of last year, which was an increase of 37% year-over-year order growth in Q2 and we saw momentum in order growth during Q3 with 83% in July and August and 117% in September. October is currently trending above 120% compared to October of last year, which is a strong benchmark as October last year was by far our strongest months in 2019. The continued strength in order speaks volumes to the relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, non-addictive prescription strength solutions for their patients in pain.\n",
      "The investment in expanding our sales force continues to progress as we expand our geographic footprint across the U.S. We continue to aggressively add sales reps and eclipsed 400 total reps in the third quarter. Our recruiting efforts have been aided by a search in candidates due to increased unemployment rates related to COVID-19. We expect these new hires to provide significant productivity increases in Q4 and beyond. We expect to have over 500 sales reps by year-end.\n",
      "Revenues slowed slightly in Q3 due to the lower Q2 orders in April and May related to COVID-19, but still grew 69% in the third quarter compared to 87% in the second quarter. As a reminder, our business model with billing for the devices monthly used and supplies as they're consumed by our patients causes a lag between orders and revenue growth. As business continues to get back to normal and orders continue to grow, we expect revenue and revenue growth to follow accordingly.\n",
      "Also want to mention that our operations continue without interruption and our supply chain remains uninterrupted. In addition, it's our practice to keep several months of finished products on the shelf, have over four months of components on hand for internal assembly and 12 to 18 months of orders placed with our vendors on top of the in-house material. We have also increased our second sourcing to become less dependent on individual vendors. It is critical for us to have the ability to ship immediately to our patient in pain.\n",
      "The opioid epidemic continues to be a serious issue in this country and we're increasingly working to get patients off opioids and for physicians to use our prescription strength technology as the first line of defense when treating pain. Currently, the devastating impact has reached the level where tens of thousands die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects.\n",
      "Our products for pain management and rehabilitation still stand out as some of the best products in the industry. The NexWave for pain management, our NeuroMove device for stroke rehabilitation and the InWave for incontinence treatment, those all puts us in a very strong product position in the rehabilitation markets. We continue to see great potential in both our product divisions, our existing revenue generating area for pain management as well as the huge unmet potential for our blood volume monitor.\n",
      "As most of you probably already know, we managed to get FDA clearance for our CM-1500 blood and fluid monitor earlier this year. The CM-1500 is a non-invasive monitor intended to monitor patients' fluid balance in hospitals and surgical centers. We expect to initially target ORs and surgeries that typically display substantial blood loss as well as recovery rooms and ICUs where internal bleedings today are common and difficult to detect until serious complications occur. We believe this product will lead to safer surgeries, fewer complications and less mortality, one of the biggest unmet needs in hospitals today.\n",
      "Last week we announced we hired Neil Friery as the President and COO of division. Neil has a strong background from primarily Zimmer Biomet, in particular the surgical side and comes with a lot of knowledge about medical devices and also blood loss monitoring in hospitals. At Zimmer Biomet, Neil managed P&L led product development, manufacturing, sales and marketing, product launches and quality functions for their 400 million surgical division with 600 employees and 35% EBITDA margins.\n",
      "He specifically built a 130 man sales force from scratch and also led several acquisition efforts in the cardiac device market. Before that, he was Director of Finance in control of five years at Zimmer Surgical. Going forward, Neil will be leading our sales, marketing, clinical research and engineering efforts. In the near-term this division still utilizes manufacturing, human resources, accounting and QA resources from Zynex Medical QA division, but will at some point have their own self sufficient functions.\n",
      "I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First, I'll review our 2020 third quarter results. Orders grew 96% year-over-year and net revenue grew 69% to $20 million from $11.8 million in 2019. Device revenue increased 99% to $5.3 million compared to $2.7 million last year. Supplies revenue increased 61% year-over-year to $14.7 million from $9.2 million. Gross margins were 79% in the third quarter of 2020.\n",
      "Sales and marketing expenses increased 125% year-over-year as we continue to aggressively grow our sales force. G&A expense grew 70% year-over-year, much of that increase was related to increased headcount in our reimbursement and patient support functions related to our order growth. Third quarter net income was $1.3 million or $0.04 per diluted share compared to net income of $2 million or $0.06 per diluted share in the third quarter last year. Adjusted EBITDA, which is a standard EBITDA calculation plus an exclusion of non-cash stock based compensation and other income expense and is reconciled in our press release, was $2.4 million in the third quarter.\n",
      "I'll now review our 2020 nine month results. Orders grew 85% year-over-year, which increased net revenue 74% to $54.5 million from $31.3 million in 2019. Device revenue increased 88% to $13 million compared to $6.9 million last year. Supplies revenue increased 70% year-over-year to $41.5 million from $24.4 million. Gross margins were 78% in the first three quarters of 2020.\n",
      "Sales and marketing expenses increased 117% year-over-year and G&A expense grew 63% year-over-year. 2020 nine months net income was $7.3 million or $0.21 per diluted share compared to net income of $6.5 million or $0.19 per diluted share through three quarters last year. Adjusted EBITDA increased 27% to $10.2 million in the first three quarters.\n",
      "On the balance sheet, as of September 30th, our cash balance was $41.2 million, up from $14 million at year-end. As many of you know, we completed an equity transaction during July, which added approximately $25 million to the balance sheet. Our working capital grew 189% to $50.3 million at September 30th compared to $17.4 million as of December 31, 2019.\n",
      "With that, I'll now turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you, Dan. I'm especially excited about our year-over-year growth in orders of 96% and our revenue growth of 69% in the midst of the COVID-19 pandemic. It's a huge testament to efforts to grow our sales force and clearly justify its investments in our sales personnel, sales management and inside support functions.\n",
      "Our focus continues to be growing our sales force at a rapid rate to eventually cover the entire country now -- in just a few months from now. It is also important that we really don't have any significant competitors left. Our increased orders due to a larger sales force combined with strong reimbursement for our products continues to drive increased revenue and profitability.\n",
      "I'd like to take a minute to review what we have accomplished so far in 2020. In the midst of a pandemic, we are forecasting to beat our original full year revenue guidance, which we gave in February of this year. This year alone and before year-end, we'll have hired over 300 new sales reps. Our reps are now more effective in the first three months than ever before and we're very bullish on expanding sales orders and what it will be able to produce in Q4.\n",
      "And therefore, the revenue of those orders will turn into -- in '21 and 2022. We estimate our fourth quarter revenue to be between $25.5 million and $26.5 million with adjusted EBITDA between $2.3 million and $3.3 million. This revenue range is 80% to 87% higher than last year's fourth quarter revenue. This is up from 69% year-over-year revenue growth in the third quarter.\n",
      "As a reminder, nearly all of our collections from billing come from insurance companies, mostly private insurance, but also government, auto insurances, workers' comp and personal injury attorneys. Payments from those are either dictated by contractual amounts we have established or allowable amounts already well established throughout our industry and negotiated amounts on a patient-by-patient basis. These amounts are typically discounted by deductibles and copay and other allowable discounts and we end up getting much less than our MSRP as is typical throughout the healthcare industry in the U.S.\n",
      "This pattern is the same whether we get paid for the device or patient supplies. We are careful to make sure our billing practices are always within the law and comply with all guidelines and regulations. We also undergo regular accreditation by a third-party to ensure we continue to be compliant. My long-term goal for our electrotherapy and rehab division is to continue to grow our share of the huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing our domestic sales force as well as potential acquisitions of complementary technologies.\n",
      "We have just recently added three employees in the monitoring solutions division, including our new President and COO, and we are in the process of adding four additional executives and managers to this division to long-term blood volume monitor. We will continue to update everyone as we continue to build out this division. In summary, we announced yet another great quarter with strong growth in the orders, growth in revenue and profit, which puts us in a position of strengths going forward.\n",
      "We will now answer questions from our listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "[Operator Instructions] Our first question today comes from Jeffrey Cohen from Ladenburg Thalmann. Please go ahead with your question.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Yeah. Hi, Thomas and Dan. How are you?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Doing well. How are you doing Jeff?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Just fine, hanging in there. So, just a few questions for you. Firstly, on the device side, it looked like about 8% higher than our estimates. Is there any read into that? Is that basically as the function of more sales coming on with earlier orders or is there something else to read into there?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Not a whole lot, but Dan.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "I don't think there's much, but there can always be changes in mix when they lease or buy the device and it's really just how the revenue comes in on the devices. So I don't think there's anything trending that you would need to know.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Maybe slight changes in the mix of insurance companies and their preferences, which is how we have set up, how we bill each insurance company.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. Got it. And could you give us a little flavor on the ratio of back-office support to the sales organization? Is that increasing kind of ticking up along with the sales organization to build out or any color there for us?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. I can say we finally completed the addition of a total of 15 regional sales managers, that obviously, each control what eventually will be their share of nearly 800 sales reps. In the back-office, we have -- we now have 15 inside salespeople that are supporting those sales reps with anything they might need during the day. And obviously then we have the whole pipeline to the system from order entry to patient enrollment, the patient experience group, a new group, we have established that call patients within a day or two after they received the device, and obviously we have a very large call center for all the questions that the patients may have. So that's all there, but really where you'd say is the core of the business, is the engine we have that the bills insurance companies that is separate from our sales force obviously and they work directly on that. We can call it the second part of the sales process, making sure that insurance companies understand with a prescription and insurance coverage and the fact that we have shipped the device. We obviously need to get paid and that's what the billing -- the biggest department we have is the billing department, but there's a lot of...\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. Okay, got it. One more if I may. Could you talk about the second sourcing and what can -- what's it for, is it specific to PCM boards or other components? Can you talk about that a little bit?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. It's every component we use. So one example is obviously the semiconductors that go in it. It's like building a cellphone or what would we do. And some of the components are automatic. It's very easy to find second sources for those. So that's not a problem. But when you get to customize LCD displays, for instance, then we, for a long period after we developed the device, just have one vendor. We have another one that's up and running. The same goes for the customized plastic enclosure for the lead wires, etc., for the bags that the device comes in. So everything there we have the second source now. Just to make sure, and we now have volumes that can justify having two multiple vendors without hurting the pricing. So, the cost price of our devices have certainly not going up.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay, perfect. Thanks for taking the questions.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Sure. Thank you.\n",
      "Operator\n",
      "Our next question comes from Yi Chen from H.C. Wainwright. Please go ahead with your question.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Thank you. Thank you for taking my question. Could you remind us currently how many sales reps do you have?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "At the end of the quarter we had approximately 410 or something like that.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "It might've been a little higher than that, but, yeah, 420, 430, somewhere in there.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, right around that. And obviously it's a high number as of today and we expect by year-end to have a 400 or 500.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Okay. Got it. So, right now the U.S. is experiencing a rebounding COVID-19 cases. It looks like the rebound is not going to end until probably the end of the coming winter. So do you expect continuing negative impact from COVID-19 for the coming quarter? And how do you see the gross trend will ramp up in -- going into the first and second quarter of 2021?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "At this point, we don't see an impact. As I mentioned, October is even stronger than September in terms of year-over-year order growth. And we can obviously attribute that a lot to additional sales reps and also how productive new reps are now becoming. What we're also seeing unlike in April and May when there was a lot of nervousness and people were not sure about how to open clinics, how to deal with patients, if they should allow them and if they should allow sales reps in etc. That has now found, you could call it a balance between making sure that there's enough distancing and just dealing with the pandemic, while still operating as a business. So, we don't, at this point, see any slowdown in terms of clinics that are willing to see our sales reps, etc. And I'm sure there's also some tailor medicine going on some of the prescribers we have see the patients on maybe zoom call and then prescribe accordingly. And obviously we're find ways to make sure still communicate with those prescribers. So, all in all, at this point, we don't see any signs of slowdown. So, compared to when we got out of COVID and how others are growing right now, it's nearly a straight line up.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Got it. So for the division of the blood volume monitor, do you -- can you give us some color on what activity the company will be conducting during the current and next quarter and any update on the timeframe for a commercial launch?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. Technically we can sell and there might be a few hospitals that might be interested in placing some purchase orders. So those are initial talks at this point. We continue to conduct a pilot studies to collect more data that we use for product development. And we also have clinical studies in the works to eventually be published when using the device in the surgical setting. And then we also have a few studies under way that are much more practical that are geared toward actually suggested by a few research/hospitals, research institutions, hospitals. They suggested to assist us with collecting data. So we pretty --in a very simple fashion can see how many minutes a week we detect earlier than and someone that's endorsing a recovery room for instance would detect that someone has an issue with maybe internal bleeding.\n",
      "So we are initiating a couple of studies that are very -- simply will be helping us significantly in terms of the sales efforts. So that's on the clinical side. We continue to develop on the CM-1600, a aversion that is a lot more elegant to use. It's also wireless and looking at some of the parameters in a fashion that's going to make it even less complicated in the OR in terms of the wires, etc. So that's what's going on and we already have initial sales efforts going. We've had a few contracts from international side that we could also or we will be looking at. And other than that, it's -- as soon as Neil becomes into the office in a few days, we've already started talking about the strategic plan for that division. And we -- that's -- that will be the first step that so many things we can do with this product. So let's make sure we start in the right corner.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Is it reasonable to expect that 1500 could be launched sometime in 2021?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, absolutely.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Okay.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "It's already launched. But in terms of maybe -- now that no trade shows right now. For that things, we can do on social media and obviously with the right sales efforts as we are doing now. And it's hard to say when we can call that a formal launch, because we're probably more just be slowly ramping up those efforts rather than a big splash. So, we'll see.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "And to follow-up on CM-1600, does that device need a separate 510(k) approval and in what timeframe do you expect the approval to occur?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We -- it doesn't, you could say technically, it would not necessarily need a separate 510(k) clearance. But our plan is to run it through the FDA with another 510(k). We should be able to in somewhere between two and maybe five months to file that application.\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Got it. And finally, regarding the use of the newly leased subsidiary. So what's the progress of moving the inventory and the related operations into the new facility? Is there any disruption to the overall operations of the company?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "All right. Good -- the good news is that the way we had set up, we won't even know that we -- that there was a difference and I think we can do that seamlessly. A big portion of our inventory is already over there, but it's taken now a couple of weeks. We do it slowly, because we do have so much to make sure we have everything ready in the pipeline. And here in a few weeks, I believe the whole assembly line and the workstations will hit toward the end of November the --over there and it all be -- everybody will start moving. I would say December 1st is probably an appropriate day. So we have -- we now have a total of 84,000 square feet here. We have 50,000, 51,000 square feet over there and we have nearly 10,000 square feet in the building next door. So that's a 145,000 square feet that we now occupy and we need more here soon. That's only getting production and the warehouse out of here. It's going to give us a little bit of breathing room.\n",
      "Operator\n",
      "Our next question comes from Matthew O'Brien from Piper Sandler. Please go ahead with your question.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Afternoon. Thanks for taking the questions. First starter is just the supplies number in the quarter was a lot lower than I had been modeling. So can you talk about the weakness there? And specifically, I think you had a payer that stopped covering starting July 1st. What kind of impact did you see in that region?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "It wasn't really a pay or issue that -- if you're talking about the TRICARE...\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "That's not issue.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "That's really not -- the decrease in orders during Q2 drove -- revenue was up from about $19.3 million to $20 million in the quarter. Devices were up just because the orders and the supplies flattened out in the quarter, but they should start driving again on the order growth that we posted in the quarter.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Okay. So I guess the next question would be on the, from the press release the employee and supply chain issues that you had seen in Q3, are those completely resolved? Do you feel comfortable that you're in good shape now as we head into Q4?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Yeah. There were any issues. I think we're pointing out that we've seen the issues of COVID-19 and we've dealt with those. And we haven't really seen a lot of issues. We've done a pretty good job on the operations side, making sure that we've gone pretty smooth through the pandemic in Q2 and Q3 and then now we're just looking toward Q4.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Okay. And then, I guess the reason for these questions is really surrounding the Q4 guide. It's a humongous step-up and I know you've got a lot more reps in place, but versus what we saw in Q3, it's a really big step up. So the confidence in that level of improvement is driven by, I get the reps, but what from a productivity perspective gives you that confidence? Are you seeing it so far here early days in October that you feel comfortable in getting to that level of a step up? And I guess to follow through on that question, as we head into '21, I know you guys are pretty bullish about what the '21 outlook is for the business, any updated thoughts as you think about next year? Thanks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I'd say without putting too many numbers on it, obviously, the growth in orders we are seeing right now, we won't see much revenue in Q4 from that. But that is what is part of building some confidence into what level of revenue we will see over the four quarters in 2021. So I think we will be expecting that we, for quite some time, can keep the growth rates on revenue at around 100%. And if we can continue order -- for order growth for another quarter or two of well over 100%, then eventually our revenue will we catch up to that and start showing growth over 100%. But here in late this year, we'll formally be working here internally on setting the -- or forecasting the numbers for next year.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Okay, Thomas. And the big step up in Q4, the confidence there?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Again, in terms of orders, absolutely, we already seeing it and a little bit of that will obviously drop into revenue for Q4. But cash collections are still strong, which is what is used to drive the net revenue numbers that we post. So I think we can say we are very confident about the numbers we just put out there.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Okay. Thank you.\n",
      "Operator\n",
      "Our next question comes from Marc Wiesenberger from B. Riley FBR. Please go ahead with your question.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Thanks. Good afternoon. Can you talk about what drove the order acceleration from the kind of 76% in July to 117% in September? Was that primarily driven by the new reps or was there some productivity gains as well from existing reps?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Primarily new reps. I would say, what we consider existing -- so those reps that have been with us for a year or two and overall really seen the -- any significant productivity gains from, but those reps that may have started in January, February, early March that had a very significant slowdown in -- during COVID. For us, we experienced COVID as April, May slowdown in orders in a little bit early June. Once we really got back into it, we've seen some incredible productivity gains as well as brand new reps that may have gotten on board in July, August that are now producing incredible numbers. So I'd still say, we believe it or not, it seems like we've been able to recruit even better and provide initial training even better than we did maybe a year or two ago. And on top of that we now have 15 regional sales managers in place. So now they really do have the time to get out there and hold the hands of brand new reps immediately after they get deployed that probably also helps a little.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Understood. Of the 200 reps that you started the year with, how many are producing at least a $1 million in trailing 12-month sales? And then how many are producing at least $500,000 in trailing 12-month sales?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I don't have that number present, but if I should guess, somewhere between 10 and 20 of those, if you look at it run rate-wise. Yeah. Maybe and not any more than that. Not yet. That's still heavy lifting.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Got it. In a steady state world, what are your expectations for the number of order a sales reps can generate per month?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "They should be able to produce over 100 orders per month. Our projections in order to make all the numbers come together is fairly conservative. As long as they do 60 orders a month on the average throughout the sales force, then we realistically may not be able to push them any more than that, and that will make our long-term goals come together. If we can get above a 100 -- I remember when our big competitor, Empi that was a division of DJO, when they were in business, if someone produced less than a 100 orders a month, they wouldn't be working for them anymore. So I think its for budgeting and forecasting purposes it's -- we have a pretty conservative number. But that...\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Got it. Thanks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Will gives us $10 million in the annual revenue -- annualized revenue per rep so.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Got it, thanks. And one more from me. Turning to the blood volume monitor, I mean, we saw that you released an announcement expanding your facilities, you've hired a new Chief Operating Officer for the Monitoring Solutions Division. Can we read between the lines to infer that you guys are closer to determining your go to market strategy and favoring a go-it-alone path as opposed to a joint venture or licensing deal? And then how should we think about the cadence of spending associated with the blood volume monitor over the next 12 to 18 months? Thank you.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. I think with Neil coming on board and with his background and the talks we've -- many talks we've had already obviously that we're pretty close to be defining the at least the initial strategy here. Without pre-empting what we'll come up with, I'm still expecting that we'll be doing a bit of everything in terms of working strategic partnerships, licensing, royalty or OEM private labeling versus going it alone until we find out what really works. As far as I know, this part of the market, that's typically a very viable strategy. So you don't box yourself in too much and too easy to negotiate with either way.\n",
      "But we'll see how all that works. We'll probably see a little bit of revenue maybe toward early or middle of next year. How much it's hard to say and that probably depends on how many resources we put on the sales side of it early on. We already have a few resources and it's -- I got to admit we get -- what we have received was very -- a lot of interest and very open arms when we talk about it, which is a little unusual when you're out there trying to sell some boxes. So that -- its very encouraging.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Great. Thank you.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you.\n",
      "Operator\n",
      "And our next question comes from James Terwilliger from Northland Capital Markets. Please go ahead with your question.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Hey, Thomas. Can you hear me?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, I can hear you. How are you doing?\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Good. How are you doing? Three quick questions, really very quickly and thanks for taking my question. On the COVID issue, you guys have put up tremendous growth numbers, even better growth numbers when you're considering the impact of COVID and the shutdown of the economy and what it's done to other companies. You had tremendous momentum and then it kind of you almost had to catch your breath or you stumbled a little bit. When it stalled or slowed down, was it more of a regional issue that you saw? Was it one particular region that said, hey, things are kind of shutdown or did you really see that slight slowdown more on the national scale? Was it coming from one region, the Northeast, the Southeast, the West Coast or was it just, hey, every sales rep is saying we're getting locked out the facility? Can you expand at all in terms of the COVID hit that you took?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. I would say when we look back at April, May, early June when that really hit us and after that we brought ourselves out of it. We obviously saw, in general, that certain parts of the country were harder hit than others. But at that point, I would say our own national coverage in terms of sales reps were in that defense. So, therefore, it was much more on a by sales rep basis. We saw, for instance, our best producing reps during the period were right smack in the middle of Manhattan. And in terms of which reps had problems were probably more a reflection of, if they had good existing relationship with prescribers, so that they could still contact them by phone, by email, by text messaging or whatever it was. And in some cases, have the ability to drive by and maybe just drop off updated prescription pads or something like that without actually entering the clinic. So there was a lot of creativity. We did -- we really produced a lot of sales material and sales training to do distance selling during those months. And it was much more on a -- it looks like it was a random, which reps picked up on that well and which ones didn't. So it was much more by rep and we couldn't see any direct correlation with the regions that were considered hotspots back then.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Okay, great. Thanks. That was an excellent additional color. And my second question is really from a high level concerning reimbursement. I mean -- and again within the healthcare marketplace, sometimes fiscal years in October and November, we might reset reimbursement, clearly were coming toward the end of the year with December. From a high level, do you view where you see it today? Do you view reimbursement as pretty stable or do you think there's going to be any significant changes with what you see today?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Having done this for very close to 25 years. I have not seen any changes in 25 years that are on a macro level. On a micro level, it's always an issue, which insurance company is the most difficult one this month. But other than that, we don't see any trends. And when it comes to traditional HMO commercial insurances, we see the same pattern right now where here toward the end of the year many of the deductibles are met. And of the allowable amounts that insurance companies produce, we therefore collect a bigger portion of the cash -- of it being cash. And so cash collections in the last three months of the year are always a little stronger and that's also why we -- that we're always somewhat upbeat when it comes to protecting fourth quarter revenue.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Okay, great. And then lastly, just very quickly, I think you're going to hate this one the most, so forgive me ahead of time. Now that we're talking about the launch of the monitor in 2021 as you put that team together, what can you see -- what can you discuss about maybe the R&D pipeline as we move into 2021? What are you excited that you're working on? And what are you able to discuss that you're working on? And I'll jump back in queue. Thanks, Thomas.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. I talked a little bit about the CM-1600 that we're probably well over halfway with. So we will see when we can here very soon start producing prototypes. And I'm also looking ahead to a CM-1700 that's a more embedded version of what we already have. Functionality will be more or less the same. But that -- having it more embedded would also mean it will be easier for us to create versions for maybe the U.S. military as well as maybe private labeling or OEM for other companies. And then I have already made some other inventions that once I think we get some patents filed and stuff like that, maybe we'll talk -- we talk more about that. And obviously, it's still an option to add more technologies that will fit into the hospital monitoring space from other companies that's an idea I'd say.\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "Alright. Well, thanks, guys. Thanks for taking my questions. I'll jump back in queue. Thanks, Thomas, thanks, Dan. Goodbye.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, James.\n",
      "Operator\n",
      "And ladies and gentlemen, with that, we will conclude today's question-and-answer session. I'd like to turn the conference call back over to management for any closing remarks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes, thank you. I hope today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening into this call. Thank you and have a great day to all.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 44 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Yi Chen -- H.C. Wainwright & Co. -- Analyst\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "James Terwilliger -- Northland Capital Markets -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of October 20, 2020\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "FULGENT GENETICS INC (FLGT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of FULGENT GENETICS INC\n",
      "Full Guru Analysis for FLGT>\n",
      "Full Factor Report for FLGT>\n",
      "ALPHA PRO TECH, LTD. (APT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: ALPHA PRO TECH, LTD. (Alpha Pro Tech) is in the business of protecting people, products and environments. The Company is engaged in developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets through its subsidiary, Alpha Pro Tech, Inc. Its products are grouped into three segments: Building Supply, which consists of construction weatherization products, such as housewrap and synthetic roof underlayment, as well as other woven material; Disposable Protective Apparel, which consists of disposable protective apparel, such as shoecovers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products, and Infection Control, which consists of face masks and eye shields. The Company also manufactures a line of building supply construction weatherization products through its subsidiary, Alpha ProTech Engineered Products, Inc.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: FAIL\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of ALPHA PRO TECH, LTD.\n",
      "Full Guru Analysis for APT>\n",
      "Full Factor Report for APT>\n",
      "RETRACTABLE TECHNOLOGIES, INC. (RVP) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of RETRACTABLE TECHNOLOGIES, INC.\n",
      "Full Guru Analysis for RVP>\n",
      "Full Factor Report for RVP>\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company operates through medical devices segment, which include electrotherapy and pain management products. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). The Company's devices are intended for pain management to reduce reliance on drugs and provide rehabilitation and mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's devices are small, portable, battery-operated and include an electrical pulse generator that is connected to the body via electrodes.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "Full Guru Analysis for ZYXI>\n",
      "Full Factor Report for ZYXI>\n",
      "REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 75% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: FAIL\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of REGENERON PHARMACEUTICALS INC\n",
      "Full Guru Analysis for REGN>\n",
      "Full Factor Report for REGN>\n",
      "More details on Validea's Motley Fool strategy\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "What happened\n",
      "Shares of Zynex (NASDAQ: ZYXI) were tanking 26.5% lower as of 11:20 a.m. EDT on Monday. The big decline came after the medical technology company announced lower-than-expected orders for the third quarter and lowered its third-quarter revenue estimate because of the impact of the COVID-19 pandemic.\n",
      "So what\n",
      "Today's sell-off might seem like an overreaction. After all, Zynex still expects that its orders in Q3 will increase 96% year over year and 87% from the previous quarter. The company's Q3 revenue estimate is now between $20 million and $20.5 million. While that's down from the previous guidance range of $22.3 million to $22.8 million, it reflects a decrease of only 10% at the midpoints of the ranges.\n",
      "Image source: Getty Images.\n",
      "Zynex also still expects that its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) will be between $2.3 million and $2.8 million, in line with its previous outlook. The company projects that full-year 2020 revenue will be between $80 million and $81 million, within its previous guidance of full-year revenue between $80 million and $85 million.\n",
      "The problem for Zynex, though, is that its valuation is priced for perfection. The healthcare stock trades at nearly 44 times expected earnings. Any bad news is likely to take a toll when a stock trades at such a lofty level.\n",
      "Now what\n",
      "In the short term, the main thing to watch with Zynex is how the COVID-19 pandemic might continue to impact its order growth. Over the longer term, though, the company's expansion of its sales force could pay off in higher revenue.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of September 24, 2020\n",
      "Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes rose for a fourth straight session on Monday on optimism that a coronavirus relief package would eventually come around, while investors geared up for the third-quarter corporate earnings season. .N\n",
      "At 12:47 ET, the Dow Jones Industrial Average .DJI was up 1.08% at 28,896.88. The S&P 500 .SPX was up 1.84% at 3,541.19 and the Nasdaq Composite .IXIC was up 2.82% at 11,906.9. The top three S&P 500 .PG.INX percentage gainers: ** Ford Motor Co , up 6.6% ** Apple Inc , up 5.7% ** Westrock Company , up 5.7% The top three S&P 500 .PL.INX percentage losers: ** Apache Corp , down 4.4% ** CF Industries Holdings Inc , down 3.7% ** LyondellBasell Industries N.V. , down 2.7% The top three NYSE .PG.N percentage gainers: ** Ihuman Inc , up 45.9% ** Dillard's Inc , up 39.5% ** Acorn International Inc , up 37.3% The top three NYSE .PL.N percentage losers: ** Renesola Ltd , down 18% ** Adams Resources & Energy Inc , down 15.6% ** AgeX Therapeutics Inc , down 15.3% The top three Nasdaq .PG.O percentage gainers: ** Wah Fu Education Group Limited , up 30.1% ** Lizhi Inc , up 29.8% ** Apex Global Brands Inc , up 25% The top three Nasdaq .PL.O percentage losers: ** Avenue Therapeutics Inc , down 58.1% ** Zynex Inc , down 27.9% ** Marine Petroleum Trust , down 27.2% ** Alibaba Group Holding Limited BABA.N: up 2.7% BUZZ- Set for record high, Jefferies raises PT on earnings expectations ** PG&E Corp PCG.N: down 2.2% BUZZ- Falls on plans to cut power in N. California to avert fire risk\n",
      "** GameStop Corp GME.N: down 1.2% BUZZ- Down after Jefferies downgrades to 'hold' ** Draftkings Inc DKNG.O: up 4.6% BUZZ- Rises as Credit Suisse starts coverage with 'outperform' ** General Motors Co GM.N: up 1.1% BUZZ- Up on first China quarterly sales growth in two years ** Walmart Inc WMT.N: up 1.5% BUZZ- Cowen raises PT on increasing ad business ** Avenue Therapeutics ATXI.O: down 58.1%\n",
      "** Fortress Biotech Inc FBIO.O: down 21.6% BUZZ- Plunges after FDA declines to approve non-opioid ** Alkermes Plc ALKS.O: up 4.7% BUZZ- Rises as FDA supports drug to treat schizophrenia, bipolar disorder ** Altimmune Inc ALT.O: up 6% BUZZ- Rises after positive pre-clinical data on COVID-19 vaccine candidate ** RedBall Acquisition Corp RBAC.N: up 3.2% BUZZ- Rises on report of deal talks with Red Sox owner ** Ford Motor Co F.N: up 6.6% BUZZ- Rises after Benchmark upgrades on leadership, new product strengths ** Twitter Inc TWTR.N: up 5.5% BUZZ- Up as DB says co well positioned for cyclical recovery, upgrades ** Twilio Inc TWLO.N: up 6.4% BUZZ-Twilio to buy customer data startup Segment in $3.2 bln deal, shares rise ** American Well Corp AMWL.N: up 5.6% BUZZ- Well-positioned to ride next wave of growth in telehealth ** DouYu International Holdings DOYU.O: up 11.3% BUZZ- Jumps on merger agreement with Huya ** Applied DNA Sciences APDN.O: up 6.1% BUZZ- Gains after bagging COVID-19 surveillance testing contracts ** Apple Inc AAPL.O: up 5.7% BUZZ- Rises ahead of expected iPhone launch; RBC raises PT ** LMP Automotive Holdings LMPX.O: up 15% BUZZ- Rises on $608 mln acquisition deal ** Eyenovia Inc EYEN.O: up 5.9%\n",
      "BUZZ- Rises on license agreement for pediatric myopia treatment ** Fat Brands Inc FAT.O: up 8.5%\n",
      "BUZZ- Rises after Noble Capital upgrades to 'outperform' ** Acorn International ATV.N: up 37.3%\n",
      "BUZZ- Surges on take-private agreement ** JFrog Ltd FROG.O: up 2.8%\n",
      "BUZZ- Gains after multiple brokerages initiate with bullish ratings ** Century Casinos CNTY.O: up 1.7%\n",
      "BUZZ- Surges on internet sports betting partnership with Tipico ** Dillard's Inc DDS.N: up 39.5%\n",
      "BUZZ-Dillard's rises after Berkshire Hathaway's Weschler grabs a stake ** Abbott ABT.N: up 1.5%\n",
      "BUZZ- Up as COVID-19 antibody test gets emergency use authorization ** Honeywell International Inc HON.N: up 0.7%\n",
      "BUZZ- Up on 5-year contract with U.S. army ** Helios Technologies HLIO.O: up 5.8%\n",
      "BUZZ- Climbs on deal to acquire Balboa Water ** Carnival Corp CCL.N: down 2.4%\n",
      "BUZZ- Falls on scrapping all November cruises ** Globus Maritime GLBS.O: up 14.3%\n",
      "BUZZ- Rises on new vessel acquisition ** Consol Energy CEIX.N: up 2.6%\n",
      "BUZZ- Up on executing sale of various assets ** Cloudflare Inc NET.N: up 16.6%\n",
      "BUZZ- Jumps on launching cloud-based digital platform\n",
      "** Lazydays Holdings LAZY.O: up 7.9%\n",
      "BUZZ- Jumps on upbeat prelim results ** JPMorgan Chase & Co JPM.N: up 0.4% ** Citigroup C.N: up 0.8% ** Goldman Sachs GS.N: up 2.5% ** Wells Fargo WFC.N: up 0.5% ** Bank of America BAC.N: up 0.5% ** Morgan Stanley MS.N: up 2%\n",
      "BUZZ-U.S. big banks track broader market rise on hopes of fiscal support ** Ligand Pharm LGND.O: up 1%\n",
      "BUZZ- Rises on sale of Vernalis research operations ** Greenlane Holdings Inc GNLN.O: up 13.7%\n",
      "BUZZ-Greenlane to distribute Marley Natural accessories globally, shares jump ** Sonoco SON.N: up 2.2%\n",
      "BUZZ-Sonoco to divest European unit for $120 mln, shares rise\n",
      "** Facebook Inc FB.O: up 4.9% ** Apple Inc AAPL.O: up 5.7% ** Amazon.com Inc AMZN.O: up 5.3%\n",
      "** Netflix Inc NFLX.O: up 1.6% ** Alphabet Inc GOOGL.O: up 3.8%\n",
      "BUZZ-FAANG stocks rise on wider market gains\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "up 2.82%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "up 2.53%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 1.59%\n",
      "Energy\n",
      ".SPNY\n",
      "down 0.36%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.73%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.98%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 0.76%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "up 2.94%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 0.51%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 0.11%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "up 0.92%\n",
      "(Compiled by Dania Nadeem in Bengaluru)\n",
      "((Dania.Nadeem@thomsonreuters.com;))\n",
      "\n",
      "(RTTNews) - Shares of Zynex, Inc. (ZYXI), a medical technology company, are falling more than 26 percent or $5.26 in Monday's morning trade at $14.47.\n",
      "Monday, Zynex said its order growth for the third quarter was 96 percent year over year and 87 percent sequentially, but slightly lower than originally projected by the company for the quarter.\n",
      "Due to lower than expected orders in the second and third quarter related to COVID-19, Zynex lowered its revenue estimate for the third quarter to between $20.0 million and $20.5 million from the prior range between $22.3 and $22.8 million. However, third-quarter adjusted EBITDA is in-line with the previous estimate and is expected to come in between $2.3 million and $2.8 million.\n",
      "For fiscal 2020, Zynex now projects revenue between $80 million and $81 million, which is within the previously announced range of $80 million to $85 million.\n",
      "The company also lowered its outlook for full-year adjusted EBITDA to a range of $12.5 million to $13.5 million, from the prior range of $15 million to $18 million, with the decrease primarily related to the accelerated hiring of sales reps.\n",
      "Zynex has traded in a range of $7.51 to $29.73 in the past 52 weeks.\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Wall Street's main indexes rose for a fourth straight session on Monday, helped by a tech boost and on optimism that Washington would reach a deal over more fiscal support, with investors also gearing up for the third-quarter corporate earnings season. .N\n",
      "At 11:00 ET, the Dow Jones Industrial Average .DJI was up 0.72% at 28,793.34, the S&P 500 .SPX was up 1.16% at 3,517.61, and the Nasdaq Composite .IXIC was up 1.83% at 11,791.424. The top three S&P 500 .PG.INX percentage gainers: ** Ford Motor Co , up 7.2% ** Twitter Inc , up 5.3% ** International Paper Co , up 4.6% The top three S&P 500 .PL.INX percentage losers: ** Apache Corp , down 4.4% ** CF Industries Holdings Inc , down 3.6% ** LyondellBasell Industries N.V. , down 2.8% The top three NYSE .PG.N percentage gainers: ** Acorn International Inc , up 35% ** Dillard's Inc , up 26.8% ** iHuman Inc , up 20.3% The top three NYSE .PL.N percentage losers: ** Adams Resources & Energy Inc , down 15.6% ** Renesola Ltd , down 15.2% ** Independence Contract Drilling Inc , down 13.4% The top three Nasdaq .PG.O percentage gainers: ** Apex Gb Brnd Inc , up 37.1% ** Lizhi Inc , up 34.7% ** JAKKS Pacific Inc , up 23.6% The top three Nasdaq .PL.O percentage losers: ** Avenue Therapeutics Inc , down 57.6% ** Marine Petroleum Trust , down 28.8% ** Zynex Inc , down 26.9% ** Alibaba Group Holding Limited BABA.N: up 2.4% BUZZ- Set for record high, Jefferies raises PT on earnings expectations ** PG&E Corp PCG.N: down 4.4% BUZZ-Falls on plans to cut power in N. California to avert fire risk ** Draftkings Inc DKNG.O: up 6.9% BUZZ-Rises as Credit Suisse starts coverage with 'outperform' ** General Motors Co GM.N: up 0.9% BUZZ-Up on first China quarterly sales growth in two years ** Walmart Inc WMT.N: up 1% BUZZ-Cowen raises PT on increasing ad business ** Avenue Therapeutics ATXI.O: down 57.6%\n",
      "** Fortress Biotech Inc FBIO.O: down 21.9% BUZZ-Plunges after FDA declines to approve non-opioid ** Alkermes Plc ALKS.O: up 4.5% BUZZ-Rises as FDA supports drug to treat schizophrenia, bipolar disorder ** Altimmune Inc ALT.O: up 6.4% BUZZ-Rises after positive pre-clinical data on COVID-19 vaccine candidate ** RedBall Acquisition Corp RBAC.N: up 3.8% BUZZ-Rises on report of deal talks with Red Sox owner ** Ford Motor Co F.N: up 7.2% BUZZ-Rises after Benchmark upgrades on leadership, new product strengths ** Twitter Inc TWTR.N: up 5.3% BUZZ-Up as DB says co well positioned for cyclical recovery, upgrades ** Twilio Inc TWLO.N: up 6.3% BUZZ-Twilio to buy customer data startup Segment in $3.2 bln deal, shares rise ** American Well Corp AMWL.N: up 9.1% BUZZ-Well-positioned to ride next wave of growth in telehealth ** DouYu International Holdings DOYU.O: up 11.8% BUZZ-Jumps on merger agreement with Huya ** Applied DNA Sciences APDN.O: up 5.5% BUZZ-Gains after bagging COVID-19 surveillance testing contracts ** Apple Inc AAPL.O: up 4.2% BUZZ-Rises ahead of expected iPhone launch; RBC raises PT ** LMP Automotive Holdings LMPX.O: up 19.9% BUZZ-Rises on $608 mln acquisition deal ** Eyenovia Inc EYEN.O: up 6.2%\n",
      "BUZZ-Rises on license agreement for pediatric myopia treatment ** Fat Brands Inc FAT.O: up 9.1%\n",
      "BUZZ-Rises after Noble Capital upgrades to 'outperform' ** Acorn International ATV.N: up 35.0%\n",
      "BUZZ-Surges on take-private agreement ** JFrog Ltd FROG.O: up 2.2%\n",
      "BUZZ-Gains after multiple brokerages initiate with bullish ratings ** Century Casinos CNTY.O: up 1.5%\n",
      "BUZZ-Surges on internet sports betting partnership with Tipico ** Dillard's Inc DDS.N: up 26.8%\n",
      "BUZZ-Rises after Berkshire Hathaway's Weschler grabs a stake ** Abbott ABT.N: up 1.3%\n",
      "BUZZ-Up as COVID-19 antibody test gets emergency use authorization ** Honeywell International Inc HON.N: up 0.3%\n",
      "BUZZ-Up on 5-year contract with U.S. army ** Helios Technologies HLIO.O: up 5.8%\n",
      "BUZZ-Climbs on deal to acquire Balboa Water ** Carnival Corp CCL.N: down 2.7%\n",
      "BUZZ-Falls on scrapping all November cruises ** Globus Maritime GLBS.O: up 13.3%\n",
      "BUZZ-Rises on new vessel acquisition ** Consol Energy CEIX.N: up 4.0%\n",
      "BUZZ-Up on executing sale of various assets ** Cloudflare Inc NET.N: up 15.1%\n",
      "BUZZ-Jumps on launching cloud-based digital platform\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "up 1.53%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "up 1.69%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 1.08%\n",
      "Energy\n",
      ".SPNY\n",
      "down 0.57%\n",
      "Financial\n",
      ".SPSY\n",
      "up 0.72%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.78%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 0.29%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "up 1.86%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 0.05%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "down 0.02%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "up 0.46%\n",
      "(Compiled by Dania Nadeem in Bengaluru)\n",
      "((Dania.Nadeem@thomsonreuters.com;))\n",
      "\n",
      "The COVID-19 pandemic has challenged many smaller companies. Investors who favor stocks below $2 billion in market capitalization for growth potential are probably wondering if it's safe to put new money there with so many uncertainties about how the pandemic is going to play out in the coming months. It's a very good question, especially since many growth stocks have already bounced back, and the share prices of some of the best growth stocks don't seem to be discounting the risks.\n",
      "Fortunately, there still are some good buys in small-cap stocks, especially in industries where the market still seems to be wary of pandemic risks. The advertising business is still shaky, but Magnite (NASDAQ: MGNI) is a small-cap stock with big-cap potential. Retail stocks have rebounded, but those of their landlords haven't, and Retail Opportunity Investments Corporation (NASDAQ: ROIC) stands out as a relatively safe place to put $1,000 of your hard-earned savings. Lastly, medical equipment stocks were hit when routine procedures were put on hold, but that has barely fazed little Zynex (NASDAQ: ZYXI), which continues put up remarkable growth numbers.\n",
      "Image source: Getty Images.\n",
      "Magnite\n",
      "The pandemic caused a rapid decline in advertising spending that caused most stocks in that industry to tumble. While that spending has been recovering, shares of Magnite, the world's largest independent sell-side advertising platform, are still 46% below their high of earlier this year. Investors have a short-term opportunity as the recovery continues to play out, but the stock should benefit from some strong long-term trends as well.\n",
      "Buy-side digital ad platforms give content publishers a way to auction off ad space to advertisers. Magnite, formerly The Rubicon Project, merged earlier this year with Telaria, a platform for selling ads on connected TV (CTV). The combined company is now an omnichannel powerhouse in programmatic advertising across desktop, mobile, audio, and CTV.\n",
      "Magnite reported second-quarter results on Aug. 10 that reflected the impact of COVID-19, but management cheered investors with news that ad spending is bouncing back. Revenue grew 12% over the period a year ago to $42.3 million and would have been down 24% without the merger. But the trend improved in late May and June, and the company issued guidance for Q3 revenue of between $51 and $55 million, well above the consensus analyst estimate of $47 million.\n",
      "The recovery may play out unevenly in coming months, and Magnite results will gradually improve as that happens, but the company's big bet on CTV is why long-term investors should be interested in this stock. CTV was only 19% of the company's Q2 revenue, but that business is growing 50% year over year in the current quarter as the pandemic accelerates the cord-cutting trend. Magnite is also gaining share as ad buyers seek out the largest players in sell-side advertising in order to reduce the number of vendors they work with and to become more efficient.\n",
      "Even with recent gains, Magnite shares are still down 43% from their high, and this company's $814 million market capitalization is a fraction of buy-side ad powerhouse The Trade Desk's $21 billion valuation, despite being only one-fourth the size on a revenue basis.\n",
      "Retail Opportunity Investments Corporation\n",
      "Investors dumped shares of retail property landlords when the economy started shutting down, and this group of stocks has yet to rebound as much as retail stocks in general. The market's concerned that these businesses will have trouble collecting rent and keeping their properties leased, but that hasn't been a huge problem for Retail Opportunity Investments Corporation (ROIC), which specializes in shopping centers and strip malls in affluent locations on the West Coast.\n",
      "Almost all of ROIC's shopping centers are anchored by groceries and drugstores -- essential businesses that didn't shut down. Even though 30% of the tenants of the real estate investment trust were forced to shut down at one point, only a handful were forced to close for good, and 87.5% were open when the company reported Q2 results on July 29. Currently, 97% of ROIC's properties are leased, just slightly less than its record 97.9% lease rate last year. By July 29, the company had collected 85% of the month's base rents, with some collections deferred on long-term agreements.\n",
      "There's no doubt that retail struggles will continue to hurt the company's year-over-year comparisons, as it did in Q2 with 9.3% decrease in same-center net operating income. And the company is being cautious in continuing to suspend the dividend, which would be yielding 6.7% at today's share price, to conserve cash flow. But ROIC is well positioned to weather the pandemic storm. The resumption of normal business and a dividend payout will eventually boost the stock. Shares are not the remarkable bargain they were three months ago, but are still 38% below their 52-week high.\n",
      "Zynex\n",
      "For investors willing to take a little more speculative risk, oft-overlooked medical device company Zynex is worth considering, with soaring revenue driven by aggressive growth of a sales force to market its prescription electrical stimulation devices for pain management and rehabilitation.\n",
      "Zynex's lead product is NexWave, a transcutaneous electrical nerve stimulation (TENS) device for pain management. The company markets the device as an alternative to opioids for treating acute and chronic pain from a wide variety of conditions, such as arthritis and sports injuries. Zynex also sells an electrical stimulation device for stroke recovery and received Food and Drug Administration (FDA) clearance earlier this year for a noninvasive blood monitor.\n",
      "The company has a razor-and-blade business model that starts with a doctor's prescription, which the company counts as an order when it's filled, and continues as a revenue stream for months and even years as the company sells supplies for the device. Recurring revenue is 78% of the total, and the company had scorching top-line growth of 77% in the first half of the year. Orders in the first quarter soared 126% from the period a year ago, portending strong recurring revenue in coming quarters. Indeed, order levels were still up 37% in Q2 despite the effects of the pandemic on routine medical care. The company is profitable, too, with enviable gross margin of 79% and earnings of $0.09 per share in Q2, based on generally accepted accounting principles (GAAP).\n",
      "What's responsible for the torrid growth? Well, the market for electrotherapy devices is growing at a robust pace, and the overall market for non-opioid pain treatments is enormous. But Zynex's supercharged growth is mostly coming from a massive expansion of its sales force. That move is proving to be just what the doctor ordered for the small, $580 million market cap company, but it's also a risk. Expenses are growing even more rapidly than revenue, and the plan depends on that sales force becoming productive.\n",
      "Not every medical practitioner is convinced that TENS actually works; hence the need for a sales force to make the case. But so far, Zynex's results are speaking for themselves. With shares selling for 44% below their recent high and 29 times analyst estimates for earnings next year, this founder-led company is a good growth opportunity in healthcare for investors willing to take some risk.\n",
      "10 stocks we like better than Retail Opportunity Investments\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Retail Opportunity Investments wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jim Crumly owns shares of Retail Opportunity Investments and The Trade Desk. The Motley Fool owns shares of and recommends Magnite, Inc, Retail Opportunity Investments, and The Trade Desk. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.\n",
      "On Friday, Wyndham Destinations' Michael Dean Brown, made a $122,742 purchase of WYND, buying 4,500 shares at a cost of $27.28 a piece. Wyndham Destinations is trading down about 2% on the day Friday. Before this latest buy, Brown bought WYND on 3 other occasions during the past twelve months, for a total cost of $498,046 at an average of $29.30 per share.\n",
      "And on Thursday, Chief Financial Officer Daniel J. Moorhead purchased $49,495 worth of Zynex, purchasing 2,733 shares at a cost of $18.11 a piece. Zynex is trading up about 1.4% on the day Friday. So far Moorhead is in the green, up about 9.4% on their purchase based on today's trading high of $19.81.\n",
      "VIDEO: Friday 7/31 Insider Buying Report: WYND, ZYXI\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, Inc (NASDAQ: ZYXI)\n",
      "Q2 2020 Earnings Call\n",
      "Jul 28, 2020, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good day and welcome to the Zynex Second Quarter 2020 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Certain statements in this release are forward-looking and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31st, 2019 as well as Forms 10-Q and 8-K and 8-K/A press releases in the company's website. Please note, this event is being recorded. I would now like to turn the conference over to Thomas Sandgaard, Founder, Chairman, and Chief Executive Officer. Please go ahead.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our 2020 second quarterearnings call I'm excited to announce another quarter of revenue growth and positive net income. Our second quarter revenue of $19.3 million was an increase of 87% compared to the same quarter last year. It was also the highest quarterly revenue in the history of the company. It was our 16th straight quarter with positive net income and earnings were $0.09 per diluted share. Adjusted EBITDA for the second quarter was $4.8 million, an increase of 69% compared to the second quarter of last year and it was also the highest in the company's history.\n",
      "Similar to many companies, we have seen the impact of COVID-19. The second quarter orders came in 37% higher than the second quarter of last year, which were substantially lower than the 126% growth year-over-year in the first quarter, but we saw momentum in order growth throughout Q2 with where we -- in April and May only saw 21% and 11% growth year-over-year while we were up [Phonetic] 76% in June. We continue to see the same increase here in the month of July and expect once we end the month to have again an increase in order growth. The continued strength in order growth speaks volumes to the relationship our sales force has with many prescribers and the need for them to prescribe non-opioid non-addictive prescription strength solutions for their patients in pain.\n",
      "The investment in expanding our sales force continues to progress as we expand our geographic footprint across United States. We continue to aggressively add sales reps and as of today have surpassed more than 335 sales reps. Our recruiting efforts have been helped by a surge in candidates due to the increased unemployment rates related to COVID-19. We expect these new hires to provide significant productivity increase in orders in the second half of 2020 and in the years to come. Applications for our over 60 open positions at our corporate office have also skyrocketed, which is obviously helpful for improving our workforce. In regards to our sales force, we expect to have over 400 sales reps in September and approximately 500 by year-end.\n",
      "Revenue continued its strong growth in the second quarter and grew 87% compared to a growth of 66% in the first quarter on a year-over-year basis. Our business model with billing for the devices monthly used and supplies as they are consumed by our patients is actually helpful in a temporary slowdown like now. Remember, approximately 80% of our revenue in the quarter is typically derived from orders received in prior periods even years earlier. In the second quarter, we also introduced a catalog with over 3,300 products, all the most popular brands and products that physical therapy clinics all over the U.S. order on a regular basis. We plan on this initiative to be a great door opener for our sales force in an effort to get into more clinics and obtain prescriptions for our NexWave device, traction devices, low back support etc.\n",
      "Our operations continue without interruption and our supply chain remains uninterrupted as we previously secured non-Chinese second sources for all of our components and raw materials. In addition, it's our practice to keep several months of finished products on the shelf, have over four months of components on hand for internal assembly, and 12 months to 18 months of orders placed with our vendors on top of the in-house materials. It's critical for us to have the ability to ship immediately to a patient in pain once we obtain the prescription.\n",
      "The opioid epidemic continues to be a serious issue in this country and we are increasingly working to get patients off opioids and and for physicians to use our prescription strength technology as the first-line of defense when treating pain. Currently, the devastating impact has reached a level where tens of thousands die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects.\n",
      "Our products for pain management and rehabilitation still stand out as some of the best products in the industry. The NexWave for pain management, our NeuroMove device for stroke rehabilitation, and the InWave for incontinence treatment puts us in a very strong product position in the rehabilitation markets. We also continue to see great potential in both of our product divisions, our existing revenue generating area for pain management as well as the huge unmet potential for our blood volume monitor.\n",
      "As most of you probably already know, we managed to get FDA clearance for our CM-1500 Fluid and Blood Volume Monitor earlier this year. The CM-1500 is a non-invasive monitor intended to monitor patient's fluid balance in hospitals and surgical centers. We expect to initially target operating rooms and surgeries that typically display substantial blood loss as well as recovery rooms and ICUs where internal bleedings today are common and difficult to detect until serious complications occur. We believe this product will lead to safer surgeries, fewer complications, and less mortality, one of the biggest unmet needs in hospitals today.\n",
      "We began hiring for this division in July and will continue building out the team during the next few quarters. We expect to have more than a dozen people employed in this division by the end of the third quarter, and short-term, we're obviously also are leveraging the common functions from the main business subsets human resources, payroll, recruiting, quality, accounting, and production. I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First, I'll review our 2020 second quarter results. Orders grew 37% year-over-year, which drove net revenue up 87% to $19.3 million from $10.3 million in 2019. Device revenue increased 87% to $4.3 million compared to $2.3 million last year. Supplies revenue also increased 87% year-over-year to $15 million from $8 million. Gross margins were 79% in the second quarter. Sales and marketing expenses increased 106% year-over-year as we continue to aggressively grow our sales force. G&A expense grew 78% year-over-year. Much of that increase was related to increased headcount in our reimbursement and patient support functions related to our order growth. Second quarter net income was $3 million or $0.09 per diluted share compared to net income of $2.2 million or $0.06 per diluted share in the second quarter last year. Adjusted EBITDA, which is a standard EBITDA calculation plus an exclusion of non-cash stock-based compensation and other income expense and is reconciled in our press release, increased 69% to $4.8 million in the second quarter of 2020.\n",
      "I'll now review our 2020 six month results. Orders grew 76% year-over-year, which increased net revenue 77% to $34.5 million from $19.5 million in 2019. Device revenue increased 81% to $7.7 million compared to $4.3 million last year. Supplies revenue increased 76% year-over-year to $26.8 million from $15.2 million. Gross margins were 78% in the first half of 2020. Sales and marketing expense increased 108% year-over-year and G&A expense grew 67% year-over-year. 2020 six months net income was $6 million or $0.17 per diluted share compared to net income of $4.5 million or $0.13 per diluted share in the second -- or in the first half of last year. Adjusted EBITDA increased 47% to $7.8 million in the first half of 2020.\n",
      "On the balance sheet as of June 30th, 2020, our cash balance was $16.9 million, up from $14 million at year-end and our working capital grew 37% to $23.8 million at June 30th compared to $17.4 million as of December 31st, 2019. With that, I'll turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you, Dan. I'm especially excited about our year-over-year growth in orders up 37% and our revenue growth of 87% in the midst of the COVID-19 pandemic. It's a huge testament to our efforts to grow our sales force and clearly justifies the investment in our sales personnel, sales management, and inside support functions. Our focus continues to be growing our sales force at a rapid rate in geographic areas we don't currently cover to take advantage of the void left in the market by two previously very large competitors. Our increased orders due to a larger sales force combined with strong reimbursement for our products continues to drive increased revenue and profitability. We estimate our third quarter revenue to come in between $22.3 million and $22.8 million with an adjusted EBITDA between $2.3 million and $2.8 million. The revenue range is 89% to 93% higher than last year's third quarter revenue. So we're getting close to doubling the revenue. This is up from 87% year-over-year revenue growth in the second quarter and 66% year-over-year growth in the first quarter.\n",
      "As a reminder, nearly all of our collections from billing come from insurance companies mostly private insurance but also government auto insurances, workers' comp and personal injury attorneys. Payments from these are either dictated by contractual amounts we have established, allowable amounts already well established throughout our industry, and negotiated amount sometimes on a patient-by-patient basis. These amounts are typically discounted by deductible and copay deductions and we end up getting much less than our MSRP as is typical throughout the healthcare industry in the U.S.\n",
      "This pattern is the same whether we get paid for the device or the patient supplies. We are careful to make sure our billing practices are always within the law and comply with all guidelines and regulations. We also undergo regular accreditation by a third-party to ensure we continue to be compliant. My long-term goal for our electrotherapy and rehab division is to continue to grow our share of the huge unmet need for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing our domestic sales force as well as potential acquisition of complementary technologies and long-term potentially international expansion.\n",
      "We are also still working with the European notified body to obtain CE marking for the CM-1500 and we will update everyone as we continue to build out on the personnel side and infrastructure in the monitoring solutions division. In summary, we have now announced yet another great quarter with strong growth in orders, growth in revenue and profit, which puts us in a very strong position of strength going forward. We will now take questions from our listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "We will now begin the question-and-answer session. [Operator Instructions] First question comes from Yi Chen from H.C. Wainwright. Please go ahead.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Thank you for taking my questions. My first question is, could you comment on the current ratio of reimbursement coming from government payers and what is the current average time needed to collect reimbursement from various payers, including private and government payers.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, this is Thomas. Let me try to answer this. We have a little over 10% Medicare, if you add other government insurers, there's some Department of Labor, there's some TRICARE, there's some Medicaid business. It may add up to less than 15%. And in terms of the time it takes to collect, there's a couple of ways to describe that. Obviously, we do have files where we end up not getting paid anything even in cases where we have a good solid contract with an insurance company and we see sometimes in personal injury cases, it might be three or four years before a case settles and we get our share of it.\n",
      "Commercial insurances typically pay pretty well. Medicare pays pretty fast. Medicare pays relatively fast as well. Workers' comp business is kind of the middle of the road in terms of how fast they pay on the average. So that doesn't really give you any actual information, but if you go to the financials we just posted, you will see -- you can take a look at our revenue, whether you do it on a trailing 12 month basis or you do it more real-time and compare that to the accounts receivables, you will see a DSO or days sales outstanding that it is just above 40 days and that is an indication of obviously how fast our bills are moving compared to when the cash comes in. So the average would be there in less than 45 days.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Okay, so would you say that quite a portion of the second quarter revenue just reported actually were related to orders placed in 2019?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, obviously, we reported the cash value of what we build out during the second quarter, but it was obviously based on orders that came in, in 2019, 2018 and also in the earlier parts of 2020.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Got it, got it. And I believe the company is currently on track to reach the target of sales rep by the end of this year. So, could you comment on the trend of average sales generated per sales rep as you get more new sales rep into the team?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, right now, it's hard to move that average up because every time we have a rep that become more productive, we just added another one that hasn't sent in any orders yet. And then obviously there is a delay between when we hire a rep, once they get trained, once they get deployed and then later, they start becoming productive and as we were just talking about them as we start getting a few orders from those reps, the revenue comes in subsequent periods. So some reps that may have started early 2020 started sending in orders maybe during where we had to peak of COVID in April, May, maybe we are just now beginning to see a little bit of revenue. So we're still running an average that is less than if you analyze the revenue per rep, that is less than $300,000 per the average rep per year or annualized.\n",
      "We'll continue actually -- we can say that COVID slowed us down a little bit. We'll get down in the middle 200s [Phonetic] in Q3 probably because we've added a lot of reps that have not produced very high numbers yet. We expect at the end of the year to be back in the $300,000 a year and by the end of next year more -- $400,000 a year. Long-term, we expect to be right around $1 million per sales rep in annual production, but that will only start maturing when the percentage of new reps we are adding, and then we are getting into 2022, 2023 then we will start seeing that average per rep go up dramatically when we're not adding as many reps as fast anymore, but obviously in terms of how that plays into actual revenue since we continue to hire 30 to 40 new reps every month, we will obviously see a growth in revenue simply as a result of that. And as I mentioned as these reps become more and more productive, we just add another one that it will take a little while before they send in the first few orders. So there's a lot of inertia in growing our revenue.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Got it. And my next question is, have you observed any change in the average reimbursement you can collect from a single patient in the year?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes, we have. Obviously, it fluctuates a lot. It mostly fluctuates with -- sometimes there's an insurance company that suddenly for three or four months can really figure out to push the button that, that actually prints a check or wire transfers payments to us and then eventually gets released. So sometimes it fluctuates a little bit. Sometimes changes to our internal organization can also have potential revenue backed up. So for that reason, we see a little bit of fluctuation. Overall, we have seen it's very constant here the last four to five years. I would say the last few months it's helped a little. It's actually gone up even though it's marginal, but we do collect better than we did a few months ago.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Would you be able to give us sort of a range for this fluctuation?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "The range is on the average order less than $200 maybe more in the $100 range per the average order. So we're talking less than 10% increase, but again it could be part of the fluctuation. Next month, it could drop down a little bit. So overall, I'd say it's very stable.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Okay, my final question is could you provide us some color on the latest trends for prescribing physicians in terms of office reopening and accessibility to your sales team?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, obviously depending on how the COVID pandemic has hit various states. It's something we are following very closely and unfortunately despite the media, there is not any increase in death, if we look at is the entire country. There's a couple of states where we have -- people call it hotspots where obviously, it's been a little harder for us in those particular cities to get into clinics, but for the most we see that the clinics are very busy. They even have extended their hours so that they can handle all the patients that may have delayed going to either a physician or going to physical therapy and obviously, need treatment that may have delayed it.\n",
      "So we see clinics obviously apply social distancing etc. So there are fewer employees, fewer patients in the clinic at all times. Sometimes, our reps have been able to at least get in and drop off for instance customized prescription pads to those clinics or they've been able to actually get in and talk to people. Some of the interaction is obviously also over phone and by other means where we may direct may have shipped material to them, but overall, I'd say we have a surprisingly good success rate with keeping in touch with those clinics and keeping a good flow of orders. In the the later part of July, we've seen very strong order numbers at the same level or maybe even higher than we've ever seen as a company.\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Got it. Thank you very much.\n",
      "Operator\n",
      "The next question comes from Matthew O'Brien from Piper Sandler. Please go ahead.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Afternoon. Thanks so much for taking my questions. Thomas for starters on the productivity expectations for Q3 and even Q4, you saw, obviously a pretty big drop on a productivity per rep basis here in Q2, but then things kind of -- based on the guidance that you're giving us and the number of reps we're expecting for Q3 kind of level off, they go down a little bit in Q3, but not nearly as much as we saw from Q1 to Q2. So what are you seeing so far from the reps that you hired earlier this year or even earlier in Q2 that gives you the confidence that, that level of productivity won't fall off dramatically given how many reps you've added especially here in Q3?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Right, fortunately, the amount of reps we are hiring. So we started doing that already early this year and that's -- when you do something like that, that's obviously a risk that we either slack on the quality of reps that we offer an employment agreement to or because of the amount of reps we are training that the quality of the training gets less than is desired and as they get deployed how well our regional sales managers can grab hold of them and hold their hands in the first few days, first few months. We have seen that the quality of reps we are hiring is probably increasing. So that helps a lot in terms of the the early productivity as well as the probability that we have sales reps that's going to survive and stay with us for a long time.\n",
      "We also see that the efforts in terms of training, we have improved significantly on that the past couple of years I would say and are running at a level where compared to about a year ago, the order production for a new rep within the first 30, 60, 90 days is a little more than twice what it used to be and more surprisingly, we actually see that kind of performance for new reps even though they haven't become high production sales reps yet. We've seen that level of production for new reps actually continue during COVID here in the second quarter and we obviously also see that here in the third quarter.\n",
      "So that is very encouraging because they have really difficult conditions out there, but improvements in the talent we hire, improvements in the training compared to a year ago have certainly mitigated that and I should also mention that we have expanded the layer of regional sales managers from five to 15 where 12 of them are in place and trained and are now managing our sales reps and we expect the last three to be hired in the next couple of weeks and that is also going to help improve on new rep initial performance.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "That's really helpful. I appreciate that color. Just to follow-up on that a little bit more. You're expanding really quickly, it seems like the reps are doing really well, they're pretty well trained. How are you going to manage through the pace of new adds making sure that he's fully trained and then making sure that churn rate especially doesn't grow to levels that could be a little bit unmanageable for the company?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, obviously the attrition rate is important. We do pretty well in that because in a class of 15 or 18 reps we train every two weeks, there are sometimes one or two, typically one that don't survive the early days, but it's my impression we're getting really good at catching them within the first few days so we don't end up wasting a lot of time. It makes a big difference if regional sales managers and the rest of the organization don't have to deal with reps that won't survive anyway and they typically also take a lot of your time and therefore, making sure we literally nip that in the bud as early as possible is very helpful. It looks like we're getting better at that.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Got it. And then last one from me, just, I know you don't want to put too much emphasis on the blood volume monitoring business especially this year, but it seems like things are going a little bit faster than expected there, 12 people by the end of Q3 and the investments that you're making there. Can this be even back half of next year a bit more of a contributor than I think some of us are anticipating and how do we kind of frame up what to think about that market given how large it is.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I think I'm going to frame my answer more in context of what do you do for a living as a research analyst and obviously try to not put a whole lot of emphasis on potential revenue from that division. We'll obviously try to not burn any more money in that division then it will still be an insignificant part of the overall flow of money through the company.\n",
      "So I think the numbers in the pain management division are so strong and so solid and we don't expect them to be tempered significantly by the initial burn here with the blood volume monitor. And also because we don't have enough people in terms of the COO and we just started the efforts of the first Business Development Director getting in touch with hospitals and some key opinion leaders. We just started that effort now. So it's too early to predict when we're going to see any real revenue. So I'll probably have a little more feedback from those people, then I'll probably be able to speak more about it.\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Okay, very helpful. Thank you.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thanks, Matt.\n",
      "Operator\n",
      "The next question comes from Jeffrey Cohen from Ladenburg Thalmann. Please go ahead.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Hi. Thomas and Dan, how are you?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Good. How are you?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I'm doing great. How are you doing there?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Just fine. Two questions, I guess the first one, to jump on the back of what Matt was asking about, how are you thinking about that commercially on the CM-1500 at least domestically and how are you thinking about as far as perhaps other commercial products as well as far as the hospital markets go in the ASCs.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I'm sorry, could you repeat the question.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "So I guess, how are you thinking about commercial expansion of the CM-1500 into the hospital?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes, so it's a kind of an extension of what I was just talking about, which is we are now getting hold of what we consider people with relevant experience and therefore influence. We call them key opinion leaders. That's our first point of attack. And as we get more into that, then we'll obviously be talking more to other points of contact, people that are responsible for recovery rooms, ICUs, and obviously the anesthesiology and OR nurses, and eventually we'll also make our way into hospital administrators because we believe at least early on that a big sales argument for us an important one is going to be the whole risk mitigation.\n",
      "What he can do to the risk profile in hospitals potentially the insurance premiums and what it can do or not do to help them in terms of the -- some high profile cases in terms of complications or mortality that potentially can be prevented using this technology. We will also obviously be in contact with other obviously larger medical device companies that have a solid distribution and build relationships and see what we can do in terms of in parallel either licensing or OEM or private labeling of device for them. I hope that answers your question.\n",
      "Operator\n",
      "The next question comes from Marc Wiesenberger from B. Riley FBR. Please go ahead.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Thank you. Following on the some of the first set of questions, I'm wondering if you can quantify the number of physician interactions from your reps both on an in-person and virtually in the second quarter, and maybe thus far in the third quarter, relative to what the activity was either in the first quarter or maybe the fourth quarter of 2019. I'm just trying to get a sense of how your reps are interacting with providers and then any detail on kind of conversion rates would be really helpful?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I am afraid I won't be able to answer that question. We obviously measure the number of orders we get by minute, by hour, by day etc. We know exactly how many reps we have employed, and I can only obviously speak to the interactions on a more soft basis in that.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Yes. Would you say that they are able to still kind of have the regular interactions and kind of the pace is continuing or is COVID limiting that and potentially hurting or helping conversion rates or kind of -- I guess maybe more qualitatively then?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Of course it has been slower. April and May was very slow for us, the last week of March as well in terms of being able to get into clinic and face-to-face interactions. Some reps especially here in the last two months have been able to get to a more normal cadence. Some have still to some degree have relied on their telephonic and maybe even texting interactions with the prescribers they already have relationships with. So it's a mix. It's really something that's better explained on a rep-by-rep basis, and then we would have to go through a 350 of them.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Understood.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We don't really measure that. We really just look at the order production per rep, and if it's not satisfactory after X amount of months having worked here, then they don't work anymore, and if they still work here, it's because they're producing a significant amount that's enough to sustain our profitability and also make a good living for them.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Understood.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I know it's tempting to look at those things, but it doesn't really help us in terms of how we operate a [Speech Overlap] sales force.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "I think there was some talk about maybe TRICARE'S decision earlier this year. I'm wondering if you could talk about the TRICARE business and any maybe potential impact to Zynex from their decision to not reimburse for TENS treatment, or if there's any impact at all?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, they certainly reimburse for TENS treatment for hundreds of indications, except one indication they decided to stop covering and TRICARE is less than 5% of our business and having one indication not to recovered. I actually looked at the-- we've talked a little earlier about that we've been able to see better collections across the board on the average file. I remember having looked at TRICARE collection, so a few days ago and how it's developed the last three or four months, and it's actually increasing. So we're doing perfectly OK with TRICARE.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Great. Have you had any unusual or out of the ordinary interactions with any kind of state insurance investigators during the second quarter? And maybe could you remind us about your general interactions with kind of insurance investigators, if at all?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, let me put it this way. We've been doing this for well over 20 years, right? And all insurance companies when you deal with them, there seems to be a flow as to -- obviously you start sending them initial claims and they either want to pay or they pay you very poorly and sometimes they pay OK, etc and that's the flow, and then after a while, all insurance companies to our experience, they have departments they most commonly label special investigations units and it's really how do we protect our employers meaning the insurance companies' cash flow. So all hospitals doctors offices, DME providers like us on a regular basis get sent letters that accuse us of the worst things between here and the moon.\n",
      "And I believe all providers, whether it's a hospital or provider like us, we have some certain tactics as to how we deal with those. We know some people just settle for a percentage of all those claims that come in with a regular basis. I believe we see more than a 1,000 of those every single month and has for many, many years, some of them large, some of them are small. So, it's just part of this industry. Our approach is typically to tear their documents apart and actually spend some resources on it and I can give you one example, a few months ago, we had a very large one from one of our big payers, obviously, amounted to $1.8 million, and once we had torn it apart, they agreed that maybe the real bill amount that they felt we owe -- we should offer them was $36,000, and then we negotiated a percentage off of that. So we paid them $24,000. That's not atypical. So, we are able to do that, and that's just part of the being in this industry and billing insurance companies. We have not seen any unusual activity, which is really where your question started and I expect it to continue for as long as insurance companies exist in this country.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Understood, thank you. Are any of your products subject to competitive bidding?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "No. There has been talks about having TENS in it, but since, we are not a full service provider, like an Apria or some of those types of companies, it doesn't really apply to us. Of course, the pricing and the price pressure that comes out of it indirectly, you could say that affects the allowable amounts that's programmed in this case Medicare's computers, and that's where we're dealing with. We're still making good money off of that, and that's tough. So you can say in a very indirect way, there is a little bit of an impact, but it's not something that we even talk about it at all here.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Understood. And final one for me, I'm just wondering how the, introduction of a catalog has progressed relative to your expectations and how we should think about its impact on the business going forward? Thank you.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, it's actually we made a decision to make the catalog a little more appealing than many other catalogs you see out there. So first impression is great and that is to, we deliberately did that, so that we -- so it fits within our overall strategy in terms of it's supposed to be a door opener, so that it's even easier for our reps to get in and start a conversation again, because such a big percentage of our sales force is brand new sales folks and we've gotten great comments, great initial feedback from our reps and obviously from clinics on this. We have seen very limited sales on the catalog products so far, which is probably related to the physical therapy clinics during COVID.\n",
      "I'm sure they're all small proprietorships. Some of them are part of bigger chains, but I'm sure all capital investments in exercise equipment or exercise balls or stretching bands or whatever they might purchase, I'm sure that's been put on hold for probably the rest of this year. So in terms of dollars, it's very minimal what we have seen, but what we are learning is that it is having the right impact, which is -- here is something -- one more thing for our sales rep that may not have relationships yet to talk about. So it's working out just as planned, and again, we want at least early on planning on any significant revenue from it. So it's very positive.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "Great. Thank you very much.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes. Thanks, Marc.\n",
      "Operator\n",
      "The next question comes from James Terwilliger from Northland Securities. Please go ahead.\n",
      "James Terwilliger -- Northland Securities -- Analyst\n",
      "Hi, Thomas and Dan, can you hear me?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes. How are you doing, James? I am doing well. Congratulations on a nice quarter. Very quickly, Thomas, I got three questions. Most of my questions have been answered or asked. You're doing such a tremendous job in terms of building out this sales and marketing infrastructure. This is a tough question though, but how do you define a territory, is it the population, the MSA, is it potential customer list, is it list of healthcare providers? When you look at a territory, say for example, Denver, and I assume it's non-ski season, how do you determine how many reps should be in that Denver market? Yes, it's actually very easy because if you look at the size of the population and the distribution of the population there, the number of people that live in an area typically equates to more or less the same amount of medical providers, there can be different specialties obviously, but since -- our core points cover so many different specialties, we can literally go by size of population. So what we did was take all the zip codes and we have territories that -- a few that are small as 350,000 to 400,000 people in the territory, and the largest are probably between 500,000, 550,000 people in a territory, that equates to very close to 800 territories and we're simply trying to fill those as fast as possible. We know that the size of those territories are still big enough because there's so many call points for us that a sales rep cannot even cover those clinics in one territory. So from here to 800 sales reps, there are no brakes, we're trying to drive as fast as we possibly can.\n",
      "James Terwilliger -- Northland Securities -- Analyst\n",
      "Okay, great. Thank you. My next question is really based on competition. What's the feedback from the sales force when you don't get an order? I mean, we've talked about this void of the negative effects of opioids is there, if you're not doing opioids and you're not doing Zynex, are you doing a non-addictive type of former or how should I think of the competition?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, there's two types of competition. Those where patients are self-directed in terms of seeking medical help. So they might buy some stuff based on a TV commercial. That can be a roll-on mental type things that that gives you a nice feeling of maybe very short-term, a little less pain. They might seek without insurance reimbursement or even without prescription to seek out someone that does acupuncture. Then you can buy some very inexpensive, certainly not prescription things. TENS devices, not like ours with the interferential current and all. You buy by that either online or Walmart. So there's a self-directed portion of it.\n",
      "And then there's the way they get into medical professionals to get a prescription. They can get referred to maybe additional physical therapy. They can obviously get, still will get a lot of opioids prescribed. In some cases, you see chiropractors trying to assist the patient, but obviously, our main argument is to use our devices, the prescription electrotherapy that we offer as first line of defense.\n",
      "And from a sales force perspective, when they walk into a clinic, let's say they walk into a new clinic, their first question should really be so do you guys see patients in pain? And if they do, what the hell is wrong with them if they're not already writing prescriptions as the first line of defense. That is what we're trying to instill in terms of our approach to sales these days. Of course, I know that our sales reps are much better in terms of delivering this message more politically correct, and I just phrased it here but that's really the mindset we walk in with.\n",
      "James Terwilliger -- Northland Securities -- Analyst\n",
      "Okay, great. Thank you. That was enlightening. And lastly, did I get this correct? So you had a little bit of slowdown in terms of future orders or current orders in April, May, because of the ramifications in COVID, and the business has kind of bounced back here in kind of the June, July. Is there any summer slowdown that we should think of typically in healthcare, but with COVID muddying the waters, it's hard to put that in there. Am I thinking about this correctly that a slowdown in April, May and kind of bounce back in June and July?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes, I think so. The impacts of COVID is much more powerful than the traditional seasonality, but If clinics are open, they probably try to get as many hours in as possible or billable hours in as possible to treat as many patients as possible, simply from a financial point of view, but we saw that in June and even though the uptick really came in only in the second half of June, we still grew 76% year-over-year in June, and we see even better growth in July. So, obviously, the addition of sales reps is certainly helping on that. There's still a damper on the economy and therefore also the available clinics for us as a result of COVID, but we're more than mitigating that by the addition of sales reps.\n",
      "James Terwilliger -- Northland Securities -- Analyst\n",
      "Great, thank you very much for taking my questions, Thomas. Congratulations on a good quarter. Keep it up. Thanks, guys. Goodbye.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yes, thank you. It sounds like everybody is beginning to be so used to how profitable we are that very few people actually make note of how profitable we are. So, I really appreciate that, James. Thank you.\n",
      "Operator\n",
      "This concludes our question-and-answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you, I hope today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening into this call. Thank you and have a great day to all.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 51 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Yi Chen -- H.C. Wainwright -- Analyst\n",
      "Matthew O'Brien -- Piper Sandler -- Analyst\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Marc Wiesenberger -- B. Riley FBR -- Analyst\n",
      "James Terwilliger -- Northland Securities -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "{%sfr%}\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of June 2, 2020\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "In this episode of Industry Focus: Wildcard, Jason Moser chats with Motley Fool analyst Brian Feroldi about three promising healthcare stocks that he personally bought. Discover their innovative products, which facilitate easy and quick diagnosis of peripheral artery disease -- plus, a \"medical device\" to treat cancer, as well as noninvasive pain management. Learn about their business strategy, financials, competitive edge, growth potential, and much more.\n",
      "To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.\n",
      "10 stocks we like better than Walmart\n",
      "When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "Stock Advisor returns as of 2/1/20\n",
      "This video was recorded on July 22, 2020.\n",
      "Jason Moser: It's Wednesday, July 22. I'm your host Jason Moser. Today it's a Wildcard Wednesday. Of course, this week we're chatting with Fool analyst Brian Feroldi a bit about a few healthcare stocks that he recently actually added to his portfolio. This is his real money; he's got some skin in the game here. And listen, this guy knows healthcare, so when he's putting his money behind it, you got to at least listen.\n",
      "Brian, good to see you, how is everything going?\n",
      "Brian Feroldi: Jason, going awesome. And I love that this Wednesday is a Healthcare Wednesday. I miss the regular weekly Healthcare episodes, so good to bring it back.\n",
      "Moser: Yeah. And I feel like the more and more we've done this Wildcard Wednesday, I've enjoyed it for a lot of reasons, every once in a while, you get some freedom to go one way or the other. But I do agree with you, healthcare is such a big market opportunity, it reaches so many different directions, to not have a weekly show on it is probably close to a sin. So, we're going to at least try to make sure, if it's not every week, we're going to do these Wildcard Wednesdays as often as we can on healthcare, because we know our listeners out there like hearing about it. And so today -- go ahead.\n",
      "Feroldi: I was going to say, as they should. There are so many attractive aspects to the healthcare industry, it's recession resistant, it's got growth tailwinds behind it, there's barriers to entry, the margins are good. There's a lot to like about investing in the healthcare sector.\n",
      "Moser: You're right. And today we're going to talk about three healthcare companies that you have purchased yourself. So, let's just dive right in here, because I like this, this is a neat eclectic bunch here. And stock No. 1, you've got Semler Scientific (OTC: SMLR). Now, this is an over-the-counter stock, so it's not something you would find on the New York Stock Exchange or Nasdaq, that doesn't mean anything necessarily good or bad, but just, if you're trying to look for the ticker, folks, that SMLR, it is over-the-counter.\n",
      "Brian, talk a little bit about Semler Scientific and what drew you to it?\n",
      "Feroldi: Yeah, sure. This is a company that I actually found about on Twitter. So, shoutout to Twitter for coming up with great ideas. Actually, two of the stocks that I bought, I first learned about on Twitter. But Semler is a $335 million market cap company. So, kind of small. It's one I've talked about on the show before, but what I love about this company is they make diagnostic products for people who are at risk of heart attack or stroke. So, their product is specifically geared toward people who have peripheral artery disease, which is when the arteries gradually become blocked due to the progressive buildup of fat.\n",
      "Now, that market, there are millions of Americans, tens of millions of Americans, who have peripheral artery disease, however, only about 25% of them know it. Seventy-five percent of people with peripheral artery disease, literally do not know that they have it. And a big reason why is, there's no fast, easy way to diagnose peripheral artery disease.\n",
      "So, that's a problem that Semler has tackled head-on. They launched an innovative product called QuantaFlo, which is a little clip that's, kind of, looking like an oxygen sensor. And during your normal physician annual screening, they put this little clip on your finger, both of your fingers, both of your hands, and both of your feet, and it measures blood flow to each of your extremities, and within five minutes of putting this little clip on, a report is produced that shows you how blood is flowing to your arms and legs. And right from there, a doctor gets a visual back saying, hey, three of these limbs are fine, but one of them, blood flow is restricted, which is a major indication that there could be peripheral artery disease going on. And it allows the physician to take action, either surgery or with drugs, to take that patient and significantly lower their chances of having a heart attack or stroke down the road.\n",
      "So, that's the business here. These guys are the only ones that are doing what they're doing. But what really attracted me to this company, Jason, is that they're not playing this technology on the hardware side, it's a software play. They sell access to the reports, so that makes the company's financials far better than if it was just a hardware company.\n",
      "Moser: Yeah. Well, I mean, and you know, when you are focused maybe on the software side of it, probably they are able to maybe protect, what David Gardner will call their \"secret sauce,\" maybe you can protect that secret sauce a little bit more, because you know, you can't see necessarily behind the curtain there. They're giving a report, there's a lot of value.\n",
      "I love the diagnostics nature of this business; it makes me think of two things. No. 1, that's a pretty staggering number there; 12 million Americans undiagnosed, essentially 75% of cases. Folks out there who have it, they don't know they have it, sounds a little bit kind of like what we're [laughs] going through today to be honest with you. And it does seem like a lot of that ties back to testing and diagnostics, right, that just, we haven't really done that great of a job on that front. And so, it just goes to show you the value in that testing and diagnostics. You know, not human healthcare, but still very valuable healthcare in animal healthcare, Idexx Laboratories, a very similar style business and just really owning that diagnostics market. It sounds like that's the case here too with Semler.\n",
      "This is a stock that's done really well. I like seeing businesses, even if that absolute revenue number isn't huge, and it's not right now, but it's growing fast and this is a profitable business too.\n",
      "Feroldi: Yeah, that's exactly right. And again, that's what really drew me to this company. I always like finding interesting technology. And to your point there, the nice thing about the diagnostic space is, with Semler, they can make the very real argument that spending a little bit of money upfront to screen patients better can lead to enormous cost savings down the road. I mean, how much does it cost when somebody has a heart attack or stroke? You're talking about tens of thousands or even hundreds of thousands of dollars. If Semler can prevent just a few of those, that more than pays for the implementation cost of the technology.\n",
      "But let's get into the finances a little bit. In the first quarter of this year revenue grew 39% year-over-year. That's a pretty healthy growth rate. But to your point, Jason, small still top line, $9.4 million in quarterly revenue. So, really, not that much top line at all. However, if you dig into the rest of the income statement, boy! Are there some attractive numbers. Gross margin here, Jason, gross margin on that $9.4 million in sales was 91%. Ninety-one percent! And amazingly, with revenue growth of 39%, their cost of goods sold declined year-over-year. I don't know if I've ever seen that before, where that kind of growth, plus a decline in the actual dollar amounts of cost of the product.\n",
      "Now, take that down the income statement, we saw pre-tax net income grew 86%. So, faster than revenue due to some margin enhancements. There were some wonky things going on with taxes, so earnings only grew 24%. But I see strong top-line growth, I see incredible margins, I see a net income of positive already. And the balance sheet looks pretty good here too, Jason, $11.2 million in cash $0 debt, as of March 31.\n",
      "Moser: Yeah, you definitely like to see that. And, man, I tell you, when I saw that gross margin number, and I thought, you know that reminds me of a few businesses that certainly -- I know you like at least one of these in Autodesk. But Autodesk, Adobe, another company called Ansys, these powerful software companies that can really just generate these amazing margins over time if they build something special. It sounds like Semler might be on the road to that same thing now.\n",
      "Now, in regard to the business itself, where do we stand? So, I see the name Semler involved in management and on the Board and ownership there. We like to see skin in the game, so to speak. What's the founding culture? What's the management setup? How does that look?\n",
      "Feroldi: So, it was founded many, many years ago. And the original founder himself was a physician. He's no longer involved with the company, but his son does own about 9% of the stock. The CEO here, Dr. Douglas Murphy-Chutorian, has really been the driving force over the last couple of years. And he, himself, owns 12% of shares outstanding. So, between those two, you're talking about more than 21% of shares outstanding owned by the management team.\n",
      "And that's pretty exciting, because the potential of this technology is massive. Semler believes that 80 million Americans -- just Americans, not including the rest of the world, Jason, just Americans -- should be screened with this technology annually. That's the number of people that are over age 50, that could potentially be at high risk of developing peripheral artery disease. And that represents about 300,000 doctors' offices that are potential customers out there.\n",
      "So, we don't have the exact penetration rates, but with only $9 million in quarterly revenue, I can't imagine that it's all that high. And when I see that, I think that this company has a tremendous growth runway ahead of it.\n",
      "Moser: Yeah, it feels like it. You know, I mean, everything comes at a cost, right? As much potential as the business has, what do you see as some of the potential bigger risks for a company like this today?\n",
      "Feroldi: To me, the biggest risk is, customer concentration. The company's two biggest customers represent 46% and 21% of sales outstanding. Customer concentration is a common issue, especially for smaller companies, where one or two big customers, if they were to not become customers any longer, could seriously dent this company's top-line growth.\n",
      "And when you're talking about a small company too, you're also even more dependent on a great management team. So, if I saw the CEO all of a sudden step away, or if I saw one of their major customers no longer decide to buy from Semler, that would blow a hole in the thesis here. And as you pointed out, the stock also trades over the counter, it doesn't trade on a major exchange like the Nasdaq or the New York Stock Exchange (NYSE). So, that makes its stock illiquid. But even factoring in those potential negatives, I like enough of what I've seen to take a small position in the company.\n",
      "Moser: Yeah. Final question and we'll move on to the next stock there, but just out of curiosity, when you see a company like this. Clearly, a lot of potential. It seems like they're really fighting a relevant problem. What are the chances, you think, of a business like this listing itself on the Nasdaq? Probably it would be a Nasdaq listed, but it could be the New York Stock Exchange too. At some point, do you feel like this is a company that will try to graduate up to one of the big leagues there, that gives you a little bit more credibility? Of course, there are some costs that come with it, but you think that's something you'll be looking for?\n",
      "Feroldi: Yeah, as you pointed out this has been a fantastic stock over the last five years; it's really gone up a lot. And even today, after all that appreciation, it's still not even $500 million, it's still [laughs] pretty darn small. So, it would not surprise me, in the future, as the company continues to grow and its market cap continues to increase, if it did decide to up-list, but that's not a major part of the thesis, that would certainly increase liquidity and increase the number of investors out there that could potentially purchase its stock, but that would be a catalyst ahead of this company, Jason.\n",
      "Moser: Yeah, this is like one of those little tiny gems. For any of you who remember our way back, you know, a long time ago, our small cap investing service Hidden Gems. And one of my favorite features of Hidden Gems every month was Tiny Gems, featuring little companies like this, had a lot of potential. And you know, it's neat to find them and get involved when they're just babies, right, you get to watch them grow up. [laughs]\n",
      "Feroldi: If all goes well; if the thesis works out, yes, it would be great to watch this company grow up. [laughs]\n",
      "Moser: If it works. If it works. Well, let's talk about one that maybe looks like it is working a little bit more obviously, at least just based on the size of the company, it's about a $6.5 billion market cap. But this is Novocure (NASDAQ: NVCR). This is ticker NVCR. Now, Novocure, this is a cancer company. I mean, immediately you just know that's a massive market. You look for companies that are doing special things. What was it about Novocure that piqued your interest?\n",
      "Feroldi: Yeah, this is a company that I've pitched on this show numerous times and with good reason. This is a company that I think is tremendously exciting. So, Novocure is a medical device company that, as you said, is focused on cancer. Now, most companies that focus on cancer are drug makers, Novocure is a medical device company. That alone makes it extremely weird. I mean, this is a weird company in a good way.\n",
      "Moser: Well, it caught my interest when I saw \"medical device,\" I thought, huh! That's a little different.\n",
      "Feroldi: It is. So, what they have developed is what they believe is a brand-new modality of treatment. So, by modality, I mean, the way that we've treated cancer historically is with chemotherapy, surgery, and radiation. Novocure literally believes that it has developed a fourth modality, a brand-new treatment category that it calls Tumor Treating Fields. Now, Tumor Treating Fields is when a device emits low-dose electric fields on the skin, and those electric fields inhibit cell division in cancerous tumors. This technology sounds like magic, it sounds crazy, but it works, it actually works. Their initial indication was in brain cancer, it's called glioblastoma multiforme. And this looks like a swimming cap that you put on your head, and it has some electrodes coming off the back to a generator. Those electrodes literally create electric fields that make it so the microtubule spindles inside a cancerous cell cannot line up to divide. This is very similar to how cancer drugs work. So, it's just doing it with physics as opposed to chemistry.\n",
      "Now, when I first learned about this, I thought, crazy. These guys are full of it. However, fast forward, I've been following them for several years, they've made believers out of thousands of physicians and insurers. And I'm talking Medicare. Medicare literally covers this technology; if that's any indication for, does it work? And they've produced scientific study after scientific study that shows adding Tumor Treating Fields alongside the standard of care treatment extends survival rates and fights cancer better.\n",
      "Moser: And when you get buy-in from the big insurers and the government providers, I mean, you know that you've gotten over a big hurdle there. I mean, that's a big hurdle. That expands your audience in a big way. And the way that you put it, though. Like, I understand why. I mean, you've put it very well there, in that, you're not fighting cancer via drugs, you're fighting it via physics. And all of these commercials that you watch with a new medicine for whatever it may be and the list of side effects that just goes on and on and on, you know, I mean, it makes me think of that old Simpsons and Viagra-Gain. If you remember that episode from back in the day. But if you can avoid medicines, drugs that offer those types of side effects -- I'm assuming that physics might not necessarily introduce the same types of side effects; is that a reasonable assumption?\n",
      "Feroldi: That is the thing that attracted me to this company the most. You have surgery, boy! There are side effects; you take chemotherapy, boy! There are side effects. The No. 1 side effect with this technology is skin irritation. That's the big side effect to having this. So, there is no systemic toxicity with this.\n",
      "And to your point, what I really like about this, is it's an additive technology. They're not trying to replace chemotherapy; they're trying to use this alongside chemotherapy to make chemotherapy better. So, it's synergistic. So, there's no competitor out there saying, don't go with Novocure, use me. Every other company out there is saying, yeah, use my product and Novocure. That's a big reason why this company has grown as fast as it has.\n",
      "And let's get into the financials for a quick second here. So, last quarter, during the pandemic, revenue grew 39% to $102 million. So, different scale, 10 times bigger than Semler, Jason. Gross margins expanded 76% now, it was 73% last year. And this company just flipped to profitability. So, last quarter, $4 million in net income. In the year ago period, they had a $12 million net loss. So, pick a number, it looked good.\n",
      "Moser: Well, you're right. I mean, looking through all of your notes on the business, the different types of markets that it tackles. I mean, it seems like that technology could have so many different applications here, just given how big of a world, unfortunately, cancer is. I mean, like, there are just so many different types, it seems, these days. And a technology like this, it feels like, would have really long-lasting impacts there.\n",
      "Feroldi: Yeah, to that point. Right now, they are really focused on brain cancer, and they also recently won a second indication for mesothelioma. Both of those are pretty small markets. Brain cancer is about 13,000 patients in the U.S. Mesothelioma is about 3,000 patients annually in the U.S. The reason I bought the stock last week was because of the pipeline and the potential of the pipeline. In the next five years, they believe that they'll be able to get label expansion claims to use this technology on brain metastasis, non-small cell lung cancer, pancreatic cancer and ovarian cancer. If they can nab those additional indications, their total addressable market literally goes up by a factor of 15.\n",
      "Now, the reason that I think that that's going to happen is because of the factors I talked about before. There's no systemic toxicity, it works alongside other cancer treatments, and they've already got this device through the FDA twice on two separate indications. So, there's risk that those other indications might not pan out, but I think the chances of it getting through is very high.\n",
      "Moser: Yeah. And I like that thinking there. And I like your point that this is additive; you're not replacing something. Honestly, it makes me think a little bit of telemedicine back in the day, as I understand this isn't a replacement, it's something that's trying to make the system better. And you have that same dynamic here. I mean, this is clearly a bigger business; like I said $6.5 billion market cap. When you look at what they're doing today, what do you see as some of the bigger risks that investors need to at least be aware of?\n",
      "Feroldi: No. 1 risk is that those additional indications do not pan out. If you look at the valuation of this company today, it is clearly pricing in continued success in those other indications. It's trading for about 17 times sales and 103 times forward earnings. Another risk that I could potentially see is pushback from insurers. This is an expensive product. It's very expensive to use. And they bill on a monthly basis. If they can't produce the clinical results that prove the clinical effectiveness of this technology when compared to the cost, they're going to get a lot of pushback. So, if, for example, the next indication they're going to go after is brain metastasis, which is a massive market, if insurers all of a sudden see the bills that they're paying for this thing, and they say, well, we don't think we're getting enough clinical benefit from this, and they pull back on that, that would really damage the thesis here.\n",
      "Moser: Yeah, that could be a problem indeed. You know, I was thinking just real quick, before we go on, the mesothelioma, like, that's the commercial you see on TV [laughs] all the time, right? I mean, that's law practices out there just trying to cover that market from front-to-back for any potential lawsuits there. I guess, those still probably go on for a while, given they're asbestos-related.\n",
      "Feroldi: Yeah. And the sad thing is, in the U.S. there's only about 3,000 diagnoses every year, and it is caused by exposure to asbestos. In emerging markets, such as China, where asbestos is far more used for far longer than it was in the U.S. before it was banned, those rates are much, much higher sadly.\n",
      "Moser: Yeah, I can certainly believe that. Well, let's take a look at stock No. 3 here, because this was another one that, when you look at it on its own, it seems like it has a pretty general, sort of, application there in treating chronic and acute pain -- it could go a number of different ways there -- but it's Zynex, ticker for this company is ZYXI. Another small cap; the market cap is just a little bit under $1 billion, so kind of in the middle between the other two companies we talked about today. But talk a little bit about Zynex and what attracted you to this business?\n",
      "Feroldi: Yeah, this is actually a company that I learned about from one of our regular Motley Fool Live viewers, ProShopGuy, Mike. He is the one that pinged me on Twitter and said, Brian, you might want to check this company out. And I did, and I bought shares, if that gives you an indication for whether I liked it or not.\n",
      "So, Zynex has three distinct FDA-approved business units. The first and the most important for now, is the noninvasive electrotherapy pain management market. So, this is a medical device that is used for people that have chronic pain. So, the pain management device is used to reduce or eliminate the need for people to take opioids by using electrotherapy to reduce pain in their body. What's attractive about that is, first off, it's a massive market; second off, it's easy to get behind a company that's reducing the use of opioids; and third, the business model for this technology is very attractive.\n",
      "So, Zynex sells both the device itself as well as a number of consumables that are used alongside the device. So, the business model here, for 90% of their revenue so far, is a razor-and-blade model. And we'll go into the financials later, but let's just say, business is good.\n",
      "Secondly, their second device is for incontinence. So, they recently launched a product here that is a nonsurgical way to manage incontinence. And similar business model here, great margins and another market where the consumables are the significant portion of revenue.\n",
      "Third is NeuroDiagnostics. So, this is a product that helps people to recover from strokes, spinal cord injuries or brain injuries. So, it's stimulation to help people retrain their muscles and increase their range of motion.\n",
      "And then finally, they just recently got FDA approval for a noninvasive blood volume monitor, and this technology produces zero revenue today but it's going to be used in operating rooms to detect blood loss and internal bleeding. So, this is a brand-new business line that has opened up. And when I read that, I immediately thought, well, they seem to have a great core market, and wow! Are they innovative, because they have already entered a number of new markets that are generating zero revenue right now. And that's what I call optionality, and we all know that I like optionality, as do you, Jason.\n",
      "Moser: Well, yeah, I think we all do. And I love the razor-and-blade business model, any time you can find one like that. I mean, I'm not saying they're all gold, but a lot of them are really good. And I mentioned Idexx earlier, Idexx is a good example, you know, they get their diagnostic equipment into veterinarians' offices and they use consumables to make that diagnostic equipment work. Another good example in human healthcare, Masimo, reminds me a little bit of similar, I guess, just in the -- you know, you talked about the blood oxygen monitoring, they're very similar to Masimo's business there. But when you have a business with that type of a model, it can be so powerful. And again, this generates strong gross margins, strong growth, particularly profitable growth. And I see here you noted, that they've been profitable for 15 quarters in a row. You cannot dismiss that.\n",
      "Feroldi: Yes. And again, this technology has been around for a long time. This company was founded by a guy named Thomas Sandgaard in 1996. He's still the CEO today. So, 24 years later, he is still the CEO of the company that he founded. And their technology has been used to treat more than 400,000 patients since day one. So, that tells me that it's the real deal, it's out there, it's making a difference in people's lives. And I love that the founder is still calling the shots.\n",
      "Now, I teed up before that this is a razor-and-blade model. And you can see that shine through when you look at the financials. Revenue growth in the first quarter was 66% to $15.2 million, 78% gross margin, and net income of $2.9 million. So, again, another one like Semler, Jason, where not a ton of revenue, $15 million, but almost $3 million in net income. That's impressive. And the balance sheet is also squeaky clean, about $15 million as of the end of the quarter and no debt. And just a few weeks ago they raised another $28 million through a common stock offering to help get them through the crisis. So, the financials here are gold.\n",
      "Moser: Yeah, absolutely. I mean, you can't hold that against anyone. And you're hearing cash conservation in every press release in everyearnings call you know, that's good to know that they were able to raise a little money just to put themselves in a good position to get past this. And it really does sound like technology that can reach a lot of different markets. I love that inside ownership. You know, it's a small company, $750 million, I understand that's a risk there. But what do you think are some of the more obvious risks for a business like this that investors need to at least keep in mind?\n",
      "Feroldi: Well, there's a couple. None of these companies are risk-free, as is no stock. So, first off, let's start with the market that this company operates in, pain therapy. The pain therapy market historically has been rife with abuse and fraud. I'm not, by any stretch, saying that that's what Zynex is doing, but I have seen the pain therapy market, in the past, come out with some unscrupulous players that do things that juice their revenue and juice their earnings, but they're not right.\n",
      "So, that just means that this company could be operating in a bad block; it doesn't mean the company is doing anything wrong, and everything that I've seen so far suggests that the company is doing something right. But that alone is a risk here.\n",
      "Another risk is, the company's growth strategy. So, the growth strategy is, add sales reps. They're adding about 20 to 25 new sales reps per month. This company is investing aggressively in its sales functionality to make its sales team larger and larger and larger, so it can rule out all of these products to more and more places. Growing that fast, adding that many people on, is a risk. What happens if you screw up the management of it, what if you hire the wrong people or what if -- you know, that's a growth strategy that has worked historically, but it's not guaranteed to work.\n",
      "And then finally, the company itself isn't exactly cheap. None of these stocks are cheap. We're talking about 14 times sales and 69 times earnings. Management just raised capital, so that could tell you that [laughs] they think their stock is dearly priced right now. But given what I've seen so far, the financials here, the story here, and the opportunity here is large enough that I thought it was worthwhile to take a small bit of my capital, become a shareholder and start to follow the story.\n",
      "Moser: Yeah. Well, to your credit too. I mean, yeah, I guess valuation is always a risk, but I mean, 16 times, 17 times sales. And I love the fact that there are actually earnings to mention, right? You've got earnings. This isn't some newfangled SaaS business or cloud business that may be growing revenue really, really quickly, but is just as much a cash incinerator, right; you got to take a longer-term view on that. It's nice to see, you get some of these companies in the healthcare space growing like this, and actually bringing some of that down to the bottom-line, it's kind of refreshing in this day-and-age, you just don't see that as much anymore, right?\n",
      "Feroldi: All three of these companies, Jason, are growing revenue over 39% quarter-over-quarter, have strong gross margins, have tremendous growth opportunities and are profitable; all three of them. That's the real reason -- that combined with the other factors, are the reasons that I decided, I'm adding to my position in two of them, and I started a new position in Zynex two weeks ago.\n",
      "Moser: Okay. Well, now, as we wrap up this week's show, and this is my tribute to my colleague that I just don't get to see as much anymore given that we're all working from home, Mac Greer. Mac has this, the desert island question, which is always fun, you know, it typically involves some companies that are a bit more desperate, maybe the answer is a little bit more obvious, but I'm going to present you with Mac Greer's desert island question here, Brian.\n",
      "If you are stranded on a desert island for the next five years, and you can choose one of these companies that you've pitched today, I understand that you already own them all, Zynex, Novocure, Semler Scientific, what stock are you going with as your desert island pick?\n",
      "Feroldi: To reiterate, I bought all three. So, this is more of a basket approach, obviously, but if you're forcing me to choose one, Mac Greer, I'm going to pick Novocure, NVCR. It's the biggest, it's the most mature, I believe it has the widest moat of the three of these companies, it's what I've been following for the longest, it's someone I have the most confidence in over the long-term.\n",
      "But if I had to pick which one is going to be the best stock performer, I would probably pick Semler.\n",
      "Moser: Interesting to see that. Well, yeah, and I mean, we just like having fun with those questions; that's just a tip of the cap to Mac Greer, and I'm always just interested to see if there's any conviction there, higher conviction on one or the other. But yeah, I love to see -- you know, listen, you like these businesses, you got all three of them in your portfolio, I think our listeners are really happy to have had the opportunity to listen to you pitch these companies for them today and explain why they look like they could be great opportunities.\n",
      "And you know what, Brian, this Wildcard Wednesday thing, I love doing the healthcares, so let's keep that trend going next time we get the chance, OK?\n",
      "Feroldi: How about we do Idexx, Massimo and Teladoc; three Jason Moser healthcare stocks next time?\n",
      "Moser: [laughs] Well you had me at Teladoc; but I think that was the third one you said. Anyway, I like them all and own them all. So, yeah, I'm down. Let's do that for sure. I'll make sure and drop you a note next time I'm on the schedule.\n",
      "Feroldi: Sounds like a plan, bud.\n",
      "Moser: All right, folks. So, that's going to do it for us this week. Remember, you can always reach out to us on Twitter @MFIndustryFocus, or drop us an email at IndustryFocus@Fool.com. You know, tell us about the stocks you're buying, ideas you have in the healthcare space or other spaces, we're always interested, always looking for new ideas for shows, and always happy to answer any and all questions that we can. But for now, that will do it.\n",
      "As always, people on the program may have interests in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear.\n",
      "A big thanks to Tim Sparks for all of his work behind the glass this week. For Brian Feroldi, I'm Jason Moser, thanks for listening and we'll see you next week.\n",
      "can we use digits in the write-up?\n",
      "Brian Feroldi owns shares of Adobe Systems, Autodesk, Novocure, and Semler Scientific. Jason Moser owns shares of Adobe Systems, ANSYS, Autodesk, Idexx Laboratories, Masimo, and Teladoc Health. The Motley Fool owns shares of and recommends Adobe Systems, Autodesk, Idexx Laboratories, Masimo, Novocure, Teladoc Health, and Twitter. The Motley Fool recommends ANSYS. The Motley Fool has a disclosure policy.\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of CHINA BIOLOGIC PRODUCTS HOLDINGS INC\n",
      "Full Guru Analysis for CBPO>\n",
      "Full Factor Report for CBPO>\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company operates through medical devices segment, which include electrotherapy and pain management products. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). The Company's devices are intended for pain management to reduce reliance on drugs and provide rehabilitation and mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's devices are small, portable, battery-operated and include an electrical pulse generator that is connected to the body via electrodes.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of ZYNEX INC.\n",
      "Full Guru Analysis for ZYXI>\n",
      "Full Factor Report for ZYXI>\n",
      "RETRACTABLE TECHNOLOGIES, INC. (RVP) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of RETRACTABLE TECHNOLOGIES, INC.\n",
      "Full Guru Analysis for RVP>\n",
      "Full Factor Report for RVP>\n",
      "USANA HEALTH SCIENCES, INC. (USNA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "Detailed Analysis of USANA HEALTH SCIENCES, INC.\n",
      "Full Guru Analysis for USNA>\n",
      "Full Factor Report for USNA>\n",
      "REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 75% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: FAIL\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "Detailed Analysis of REGENERON PHARMACEUTICALS INC\n",
      "Full Guru Analysis for REGN>\n",
      "Full Factor Report for REGN>\n",
      "More details on Validea's Motley Fool strategy\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Wall Street gained on Wednesday with the S&P 500 hitting its highest in more than four months following a strong quarterly showing by Goldman Sachs and promising early data for a potential COVID-19 vaccine. .N\n",
      "At 11:46 ET, the Dow Jones Industrial Average .DJI was up 0.50% at 26,776.62. The S&P 500 .SPX was up 0.87% at 3,225.24 and the Nasdaq Composite .IXIC was up 0.37% at 10,527.006. The top three S&P 500 .PG.INX percentage gainers: ** Royal Caribbean Cruises Ltd , up 17% ** Waters Corp , up 14.5% ** Norwegian Cruise Line Holdings Ltd , up 14.4% The top three S&P 500 .PL.INX percentage losers: ** BNY Mellon , down 6.9% ** Fortinet , down 5.8% ** Amazon Com , down 2.8% The top two NYSE .PG.N percentage gainers: ** Bloom Energy Corp , up 30.3% ** Barnes & Noble Education Inc , up 21.1% The top three Nasdaq .PG.O percentage gainers: ** China Finance Online Co , up 156.4% ** Genetic Technologies Ltd , up 146.2% ** Taiwan Liposome Company Ltd , up 65.8% The top three Nasdaq .PL.O percentage losers: ** Perceptron Inc , down 27.4% ** Cleveland BioLabs Inc , down 26.9% ** Sphere 3D Corp , down 23.7% ** Moderna MRNA.O: up 7.0% BUZZ-Record high on promising data from early COVID-19 vaccine trial BUZZ-Street View: Moderna vaccine has potential for blockbuster sales ** Zynex ZYXI.O: down 11.1% BUZZ-Zynex drops after medical device firm prices stock offering ** American Airlines AAL.O: up 8.8% ** United Airlines UAL.O: up 8.1% ** Delta Air Lines DAL.N: up 5.1% ** Southwest Airlines LUV.N: up 5.7% BUZZ-U.S. airlines: Gain on hopes of a COVID-19 vaccine ** China Finance Online Co JRJC.O: up 156.4% BUZZ-More than doubles on partnership with Dow Jones ** Gap GPS.N: up 9.1% BUZZ-Gap rises on RBC upgrade ** Immutep Ltd IMMP.O: up 48.6% BUZZ-Jumps on U.S. patent for cancer treatment ** Goldman Sachs GS.N: up 0.9% BUZZ-Rises as trading, underwriting gains boost Q2 profit ** Can-Fite Biopharma CPTA.O: up 30.5% BUZZ-Can-Fite Biopharma gains as potential COVID-19 drug nears clinical trial ** Capitala Finance CPTA.O: up 30.5% BUZZ-Surges on receiving repayments from portfolio companies ** Sphere 3D Corp ANY.O: down 23.7%\n",
      "BUZZ-Jumps on acquisition of Rainmaker Worldwide ** Chevron Corp CVX.N: up 0.4% ** Exxon Mobil XOM.N: up 0.7%\n",
      "BUZZ-Rise on drop in U.S. crude inventories, OPEC+ meeting hopes ** Moleculin MBRX.O: up 50.3%\n",
      "BUZZ-Up on deal to expand development of potential COVID-19 drug ** Organogenesis Holdings ORGO.O: up 14.3%\n",
      "BUZZ-Jumps on upbeat Q2 revenue forecast ** FLIR Systems FLIR.O: up 3.0%\n",
      "BUZZ-Rises on upbeat Q2 revenue outlook ** Oramed Pharma ORMP.O: up 6.4%\n",
      "BUZZ-Up on positive FDA feedback for oral insulin ** LMP Automotive LMPX.O: up 1.9%\n",
      "BUZZ-Rises on upbeat Q2 forecast ** Fortress Value Acquisition FVAC.N: up 10.9%\n",
      "BUZZ-Fortress Value Acquisition enters deal to take rare earth miner public, shares up ** ForeScout Technologies FSCT.O: up 15.4%\n",
      "BUZZ-Jumps on revised $1.43 bln buyout deal with Advent ** BNY Mellon BK.N: down 6.9%\n",
      "BUZZ-BNY Mellon biggest S&P loser after CEO signals caution ** Atossa ATOS.O: up 10.4%\n",
      "BUZZ-Atossa rises on positive lab results of potential COVID-19 nasal spray ** Waters Corp WAT.N: up 14.5%\n",
      "BUZZ-Eyes best day in 11 yrs on estimated sales beat, new CEO ** Otonomy OTIC.O: up 5.6%\n",
      "BUZZ-Hits two-year high as Steven Cohen's Point72 reports passive stake\n",
      "The 11 major S&P 500 sectors:\n",
      "Communication Services\n",
      ".SPLRCL\n",
      "down 0.20%\n",
      "Consumer Discretionary\n",
      ".SPLRCD\n",
      "down 0.36%\n",
      "Consumer Staples\n",
      ".SPLRCS\n",
      "up 0.76%\n",
      "Energy\n",
      ".SPNY\n",
      "up 1.02%\n",
      "Financial\n",
      ".SPSY\n",
      "up 1.17%\n",
      "Health\n",
      ".SPXHC\n",
      "up 0.90%\n",
      "Industrial\n",
      ".SPLRCI\n",
      "up 2.00%\n",
      "Information Technology\n",
      ".SPLRCT\n",
      "down 0.11%\n",
      "Materials\n",
      ".SPLRCM\n",
      "up 1.47%\n",
      "Real Estate\n",
      ".SPLRCR\n",
      "up 0.31%\n",
      "Utilities\n",
      ".SPLRCU\n",
      "up 0.56%\n",
      "(Compiled by Bharath Manjesh in Bengaluru)\n",
      "((Bharath.ManjeshR@thomsonreuters.com; outside U.S. +91 80 6749 2703;))\n",
      "\n",
      "What happened?\n",
      "Shares of Zynex (NASDAQ: ZYXI), a medical device manufacturer, are down by 9.9% as of 11:23 a.m. EDT on Wednesday, after the company announced the pricing of a public offering of common stock after the market closed on Tuesday. Zynex's decision to sell additional shares isn't sitting well with investors. So what\n",
      "Zynex expects to sell 2.5 million shares for $22 per share in this public offering of common stock. Note that half of these shares are being sold directly by Zynex, while the remaining shares are being sold by certain stockholders. The company is granting underwriters a 30-day option to acquire an additional 187,500 shares, while the stockholders participating in this transaction are also giving underwriters the option of buying 187,500 of their shares of common stock.\n",
      "Zynex expects to raise $27.5 million (in gross proceeds) through this offering of common stock, which should close by July 17. The company will not receive any proceeds from the sale of the shares that are being offered by the stockholders.\n",
      "Image source: Getty Images.\n",
      "Now what\n",
      "At the close of the previous trading session, Zynex's shares were worth $26.22 apiece. And considering the company priced its public offering at $22 per share, it isn't surprising that investors responded by selling off its stock. At writing, Zynex's stock price is down to $23.49. The healthcare company expects to use the proceeds from this transaction to ramp up its marketing efforts and for working capital purposes, among other things.\n",
      "This slump may present an opportunity for interested investors to purchase shares of Zynex. The company's business has been picking up steam since several states have started reopening their economies. As such, Zynex's second-quarter financial results should be strong, and could help the company recover from today's losses. 10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 2, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: Futures linked to the S&P 500 and the Dow indexes hit near five-month highs on Wednesday as signs of progress in developing a COVID-19 vaccine and a much better-than-expected quarterly profit for Goldman Sachs brightened the mood. .N\n",
      "At 8:47 ET, Dow e-minis 1YMc1 were up 2.09% at 27,044. S&P 500 e-minis ESc1 were up 1.41% at 3,228.5, while Nasdaq 100 e-minis NQc1 were up 0.64% at 10,714. The top three NYSE percentage gainers premarket .PRPG.N: ** Fortress Value Acquisition Corp , up 17.7% ** Sequans Communications S.A. SQNS.N, up 14.8% ** Chaparral Energy Inc , up 14.3% The top three NYSE percentage losers premarket .PRPL.N: ** Hermitage Offshore Services Ltd , down 6% ** The Bank of New York Mellon Corp , down 6% ** AptarGroup Inc , down 5.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** China Finance Online Co , up 177.0% ** Immutep Ltd , up 58.2% ** Capitala Finance Corp , up 42.0% The top two Nasdaq percentage losers premarket .PRPL.O: ** Perceptron Inc , down 16.2% ** Zynex Inc , down 15.4% ** Apple Inc AAPL.O: up 1.6% premarket BUZZ-Apple: Rises as co wins tax dispute against European Commission ** Zynex ZYXI.O: down 15.4% premarket BUZZ-Zynex drops after medical device firm prices stock offering ** American Airlines AAL.O: up 8.0% premarket ** United Airlines UAL.O: up 8.5% premarket ** Delta Air Lines DAL.N: up 6.1% premarket ** Southwest Airlines LUV.N: up 6.3% premarket BUZZ-U.S. airlines: Gain on hopes of a COVID-19 vaccine ** China Finance Online Co JRJC.O: up 177.0% premarket BUZZ-More than doubles on partnership with Dow Jones ** Gap GPS.N: up 6.1% premarket BUZZ-Gap rises on RBC upgrade ** Moderna MRNA.O: up 15.8% premarket BUZZ-Street View: Moderna vaccine has potential for blockbuster sales ** Lemonade Inc LMND.N: up 5.1% premarket BUZZ-Lemonade adds pet insurance to the mix, shares rise ** Immutep Ltd IMMP.O: up 58.2% premarket BUZZ-Jumps on U.S. patent for cancer treatment ** Goldman Sachs GS.N: up 4.2% premarket BUZZ-Rises as trading, underwriting gains boost Q2 profit ** Can-Fite Biopharma CPTA.O: up 42.0% premarket BUZZ-Can-Fite Biopharma gains as potential COVID-19 drug nears clinical trial ** Capitala Finance CPTA.O: up 42.0% premarket BUZZ-Surges on receiving repayments from portfolio companies\n",
      "(Compiled by Bharath Manjesh in Bengaluru)\n",
      "((Bharath.ManjeshR@thomsonreuters.com; outside U.S. +91 80 6749 2703;))\n",
      "\n",
      "Eikon search string for individual stock moves: STXBZ\n",
      "The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures rose on Wednesday as investors took heart from signs of progress in developing a COVID-19 vaccine, looking past record daily death rates in some states and brewing tensions between Washington and Beijing. .N\n",
      "At 7:55 ET, Dow e-minis 1YMc1 were up 1.86% at 26,983. S&P 500 e-minis ESc1 were up 1.34% at 3,226, while Nasdaq 100 e-minis NQc1 were up 0.72% at 10,722.75. The top three NYSE percentage gainers premarket .PRPG.N: ** Fortress Value Acquisition Corp , up 21.3% ** Barnes & Noble Education Inc , up 19.4% ** Nubian Resources Ltd , up 13.3% The top three NYSE percentage losers premarket .PRPL.N: ** Hermitage Offshore Services Ltd , down 6.8% ** AptarGroup Inc , down 5.7% ** Enzo Biochem Inc , down 3.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** China Finance Online Co , up 155.4% ** Immutep Ltd , up 56.4% ** Capitala Finance Corp , up 41.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Perceptron Inc , down 15.2% ** Zynex Inc ZYXI.O, down 11.5% ** Cleveland Biolabs Inc , down 11% ** Moderna MRNA.O: up 17.4% premarket BUZZ-Street View: Moderna vaccine has potential for blockbuster sales\n",
      "** Apple Inc AAPL.O: up 1.6% premarket BUZZ-Apple: Rises as co wins tax dispute against European Commission ** Zynex ZYXI.O: down 11.5% premarket BUZZ-Zynex drops after medical device firm prices stock offering ** American Airlines AAL.O: up 9.1% premarket ** United Airlines UAL.O: up 8.7% premarket ** Delta Air Lines DAL.N: up 6.5% premarket ** Southwest Airlines LUV.N: up 6.3% premarket BUZZ-U.S. airlines: Gain on hopes of a COVID-19 vaccine ** China Finance Online Co JRJC.O: up 155.4% premarket BUZZ-More than doubles on partnership with Dow Jones ** Gap GPS.N: up 6.3% premarket BUZZ-Gap rises on RBC upgrade\n",
      "(Compiled by Bharath Manjesh in Bengaluru)\n",
      "((Bharath.ManjeshR@thomsonreuters.com; outside U.S. +91 80 6749 2703;))\n",
      "\n",
      "What happened\n",
      "Shares of Zynex (NASDAQ: ZYXI), a medical devices manufacturer, are up by 12.1% as of 12:22 p.m. EDT on Friday, after the company announced on Thursday that it had experienced an increase in orders during the second quarter. As a result, Zynex revised its second-quarter and full-year revenue guidance. So what\n",
      "The demand for some of Zynex's medical devices -- which include devices for pain management and cardiac monitoring -- grew during the second quarter as many states started relaxing social distancing measures and reopening their economies. Specifically, the company said that it experienced a 37% increase in orders compared to the year-ago period. What's more, Zynex expects that trend to continue during the third quarter. The company had previously said that its revenue for the second quarter would come in between $17.5 million and $18 million. Image source: Getty Images.\n",
      "Now Zynex expects its top line to be in the range of $18.9 million to $19.4 million. Note that on average, analysts expect the company's revenue to be $17.98 million for the quarter. Further, Zynex increased its full-year revenue estimates to between $80 million and $85 million, up from between $78 million and $83 million. This would represent revenue growth of between 76% and 87% over fiscal 2019.\n",
      "Now what\n",
      "Zynex has been performing well all year long, even as many other medical device companies have struggled amid the ongoing outbreak: The company's stock is up by 267.5% year to date. Given its latest business update, the healthcare company will likely continue on its upward trajectory at least until the end of the year. 10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 2, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "(RTTNews) - Citing solid increase in orders and strong collections, medical technology company Zynex Inc. (ZYXI) raised its Q2 revenue outlook to a range of $18.9 million - $19.4 million from the previously communicated range of $17.5 million - $18.0 million.\n",
      "Analysts polled by Thomson Reuters expect revenue of $17.98 million for the quarter. Analysts' estimate typically exclude certain special items.\n",
      "The Englewood, Colorado-based company also boosted its fiscal 2020 revenue guidance range to $80 million - $85 million compared to the prior estimated view of $78 million - $83 million. The updated revenue estimate is now about 76% - 87% above last year's full year revenue of $45.5 million. Four Wall Street analysts have a consensus revenue estimate of $81.02 million for fiscal 2020.\n",
      "Orders in the second quarter were 37% above the number of orders in the second quarter of 2019 and 23% sequentially below the first quarter of 2020 due to COVID-19.\n",
      "Thomas Sandgaard, CEO of Zynex said, \"Similar to most companies we have seen the impact of the COVID-19 pandemic, not only on the availability of physicians to prescribe our products but also on navigating employee and supply chain issues. Our continued order growth during this pandemic shows the strength of relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, non-addictive prescription strength solutions for their patients in pain.\"\n",
      "ZYXI closed Thursday's regular trading session at $25.71, down 65 cents or 2.47%. However, in the extended session, the stock rose $1.24 or 4.82% to $26.95. Trading volume was 619K shares versus an average volume of 1.08 million shares.\n",
      "\n",
      "Last week was a big one for Zynex (NASDAQ: ZYXI). The Colorado-based medical technology company specializes in manufacturing and selling noninvasive devices for pain management, stroke rehabilitation, neurological diagnostics, and cardiac monitoring.\n",
      "Last Tuesday, it joined the S&P SmallCap 600 list. On Thursday, when everything else in the market seemed to be down, it rose to a 52-week high of $25.39. It slipped a little on Friday to $22.19, but is still up an incredible 182% for the year.\n",
      "Yes, you read that last sentence correctly. Despite all the turmoil in the market this year, Zynex's share price has skyrocketed, with a 122% rise in the past three months alone. The question is: Can it continue? IMAGE SOURCE: GETTY IMAGES\n",
      "The company's finances are in a good place\n",
      "Zynex, which was founded in 1996 by CEO Thomas Sandgaard, has had 15 consecutive profitable quarters. In the first quarter of 2020, it reported net revenue of $15.2 million -- a 66% increase over the same quarter a year ago. Net income was $2.9 million, up 24.9% year over year.\n",
      "It also maintained its full-year guidance, estimating revenue of between $78 million and $83 million, or 72% to 83% above 2019's revenue of $45.5 million.\n",
      "IMAGE SOURCE: YCHARTS\n",
      "The company has three divisions: medical, which provides electrotherapy products for home use; monitoring solutions, which develops cardiac monitoring products for hospitals; and neurodiagnostics, which develops devices for electromyograms (which assess the health of muscles and the nerve cells that control them) and electroencephalograms (which measure electric signals to the brain).\n",
      "The company's business model is heavily based on providing pain relief through its line of electrotherapy products. It hopes to serve as an antidote to what some see as the healthcare industry's excessive reliance on opioids for chronic pain treatment.\n",
      "Many of Zynex's products are designed for long-term use, which partly explains why the company hasn't been affected by supply disruptions the way other companies have. March orders were down 14% and April orders were down 35% compared with January and February averages.\n",
      "\"This minor temporary decline in orders speaks volumes [about] the relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, nonaddictive, prescription-strength solutions for the patients in pain,\" CEO Sandgaard said in Zynex's first-quarter earnings call.\n",
      "The stock may be overheated\n",
      "The first sign of overheating is that the company has expanded its sales staff, which is largely why revenue is growing.\n",
      "In 2018, the company had no employees in direct sales. By the end of last year, the company listed 134 direct sales representatives among its 283 full-time employees, in addition to 42 independent, commission-only sales contractors. And Sandgaard said in March that he would like to see his sales force grow to cover 400 territories by the end of the year.\n",
      "Orders in the first quarter were up 126% up year over year and 3% over the fourth quarter of 2019. While sales have risen, operating margins have actually declined since 2018.\n",
      "The second warning sign is that the company's income comes primarily from being reimbursed by insurance companies, so any change in reimbursement policies can negatively affect the company. TRICARE, the healthcare program of the United States Department of Defense Military Health System, recently announced that on June 1, Transcutaneous Electrical Nerve Stimulation (TENS) units and the supplies to support the devices will no longer be covered for acute, subacute, and chronic lower back pain. That includes Zynex's NexWave TENS device.\n",
      "A third warning sign is that there has been a lot of insider selling lately. Executives sell stock all the time for a variety of reasons, but the amount of shares being sold right now makes one wonder. Since the start of the year, Sandgaard and Chief Financial Officer Dan Moorhead have sold 380,152 shares of stock and have acquired 164,000 shares.\n",
      "A better long-term play than a short-term one\n",
      "It's not a reach to say the company's share price may be due for an adjustment based on how much its share-price growth has outpaced its rise in revenues. Its price-to-earnings ratio as of Friday was 71.8, way above the medical equipment industry average of 45.3.\n",
      "As a long-term investment, however, the company still appears to be a solid bet. It is one of only a handful of players in neuromodulation, a market that analysts expect will see 10.7% year-over-year growth through 2024.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 2, 2020 Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "(RTTNews) - Today's Daily Dose brings you news about Denali halting the development of DNL747 in Alzheimer's disease and amyotrophic lateral sclerosis; the update on Immuron's research collaboration with the U.S. Naval Medical Research Center that was inked last October; the retirement plan of Inogen CEO and Intersect ENT's Sinus implant getting approval for reimbursement with a new C-Code.\n",
      "Read on\n",
      "1. Denali Halts Development Of DNL747; To Focus On Backup Compound DNL788\n",
      "Denali Therapeutics Inc. (DNLI) and its partner Sanofi (SNY) have decided to pause the clinical activities of DNL747 in Alzheimer's disease and amyotrophic lateral sclerosis (ALS), based on molecule-specific toxicity findings and a superior profile of backup compound DNL788.\n",
      "In two phase Ib studies in Alzheimer's disease and ALS, and in an open-label extension study of ALS, DNL747 has been shown to be safe and well-tolerated at the dose tested with no significant treatment-related adverse events. But chronic toxicity studies with DNL747 in cynomolgus monkeys, conducted in parallel with clinical studies, have shown dose- and duration-dependent adverse preclinical findings at exposures higher than those tested in the clinic.\n",
      "In addition, data from the completed phase I study with DNL758, the backup compound to DNL747, in healthy volunteer subjects suggest an encouraging profile, as the molecule appears safe and tolerable at doses tested, added the Company.\n",
      "DNLI closed Tuesday's trading at $25.71, down 1.42%. In after-hours, the stock fell another 6.85% to $23.95.\n",
      "2. Fate Prices Offering\n",
      "Fate Therapeutics Inc. (FATE) has offered to sell 6.18 million shares of its common stock at a public offering price of $28.31 per share. The underwriters have a 30-day option to purchase up to an additional 927,234 shares of its common stock.\n",
      "The proceeds from this offering are expected to be approximately $164.2 million. The offering is expected to close on or about June 11, 2020.\n",
      "Subject to the completion of the offering, the Company also expects to sell to Johnson & Johnson Innovation-JJDC, Inc. in a private placement, 1.77 million shares of common stock for an aggregate purchase price of approximately $50.0 million.\n",
      "FATE closed Tuesday's trading at $32.72, up 15.58%.\n",
      "3. Immuron Soars On US DoD Naval Medical Research Center Collaboration Update\n",
      "Shares of Immuron Limited (IMRN) jumped as much as 1,280 percent in intraday trading on Tuesday, following an update on the Company's research collaboration with the U.S. Naval Medical Research Center that was inked last October.\n",
      "The research collaboration is intended to develop a new oral therapeutic targeting Campylobacter and enterotoxigenic E. coli (ETEC) to prevent acute infectious diarrhea.\n",
      "The Naval Medical Research Center plans to file an investigational new drug (IND) application for the new oral therapeutic later this year and commence two phase II clinical studies during the first half of 2021. One trial will focus on the ability of the drug candidate to protect volunteers against moderate to severe campylobacteriosis while the second trial will focus on ETEC infections.\n",
      "Immuron's flagship product is Travelan, a novel, over the counter (\"OTC\") product for the prevention of Travellers' diarrhea. For the third quarter of fiscal 2020, which ended on March 31, 2020, global sales of Travelan were A$983 thousand compared to A$616 thousand in the year-ago quarter.\n",
      "IMRN touched a new high of $28.99 in intraday trading on Tuesday, before closing the day at $20, up 809.09%. In after-hours, the stock fell 21.25% to $15.75.\n",
      "4. Inogen CEO To Retire Before End Of 2021\n",
      "Inogen Inc.'s (INGN) Chief Executive Officer and President Scott Wilkinson has announced his intention to retire before the end of 2021. Wilkinson will remain in his current position until a successor is appointed.\n",
      "The Company has begun the process to identify a successor for Wilkinson and intends to engage an executive search firm to support the search.\n",
      "INGN closed Tuesday's trading at $40.15, down 1.47%.\n",
      "5. Intersect ENT's Sinus Implant Approved For Reimbursement with New C-Code\n",
      "Intersect ENT Inc.'s (XENT) SINUVA Sinus Implant has been approved by the Centers for Medicare and Medicaid Services for transitional pass-through payment status for reimbursement with a new C-Code. The new Code 'C9122 Mometasone furoate sinus implant' is slated to take effect July 1, 2020, and the pass-through payment status will last for three years.\n",
      "According to the Company, the new C code will simplify the reimbursement process for ENT physicians and their practices, as well as provide Medicare patients easier access to this novel drug-eluting sinus implant.\n",
      "Thomas West, President & Chief Executive Officer of Intersect ENT, said, \" With over 70 percent of commercial lives already covered for SINUVA, this new C Code assignment further expands access to SINUVA in a very important patient population, Fee for Service Medicare, comprised of approximately 40 million additional lives.\"\n",
      "XENT closed Tuesday's trading at $14.53, up 14.5%.\n",
      "6. Stocks That Moved On No News\n",
      "Plus Therapeutics Inc. (PSTV) closed Tuesday's trading at $2.33, up 33.91%.\n",
      "Aptorum Group Limited (APM) closed Tuesday's trading at $4.71, up 34.57%.\n",
      "Enlivex Therapeutics Ltd. (ENLV) closed Tuesday's trading at $6.20, up 16.54%.\n",
      "Zynex Inc. (ZYXI) closed Tuesday's trading at $20, down 12.63%.\n",
      "Community Health Systems Inc. (CYH) closed Tuesday's trading at $3.65, down 11.19%.\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "REGENERON PHARMACEUTICALS INC (REGN) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 81% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: FAIL\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: FAIL\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "STAAR SURGICAL COMPANY (STAA) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It manufactures lenses used in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. As of December 29, 2017, the Company sold its products in over 75 countries, with distribution in the United States, Canada, Japan and Spain.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "USANA HEALTH SCIENCES, INC. (USNA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ORASURE TECHNOLOGIES, INC. (OSUR) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 73% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 490.91% vs. 188.07% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "HCA HEALTHCARE INC (HCA) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: HCA Healthcare, Inc., formerly HCA Holdings, Inc., is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. As of December 31, 2016, the American Group included 80 hospitals, which were located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. As of December 31, 2016, the Company operated six hospitals in England. The Company owns, manages or operates hospitals, freestanding surgery centers and freestanding emergency care facilities, walk-in clinics, diagnostic and imaging centers, among others.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "INMODE LTD (INMD) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ORASURE TECHNOLOGIES, INC. (OSUR) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 73% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 457.42% vs. 189.17% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: FAIL\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "FULGENT GENETICS INC (FLGT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: FAIL\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: FAIL\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "MASIMO CORPORATION (MASI) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 68% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 413.50% vs. 172.71% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, Inc (NASDAQ: ZYXI)\n",
      "Q4 2019 Earnings Call\n",
      "Feb 27, 2020, 4:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good afternoon, and welcome to the Zynex 2019 Q4 and Full Year Earnings Conference Call. [Operator Instructions]\n",
      "Certain statements in this release are forward looking, and as such, are subject to numerous risks and uncertainty. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31st, 2019, as well as forms 10-Q, 8-K and 8-K/A, press releases in the Company's website. Please note this event is being recorded.\n",
      "I would now like to turn the conference over to Thomas Sandgaard, Founder, Chairman, and Chief Executive Officer. Please go ahead, sir.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Good afternoon, my name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our fourth quarter and full year 2019earnings call I'm excited to announce another quarter of revenue growth and positive net income.\n",
      "Our fourth quarter revenue of $14.2 million, increased 52% compared to the same quarter last year, which was the highest quarterly growth rate of 2019. It was also the highest quarterly revenue in the history of the Company. It was our 14th straight quarter with positive net income, as we reported $0.09 per fully diluted share. Adjusted EBITDA for the fourth quarter was also an all-time high at $4.1 million, an increase of 30% compared to the fourth quarter of 2019.\n",
      "The investment in expanding our sales force continues to progress as we expand our geographic footprint across the U.S. We grew orders 129% year-over-year in the fourth quarter, and we continued to see strong reimbursement for our products. Orders grew consecutively 31% between the third and the fourth quarters, as a result of more of our sales force becoming productive. This order growth is a result of aggressively adding new sales reps to the sales force every month and the steep order growth is a continued sign of strong demand for our products, order growth momentum and the subsequent revenue growth, we expect to see from these orders in future periods.\n",
      "As you may know already, the revenue of an order is typically recognized many months or years after the order or the prescription, as patients continue to use our device and the related supplies for continued pain relief. The length of time the patient uses our device is primarily decided by the health insurance company, as well as if the patient reaches the point of no longer needing the device.\n",
      "In Q4, we sustained our aggressive sales force growth. Our 10-K will report 176 total sales reps that included 134 direct-Zynex only reps, but that number doesn't include new hires that have start date in 2020, due to end year holidays. As of today, we have well over 200 sales reps and through last week, we've added more than 42 direct reps this year, 16 in January and 24 alone in February, as we push hard to reach our goal of filling all 400 territories across United States.\n",
      "And another important achievement during 2019 was the improvement of our sales on boarding and training. Our investments have paid off and the average sales rep production during the first 90 days has more than doubled during 2019. We will continue to refine our training program, as it's critical for our reps to get off to a good and fast start. We also continued to improve on our efforts to provide warm leads for our newly trained reps, as soon as they are deployed. I should point out that our orders continue to grow at an accelerating rate and cash collection from insurance companies, they remained fairly constant and as monthly rentals and supplies are built [Phonetic] for many months and years after the prescription is received.\n",
      "So to put it into perspective and some of you that look at these things might want to take notes here. And so, if we try to follow order growth and revenue growth, orders grew between 21% and 27% in the second half of 2018 compared to the year before, while revenue only grew between 15% and 19%. Then in the first quarter of 2019, orders grew 28% and revenue grew 34%. So there was a little catch up from prior periods.\n",
      "In the second quarter of 2019, orders grew 65% as we have reported, while revenue grew 36% year-over-year. In the third quarter of 2019 orders grew 95%, while revenue now had increased up to a growth rate of 45%. In the fourth quarter last year, orders grew 129%, so more than double over the year before, while revenue slowly grew up to a growth rate of 52%. And for the first quarter of this year, right now we are two-third into the quarter, we are on pace to beat the fourth quarter year-over-year order growth, while we are estimating revenue growth at approximately 55%. I believe this gives a pretty good overview of how much lag days from prescriptions are received to revenue recognition.\n",
      "I'm very pleased to see our gross profit margin remain at the 81% level for 2019, an indication that the industry for prescription strength electrotherapy is still not only stable but very healthy and viable. The opioid epidemic continues to be a serious issue in this country, and we are increasingly working to get patients off opioids and for physicians to use our prescription strength technology as the first line of defense when treating pain. Currently, the devastating impact of the opioid crisis has reached a level where tens of thousands die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects.\n",
      "Our products for pain management and rehabilitation still standout as some of the best in the industry. The NexWave for pain management, our new move device for stroke rehabilitation and the InWave for incontinence treatment, those products put us in a very strong product position in the rehabilitation markets. We continued to see great potential in both of our product divisions. Our existing revenue generating area for pain management, as well as the huge unmet potential for Blood Volume Monitor.\n",
      "As most of you probably already know, we managed to get FDA clearance for our CM-1500 Blood and Fluid Monitor, a few days ago. The CM-1500 is a noninvasive monitor intended to monitor patients fluid balance in hospitals and surgical centers. We expect to initially target ORs and surgeries that typically display substantial blood loss, as well as recovery rooms and ICUs were internal bleedings today are common and difficult to take -- to detect until serious complications occur. We believe this product will lead to safer surgeries, fewer complications and less mortality, one of the biggest unmet needs in hospitals today.\n",
      "Until now, our effort has primarily been in -- on engineering, regulatory and clinical research. The product works well. We have so far produced three dozen of these devices, we get all the packaging, production procedures and everything ready to go for a market launch. And we will initially focus on developing key opinion leaders of KOLs in the medical hospital and research communities, building an organization of business development people, marketing will be increasing the clinical research and also expand our production capabilities for this product line.\n",
      "Even though this is a very different call point then our pain management business, and therefore a separate business unit, we will initially be able to leverage and take advantage of the synergies from our well-established production lines, Human Resources, quality control, etc.\n",
      "I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First, I'll review our 2019 fourth quarter results. Orders grew 129% year-over-year, which drove net revenue up 52% to $14.2 million from $9.3 million in 2018. Device revenue increased 117% to $3.8 million compared to $1.8 million last year. Supplies revenue increased 37% year-over-year to $10.4 million from $7.6 million.\n",
      "Gross margins were 80% in the fourth quarter of 2019 and 2018. Beginning in 2019, we began breaking out sales and marketing expense from G&A. This breakout provides greater clarity related to our sales growth initiative and the overall financial statement impact. Sales and marketing expenses increased a 110% year-over-year, as we continued to grow our sales force. G&A expense grew 25% year-over-year. Much of the increase was related to the increased headcount in our billing and patient support functions related to our order growth.\n",
      "Fourth quarter net income was $2.9 million or $0.09 per diluted share compared to net income of $2.6 million or $0.08 per diluted share in the fourth quarter last year. Adjusted EBITDA, which is a standard EBITDA calculation, plus an exclusion of non-cash stock-based compensation and other income and expense, and is reconciled in our press release, increased 30% to $4.1 million in the fourth quarter of 2019. We have increased income tax expense year-over-year due to our profitability over the last two years, which utilize our net operating losses and put us in a taxable position.\n",
      "Now on to the full-year results. Orders grew 83% year-over-year, which drove net revenue up 42% to $45.5 million from $31.9 million in 2018. Device revenue increased 57% to $10.7 million, compared to $6.8 million last year. Supplies revenue increased 39% year-over-year to $34.8 million from $25.1 million. Gross margins were 81% for the years 2019 and 2018.\n",
      "2019 net income was $9.5 million or $0.28 per diluted share, compared to net income of $9.6 million last year. 2019 net income was impacted by an additional $1.8 million in tax expense as we utilized our NOLs during 2018. Adjusted EBITDA was $12.1 million, up 11% from $10.9 million last year. We generated operating cash flows during 2019 of $6.3 million compared to $9.4 million in 2018. Cash flows were affected by increased tax expense in 2019 and growth in inventory and receivables.\n",
      "On the balance sheet, as of December 31, 2019, our cash balance was $14 million, up from $10.1 million at year-end and net of the $2.3 million dividend which was paid in the first quarter. Our working capital grew 137% to $17.4 million at year-end compared to $7.3 million as of December 31, 2018.\n",
      "With that, I'll now turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you, Dan. I'm especially excited about our year-over-year growth in orders of 129% and our revenue growth of 52%. It's a huge testament to efforts to grow our sales force and clearly justifies the investments in our sales personnel, sales management and inside support functions. Our focus continues to be growing our sales force at a rapid rate in geographic areas, which we don't currently cover to take advantage of the void left in the market by two previous very large competitors.\n",
      "Our increased orders due to a larger sales force, combined with strong reimbursement for our products, continues to drive increased revenue and profitability. We estimate our first quarter revenue to come in between $14 million and $14.5 million with adjusted EBITDA between $2.3 million and $2.8 million. As a reminder, first quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year. And for the full year of 2020, we estimate revenue between $75 million and $80 million, and adjusted EBITDA in the range of $15 million to $18 million.\n",
      "As a reminder, nearly all of our collections from billing comes from insurance companies, mostly private insurers but also government, auto insurances, workers' comp and personal injury attorneys. Payments from those are either dictated by contractual amounts we have established, allowable amounts already well established throughout our industry and negotiated amounts sometimes on a patient-by-patient basis. These amounts are typically discounted by deductible and copay deductions, and we end up getting much less than our MSRP as is typical through the healthcare industry in the U.S. This pattern is the same whether we get paid for the device or whether we get paid for the patient supplies.\n",
      "We are careful to make sure our billing practices are always within the law and comply with our guidelines and regulations. We also undergo regular accreditation by a third party to ensure that we continue to be compliant. My long-term goal for our electrotherapy and rehab division is to continue to grow our share of the huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing our domestic sales force as well as potential acquisitions of complementary technologies.\n",
      "The latest news as you've heard is that the FDA just now decided to clear our CM1500 non-invasive blood volume monitor for sale in the U.S. We have already obtained patent protection in both the U.S. and Europe. And while we have obtained FDA clearance in the U.S., we are still working with the European notified body to obtain CE Marking. We will continue to update everyone as we are building out this division.\n",
      "In summary, we announced yet another great quarter with strong growth in orders, growth in revenue and profit, which puts us in a very strong position going forward. We will now answer questions from our listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "Thank you. We will now begin the question-and-answer session. [Operator Instructions] And the first question today will come from Yi Chen with H.C. Wainwright. Please go ahead.\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "Hi, this is Boobalan calling in for Yi Chen, and congratulations on the strong quarter. So I wanted to talk a little bit about the NexWave. So how many sales reps have been -- have you guys added so far in 1Q '20 for the marketing needs of NexWave? And how many additional reps are expected to add during the rest of the year?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We -- yeah, this is Thomas. We have added 40 reps so far, 16 in January, 24 in February, and we're looking to increase that number substantially in March. And before the end of the year we expect to be up to a full coverage of 400 sales reps.\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "For the blood volume monitor, how large of a sales force do you consider to launch?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. Technically, you could say that we have already launched now, we have the ability to sell. I expect that we will start adding some business development people that can start working with key opinion leaders and potentially also start selling direct to some hospitals say initially, but that's something that's probably going to develop slowly. But it's happening separate from our existing sales force and separate from the rest of the organization. We are working -- already looking for additional space just for that separate division.\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "And what is the estimated timeframe for the launch of blood volume monitor and how many hospitals would you like to target in the initial phase?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, we don't have a specific number of hospitals there. We will be targeting write-off [Phonetic]. We still have a month or two, I believe, of getting settled with the whole sales and marketing and business development of that division.\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "And with regards to the price level, what's the approximate price level? And maybe you can talk about the gross margin of the device? And then how many units, would you like to -- or do you expect to deliver in 2020?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We don't have a number on how many units we expect to deliver, but we expect the MSRP to be $30,000 or right around that level, both in the U.S. and later more or less the same price level in Europe. There is going to be an element of consumables that go with the product, and we are still to settle on the pricing of those. But they'll obviously -- the consumables will add to the revenue stream, as well long-term.\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "Okay. That's it from me, and congrats again.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you very much.\n",
      "Operator\n",
      "Your next question comes from Jeffrey Cohen with Ladenburg Thalmann. Please go ahead.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Hi. Thomas and Dan, how are you?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "We're doing great. How are you doing Jeff?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Awesome. Okay. Just a couple of questions. Firstly on BVM can you talk a little bit about your physical facility there were four floors? How many floors may be added and how many square feet? It sounds like you're going to do all the assembles there in front and manufacturing. And could you talk about, perhaps from Dan's side, how you're planning on reporting it out for [Indecipherable] 10%, will you be reporting it separately or not?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Once we get to that level, we'll definitely report it separately. Obviously, initially, it's going to be less than that. So when it becomes material, it will be a segment that we we report.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "And we're looking for somewhere between 10,000 and 20,000 square feet initially for that group. But in a setup, where we can be pretty agile in terms of growing out this base. We obviously have a pretty good experience with building these devices. It's not that different from building our NexWave and NeuroMove and InWave devices. And that shouldn't be that -- so the production won't be the bottom line. [Speech Overlap]\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Will it be in your same building or same campus?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We hope to keep things in the same campus. It's a good question. Obviously, the production part of it can stay here in the -- at least initially, in the same building.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And then, big picture what you're talking about on guidance Q1 and the year, I mean, that's pretty dramatic and significant growth write off of what we're currently forecasting. So based on the continued trajectory as far as the orders and the revenue, I would assume that you would expect those rates to continue to move north on arguably both sides, both orders and revenues? Is that right?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. Obviously, in the first part of this year, we are two months into it, unless the bottom falls out of March, which obviously with the increase in sales reps and how productive new reps from last year are quickly becoming -- we have an expectation of growing even faster in the first quarter than we did in the fourth quarter. Yeah.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And then as far as the numbers you threw out on the guidance side on the EBITDA side, the $2.3 million and $2.8 million of the $14 million to $14.5 million for Q1 and the $15 million to $18 million of the $75 million to $80 million for the year. Your 2019 EBITDA of $12.1 million of the $45.47 million, 26% so -- as we are showing is $17.5 million for the first quarter and then $21.2 million. Could you talk about maybe the $26 million going to $22 million as far as, where that money is being spent. Is it more on -- is it more on personnel or is it more equipment in equipment or is just the dramatic increases for our sales organization?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Obviously, personnel -- we will have to keep increasing our personnel to just keep up with the orders and processing them to get paid. And then there all the support functions that needs to grow with the increase in personnel. But dollar wise for the next quarter or two from here, we will definitely see a steep increase in the sales expenses, the base salaries and obviously the commissions -- sales commissions, as orders continue to grow. So that's where you're going to see the most. We hope at all times to keep the G&A portion of the expenses below the -- well below the top line growth. But for short while we'll still see the growth in sales expenses to be higher than the revenue growth. We got a -- we are investing in the sales force, basically.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And then, remind us of now or current total FTEs and square footage on your facility, all the floors, all four.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "I believe we have 85,000 square feet or 86,000 square feet by now.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Correct. We have -- in the building, we have 160 employees, somewhere in that range.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And that's about what percent of total?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "We are just taking -- say that again.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "What's the total employees?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Well, you just have to add the sales on top of that. So out of 300...\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Perfect.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Yeah, 330 it's something like that. Yeah, that is.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Okay. And then, Thomas, you talked about in the past previous terms when you've talked about this BVM with me. So how do we think about this? There is 4000, 5000, 6000 hospitals of which units could be highly utilized in a number of departments.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Right. So, ideally, I would like to -- eventually, have sold up to about 20 of our devices to an average hospital or surgical center. And that -- if that all comes true and it all had a $30,000 price point. We're obviously talking about $3 billion. That's -- that would be an ideal scenario. We'll see how it works out\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Excellent. Thanks for taking the questions.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah, thanks, Jeff.\n",
      "Operator\n",
      "And our next question comes from Marc Wiesenberger with B.Riley FBR. Please go ahead.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Yeah. Thank you. I dialed in a little late. So I apologize if maybe you addressed any of this in your remarks. But how many new territories did you expand into in the fourth quarter? And then maybe how many new territory you're looking to expand into for the full year 2020?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah the 2020 question is obviously, pretty easy because we have a little less than 200 open territories right now. And so that's what we expect to expand into between now and the end of the year. In the fourth quarter, we had a -- quite a mix -- quite a few additions, but we also had quite a bit of clean up in our sales force in the month of December. That's why we -- on the payroll a little below 200 at year-end. But right now, we got about 200, because we added 40 sales reps in January and February, 16 in January, 24 in February, and it looks like we're behind -- will more than that in March.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Understood. Can you provide some updates on the productivity of new reps on an absolute basis and maybe relative to the cohorts kind of from the fourth quarter in 2018 and the first quarter in 2019. Kind of, how quickly are they getting their first orders, how long to breakeven that kind of thing?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. If you look at our gross profit margins and the base salaries of close to $50,000 a year, and the commission rates -- we breakeven on a rep when they exceed three or four orders. So that's pretty good, because -- all because of the high gross profit margins. Excuse me. Then if you look at how well our training is playing out right now, we are well over double in the first 90 days of new reps order production compared to as you said a year ago. So things are getting better in terms of the better productivity and that also speaks for that. We should have less retention in our new sales force going forward compared to what we had last year.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Sure. As you're scaling the business, can you talk about some of the initiatives that you put in place with regards to maybe automating some more processes to help scale up and quantify either the time or the monetary benefit you're getting from that?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Well, we have so many initiatives going on all the time. But one of them a while back was that Mike have mentioned, new files would take us with -- our billing system would take us up to 20 minutes to get set up correctly in the system after order entry and all that, and eventually be able to build an insurance company after we ship the device. We've automated that and in a manner, where it's just a matter of seconds now after everything is -- all the boxes are checked etc. So if you can imagine that we are -- we will -- it won't be long before we will be smelling 10,000 orders a month and what kind of bottleneck that would be, if we were to take 20 minutes on the average order before we could even bill it and the amount of people that would take to process. So that's a significant improvement.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Understood. With the growth that you're seeing, is there a reason that you are not deploying capital at a faster rate to capture additional business? I mean, would you consider maybe taking on some debt to add leverage and fuel the growth even further? Or kind of how should we think about your kind of capital allocation strategy for supercharging?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Yeah. Because of how cash flow positive we are, we can grow faster by adding more cash. We have 14 -- or at the end of last year, we have $14 million in the bank and continued to grow our cash balance at that rate or better I should say, because we don't have those items that are non-operational such as dividends and stock buybacks, etc.\n",
      "So, even at a right where we are growing as fast as we possibly can, we still keep adding to our cash balance. So, I would say, unless we run into an acquisition where we would need more money than -- would be healthy for our cash balance or for the new division will be expenses that would tap unreasonably into that cash balance, then we could potentially get it. But it's -- there's absolutely no urgency in raising money here, on the contrary.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Okay. Can you talk about progress that reps are making selling additional products beyond the NexWave?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "We carry products from other manufacturers. Cervical traction is one of them, low-back support device is another one, cold therapy that's primarily used after orthopedic surgery, products like that. And we've begun promoting those products a little bit here recently and have seen a good response from the clinics that our sales force service in terms of that. So, we're getting a little of diversification on that end. And that's obviously helpful from a strategic point of view.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Do you expect that to kind of accelerate throughout the year or kind of stay status quo or?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "I would peg a point in between. Not necessarily accelerate, but continue to be -- we will continue to see more and more of it, yes.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Okay. Understood. Have you changed anything with the amount of consumables being shipped to patients? And maybe can you remind us the quantity the average patient receives on a monthly basis and kind of how that flexes up and down?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "It is so individual by patient, by insurance company. Even within the same insurance company, they tend to approve a different quantities of supplies and all that. So, I couldn't really give you a number on that. But obviously, we report supplies and devices separately. As you've noticed, there is a little bit of a bump in in device revenue in the last quarter here that was because of we saw a significant increase in orders, and that's obviously where you would see more device revenue as the supplies revenue will be coming in the following months and years after that.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Sure. And one...\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Depending on insurance coverage.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Understood. And one final one for me. Thomas, you've been at this from a while, maybe could you just share what you learned from your competitors exiting the market? And maybe more importantly, what specific things have you put in place to prevent what happened from them to happening from Zynex?\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Number one is, obviously, we try to, at all times, stay ahead of issues that our compliance-related and also our quality systems -- we try to stay ahead of the game. So that's definitely one. And then, I would say that we could see compared to the kind of financial performance they -- those competitors show, that our investments in high-quality, smart and with good negotiating skills employees throughout the organization, but it's primarily something that has benefited our billing part of the organization, has really paid off well.\n",
      "Good quality employees gone a long way in. I believe we're also smarter than maybe we have seen other companies in the industry when it comes to negotiating contracts etc., with insurance companies. So it's really an overall saying that makes all these click, but our improved financial performance really started five years ago when we started putting an emphasis on hiring better quality employees, and it's really paying off. I'd say that 99% the reason why we're doing so well today is good quality employees.\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "Great. Thank you very much.\n",
      "Operator\n",
      "Ladies and gentlemen, this concludes our question-and-answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Thank you. I hope today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening into this call. Thank you all, and have a great day.\n",
      "Operator\n",
      "[Operator Closing Remarks]\n",
      "Duration: 36 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Chairman of the Board, President and Chief Executive Officer\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Boobalan P. -- H.C. Wainwright -- Analyst\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Analyst\n",
      "Marc Wiesenberger -- B.Riley FBR -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks\n",
      "*Stock Advisor returns as of December 1, 2019\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "CORCEPT THERAPEUTICS INCORPORATED (CORT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: FAIL\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "CRISPR THERAPEUTICS AG (CRSP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: FAIL\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 625.78% vs. 240.03% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "LEMAITRE VASCULAR INC (LMAT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 80% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: PASS\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS\n",
      "INSIDER HOLDINGS: FAIL\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: FAIL\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "BIOLIFE SOLUTIONS INC (BLFS) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: NEUTRAL\n",
      "CASH AND CASH EQUIVALENTS: PASS\n",
      "INVENTORY TO SALES: PASS\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): FAIL\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: PASS\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: FAIL\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "PROFIT MARGIN: PASS\n",
      "RELATIVE STRENGTH: FAIL\n",
      "COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL\n",
      "INSIDER HOLDINGS: PASS\n",
      "CASH FLOW FROM OPERATIONS: PASS\n",
      "PROFIT MARGIN CONSISTENCY: PASS\n",
      "R&D AS A PERCENTAGE OF SALES: PASS\n",
      "CASH AND CASH EQUIVALENTS: FAIL\n",
      "ACCOUNTS RECEIVABLE TO SALES: PASS\n",
      "LONG TERM DEBT/EQUITY RATIO: PASS\n",
      "\"THE FOOL RATIO\" (P/E TO GROWTH): PASS\n",
      "AVERAGE SHARES OUTSTANDING: PASS\n",
      "SALES: FAIL\n",
      "DAILY DOLLAR VOLUME: PASS\n",
      "PRICE: PASS\n",
      "INCOME TAX PERCENTAGE: PASS\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 639.27% vs. 234.94% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.\n",
      "ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ADVERUM BIOTECHNOLOGIES INC (ADVM) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "ANIKA THERAPEUTICS INC (ANIK) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "CORVEL CORPORATION (CRVL) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Motley Fool is 69% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.\n",
      "Company Description: CorVel Corporation (Corvel) is a provider of workers' compensation solutions for employers, third party administrators, insurance companies and government agencies. The Company offers its services as a bundled solution, which includes claims management, as a standalone service, or as add-on services to existing customers. The Company offers its services as a bundled solution, which includes claims management, as a standalone service, or as add-on services to existing customers. The Company's network solutions include bill review, preferred provider organization (PPO) management, professional review, provider reimbursement, pharmacy services, directed care services, medicare solutions and clearinghouse services. The Company's patient management services include claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, life care planning, disability management, liability claims management and auto claims management.\n",
      "The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.\n",
      "For a full detailed analysis using NASDAQ's Guru Analysis tool, click here\n",
      "Since its inception, Validea's strategy based on Motley Fool has returned 576.57% vs. 218.76% for the S&P 500. For more details on this strategy, click here\n",
      "About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' \"Fool\" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.\n",
      "About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here\n",
      "\n",
      "(RTTNews) - The following are some of today's top gainers in the healthcare sector.\n",
      "1. Sorrento Therapeutics Inc. (SRNE)\n",
      "Sorrento is a clinical-stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases.\n",
      "Gained 94.37% to close Monday's (Nov.25) trading at $3.11.\n",
      "News: The Company received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of its issued and outstanding shares for between $3.00 and $5.00 per share in cash.\n",
      "However, Sorrento's Board of Directors has unanimously rejected the proposal.\n",
      "2. RAPT Therapeutics Inc. (RAPT)\n",
      "RAPT is a clinical-stage immunology-based biopharmaceutical company focusing on oncology and inflammatory diseases.\n",
      "Gained 44.25% to close Monday's trading at $29.47.\n",
      "News: No news\n",
      "Recent event:\n",
      "The Company went public on the Nasdaq Global Market on October 31, 2019, offering its shares at a price of $12 each.\n",
      "Clinical Trials & Near-term Catalyst:\n",
      "-- A phase I/II trial of FLX475 as a monotherapy, and in combination with Merck's Keytruda in patients with \"charged\" tumors is ongoing, with results from the phase II portion of the trial expected in the first half of 2020. -- A phase 1 clinical trial for RPT193 for the treatment of atopic dermatitis is underway. Results from the phase Ib portion of the study are expected by mid-2020.\n",
      "3. The Medicines Company (MDCO)\n",
      "The Medicines Company is a biopharmaceutical company with a main focus on addressing cardiovascular disease. The lead drug candidate is Inclisiran, a cholesterol-lowering therapy.\n",
      "Gained 22.25% to close Monday's trading at $83.80.\n",
      "News: The Medicines Company is all set to be acquired by Novartis AG for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion.\n",
      "Completion of the transaction is expected in the first quarter of 2020, pending the successful completion of the tender offer and other customary closing conditions. Until that time, The Medicines Company will continue to operate as a separate and independent company. The company expects to file regulatory submissions for Inclisiran in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.\n",
      "4. Neoleukin Therapeutics Inc. (NLTX)\n",
      "Neoleukin is a biopharmaceutical company creating next-generation immunotherapies using de novo protein design technology. The Company is the result of the reverse merger between Aquinox Pharmaceuticals and Neoleukin Therapeutics.\n",
      "Gained 22.19% to close Monday's trading at $4.24.\n",
      "News: No news\n",
      "Cash position:\n",
      "As of September 30, 2019, the Company had cash of $66.3 million.\n",
      "5. Zynex Inc. (ZYXI)\n",
      "Zynex is a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring, and neurological diagnostics.\n",
      "Gained 20.18% to close Monday's trading at $10.72.\n",
      "News: No news\n",
      "Recent event:\n",
      "On October 29, 2019, the Company reported financial results for its third quarter ended September 30, 2019.\n",
      "Net income for the third quarter of 2019 was $2.03 million or $0.06 per share on revenue of $11.8 million. This compared with a net income of $2.59 million or $0.08 per share and revenue of $8.13 million in the year-ago quarter.\n",
      "Looking ahead, the Company expects fourth quarter 2019 revenue to range between $12.3 and $12.8 million. Revenue in the fourth quarter of 2018 was $9.3 million.\n",
      "6. Arrowhead Pharmaceuticals Inc. (ARWR)\n",
      "Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. The Company generates revenue from licensing and collaboration agreements.\n",
      "Gained 15.83% to close Monday's trading at $56.99.\n",
      "Clinical Trials & Near-term Catalysts:\n",
      "-- A phase II/III trial of ARO-AAT, a second-generation subcutaneously administered RNAi therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin (AAT) deficiency, dubbed SEQUOIA, is underway. -- A pilot open-label, multi-dose, phase II study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease is also ongoing. -- A phase I single and multiple-dose study of ARO-APOC3, a subcutaneously administered RNAi therapeutic, being developed as a potential treatment for patients with hypertriglyceridemia is underway. -- A phase I single and multiple-dose study of ARO-ANG3, a subcutaneously administered RNAi therapeutic, being developed as a potential treatment for patients with dyslipidemias and metabolic diseases is ongoing. -- A phase I/II study of JNJ-3989 (formerly ARO-HBV), being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection is underway.\n",
      "\n",
      "(RTTNews) - Shares of Zynex Inc. (ZYXI) which touched an all-time intraday high of $13.10 on October 7, 2019, a gain of a whopping 345 percent year-to-date, have given back some of the gains and trade around $10.\n",
      "Zynex is a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring, and neurological diagnostics.\n",
      "The Company operates under three subsidiaries - Zynex Medical, a provider of electrotherapy pain management devices \"TENS\"; Zynex Monitoring Solutions, which has developed a blood volume monitoring device, and is awaiting FDA approval and CE Marking in Europe; and Zynex NeuroDiagnostics, a developer of devices for EMG and EEG diagnostic purposes in the neurology clinic markets.\n",
      "The Zynex Medical segment accounts for 90% of historical revenue and Zynex NeuroDiagnostics unit contributes less than 2% of the revenue.\n",
      "The Company has improved its bottom line over the years while significantly growing its revenue, as can be seen from the numbers.\n",
      "In the first half of 2019, the Company reported a net income of $4.51 million on revenue of $19.49 million.\n",
      "For the third quarter, the Company expects revenue to be between $10.7 and $11.2 million, which is approximately 32% to 38% above last year's third-quarter revenue of $8.1 million.\n",
      "Zynex is slated to report 2019 third-quarter financial results on Tuesday, October 29, 2019.\n",
      "With 12 consecutive profitable quarters and with long-term objectives like increasing its national footprint, growing recurring revenue streams and driving value through organic growth and strategic acquisitions, Zynex is a stock worth keeping an eye on.\n",
      "Zynex transitioned from being a privately held company to a publicly held company in February 2004, following a reverse acquisition, and its shares were listed on the OTCQB under ticker ZYXI. The stock was uplisted to the Nasdaq Capital Market on February 12, 2019.\n",
      "ZYXI has traded in a range of $2.58 to $13.10 in the last 1 year. The stock closed Monday's trading at $10.88, up 3.82%.\n",
      "\n",
      "Wall Street went through a minor panic attack on Wednesday, with investors sending major indexes down roughly 2% to add to Tuesday's losses. Some more poor economic data signaled that the U.S. economy might finally be faltering after a long bull run, and that has market participants trying to anticipate the end of the 10-year-old bull market. Even with the downward pressure, though, some stocks defied the odds and gained ground. Stars Group (NASDAQ: TSG), Sibanye-Stillwater (NYSE: SBGL), and Zynex (NASDAQ: ZYXI) were among the top performers. Here's why they did so well.\n",
      "Flutter bets big on Stars Group\n",
      "Shares of Stars Group jumped 30% after the sports betting company got a merger offer from one of its largest peers. Flutter Entertainment, which operates a similar business in the U.K. that includes the once-dominant Party Poker website, offered to combine with Stars Group in a deal that would create the biggest global player in the industry. The $6 billion merger would give Stars Group investors 0.2253 shares of Flutter in exchange for their stock. Flutter's share price also climbed, and many gambling industry watchers believe that further consolidation is not only likely but necessary.\n",
      "Image source: Getty Images.\n",
      "Sibanye-Stillwater shines thanks to precious metals gains\n",
      "Sibanye-Stillwater stock picked up 7% on a good day for the precious metals markets. The mining company benefited from the $25-per-ounce rise in gold prices to move above the $1,500 level. However, it also got a nice boost from a $32-per-ounce jump in palladium to record levels around $1,670. Sibanye-Stillwater has operational challenges in making the most of its mining opportunities. Yet the uncertainty in the stock market has some investors looking to gold and other precious metals as a safe haven, and that could help the company's prospects in the immediate future.\n",
      "Zynex sees huge order growth\n",
      "Finally, shares of Zynex climbed 11%. The medical technology company said that it saw 95% order growth in the third quarter of 2019 compared to the year-ago period. Zynex's non-invasive medical devices for treating pain management, cardiac monitoring, and various other functions saw order counts jump 30% just from three months ago. CEO Thomas Sandgaard attributed the rise to the company's expansion of its sales force that it's been implementing for a while now, and it's positioning its NexWave pain treatment device as a superior alternative to opioids. If customers keep finding that argument compelling, it could keep driving Zynex higher.\n",
      "Offer from The Motley Fool: The 10 best stocks to buy now\n",
      "Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor, has quadrupled the S&P 500!*\n",
      "Tom and David just revealed their ten top stock picks for investors to buy right now.\n",
      "Click here to get access to the full list!\n",
      "*Stock Advisor returns as of June 1, 2019.\n",
      "Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Last week, President Donald Trump ordered United States companies to move their China-based operations elsewhere. The news sent the S&P 500 down by more than 2.5% in a single day of trading. The decline provided investors with some cheap stocks to buy. But which ones?\n",
      "A quick scan of stocks with market caps of $300 million or more that were down more than 10% over the past week brings up a total of options, the largest being Dow (NYSE:DOW) at $31.3 billion and the smallest being Zynex (NASDAQ:) at $300.9 million. In terms of sectors that were down, healthcare saw the most carnage with 36 stocks losing more than 10% last week, followed closely by basic materials at 35 and services at 21.\n",
      "Of the 123 stocks that lost more than 10% last week, 95 were small-caps with a market cap between $300 million and $2 billion; 24 were mid-caps between $2 billion and $10 billion, and just four had a market cap of more than $10 billion. Ive recommended two of them in my group of seven cheap stocks to buy down more than 10% last week. Stocks to Buy: Dow (DOW)\n",
      "Source: JHVEPhoto / Shutterstock.com\n",
      "Over the past five days of trading through August 26, Dow stock lost .\n",
      "Dows stock has been under pressure due to in a less than a month from Bank of America Merrill Lynch. The analysts expect lower demand of the companys chemical products to hurt future earnings. On July 26, Bank of America Merrill Lynch Dows rating from buy to neutral suggesting its chemicals business was stuck in the mud with not much optimism for growth in the near term. This came one day after releasing second-quarter 2019 results that included a 14% decline in sales to $11.0 billion, a 3% decline in volumes and a 35% drop in operating earnings before interest and taxes to $1.1 billion. In spite of challenging market conditions, our results reflect the benefits of Dows streamlined and more focused portfolio, continued cost synergy savings and stranded cost removal. In the quarter, we faced margin compression in our intermediate products in both our core business and equity earnings, CEO Jim Fitterling. Then on Aug. 16, Bank of America Merrill Lynch downgraded DOW stock a second time to underperform from neutral. We do continue to hold a favorable relative view on the long-term supply for caustic soda over polyethylene, but see these commodities driven in the near-term by sluggish demand, the firm in a note to clients.\n",
      "Dow stock currently yields 6.8%. Get paid a quarter to wait for these commodities to recover. Suzano (SUZ)\n",
      "Source: Shutterstock\n",
      "Over the five days of trading through Aug. 26, Suzano (NYSE:) stock lost 13.6%. What is Suzano? Its a Brazilian company that uses renewable resources to manufacture pulp and paper made from planted specifically for this purpose. It is the first pulp and paper producer in Brazil to use eucalyptus pulp in its products.\n",
      "Started in by Leon Feffer, the company originally was a reseller of domestic and imported paper for business cards, writing pads, etc. In 1930, it bought its first machine and began making its own paper. The rest is history. The Feffer family and related parties own approximately 46% of the companys shares. David Ferrer is currently the companys chairman of the board. It has 13 million hectares of tree plantations, the equivalent of 200 times the size of Manhattan. It has approximately a share of the Brazilian paper market with more than 35,000 clients. Suzano is by far the biggest pulp producer in Brazil with more than 10.9 million tons capacity in 2018. Over the past four years, its lowered its cash cost by 12% from $171 per ton to $150 per ton. In April, Suzano completed its acquisition of Brazilian rival Fibria Celulose to become the worlds largest cellulose producer. Why is Suzanos stock down?\n",
      "In the first half of 2019, there was a significant imbalance between pulp supply and demand leading to lower pulp prices. As a result, Suzanos net revenues in the second quarter fell by over last year while its cash cost per ton increased by 11% reducing the divisions profitability. Suzanos paper business did much better in the second quarter with net revenues 15% higher and its adjusted earnings before interest, taxes, debt and amortization 45% higher. This compares to a 28% decline in adjusted EBITDA for its pulp segment. Long term, I like the companys prospects, but it first has to get through the current pricing weakness in the industry due to . Elanco Animal Health (ELAN)\n",
      "Source: Shutterstock\n",
      "Over the five days of trading through Aug. 26, Elanco Animal Health (NYSE:) stock lost 13.2%.\n",
      "The cause of last weeks decline in Elancos stock price had everything to do with the companys announcement that it would pay to buy Bayers (OTCMKTS:BAYRY) animal health unit. Elanco is paying $5.32 billion in cash and issuing approximately 68 million shares of its stock. As a result of the deal, which will double the size of Elancos companion animal business, the companys debt will increase to five times its adjusted EBITDA. Not only that, but Elancos share count will increase by 18%, seriously diluting existing shareholders. As a result of the additional debt, S&P and Fitch d that the deal could result in a credit rating downgrade from the rating agencies. Analysts believe that Bayer got top dollar for its animal health assets. While Elanco does plan to reduce its debt to adjusted EBITDA ratio to a multiple of three from five currently, the markets believe it might have overpaid for the assets. The merged company will be the second-largest animal health business in the world behind Zoetis (NYSE:). Although there is some question about Elancos future growth, opportunities to buy quality assets like these dont come around every day. Long term, this deal should turn out to be a good one for Elanco shareholders. L Brands (LB)\n",
      "Source: JHVEPhoto / Shutterstock.com\n",
      "Over the five days of trading through Aug. 26, L Brands (NYSE:) stock lost 15.0%.\n",
      "As if things werent going poorly enough for the owner of Victorias Secret and Bath & Body Works, then-CEO and founder Les Wexner got his name all tangled up with the late financier , who pretended to be a talent scout for the lingerie retailer. Worth several billion dollars, investors started to wonder if the man who trusted such a sinister person with some of his finances could be trusted to turn around a struggling Victorias Secret. Now, the company has been hit with a financial class-action suit that the company and its executives, including Wexner, made misleading statements about its finances and ability to pay a high dividend despite an ongoing deterioration of its top and bottom line. Essentially, the suit claims that Wexner and company were way too optimistic about the businesss overall financial condition in order to keep the stock price as high as possible. However, the worst blow to LB stock came Aug. 22 when it reported poor second-quarter 2019 sales that pushed L Brands stock to levels not seen since December 2009. Thats a trifecta of doom that no stock can overcome. L Brands still believes Victorias Secret problems are product related, but we believe they are brand and competition related which means these problems are difficult to fix, Jefferies analyst Randal Konik in a note to clients. Bath & Body Works comps are slowing and margins are compressing which means the biz has peaked.\n",
      "If not for the success of Bath & Body Works in the past two or three years, L Brands stock would likely be in single digits. Now that Bath & Body Works growth is slowing somewhat, the only investors who should consider investing are aggressive investors willing to accept a ton of risk. As a contrarian bet, I like it. After all, when investors get fearful, its time to get greedy. Madison Square Garden (MSG)\n",
      "Source: Shutterstock\n",
      "Over the five days of trading through Aug. 26, Madison Square Garden (NYSE:) stock lost 13.9%.\n",
      "The company that owns the New York Knicks and Rangers as well as the iconic Madison Square Garden among its many assets, announced Q4 2019 earnings Aug. 21 that was much worse than expected. The consensus estimate for the fourth quarter was a loss of a share with revenue of $270.1 million. MSG actually delivered a loss of $3.08, 57 cents worse than expected, and revenue of $263.6 million; a miss on both the top and bottom line. The biggest investor concern seems to be the companys spherical entertainment venue that its building in Las Vegas. At the same time it announced earnings, company president Andrew Lustgarten let investors know that the project would cost between and $1.7 billion by the time its completed. MSG Sphere, a partnership between the company and Las Vegas Sands (NYSE:), is a state-of-the-art 18,000-seat arena thats expected to open in 2021. Unfortunately, investors see the T-Mobile (NASDAQ:) Arena just down the road that was built for $375 million in 2016, and cant help but think its nothing but CEO and controlling shareholder James Dolans ego project. While it might be Dolans ego driving the project in Vegas, Im sure the venue will become just as highly visited as the rest of MSG properties. Down 15% over the past year, the poor optics of MSG Sphere make the current correction a perfect time to buy MSG stock. CrowdStrike (CRWD)\n",
      "Source: Piotr Swat / Shutterstock.com\n",
      "Over the five days of trading through Aug. 26, CrowdStrike (NASDAQ:) stock lost 10.6%.\n",
      "The California-based cybersecurity company has only been a public company for a little over two months selling its stock to the public June 11 at $34 a share. On its first day of trading, it gained ; its up 161.4% through August 27, making it one of the more successful IPOs in 2019, tech or otherwise. CrowdStrike delivers its second quarterly report as a public company on . If Q2 2020 results are as good as the results in its first quarter, investors can rest easy. On July 19, CrowdStrike reported Q1 2020 revenue of , $500,000 higher than the consensus estimate while its loss per share was 47 cents, on par with the analyst estimate. In the second quarter, CrowdStrike expects a loss of between 23 and 24 cents with revenue of at least $103 million. For all of 2020, it expects a loss of 70 to 72 cents with revenue of at least $430 million. At the time of its earnings release, CEO George Kurtz said that the company  which provides endpoint network protection for companies whose employees access remote devices such as smartphones, laptops, tablets and other wireless devices  is benefiting from the ongoing move by corporations to the cloud. To put the companys Q1 2019 report in perspective, overall revenues grew year-over-year, subscription revenues grew 116% to $86.0 million, accounting for 89% of its sales and annual recurring revenue grew 114% to $364.6 million. Even its non-GAAP losses were 30% lower in the first quarter compared to a year earlier. While I try not to invest in money-losing businesses, the need for platform is real. In a couple of years, you will have forgotten that it once lost money. OrganiGram (OGI) Source: Shutterstock\n",
      "Over the five days of trading through Aug. 26, OrganiGram (NASDAQ:) stock lost 10.6%.\n",
      "Cannabis stocks, in general, have taken it on the chin in recent days and weeks. The ETFMG Alternative Harvest ETF (NYSEARCA:), which has total net assets of $1 billion and is the largest cannabis ETF listed in the U.S., has seen its shares lose 4.9% over those five days, 16.2% over the past month, and 28.3% over the past three months. So, the fact that the OrganiGram lost almost 11% in the past week should not come as a shock. OrganiGram is one of only four licensed producers that have supply agreements for all Canadian provinces, it is ideally positioned to benefit from the growth in the Canadian cannabis market. On July 15, OrganiGram reported its Q3 2019 results. The companys net revenue was , 621% higher than a year earlier. Its gross margin in the quarter was $12.3 million CAD, 647% higher than in the same quarter a year earlier. It had a surprise loss of $10.2 million CAD in the third quarter, down from a profit of $2.8 million CAD a year earlier. But CEO Greg Engel is very excited about the companys future.\n",
      "We are very excited for fiscal 2020 which should build upon an already successful 2019, the company stated in its . By the first half of fiscal 2020, we expect to benefit from record harvests of high-quality indoor-grown dried flower, the sale of a variety of vape pen products as well as our initial edible product forms.\n",
      "The companys state-of-the-art three-level indoor cultivation facilitys expansion in New Brunswick will be completed by the end of 2019. At that time, it will have 113,000 kilograms of cannabis production capacity to meet the needs of all 10 provinces. As for edibles and derivative products, it expects to complete the square-foot addition to its Moncton facility by the end of October at a cost of $48 million CAD. It is well-positioned to benefit from Canadian legalization in December. OrganiGrams chocolate products alone should bring it significant revenue in 2020. This is one of the cannabis companies I havent paid much attention to but you shouldnt repeat my mistake. The stocks correction makes it an excellent time to take a closer look.\n",
      "I know I will. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities.\n",
      "The post appeared first on InvestorPlace.\n",
      "\n",
      "Image source: The Motley Fool.\n",
      "Zynex, Inc. (NASDAQ: ZYXI)\n",
      "Q2 2019 Earnings Call\n",
      "Jul. 31, 2019, 3:15 p.m. ET\n",
      "Contents:\n",
      "Prepared Remarks\n",
      "Questions and Answers\n",
      "Call Participants\n",
      "Prepared Remarks:\n",
      "Operator\n",
      "Good day and welcome to the Zynex's Second Quarter 2019 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing *0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press *1 on your telephone keypad. To withdraw your question, please press *2.\n",
      "Certain statements in this release are forward-looking and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Risk factors that could cause actual results to materially differ from forward-looking statements are described in our filings with the Securities and Exchange Commission, including the Risk Factors section of our annual report on Form 10-K for the year ending December 31, 2018, as well as forms 10-Q, 8-K and 8-K&A, press releases, and the company's website. Please know that this event is being recorded.\n",
      "I would now like to turn the conference over to Thomas Sandgaard, Founder, Chairman, and Chief Executive Officer. Please go ahead.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Good afternoon. My name is Thomas Sandgaard, President and CEO of Zynex. Welcome to our second quarter 2019earnings call\n",
      "I'm pleased to announce that the second quarter was our 12th consecutive quarter with positive net income. Our second quarter revenue was $10.3, with a net income of $0.06 per fully diluted share. Revenue increased 36% compared to the same quarter last year, and we reported positive net income of $2.2 million. Adjusted EBITDA in the quarter was just over $2.8 million, slightly above our estimate for the quarter.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 1, 2019 Many of you may have seen our press release earlier this month. We were named the fastest growing company in Colorado from a net income perspective during the last two years. This speaks not only to our growth but also cost controls as well. We are very proud to have received this honor.\n",
      "Our cash position was $10.1 million at the end of the second quarter. We had some significant cash payments in the first half of 2019, including the payment of our first quarter special dividend of $2.3 million and a significant amount of income taxes. As we keep growing our sales force and geographic footprint across the U.S., we've grown over 65% year-over-year, comparing the second quarter, and we continue to see strong reimbursement for our products.\n",
      "Orders grew 29% between the first and the second quarters, as we saw more new sales reps becoming productive. This order growth is the result of aggressively adding new sales reps to the sales force every month, and to see all the growth is an early sign of order growth momentum and the subsequent revenue growth that we expect to see over future periods. As you may know already, the revenue of an order is typically recognized over many months as patients continue to use our device and the related supplies for continued pain relief.\n",
      "In the second quarter, we sustained our aggressive sales force growth. We continue to add 10 new reps every month. That pace should get us through around 200 sales reps by the end of 2019 with reduction in our independent sales reps down to approximately 60 reps stemming from before 2018 and approximately 140 direct new sales reps, all added in 2018 and 2019. I'm also very pleased to see our gross profit margin remain at a level of 81%, an indication that the industry for prescription strength electrotherapies still is not only stable but very healthy and viable.\n",
      "The opioid epidemic continues to be a serious issue in this country, and we are increasingly working to get patients off opioids and propositioned to use our prescription strength technology as a first line of defense with treating pain. Currently, the devastating impact has reached the level where tens of thousands die yearly due to opioid abuse. We continue to develop more tools to make physicians aware of our technology that literally has no side effects.\n",
      "Our products for pain management and rehabilitation still stand out as some of the best products in the industry. The NexWave for pain management, our NeuroMove device for stroke rehabilitation, and the InWave for incontinence treatment puts us in a very strong product position in the rehabilitation markets. We also continue to see great potential in both of our product divisions, our existing revenue-generating area for pain management, as well as the huge, unmet potential for our blood volume monitor.\n",
      "2019 has been a transformational year from an investor perspective. In February, we succeeded in getting listed on Nasdaq, and in June, we were added to the Russell 2000 Index. The combination of these events increased our daily traded volume over 10 times from approximately 30,000 shares traded per day to over 350,000 shares traded per day presently.\n",
      "We also continue to add talent to our organization to help facilitate our continued growth. In February, we added Chris Brown as our new VP of Sales, and last week, we added a new Chief Operating Officer, Joseph Papandrea. Both Joseph and Chris will help us accelerate and streamline our growth as we finish 2019 and head into 2020.\n",
      "I will now turn the call over to Dan Moorhead, our CFO.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Thanks, Thomas. First, I'll review our 2019 second quarter results. Orders grew 65% year-over-year, which drove net revenue up 36% to $10.3 million from $7.6 million in 2018. Device revenue increased 37% to $2.3 million, compared to $1.7 million last year. Supplies revenue increased 36% year-over-year to $8 million from $5.9 million. Gross margins were 81% in the second quarter.\n",
      "Beginning in 2019, we began breaking out sales and marketing expense from G&A. This breakout provides greater clarity related to our sales growth initiative and the overall financial statement impact. Sales and marketing expenses increased 111% year-over-year, as we continue to grow our sales force. G&A expense grew 30% year-over-year. Much of the increase was related to increased headcount in our billing and patient support functions related to our order growth. G&A was flat compared to Q1 of 2019.\n",
      "Second quarter net income was $2.2 million, or $0.06 per diluted share, compared to net income of $2.4 million, or $0.07 per diluted share, in the second quarter last year. Adjusted EBITDA, which is a standard EBITDA calculation, plus an exclusion of non-cash stock-based compensation and other income expense and as reconciled in our press release was $2.8 million in the second quarter of 2019 and 2018. We've increased income tax expense year-over-year due to our profitability over the last two years, which utilized our net operating losses and puts us in a taxable position.\n",
      "Now, on to our six-month results. Orders grew 48% year-over-year, which drove net revenue up 35% to $19.5 million from $14.5 million in 2018. Device revenue increased 31% to $4.3 million, compared to $3.3 million last year. Supplies revenue increased 36% year-over-year to $15.2 million from $11.2 million. Gross margins were 81% in the first half of 2019. 2019 net income increased 4% to $4.5 million, or $0.13 per diluted share, compared to net income of $4.3 million last year. Adjusted EBITDA was $5.3 million, up 9% from $4.9 million last year.\n",
      "We generated operating cash flows during the first six months of 2019 of $2.4 million, compared to $3.6 million in 2018. Cash flows were affected by increased tax expense in 2019 and the timing of 2018 tax payments, both of which were related to our NOLs, which were 100% utilized in 2018. On the balance sheet, as of June 30, 2019, our cash balance was $10.1 million and was affected by the tax expense that I've already mentioned and the fourth quarter special dividend of $2.3 million, which was paid in January. Working capital grew 62% to $11.9 million in Q2, compared to $7.3 million as of December 31st, 2018.\n",
      "During Q2, we entered into a new lease for additional office space, which caused us to record approximately $1.6 million in lease liabilities on the balance sheet, of which approximately 300,000 are current. We recorded the related assets, but those are all non-current in nature, so there was a negative effect on working capital related to the new lease.\n",
      "With that, I'll turn the call back over to Thomas.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Thank you, Dan. I'm especially excited about our year-over-year growth in orders of 65% compared to our revenue growth of 36%. It's a huge testament to our efforts to grow our sales force and clearly justifies the investments in our sales personnel, sales management, and inside support functions. Our focus continues to be growing our sales force at a rapid rate in geographic areas which we don't currently cover to take advantage of the void left in the market by two previously very large competitors.\n",
      "Our increased orders due to a larger sales force combined with strong reimbursement for our products continue to drive increased revenue and profitability. We estimate our third quarter revenue to be between $10.7 and $11.2 million with an adjusted EBITDA in the third quarter between $2.4 million and $2.9 million. My long-term goal for our electrotherapy and rehabilitation is to continue to grow our share of the huge market for prescription pain management and to take advantage of the huge void in the market after the disappearance of our main competitors. This includes growing our domestic sales force, as well as potential acquisitions of complementary technologies.\n",
      "On the product side, the patent obtained last year on our blood volume monitor indicates the beginning of the next phase of developing this division with more clinical research to support our advertising, staffing, and our business development, etc. We're also looking at adding more products to add to this division, including additional product development internally.\n",
      "In summary, we announced yet another great quarter with strong growth in orders and revenue, plus we added some great talent, including the addition of a COO to the organization, which sets us up for seamless growth and strong financial performance going forward.\n",
      "...\n",
      "We will now answer questions from our listeners.\n",
      "Questions and Answers:\n",
      "Operator\n",
      "We will now begin the question and answer session. To ask a question, you may press *1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press *2. At this time, we will pause momentarily to assemble our roster.\n",
      "The first question comes from Jeffrey Cohen with Ladenburg Thalmann. Please go ahead.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Hi, Thomas and Dan. How are you?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Good. How are you doing, Jeff?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Just fine. So, again, nice quarter. Seem to be saying that fairly frequently these days. So, talk a little bit about the sales channel. You were talking about 60 previous independent reps plus 140 now direct that you have, total 200 growing at 10 a month. Is that a good way to envision that for the rest of this year?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Yeah, that's sort of a round-number target for where we should be at at the end of the year.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Got it. And talk to me a little bit about the facility that you took on, Floor No. 4, correct? Fourth floor?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "That's the third floor. So, we have the first floor where we have production, and quality, and IT, and engineering, and many other functions. We have the fourth floor in the building, which was basically all the other functions, and our billing group has now grown so much that we have moved them to the third floor. So, we have a total of 64,000 square feet in this building now.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "And what's the FT count in Colorado in total? Or corporate total?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "It's about 120, give or take.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Got it. Perfect. And then, Thomas, talk to me a little bit about your commentary regarding getting more favorable therapy into first-line as opposed to beyond. How does one kind of grapple with getting earlier among physicians, and clinicians, and prescribers of the technology?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "There's really two parameters, and they all spin around our sales force. One is obviously to have the geographical footprint, so we have sales reps that can meet with these physicians as well as physical therapists face-to-face and discuss our treatment option as an alternative. And second, the quality of those sales reps are obviously very important, as the better the quality of the sales reps and the message we can deliver, the more efficient they should be in terms of convincing the physician to write prescriptions for our device before they start heading into prescribing a whole lot of opioids for patients in pain.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Got it. And then, how do you think about if you successfully leapfrog drugs, what's the differential in the CAM as you get closer to the first-line or at first-line versus where you currently stand predominantly currently?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Could you rephrase that question?\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "If you're able to successfully leapfrog into first-line versus where you are today, that addressable market is how many times the size?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "That's obviously in the tens of millions of patients that are in so much pain that they seek some level of treatment for it. So, we're talking tens of billions when you multiply that by the revenue we typically see on an average prescription. So, it's in the tens of billions.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "So, it's upwards of 5-10-15 times greater market if you're able to get more writing in first-line?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "That's right. That's right. That's obviously the very long-term scenario, assuming that we are successful in, first of all, picking up the low-hanging fruit in that this market is well-developed, well-established in terms of reimbursement as well. And once we get past the point where the number of prescriptions that were traditionally written in this market and we capture all that, developing it further from that and possibly getting into the billions of revenue on the very long term. That will also require different strategy on our part that it'll be more educational rather than just asking physicians that used to prescribe this technology and send the orders our way instead, which is a very simple sales process, the more educational our sales process that may come into play in the future. It is obviously more complex, but I certainly look forward to hopefully getting there and really make lives better for people that are in pain in terms of providing pain relief, and yet at the same time, avoiding or limiting the amount of opioids that they need to take.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "And are you seeing prescribing trends currently that lead you to believe that you're jumping in front of drug therapy?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Not necessarily. We are very focused on hiring 10 reps every month, getting them trained, getting them deployed. We just restructured our sales management with a new VP of Sales and added five regional sales managers that are now holding the hands of the sales reps in these regions and making sure that we develop the sales force we have right now and that we keep adding, develop that into a good quality sales force. And also, compared to how the sales force looked in the past, which was comprised of primarily independent sales reps carrying many, many different product line, now having a much more unified sales force that are aligned more with the company rather than many different scenarios.\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Perfect. Thank you. That does it for me.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Thanks, Jeff.\n",
      "Operator\n",
      "The next question comes from Yi Chen of HC Wainwright. Please go ahead.\n",
      "Yi Chen -- HC Wainwright -- Managing Director\n",
      "Thank you for taking my questions. First question is how many more sales reps you plan to add each quarter going forward? And have the top-line revenue grows in proportion to the number of sales reps you've added in the past quarters?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "To answer your last question first, yes, we've been positively surprised as to how well new reps have been performing. We've also seen that directly hired in 2019, if we compare the first 90-day performance to the performance in the first 90 days of those reps that got hired last year, we've introduced better training and now see the first 90 days of orders from these new reps approximately 50% better than those that were not trained as efficiently last year, so we're very encouraged by that. And something that really stands out when we look at the second quarter is that we were able to grow year-over-year 65% on the orders by adding all these sales reps. It's a significant investment, but we saw that obviously in the increase of orders. So, compared to the revenue growth we've seen for a while being in the 35%-36% range, I'm very encouraged because that would indicate that we'll continue to grow as a company.\n",
      "In terms of how we expect to add sales reps, we mapped that so we ultimately will have sales reps in 400 territories across the United States with a little less than a million citizens in each territory, and we expect to get there in approximately 23-24 months from today. So, we still need to add approximately 200 over the next eight quarters, so I guess you can do the math in terms of the pace we'll be hiring at. So, that's approximately 25 a quarter that needs to be added. So, a little less than 10 a month that we're currently running at, but we should also expect a little bit of attrition, so it should all come together that way.\n",
      "Yi Chen -- HC Wainwright -- Managing Director\n",
      "Thank you. My second question is of all the patients who received a NexWave device in the second quarter, what percentage of them are newly diagnosed patients receiving each treatment and what percentage were patients who have switched from opioid product treatments to NexWave?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Sometimes we have that information in the form of very expensive medical records. These days they're not always just handwritten but printouts from hospitals or doctors offices, and in some cases, we barely have a prescription and a photocopy of an insurance card, and we may obtain some information as we contact the patient the same day as we receive the prescription and get the patient involved. So, we don't exactly have that information, so that would just be a qualified guess, but I would expect it to be, at this point, probably well below 50% showing that scenario that you're asking about there. But it's not something that we're exactly able to measure.\n",
      "Yi Chen -- HC Wainwright -- Managing Director\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Thank you.\n",
      "Operator\n",
      "The next question comes from Marc Wiesenberger with B. Riley FBR. Please go ahead.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Thank you. Good afternoon. Can you talk about any changes to the types of physicians the sales staff is targeting and some impacts on the business?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "There's not a whole lot of change in who we are targeting. A significant group that we're targeting is obviously orthopedic surgeons. It's a great, great technology for getting pain management introduced, in some cases even before the surgery so the patient is used to the device and how to operate it but increasing blood circulation and getting some pain management right after orthopedic surgery. We see quite a bit of prescriptions also from pain management doctors, physical medicine and rehabilitation doctors, and we also see quite a bit prescribed by anesthesiologists, and you can probably expect doctors of physical therapy also account for a significant amount of orders.\n",
      "And then, it's literally spread out over all kinds of specialties, family physicians, podiatrists, chiropractors, etc., but our primary target for a long time has been orthopedic surgeons. That is about 20-something percent of all orders coming in with a couple of the other groups I just mentioned are nearly up there in the 20% range. But nothing has really changed in terms of our focus. That's still the same, but it's a very, very broad spectrum of physicians that we see.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Understood. Thank you. On previous calls and even earlier, you alluded to the realignment of sales territories and adding the five sales regional managers. Can you talk about how that's impacted the sales reps and their business?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "It's gone really well. Obviously, there has been some -- we call them legacy reps that's been with us for many, many years that not necessarily fit into the territories we defined that was very computer-based and based on population. And we have to obviously carve out a few exceptions so that they could keep seeing the clinics that historically have produced a very high volume, but for the most, it's gone really well. I can kind of tell from your question that that's something that you -- we can always expect that when we're talking about that many sales reps and then some of them being impacted, that created a lot of noise.\n",
      "That's actually gone over really well. We've been very structured about it and approached it very delicately, so I really applaud our sales management team for having implemented that in a very professional manner, and that really sets us up for the future, so it's very easy to just take one territory at a time -- or I should say 10 territories per month -- and plug in new reps with the whole interviewing, the qualifying and getting them hired and trained. It's working like a well-oiled machine at this point.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "That's really good to hear, and that kinda goes along with my next question. Are you having any difficulty at this point finding qualified sales reps? And as you kind of ramp that process, do you anticipate having trouble with the tight labor market?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "No. I can see the logic here that as we add more sales reps, that it should maybe be a little harder to keep finding good sales reps, but the fact that we have mapped out the territories the way we have, and every time we add a sales rep in a new territory after having interviewed a number of applicants, the number of applicants is always the same because the population we're putting them into, whether it's a rural area or high-density area, the amount of square miles might be different, but the size of the population, and therefore also the percentage of that population that has a sales background or are interested in selling medical devices, is about the same every time. So, that's why we can keep that cadence and that pace, and there doesn't seem to be any slowing down because the pool of talent is sustained for every new territory we interview for. So, that's actually good news.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "That is good to hear. Have you noticed in any changes in reimbursements in terms of dollar value or maybe timing of payments? And what are your expectations for the near and medium term?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "It's what we've seen for several years now. It's pretty constant. The thing that keeps changing is, as I believe I mentioned before, the name of the insurance company that is the most difficult this month. But other than that, across the board, it's still the same as it was 20 years ago, 25 years ago, 10 years ago. As I also have mentioned or talked about in previous earnings calls, over the past three years, we've gotten a lot better at just processing the files and not making so many mistakes internally, and that seems to be at a fairly constant level. We keep getting high and great talent into all parts of the company, including the billing department as the orders grow, and I expect we can keep being as efficient as we've been in the past.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Sure. With the success you've been having, are you seeing any changes in the competitive landscape with new insurance?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Not yet. I know that question comes up on everyearnings call and it's another one where we haven't really seen anything. I'm sure we would hear about it pretty quickly through the grapevine and the sales force, so that is still the same. So, we are obviously in a very unique position here with a well-developed market, well-established reimbursement, and with basically no significant competition, and we just keep adding sales reps to expand our geographic coverage.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Got it. And one final one from me, gotta have an obligatory blood volume question on the call. Any updates on FDA or CE Marking approval, and I guess how are the clinical studies progressing as well?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Clinical studies are progressing well. There were some technicalities at the site where we had an initial test through our clinical research organization, and so we're doing that here in a few weeks. That should be fairly easy. And then, all the studies we have lined up there should follow shortly after that. And in terms of the FDA and CE Marking, I would say we are probably closer today than we were three months ago.\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Understood. Thank you very much.\n",
      "Operator\n",
      "The next question comes from Shawn Boyd with Next Mark Capital. Please go ahead.\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "Good afternoon. Can you hear me OK?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Yeah. Good afternoon.\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "Great. I just wanna clarify one thing. The sales force expansion, which is of course near and dear to all of our hearts here, if I understood it correctly, you indicated you were at about 200 reps right now, going to 400 about two years now --\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "By year end. So, right now, we're more in the 175-180 range, and by year end, maybe we can be over 200, but that's kind of a round number target.\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "So, 200 or so by year end, and then with intention to expand that to 400 another two years out, 24 months out, and so that's what got you to that cadence of 25 per quarter?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Yeah. Exactly.\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "And perhaps I just misunderstood this, but I originally thought that 2020 might involve a little bit of a slowdown on adding reps are you kinda refined territories. So, either I just got that wrong, or you kinda changed the plan a little bit and you accelerated your hiring possibly because you're seeing the good payback on the hires. Can you just --\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "So, what that does is it buys us a little bit of cushion to maybe aggressively trim some of the independent sales reps that are not as productive, and it also has some cushion built in if we have a higher than expected attrition, but else, you're right. We could slow down a little bit, but I'd say since we don't really have any resistance, or bottlenecks, or barriers to adding 10 reps a month, I'd like to continue to do that as fast as possible. So, if we can get to the 400 in 22 or 23 months instead of 24 months, that'll obviously be even better.\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "Got it. Thank you very much for the clarification.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Okay.\n",
      "Operator\n",
      "Again, if you have a question, please press *1. The next question comes from Kevin Mackey with Analyst. Please go ahead.\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "Hi. Thank you for taking my questions, and also, thank you for the responses that you've given me previously, privately. I appreciate your help. I'm wondering if you could give us a more exact number on how many orders you had this quarter?\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "The disclosure we give, we don't get to the exact order. We give growth percentages, and from the materials in the decks that we have, you can semi-extrapolate those, but what we give is the numbers we're comfortable with.\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "All right. If my understanding is correct, last year in December, the competitive bidding program ended for Medicare, and that had previously excluded you guys from nine metropolitan markets, I believe your 10-K had said. Are you working to push into those markets you were previously excluded from? And do you plan on bidding in the next round that is due for 2021?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "No. We don't plan on bidding, and we don't see that we are really excluded from any markets.\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "And in terms of the NeuroMove, it sounds like an amazing device. I personally know people that have had a stroke and could really benefit from that, but through the years, you've continued to report that you have a negligible amount of sales from the NeuroMove. I'm just curious what might be hampering you from getting that product to stick. Is it patient acceptance? Is it physician acceptance? Is it a hurdle in the marketing environment? If you could speak to that, please?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Yeah, it is. You're right. The NeuroMove is a very exciting device. It can literally detect attempts from the brain when you're attempting to move muscles. It could be trying to extend your fingers and hands, so it's a very unique device and designed so it can also be used in the home. And more than 10 years ago, when it was introduced, we actually had a decent amount of revenue when our total revenue was only a few million dollars annually. Nearly half of the revenue came from the NeuroMove device.\n",
      "What has happened since is we've, until recently, had fairly limited resources. We saw a bigger opportunity in terms of growing revenue, and therefore also creating profits for the company in growing the pain management market, so it's been a very deliberate decision to focus on that. Unfortunately, therefore, we've decreased the efforts on promoting the NeuroMove device. It's something that we see to really get significant revenue on will require quite a bit of heavy lifting, and that translates into a significant financial investment in the marketing of it.\n",
      "We occasionally sell some to clinics as a clinical sale, and we have patient-friendly programs with a relatively low self-pay option, so it's obviously something we could do much more of in terms of promoting it to stroke survivors. There are 600,000 or more new strokes every year in this country, so there's a lot of potential here. However, in order to not spread ourselves too thin, we're still focusing on the pain management market, but as you're alluding to, it could be one of the things we do more of going forward to diversify our revenue a little bit, and fortunately, it's somewhat of the same call point for our sales force. I hope that answers --\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "Thank you. Yeah, yeah, that helps a lot. And finally, also on the blood volume monitor, you guys mention in your reports that you're kind of fielding questions from the FDA, responding to questions that they have. Could you give us an idea of what those questions might be and what your responses have been just so we can get a better feel for how that progress is coming?\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "The nature of those questions have changed over time. In the beginning, it was very much pointed at our inability to literally write up the application so that it fit their framework. We spent some time on that. There's been questions a little while back as to getting additional safety testing done to a new standard that had been introduced in the meantime, so that took some time to get that done and have our device pass those additional tests. And here more recently, they have had specific questions as to the specific six parameters we used to combine into an index, and basically getting the wording right so it fits into the framework of the five 10-K clearances that we are trying to get it through.\n",
      "So, recently, we have submitted a response that should be aligned nearly word-for-word with their suggestions as to how we should phrase things, so with a bit of luck, the next response, they don't have any further questions or suggestions to us, and else, we'll just keep answering the questions. So, in summary, there hasn't really been any very heavy, very difficult questions. It's just getting the technicalities right. And unfortunately, every time we get a round of questions, it takes some times -- several months -- before we are able to get back to them, and then they have that time to respond back to us. So, unfortunately, it's taking some time. And it's somewhat similar, all the different kind of questions, in terms of moving forward on the CE Marking process.\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "Thank you. And the last one from me, I just kinda ran some rough numbers based on your orders growth and how many sales reps you have, and it looks like your revenue per rep went up for the last quarter, but your revenue per order went down slightly. I'm just wondering if you could speak to that, maybe in particular what your billing department, be it efficiency that you're trying to create there because I understand that they're the ones that are responsible for collecting the revenue after the order's placed. So, with that number going down slightly, just wondering if there's anything we should be aware of there.\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "There aren't any changes in reimbursement or productivity. It's really you have to take into account the sales headcount number still aren't huge numbers, so when you bring in a large number of people at the end of the quarter, beginning of the quarter, it can skew that revenue per order or dollars per submission. So, I think I would say your numbers aren't correct.\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "All right. Thank you for that. Appreciate it. That's it for me.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Thanks again.\n",
      "Operator\n",
      "This concludes our question and answer session. I would like to turn the conference back over to Thomas Sandgaard for any closing remarks.\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Thank you. I hope today'searnings callhas been informative for everyone, and I appreciate the interest in Zynex and listening in on this call. Thank you and a great day to all.\n",
      "...\n",
      "Operator\n",
      "The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.\n",
      "Duration: 43 minutes\n",
      "Call participants:\n",
      "Thomas Sandgaard -- Founder, Chairman, and Chief Executive Officer\n",
      "Dan Moorhead -- Chief Financial Officer\n",
      "Jeffrey Cohen -- Ladenburg Thalmann -- Managing Director\n",
      "Yi Chen -- HC Wainwright -- Managing Director\n",
      "Marc Wiesenberger -- B. Riley FBR -- Equity Research Analyst\n",
      "Shawn Boyd -- Next Mark Capital -- Founder and Portfolio Manager\n",
      "Kevin Mackey -- Unknown -- Analyst\n",
      "More ZYXI analysis\n",
      "All earnings call transcripts\n",
      "This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.\n",
      "10 stocks we like better than Zynex, Inc.\n",
      "When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*\n",
      "David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zynex, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.\n",
      "See the 10 stocks *Stock Advisor returns as of June 1, 2019 Motley Fool Transcription has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.\n",
      "\n",
      "Thursday was a largely positive day on Wall Street, and most major indexes moved modestly higher. Small-cap stocks showed particularly sharp gains, highlighting the perceived likelihood of moves to help support the domestic economy even as multinational corporations remain under pressure from potential trade issues. Investors are increasingly looking forward to the G-20 summit over the coming weekend, with expectations that a trade deal could send the market soaring even further. Yet some stocks missed out on today's rally and lost ground. Conagra Brands (NYSE: CAG), Patterson Companies (NASDAQ: PDCO), and Zynex (NASDAQ: ZYXI) were among the worst performers. Here's why they did so poorly.\n",
      "Conagra leaves investors hungry\n",
      "Shares of Conagra Brands fell 12% after the food giant reported its fiscal fourth-quarter financial results. Sales soared 34% from year-ago levels, but all of that growth came from the acquisition of Pinnacle. After accounting for that purchase and the divestiture and sale of various other business units, organic net revenue was down 0.7%. CEO Sean Connolly also pointed to a tough promotional environment and manufacturing issues as holding back the company's growth. In the long run, Conagra sees its strategy working out well, and even though the food giant boosted its guidance for organic sales growth over the coming fiscal year, investors seemed disappointed with the challenges the company still faces.\n",
      "Image source: Conagra Brands.\n",
      "Patterson sees potential trouble ahead\n",
      "Animal health and dental products distributor Patterson Companies saw its stock fall 5% following its release of its fiscal fourth-quarter financial report. Revenue for the period came in 2.6% higher than in the previous year's quarter, with reasonably solid performance from both of its key business segments. Bottom-line gains of 24% on an adjusted basis were also encouraging, but investors had hoped for an even larger earnings jump of about 30%. Moreover, Patterson's guidance for the coming fiscal year was a bit weaker than most of those following the company had expected. With Patterson stock still down by half since 2017, the company needs to boost its business quickly to regain investor confidence.\n",
      "Zynex finally falls back\n",
      "Finally, shares of Zynex plunged 17%. The high-flying medical device company filed a prospectus with the U.S. Securities and Exchange Commission, allowing its selling stockholders to sell roughly 16.7 million shares. Zynex itself won't receive any proceeds from the offering, instead giving CEO Thomas Sandgaard an opportunity to sell off roughly half of the 31.6 million shares he directly or indirectly holds. Zynex stock had doubled just since late April on hopes that its non-invasive medical devices for pain management will gain acceptance, but shareholders seem worried that the move to sell means that Sandgaard won't be as interested in the business going forward.\n",
      "Offer from The Motley Fool: The 10 best stocks to buy now\n",
      "Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor, has quadrupled the S&P 500!*\n",
      "Tom and David just revealed their ten top stock picks for investors to buy right now.\n",
      "Click here to get access to the full list!\n",
      "*Stock Advisor returns as of June 1, 2019.\n",
      "\n",
      "Toward the end of trading Thursday, the Dow traded up 0.21% to 26591.97 while the NASDAQ rose 0.73% to 7,967.52. The S&P also rose, gaining 0.49% to 2,928.04.\n",
      "Leading and Lagging Sectors\n",
      "Financial shares rose 1% on Thursday. Meanwhile, top gainers in the sector included OFG Bancorp (NYSE: OFG), up 14%, and Lyons Bancorp Inc. (OTC: LYBC), up 15%.\n",
      "In trading on Thursday, energy shares fell 0.2%.\n",
      "Top Headline\n",
      "Walgreens Boots Alliance Inc (NASDAQ: WBA) posted upbeat earnings for its third quarter.\n",
      "Walgreens Boots Alliance reported third-quarter earnings of $1.47 per share, which beat the analyst consensus estimate of $1.43. The company reported quarterly sales of $34.591 billion, which beat the analyst consensus estimate of $34.47 billion.\n",
      "Equities Trading UP\n",
      "Cemtrex, Inc. (NASDAQ: CETX) shares shot up 121% to $4.0490 after the company's electronic manufacturing services unit won a $6 million in new orders over the last few months.\n",
      "Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) got a boost, shooting up 99% to $39.72 after pricing 15 million share IPO at $20 per share.\n",
      "ASV Holdings, Inc. (NASDAQ: ASV) shares were also up, gaining 284% to $6.79 after the company reported a merger deal with Yanmar Holdings at $7.05 per share in cash.\n",
      "Equities Trading DOWN\n",
      "XpresSpa Group, Inc. (NASDAQ: XSPA) shares tumbled 58% to $1.9701 after a third amendment to outstanding secured convertible notes due November 17, 2019, resulting in added 941,000 shares to outstanding common stock count.\n",
      "Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) were down 49% to $2.2820 after the company reported Phase 2 Trial results for ATI-502 did not meet its primary or secondary endpoints.\n",
      "Zynex, Inc. (NASDAQ: ZYXI) was down, falling 18% to $8.65 after reporting a 16.66 million share common stock offering via selling shareholders.\n",
      "Commodities\n",
      "In commodity news, oil traded up 0.1% to $59.40, while gold traded down 0.3% to $1,411.10.\n",
      "Silver traded down 0.7% Thursday to $15.19, while copper rose 0.2% to $2.7185.\n",
      "Euro zone\n",
      "European shares closed mostly lower today. The eurozones STOXX 600 rose 0.01%, the Spanish Ibex Index fell 0.1%, while Italys FTSE MIB Index gained 0.26%. Meanwhile, the German DAX gained 0.21%, and the French CAC 40 fell 0.13% while UK shares fell 0.19%.\n",
      "Economics\n",
      "The U.S. grew its gross domestic product by 3.1% in the first quarter of 2019, up from just 2.2% growth in the fourth quarter of 2018. Economists were projecting a growth of 3.1%.\n",
      "Initial jobless claims rose 10,000 to 227,000 last week. However, analysts were expecting a reading of 220,000.\n",
      "The pending home sales index rose 1.1% for May, versus economists expectations for a 1.1% increase.\n",
      "Domestic supplies of natural gas climbed 98 billion cubic feet for the week ended June 21, the U.S. Energy Information Administration reported. However, analysts projected a gain of 100 billion cubic feet.\n",
      "Data on farm prices for May will be released at 3:00 p.m. ET.\n",
      "Data on money supply for the recent week will be released at 4:30 p.m. ET.\n",
      " 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.\n",
      "Get insight into trading platforms. Compare the best online stock brokerages.\n",
      "\n",
      "Midway through trading Thursday, the Dow traded up 0.13% to 26,570.69 while the NASDAQ rose 0.68% to 7,963.66. The S&P also rose, gaining 0.43% to 2,926.42.\n",
      "Leading and Lagging Sectors\n",
      "Financial shares rose 0.9% on Thursday. Meanwhile, top gainers in the sector included OFG Bancorp (NYSE: OFG), up 12%, and 360 Finance, Inc. (NASDAQ: QFIN), up 8%.\n",
      "In trading on Thursday, energy shares fell 0.1%.\n",
      "Top Headline\n",
      "Walgreens Boots Alliance Inc (NASDAQ: WBA) posted upbeat earnings for its third quarter.\n",
      "Walgreens Boots Alliance reported third-quarter earnings of $1.47 per share, which beat the analyst consensus estimate of $1.43. The company reported quarterly sales of $34.591 billion, which beat the analyst consensus estimate of $34.47 billion.\n",
      "Equities Trading UP\n",
      "Cemtrex, Inc. (NASDAQ: CETX) shares shot up 123% to $4.0825 after the company's electronic manufacturing services unit won a $6 million in new orders over the last few months.\n",
      "Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) got a boost, shooting up 96% to $39.26 after pricing 15 million share IPO at $20 per share.\n",
      "ASV Holdings, Inc. (NASDAQ: ASV) shares were also up, gaining 281% to $6.74 after the company reported a merger deal with Yanmar Holdings at $7.05 per share in cash.\n",
      "Equities Trading DOWN\n",
      "XpresSpa Group, Inc. (NASDAQ: XSPA) shares tumbled 59% to $1.9358 after a third amendment to outstanding secured convertible notes due November 17, 2019, resulting in added 941,000 shares to outstanding common stock count.\n",
      "Shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) were down 46% to $2.4210 after the company reported Phase 2 Trial results for ATI-502 did not meet its primary or secondary endpoints.\n",
      "Zynex, Inc. (NASDAQ: ZYXI) was down, falling 19% to $8.48 after reporting a 16.66 million share common stock offering via selling shareholders.\n",
      "Commodities\n",
      "In commodity news, oil traded up 0.4% to $59.60, while gold traded down 0.4% to $1,410.40.\n",
      "Silver traded down 0.7% Thursday to $15.185, while copper rose 0.1% to $2.716.\n",
      "Euro zone\n",
      "European shares were mostly lower today. The eurozones STOXX 600 rose 0.01%, the Spanish Ibex Index fell 0.1%, while Italys FTSE MIB Index gained 0.26%. Meanwhile, the German DAX gained 0.21%, and the French CAC 40 fell 0.2% while UK shares fell 0.19%.\n",
      "Economics\n",
      "The U.S. grew its gross domestic product by 3.1% in the first quarter of 2019, up from just 2.2% growth in the fourth quarter of 2018. Economists were projecting a growth of 3.1%.\n",
      "Initial jobless claims rose 10,000 to 227,000 last week. However, analysts were expecting a reading of 220,000.\n",
      "The pending home sales index rose 1.1% for May, versus economists expectations for a 1.1% increase.\n",
      "Domestic supplies of natural gas climbed 98 billion cubic feet for the week ended June 21, the U.S. Energy Information Administration reported. However, analysts projected a gain of 100 billion cubic feet.\n",
      "The Treasury will auction 7-year notes at 1:00 p.m. ET.\n",
      "Data on farm prices for May will be released at 3:00 p.m. ET.\n",
      "Data on money supply for the recent week will be released at 4:30 p.m. ET.\n",
      " 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.\n",
      "Profit with More New & Research. Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional\n",
      "\n",
      "The following companies are expected to report earnings prior to market open on 09/18/2014. Visit our Earnings Calendar for a full list of expected earnings releases.\n",
      "ConAgra Foods, Inc. ( CAG ) is reporting for the quarter ending August 31, 2014. The food company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.35. This value represents a 5.41% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for CAG is 14.32 vs. an industry ratio of 14.20, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "IHS Inc. ( IHS ) is reporting for the quarter ending August 31, 2014. The business info service company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.90. This value represents a 8.43% increase compared to the same quarter last year. In the past year IHS has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 14.14%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for IHS is 36.21 vs. an industry ratio of 25.10, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "Rite Aid Corporation ( RAD ) is reporting for the quarter ending August 31, 2014. The drug store company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.06. This value represents a 25.00% decrease compared to the same quarter last year. In the past year RAD has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for RAD is 20.03 vs. an industry ratio of 37.50.\n",
      "Marcus Corporation ( MCS ) is reporting for the quarter ending August 31, 2014. The hotel company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.50. This value represents a no change for the same quarter last year. MCS missed the consensus earnings per share in the 4th calendar quarter of 2013 by -12.5%. The \"days to cover\" for this stock exceeds 10 days. Zacks Investment Research reports that the 2015 Price to Earnings ratio for MCS is 18.82 vs. an industry ratio of 41.40.\n",
      "Zynex, Inc. ( ZYXI ) is reporting for the quarter ending June 30, 2014. The medical products company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.03. This value represents a 50.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ZYXI is -1.49 vs. an industry ratio of -2.10, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "\n",
      "The following companies are expected to report earnings prior to market open on 03/27/2014. Visit our Earnings Calendar for a full list of expected earnings releases.\n",
      "Accenture plc. ( ACN ) is reporting for the quarter ending February 28, 2014. The consulting company's consensus earnings per share forecast from the 13 analysts that follow the stock is $1.04. This value represents a 4.00% increase compared to the same quarter last year. In the past year ACN has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACN is 18.56 vs. an industry ratio of 22.70.\n",
      "Signet Jewelers Limited ( SIG ) is reporting for the quarter ending January 31, 2014. The jewelry retail company's consensus earnings per share forecast from the 6 analysts that follow the stock is $2.15. This value represents a 1.42% increase compared to the same quarter last year. In the past year SIG has met analyst expectations twice and beat the expectations the other two quarters. The days to cover, as reported in the 3/14/2014 short interest update, increased 170.42% from previous report on 2/28/2014. Zacks Investment Research reports that the 2014 Price to Earnings ratio for SIG is 21.97 vs. an industry ratio of 23.80.\n",
      "lululemon athletica inc. ( LULU ) is reporting for the quarter ending January 31, 2014. The retail (shoe) company's consensus earnings per share forecast from the 20 analysts that follow the stock is $0.72. This value represents a 4.00% decrease compared to the same quarter last year. In the past year LULU has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 9.76%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for LULU is 25.39 vs. an industry ratio of 3.60, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "Gamestop Corporation ( GME ) is reporting for the quarter ending January 31, 2014. The retail company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.92. This value represents a 11.11% decrease compared to the same quarter last year. In the past year GME has met analyst expectations once and beat the expectations the other three quarters. The \"days to cover\" for this stock exceeds 13 days. Zacks Investment Research reports that the 2014 Price to Earnings ratio for GME is 12.51 vs. an industry ratio of 14.60.\n",
      "Worthington Industries, Inc. ( WOR ) is reporting for the quarter ending February 28, 2014. The metal processing & fabrication company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.60. This value represents a 15.38% increase compared to the same quarter last year. WOR missed the consensus earnings per share in the 2nd calendar quarter of 2013 by -7.46%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for WOR is 16.73 vs. an industry ratio of 15.20, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "Commercial Metals Company ( CMC ) is reporting for the quarter ending February 28, 2014. The steel company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.10. This value represents a 150.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CMC is 16.75 vs. an industry ratio of 22.10.\n",
      "Conn's, Inc. ( CONN ) is reporting for the quarter ending January 31, 2014. The retail company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.78. This value represents a 44.44% increase compared to the same quarter last year. CONN missed the consensus earnings per share in the 3rd calendar quarter of 2013 by -13.33%. The days to cover, as reported in the 3/14/2014 short interest update, increased 369.87% from previous report on 2/28/2014. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CONN is 13.01 vs. an industry ratio of 14.60.\n",
      "Winnebago Industries, Inc. ( WGO ) is reporting for the quarter ending February 28, 2014. The building company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.31. This value represents a 40.91% increase compared to the same quarter last year. In the past year WGO has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for WGO is 17.09 vs. an industry ratio of 17.20.\n",
      "Fred's, Inc. ( FRED ) is reporting for the quarter ending January 31, 2014. The discount retail company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.15. This value represents a 16.67% decrease compared to the same quarter last year. FRED missed the consensus earnings per share in the 1st calendar quarter of 2013 by -5.26%. The \"days to cover\" for this stock exceeds 10 days. Zacks Investment Research reports that the 2014 Price to Earnings ratio for FRED is 25.84 vs. an industry ratio of 18.90, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "Cardiome Pharma Corporation ( CRME ) is reporting for the quarter ending December 31, 2013. The drug company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.31. This value represents a 3.33% decrease compared to the same quarter last year. In the past year CRME has met analyst expectations once Zacks Investment Research reports that the 2013 Price to Earnings ratio for CRME is -9.32 vs. an industry ratio of 35.00.\n",
      "Echo Therapeutics, Inc. ( ECTE ) is reporting for the quarter ending December 31, 2013. The medical instruments company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.36. This value represents a 67.27% increase compared to the same quarter last year. Zacks Investment Research reports that the 2013 Price to Earnings ratio for ECTE is -1.10 vs. an industry ratio of -1.70, implying that they will have a higher earnings growth than their competitors in the same industry.\n",
      "Zynex, Inc. ( ZYXI ) is reporting for the quarter ending December 31, 2013. The medical products company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.03. This value represents a 400.00% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2013 Price to Earnings ratio for ZYXI is -3.92 vs. an industry ratio of 5.40.\n",
      "\n",
      "By Brian Marckx, CFA\n",
      "Q4 2012 Financial Results:Revenue In-Line, Nice Reduction in SG&A But GM Softer\n",
      "Zynex (OTC:ZYXI) reported financial results for the fourth quarter ending December 31, 2012 on March 14th. Revenue growth continued, remained at about the same level as the 2nd and 3rd quarters of the year, and came in just about dead-on with our estimate. Q4 also saw a nice reduction in SG&A as a % of revenue - which management noted is expected to be a theme reflected in 2013 as well. Despite the almost double-digit revenue growth and reduction in operating expenses, all of this benefit did not flow through to net income and EPS due to a meaningful contraction in gross margin (with both sales and rental margins coming in).\n",
      "Revenue of $10.6 million was up 9% from Q4 2011 and was in-line with our $10.4 million estimate. Rental revenue was $2.1 million, down 15% yoy and below our $2.3 million (-8%) estimate. Meanwhile sales of equipment and consumables posted approximate growth of 13% and 23%, respectively. Consumables sales continue to benefit from the ever larger and growing installed base.\n",
      "Total revenue growth remains mostly tied to expansion of the sales force and feeding consumables to a growing installed base. Zynex expects to continue building their sales force - both from sales consultants and direct hires - to facilitate sales growth. The company has recently diversified its potential revenue sources, however, including new product launches and new business lines - the former including InWave for the treatment of female incontinence and the latter including a medical billing segment (called Zynex Billing and Consulting) which the company formed in Q4 2012 and which aims to leverage the company's expertise in that area to engage private medical practices and generate additional revenue for the company. And while the vast majority of revenue continues to come from electrical stimulation devices and related consumables from the Zynex Medical segment, management remains focused on bringing new products to market which includes a blood monitoring device that is currently in clinical testing but which Zynex believes could potentially launch sometime in 2013 or 2014.\n",
      "Revenue\n",
      "Total revenue consisted of $2.1 million (-15% y-o-y) in rentals and $8.5 million (+18% y-o-y) in product sales. The equipment portion of product sales was in-line with our estimate while the consumables portion handily beat (+9%) our number.\n",
      "Gross Margin\n",
      "Gross margin at 72.1% was relatively very soft, the lowest of any quarter since Q4 2009 and significantly lower than our 80.1% estimate. Both the sales margin and rental margin were relatively weak in Q4. For the full year 2012 GM was 77.9%, down slightly from 78.4% in 2011. Zynex did not provide much detail on gross margin on the call. While we think the Billing and Consulting business may provide greater margins, there may not be much in the way of revenue contribution from this business in the current year. We also note that Zynex may see some impact from the recently implemented 2.3% medical device tax - although management noted on the call that this should not be overly significant. While we continue to model GM in 2013 and beyond at above 75%, we have lowered our GM estimates slightly as we think ZYXI may see a slight headwind.\n",
      "Net Income / EPS\n",
      "Net income and EPS were $397k and $0.01 compared to our $567k and $0.02 estimates. The difference due entirely to the weaker than expected gross margin.\n",
      "Despite somewhat disappointing GM, one very meaningful highlight in Q4 was that SG&A as a % of sales improved considerably and was relatively low at just 66.4%. As we've consistently noted in the past, elevated SG&A expense has really constrained much EPS growth despite fairly rapidly growing revenue over the last several years. Management noted on the call that in Q4 they began implementing operational improvements which has had the effect of wringing out some SG&A related expenses - in addition, the company expects the combination of continued operational efficiencies and normal leverage from growing revenue to continue to benefit operating margin in 2013 and beyond. We currently model SG&A as a % of sales to improve from the 71% in 2012 to 68.5% in 2013.\n",
      "Cash\n",
      "Zynex exited Q4 with $823k in cash and equivalents, roughly flat from the end of Q3. Cash from operating activities was an inflow of $321k in Q4, ex-changes in working capital this was an inflow of $926k. For the full year 2012 cash flow from operating activities was an outflow of $879k but ex-changes in working capital (which included $1.7MM increase in A/R and $2.1MM increase in inventory) and it was an inflow of $3.3 million. We model the company to again generate positive operating cash flow in 2013. Management reiterated their expectations on the call that cash from operating activities should show some improvement going forward and believes the current credit line and cash balance will be sufficient to fund operations.\n",
      "Cash used in investing activities was $139k in Q4 and $1.6MM for the full year - mostly relating to the purchase of equipment and inventory for rentals.\n",
      "Guidance\n",
      "Management issued initial revenue and EPS guidance for the full year 2013. They look for revenue and EPS to come in the ranges of $41MM - $44MM and $0.06 - $0.09 (compared to 2012 actuals of $39.7MM and $0.05). We currently model 2013 revenue and EPS of $43.7MM (+10%) and $0.07.\n",
      "OUTLOOK :Largely unchanged since our last update\n",
      "Our outlook remains largely unchanged although we have made some adjustments to our model, mostly reflecting continued tweaking of our assumptions relative to how recent trends extrapolate into the future. We also note that additional risk has been introduced from the Centers for Medicare & Medicaid Services (CMS) deciding in June 2012 that, effective immediately, they would no longer provide reimbursement for TENS for chronic low back pain. Exactly how much of an impact this may have on Zynex might yet to be seen but we think it's safe to assume that there is a significant chance that it may adversely effect revenue growth. Only a relatively small percentage of Zynex's (we estimate it's less than 10%) revenue comes from Medicare and CMS's recent decision relates only to chronic low back pain - both of which could help insulate the impact to Zynex. However, as Medicare reimbursement policies go, so often does private insurers - if private insurers follow Medicare's lead, the company's TENS related revenue could be significantly effected. This will be something to keep an eye on.\n",
      "Management addressed this potential issue on the Q3 call and noted that they have not experienced any adverse effects from the recent CMS action but also noted that they have plans relative to budgeting if and when this might become problematic.\n",
      "And as we noted above, our model now also incorporates a consideration of some impact to margins from the 2.3% medical device tax.\n",
      "Our model continues to incorporate the assumption that expansion of the sales force is the main impetus for revenue growth and we still do not incorporate any contribution from the aforementioned blood monitoring device or any contribution from the new Billing and Consulting business - both of which could provide some upside to our model - particularly in the out-years. While our model does not incorporate any revenue contribution from the blood monitoring device as few details have been revealed about the device or the related development/trials, we will update our model when we are more comfortable with the chances of eventual regulatory approval and commercialization of this product as well as other products under development. We will also incorporate a contribution from the new Billing and Consulting business if and when it's appropriate.\n",
      "Please visit SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning\n",
      "ZYNEX INC (ZYXI): Get Free Report\n",
      "To read this article on Zacks.com click here.\n",
      "\n",
      "Q3 Results In-Line, Maintaining Outlook/Recommendation\n",
      "By Brian Marckx, CFA\n",
      "Q3 2012 Financial Results:Largely In-line with our estimates. Maintaining Outperform rating and $1.35/share price target\n",
      "Zynex ( ZYXI) reported financial results for third quarter ending September 30, 2012 on November 7th. Revenue growth continued, albeit it at a slower pace than the first six months of the year, with sales coming in very much in-line with our estimate. Revenue of $10.1 million was up 7% from Q3 2011 and was only slightly lower (1.7%) than our $10.3 million estimate. Rental revenue, while continuing to contract, fell less than we anticipated. Rental revenue was $2.3 million, down 8% y-o-y but better than our $2.0 million (-18%) estimate. Meanwhile sales of equipment and consumables posted growth of 8% and 17%, respectively, which were both lower than our estimates. It's worth noting, however, that consumables sales have been very strong throughout the year, reflecting the ever larger equipment installed base.\n",
      "Total revenue growth remains mostly tied to expansion of the sales force and feeding consumables to a growing installed based. Management again noted that revenue from the Zynex NeuroDiagnostics business, which includes the recently acquired NeuroDyne product line, continues to grow, although remains relatively small comparatively. The vast majority of revenue continues to come from electrical stimulation devices and related consumables from the Zynex Medical segment, although management remains focused on diversifying their product line including from a blood monitoring device that is currently in clinical testing but which Zynex believes could launch sometime next year. Zynex also launched a new product during Q3 called InWave which recently received FDA 501(k) clearance. InWave is used for female urinary incontinence, a worldwide market management estimates at ~$160 million. The product is currently still in the midst of being rolled out to Zynex's entire ~200 person sales force and is expected to be a meaningful contributor to revenue going forward.\n",
      "Revenue\n",
      "Total revenue consisted of $2.3 million (-8% y-o-y) in rentals and $7.8 million (+13% y-o-y) in product sales. Both the equipment and consumables portion of product sales came in softer than our estimate but, as noted above, consumables growth continues to be very strong.\n",
      "Gross Margin\n",
      "Gross margin at 78.1% dipped from the 82.2% reported in Q2 and was below our 80.8% estimate. GM tends to jump around from quarter-to-quarter but continues to benefit from a higher % of total sales coming from the high margin consumables segment as well as the next-generation TENS device which has lower input costs compared to earlier TENS products. Consumables accounted for 40% of total sales in Q3 2012 compared to 36% in Q3 2011 and 38% for the full year 2011. Gross margin should continue to benefit as consumables grows as a % of total revenue (we model consumables to account for 41% of revenue in 2012). We also note that the rentals margin has been in the high 80% through the first nine months of 2012, much stronger than in all of 2011 which has also clearly benefitted aggregate GM recently.\n",
      "Net Income / EPS\n",
      "Net income and EPS were $358k and $0.01 compared to our $552k and $0.02 estimates. The difference due to a slight miss on revenue and the lower than modeled GM. Meanwhile, SG&A as a % of sales was 71%, just about dead-on with out 70.8% estimate. Elevated SG&A expense, as we've noted in the past, continues to hinder the robust growth in sales translating into similar growth in EPS. But management has indicated that they expect to see some more operating leverage in these expenses as revenue continues to grow - which we've incorporated into our modeled assumptions for 2013 and beyond.\n",
      "Part of the recent increase in SG&A as a % of sales is due to clinical trials expense related to the blood monitoring device (engineering and ops expenses runs through Zynex's SG&A. Zynex also recently beefed up its billing and reimbursement staff in anticipation of growing sales - which we hope will be leverageable as revenue grows, although we had already expected to see more in this regard at the current revenue levels. We think it's worth reiterating that, notwithstanding the recent improvement in GM and strong sales growth, unless Zynex can better control operating expenses, EPS growth will be constrained.\n",
      "Cash\n",
      "Zynex exited Q3 with $843k in cash and equivalents, up from $623k at the end of Q2. Cash used in operating and investing activities were $158k and $464k, respectively. Total drawn on the credit line was $6.1 million, leaving $900k in borrowing capacity at the end of Q3. Management indicated on the call that cash from operating activities should show some improvement going forward and believes the current credit line and cash balance will be sufficient to fund operations.\n",
      "Zynex noted in the Q1 2012 10-Q that the recent Health and Human Services mandate requiring companies to implement the new HIPPA 5010 coding system and use newly created billing codes when billing for reimbursement has created some difficulty in Zynex (and other companies) receiving payment from third party payors. Zynex noted that this had slowed some cash collections but indicated on the Q2 call that this is more of an administrative issue that should be rectified and that they do not expect this to be an ongoing problem. Presumably, as these cash collections begin to flow more regularly this should benefit Zynex's cash flow from operations.\n",
      "Guidance\n",
      "Management had previously issued 2012 revenue and EPS guidance of $38MM - $40MM and $0.06 - $0.08. With Q3 earnings, management narrowed the range of this guidance to revenue and EPS of $39MM - $40MM and $0.06 - $0.07. Our Q4 revenue and EPS estimates remain materially unchanged but with the $0.01 EPS miss in Q3, our full-year 2012 EPS estimate has moved $0.07 to $0.06. We look for full-year revenue of $39.5MM, implying annual growth of 16%.\n",
      "OUTLOOK :Largely unchanged since our last update\n",
      "Our outlook remains largely unchanged although we have made some adjustments to our model, mostly reflecting continued tweaking of our assumptions relative to how recent trends extrapolate into the future. We also note that additional risk has been introduced from the Centers for Medicare & Medicaid Services (CMS) deciding in June 2012 that, effective immediately, they would no longer provide reimbursement for TENS for chronic low back pain. Exactly how much of an impact this may have on Zynex has obviously yet to be seen but we think it's safe to assume that there is a significant chance that it may adversely effect revenue growth. Only a relatively small percentage of Zynex's (we estimate it's less than 10%) revenue comes from Medicare and CMS's recent decision relates only to chronic low back pain - both of which could help insulate the impact to Zynex. However, as Medicare reimbursement policies go, so often does private insurers - if private insurers follow Medicare's lead, the company's TENS related revenue could be significantly effected. This will be something to keep an eye on.\n",
      "Management addressed this potential issue on the Q3 call and noted that they have not experienced any adverse effects from the recent CMS action but also noted that they have plans relative to budgeting if and when this might become problematic.\n",
      "We look for revenue of $39.5 million in 2012, growing to $50.3 million in 2015, largely unchanged from our last update. Our model continues to incorporate the assumption that expansion of the sales force is the main impetus for revenue growth and we still do not incorporate any contribution from the aforementioned blood monitoring device. As we've noted in the past, while our model does not incorporate any revenue contribution from this product as few details have been revealed about the device or the related development/trials, we will update our model when we are more comfortable with the chances of eventual regulatory approval and commercialization of this product as well as other products under development. Management referenced on the call that the device is still in clinical trials, will be entering additional trials in 2012, and could possibly launch in 2013.\n",
      "For a free copy of the most recent ZYXI research report, please CLICK HERE.\n",
      "ZYNEX INC (ZYXI): Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Q2 2012 Financial Results: Strong Revenue and Gross Margin But Op Expenses Remain High\n",
      "Brian Marckx, CFA\n",
      "Zynex Inc (ZYXI) reported financial results for second quarter ending June 30, 2012 on August 7th. Revenue growth continues to impress and for the fifth consecutive quarter came in ahead or our estimate. Revenue of $10.0 million was up 19% from Q2 2011 and beat our $9.6 million estimate by about 5%. Sales of both equipment and consumables remained very strong while rental revenue was flat y-o-y. Revenue growth remains mostly tied to expansion of the sales force and feeding consumables to a growing installed based. Management noted that revenue from the Zynex NeuroDiagnostics business, which includes the recently acquired NeuroDyne product line, continues to grow, although remains relatively insignificant. The vast majority of revenue continues to come from electrical stimulation devices and related consumables from the Zynex Medical segment, although management remains focused on diversifying their product line including from a blood monitoring device that is currently in clinical testing but which Zynex believes could launch sometime next year. Management also noted on the call that they expect to introduce other new products during the current year.\n",
      "Revenue\n",
      "Total revenue consisted of $2.4 million (+0% y-o-y) in rentals and $7.6 million in product sales. While the equipment portion of product sales came in slightly softer than our estimate, rental revenue and consumables were 14% and 11% better than our numbers.\n",
      "Gross Margin\n",
      "Gross margin at 82.2% remained very strong, was well wider than our 78.1% estimate and broke through the 80% mark for the first time since Q3 2009. GM continues to benefit from a higher % of total sales coming from the high margin consumables segment as well as the next-generation TENS device which has lower input costs compared to earlier TENS products. Consumables accounted for 40% of total sales in Q2 2012 compared to 37% in Q2 2011 and 38% for the full year 2011. Gross margin should continue to benefit as consumables grows as a % of total revenue (we model consumables to account for 41% of revenue in 2012). We also note that the rentals margin has been in the high 80% through the first half of 2012, much stronger than in all of 2011 which has also clearly benefitted aggregate GM recently.\n",
      "Net Income / EPS\n",
      "Net income and EPS were $473k and $0.02 compared to our $561k and $0.02 estimates. The difference due to much higher than modeled SG&A expense more than offsetting the beat on the top-line and better GM. SG&A of $7.3 million or 73% of revenue was more than $900k higher than our $6.4 million (67% of estimated sales) estimate. Elevated SG&A expense, as we've noted in the past, continues to hinder the robust growth in sales translating into similar growth in EPS.\n",
      "Part of the recent increase in SG&A as a % of sales is due to clinical trials expense related to the blood monitoring device (engineering and ops expenses runs through Zynex's SG&A) - although, based on the footnotes in the Q1 2012 10-Q, engineering and operations expense was fairly benign (Q2 10-Q is not yet filed). Zynex also recently beefed up its billing and reimbursement staff in anticipation of growing sales - which we hope will be leverageable as revenue grows, although we had already expected to see more in this regard at the current revenue levels. We think it's worth reiterating that, notwithstanding the recent improvement in GM and strong sales growth, unless Zynex can better control operating expenses, EPS growth will be constrained.\n",
      "Cash\n",
      "Zynex exited Q2 with $623k in cash and equivalents, down from $742k at the end of Q1. Cash used in operating and investing activities were $272k and $641k ($100k of investing was related to the purchase of NeuroDyne), respectively. Total drawn on the credit line was $5.2 million, leaving $1.8 million in borrowing capacity at the end of Q2. Management noted on the call that they expect the credit line to be sufficient to fund operations.\n",
      "Zynex noted in the Q1 2012 10-Q that the recent Health and Human Services mandate requiring companies to implement the new HIPPA 5010 coding system and use newly created billing codes when billing for reimbursement has created some difficulty in Zynex (and other companies) receiving payment from third party payors. Zynex notes that this has slowed some cash collections but indicated on the Q2 call that this is more of an administrative issue that should be rectified and that they do not expect this to be an ongoing problem.\n",
      "Guidance\n",
      "Management reiterated previously issued 2012 guidance of revenue in the range of $38MM - $40MM and EPS in the range of $0.06 - $0.08. We have made some small adjustments to our 2012 estimates, with the majority related to tweaking down our Q4 revenue estimate (reflective of the risk posed by CMS decision - explained below), increasing our estimated SG&A expense but also increasing our estimated GM for 2H 2012.\n",
      "Our 2012 revenue and EPS estimates have moved from $39.7 million and $0.08 prior to Q2 results to $39.6 million and $0.07 currently.\n",
      "OUTLOOK: Mostly unchanged but CMS decision could effect revenue growth\n",
      "Our outlook remains largely unchanged although we have made some adjustments to our model, mostly reflecting continued tweaking of our assumptions relative to how recent trends extrapolate into the future. We also note that additional risk has been introduced from the Centers for Medicare & Medicaid Services (CMS) deciding in June 2012 that, effective immediately, they would no longer provide reimbursement for TENS for chronic low back pain. Exactly how much of an impact this may have on Zynex has obviously yet to be seen but we think it's safe to assume that there is a significant chance that it may adversely effect revenue growth. Only a relatively small percentage of Zynex's (we estimate it's less than 10%) revenue comes from Medicare and CMS's recent decision relates only to chronic low back pain - both of which could help insulate the impact to Zynex. However, as Medicare reimbursement policies go, so often does private insurers - if private insurers follow Medicare's lead, the company's TENS related revenue could be significantly effected. This will be something to keep an eye on.\n",
      "We have trimmed our revenue estimates to account for the risk posed by CMS's decision. We now look for revenue of $39.6 million in 2012, growing to $50.6 million in 2015, reduced from $39.7 million in 2012 and $51.5 million. Our model continues to incorporate the assumption that expansion of the sales force is the main impetus for revenue growth and we still do not incorporate any contribution from the aforementioned blood monitoring device. As we've noted in the past, while our model does not incorporate any revenue contribution from this product as few details have been revealed about the device or the related development/trials, we will update our model when we are more comfortable with the chances of eventual regulatory approval and commercialization of this product as well as other products under development. Management referenced on the call that the device is still in clinical trials, will be entering additional trials in 2012, and could possibly launch in 2013.\n",
      "Please visit scr.zacks.com to access a free copy of the ZYXI research report.\n",
      "ZYNEX INC (ZYXI): Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "35% Revenue Growth in Q1\n",
      "Brian Marckx, CFA\n",
      "Revenue\n",
      "Zynex Inc. (ZYXI) reported financial results for the first quarter ending March 31, 2012 on May 8th. Coming off revenue growth of 42% for the full-year 2011, Zynex started out 2012 with a bang. Revenue of $8.9 million was up 35% from Q1 2011 and well ahead of our $7.7 million (+16%) estimate on very strong sales of both equipment and consumables. Revenue growth continues to be mainly driven by rapidly expanding the sales force and tapping new geographic territories throughout the U.S.\n",
      "Total revenue consisted of $2.1 million (-16% y-o-y) in rentals and $6.9 million (+65% y-o-y) in product sales. While rentals came in slightly softer than our number, both components (equipment and consumables) of the product category were well ahead of our estimates.\n",
      "We continue to model strong growth in products sales coming from further expansion in the sales force, incremental contribution from the recent NeuroDyne acquisition, the recurring revenue stream from consumables (over an ever larger installed base), and introduction of new products in the Zynex Medical (i.e. - electrotherapy) business. As we've noted in the past, we do not currently model any contribution from Zynex's pipeline, namely their blood volume monitoring device. Depending on if and when the device launches and its ultimate commercial success, this could provide some upside to our estimates, especially relative to the out-years in our model.\n",
      "Gross Margin\n",
      "Gross margin was very strong at 79.7% and significantly wider than our 76.4% estimate. Management attributed the strength in the GM to growth in revenue from consumables as well as greater sales of next-generation TENS device which has lower input costs compared to earlier TENS products. GM does jump around from quarter to quarter, however, and can be highly dependent on the mix of products sold and the percentage of total revenue coming from rentals. We continue to model gross margin to remain near, to slightly below the level for the full-year 2011 (78.4%) going forward based on our assumption that lower margin product sales grow faster than the higher margin rentals business.\n",
      "Net Income / EPS\n",
      "Net income and EPS were $320k and $0.01, ahead of our $62k and $0.00 estimates. The difference, mostly attributable to the big beat on the top-line, also aided by a lower than modeled income tax rate. Meanwhile, SG&A as a percentage of sales, which can have a big influence on net income and EPS, was pretty much dead-on with our estimate (74.3% A vs 74.0% E).\n",
      "We continue to model an incremental improvement in SG&A as a percentage of sales for the full year 2012 compared to 2011. This, along with modeled strong revenue growth, are the main impetus for our estimated EPS of $0.08 in 2012, up from $0.05 in 2011. As a reminder, management has been successful in trimming expenses and cut SG&A as a percentage of sales from 71.9% in 2010 to 69.3% in 2011. If Zynex can continue to grow revenues, maintain gross margin at the 2011 level (or at least only slightly below), and continue to gain leverage on SG&A (all of which are assumptions incorporated into our model), then net income and EPS should exhibit healthy growth.\n",
      "Cash\n",
      "Zynex exited Q1 with $742k in cash, roughly flat from the end of Q4 2011. Cash used in operating and investing activities were $770k and $340 ($145k of which is related to the purchase of NeuroDyne), respectively. Total drawn on the credit line was $4.4MM, up from $3.3MM at the end of Q4 2011.\n",
      "Late last year Zynex replaced their legacy credit facility with one with a higher borrowing limit and a more favorable rate. The facility matures in December 2014 and has a maximum borrowing capacity of $7MM. Actual borrowing availability is also dependent on compliance with financial covenants and A/R balance (which secures the loan). Assuming Zynex can borrow the full $7MM, there was approximately $2.6MM availability left at the end of Q1. Management noted on the call that they expect cash on the balance sheet and borrowing availability under this loan to be sufficient to fund operations until at least the end of the current year.\n",
      "BUSINESS UPDATE / GUIDANCE\n",
      " Blood Monitoring Device Development: In April 2011 Zynex announced they had signed an agreement with OmniaVincit, LLC to conduct the first clinical evaluation of the company's blood volume monitoring device which is being developed in Zynex's new Monitoring division. The device is being developed to monitor the amount of blood loss during surgery and for the detection of internal bleeding in the recovery room. Management noted on the Q4 call that initial studies have been completed and results looked encouraging. The company now has a working prototype and they will continue with development and testing. Management noted on the Q1 call that they expect to build on the studies done in 2011 to conduct further trials in 2012. Management believes that if everything goes right, the device could possibly be on the U.S. market by sometime in 2013. As we've noted previously, while our model does not incorporate any revenue contribution from this product as few details have been revealed about the device or the related development/trials, we will update our model when we are more comfortable with the chances of eventual regulatory approval and commercialization of this product as well as other products under development.\n",
      " International Sales: International sales remain insignificant although Zynex continues to place a greater emphasis on expanding its international presence through signing new distribution contracts. In that regard, the company announced in February that they created a wholly-owned European subsidiary with a sole focus of selling into the European market. Zynex also expects to leverage NeuroDyne's international relationships to help grow their overseas business.\n",
      " NeuroDyne: In August 2011 Zynex announced that they signed a letter of intent to acquire NeuroDyne Medical Corp, a privately-held Cambridge, MA based manufacturer of medical devices for electromyography (sEMD) and autonomic nervous system monitoring. On March 12, 2012 Zynex announced that they closed the transaction. NeuroDyne's suite of products appear to be complementary to Zynex's and are used for a variety of purposes including spinal imaging (via sEMD) and neuromuscular rehabilitation. NeuroDyne's website noted their world-wide customer base is 3,000 strong and includes notable names such as the U.S. Air Force, Mayo Clinic and J&J, among several others. NeuroDyne's financial history was not disclosed and although we presume (based on the acquisition price) that NeuroDyne's revenue is relatively insignificant compared to Zynex's, we still view this as a potentially positive step towards Zynex's quest to further grow sales and profitability. Zynex acquired NeuroDyne for $420k ($145k cash and $175k restricted shares due at closing, $100k due in 60 days) and NeuroDyne's owners will be entitled to receive earn-outs over seven years based on sales of the NeuroDyne products. Zynex is currently in process of integrating NeuroDyne's operations with Zynex's Colorado headquarters (which should afford some cost synergies). NeuroDyne's CEO remains on in the capacity of Vice-President of Technical Support for Zynex's NeuroDiagnostics division.\n",
      " ActivaTek Inc: On October 31st Zynex announced that it signed an agreement with ActivaTek, Inc. to sell their lontophoresis products via Zynex's U.S. sales force. Lontophoresis is a non-invasive medication delivery system using a small electrical charge applied to a patch which is affixed to the skin. Zynex began selling the products during Q4 and indicated on the call that the reception has been encouraging. Management believes these lontophoresis products could also be a meaningful contributor to revenue growth going forward.\n",
      " Sales Rep Growth: Zynex has approximately 200 reps selling their products in 38 states, up from about 100 one year ago. The company expects to continue to add to their sales force, which we believe will remain the main catalyst driving sales over the near-to-mid term.\n",
      " Shareholder Lawsuit Settlement: As a reminder, on April 9, 2009 Zynex announced that it would restate their financial statements for the first three quarters of 2008. A class-action lawsuit was subsequently brought by shareholders of Zynex common stock (as of May 21, 2008 - March 31, 2009). The suit essentially alleged that the CEO and former CFO intentionally reported inflated revenue figures (which basically accused them of booking accounts receivable and revenue that they knew was likely not collectible) covering the restatement period. Revenue through the first nine months of 2008 was restated from $12,292k to $7,828k (36% haircut). Accounts receivable as of 9/30/2008 was restated from $9,433k to $4,970k. We cited this lawsuit as a concern and one that would likely limit the upside in the shares until it was favorably resolved.\n",
      "In their Q3 10-Q Zynex announced that on November 11, 2011 an agreement was entered into to settle the lawsuit for a payment to the plaintiffs in the amount of $2.5 million. Final court approval is scheduled for September. Derivative lawsuits have also been settled and are expected to get final court approval next month. Zynex expects settlement of the lawsuits to be fully funded by insurance. We view settlement of lawsuits as a significant positive.\n",
      " 2012 Guidance: Management reiterated previously issued 2012 guidance of revenue in the range of $38MM - $40MM and EPS in the range of $0.06 - $0.08. We have made some minor tweaks to our model following Q1 results although our revenue and EPS estimates for 2012 (and beyond) are not materially changed. We still look for 2012 revenue of approximately $39.7MM (+16%) and EPS of $0.08, both on the high side of management's guidance. We are maintaining our $1.50 / share price target and Outperform rating.\n",
      "For a free copy of the full research report, please visit scr.zacks.com.\n",
      "ZYNEX INC (ZYXI): Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "Q4 2011 Financial Results: Largely In-Line with Our Numbers...\n",
      "Brian Marckx, CFA\n",
      "Revenue\n",
      "Zynex Inc. (ZYXI) reported financial results for the fourth quarter ending December 31, 2011 on March 15th. Revenue of $9.7 million beat our $9.4 million estimate by just over 3%.\n",
      "Total revenue consisted of $2.5 million (+33% y-o-y) in rentals and $7.2 million (+46% y-o-y) in product sales. Both categories' revenue came in stronger than our respective estimates, especially noteworthy was rentals beating our number by 8%.\n",
      "Gross Margin\n",
      "Gross margin was 76.6%, compared to our 80.5% estimate. Gross margin had shown sequential improvement every quarter during 2011, save for Q4. Gross margin can jump around from quarter to quarter so the 290 basis point contraction from Q3 to Q4 is not necessarily indicative of a trend. Noteworthy is that gross margin for the full year 2011 remained constant at 78.4% from 2010. We currently model gross margin to remain near, to slightly below, this level going forward based on our assumption that lower margin product sales grow faster than the higher margin rentals business.\n",
      "Net Income / EPS\n",
      "Net income and EPS were $601k and $0.02, slightly below our $935k and $0.03 estimates - the difference due to the lower than modeled gross margin and higher interest expense, which were slightly offset by the higher revenue number. The spike in the interest expense line item relates to fees in connection with Zynex terminating their legacy credit facility - management replaced the credit line with one which has about twice the borrowing limit and a more favorable rate.\n",
      "Noteworthy, and positive, is that SG&A as a percentage of sales in Q4 was right on with our 64% estimate. This is a metric that we have placed a lot of emphasis on and one that, as we noted since initiating on Zynex, is important that the company can wring leverage out of in order to grow their bottom line. ZYXI did a good job of doing exactly that throughout 2011, with SG&A as % of sales falling from 71.9% in 2010 to 69.3% in 2011. As gross margin remained constant at 78.4% in both 2010 and 2011, all of the benefit from this SGA leverage flowed through to operating margins (operating margin expanded from 6.5% in 2010 to 9.1% in 2011). If Zynex can continue to grow revenues, maintain gross margin at the 2010/2011 level (or at least only slightly below), and continue to gain leverage on SG&A (all of which are assumptions incorporated into our model), then net income and EPS should exhibit healthy growth.\n",
      "Cash\n",
      "Zynex exited Q4 with $789k in cash, approximately flat from Q3 ($761k). Cash from operating activities was an inflow of $413k. Investing activities used $144k. Total drawn on the credit line was $3.29 million at the end of Q4, basically flat from $3.38 million at Q3.\n",
      "In December 2011 Zynex announced that they terminated their legacy credit facility and replaced it with a new credit line from Doral Healthcare Finance - which we view as a positive development. As we noted since initiating on Zynex, we had had some concerns relative to the company's liquidity position and pointed out that we would view renegotiating terms of their credit line as a positive step. Zynex regularly bumped up against the $3.5 million maximum borrowing limit of their legacy line and had in the past tripped covenants. The effective borrowing rates on their previous credit lines were also less than favorable to the company (averaging ~ between 10% - 14%) . This Doral line has a maximum borrowing capacity of up to $7 million (twice the size of the legacy facility), three-year term and carries a rate of LIBOR or 3% (whichever is greater) plus a margin of 3.75%.\n",
      "BUSINESS UPDATE / GUIDANCE\n",
      " Blood Monitoring Device Development: In April 2011 Zynex announced they had signed an agreement with OmniaVincit, LLC to conduct the first clinical evaluation of the company's blood volume monitoring device which is being developed in Zynex's new Monitoring division. The device is being developed to monitor the amount of blood loss during surgery and for the detection of internal bleeding in the recovery room. Management noted on the Q4 call that initial studies have been completed and results looked encouraging. The company now has a working prototype and they will continue with development and testing. Management believes that if everything goes right, the device could possibly be on the U.S. market by sometime in 2013. Our model does not currently incorporate any revenue contribution from this product as few details have been revealed about the device or the related development/trials. As we have noted in the past, our model will be updated when we are more comfortable with the chances of eventual regulatory approval and commercialization of this product as well as other products under development.\n",
      " International Sales: International sales for Q4 were not disclosed but management noted that they remain insignificant, although growing. Zynex will continue to place a greater emphasis on expanding its international presence through signing new distribution contracts. In that regard, the company announced in February that they created a wholly-owned European subsidiary with a sole focus of selling into the European market. Zynex also expects to leverage NeuroDyne's international relationships to help grow their overseas business.\n",
      " Shareholder Lawsuit / Anthem: As we noted in our previous update, Zynex filed an 8-K on September 23, 2011 reporting that they came to terms with Anthem Blue Cross Blue Shield relative to a dispute between the two companies over refund requests. As a reminder, in April 2010 Zynex received a refund request from Anthem in the amount of $1.3 million. Zynex estimated at the time that they had about $1.5 million worth of rebillings that were not properly reimbursed by Anthem - which would more than offset Anthem's claim. The 8-K notes that, per a settlement agreement, Zynex will pay Anthem $226k and all claims will be resolved. Zynex made an initial $60k payment and will pay the balance over the next 12 months. We view this settlement as good news for Zynex and removes an issue that had been hanging over the company since the initial claim was filed by Anthem.\n",
      " NeuroDyne: In August 2011 Zynex announced that they signed a letter of intent to acquire NeuroDyne Medical Corp, a privately-held Cambridge, MA based manufacturer of medical devices for electromyography (sEMD) and autonomic nervous system monitoring. On March 12, 2012 Zynex announced that they closed the transaction. NeuroDyne's suite of products appear to be complementary to Zynex's and are used for a variety of purposes including spinal imaging (via sEMD) and neuromuscular rehabilitation. NeuroDyne's website notes their world-wide customer base is 3,000 strong and includes notable names such as the U.S. Air Force, Mayo Clinic and J&J, among several others. NeuroDyne's financial history was not disclosed and although we presume (based on the acquisition price) that NeuroDyne's revenue is relatively insignificant compared to Zynex's, we still view this as a potentially positive step towards Zynex's quest to further grow sales and profitability. Zynex will acquire NeuroDyne for $420k ($145k cash and $175k restricted shares due at closing, $100k due in 60 days) and NeuroDyne's owners will be entitled to receive earn-outs over seven years based on sales of the NeuroDyne products. On the Q4 call Zynex noted that all of NeuroDyne's operations would be transferred to Zynex's Colorado headquarters (implying cost synergies). NeuroDyne's CEO will remain on in the capacity of Vice-President of Technical Support for Zynex's NeuroDiagnostics division.\n",
      " ActivaTek Inc: On October 31st Zynex announced that it signed an agreement with ActivaTek, Inc. to sell their lontophoresis products via Zynex's U.S. sales force. Lontophoresis is a non-invasive medication delivery system using a small electrical charge applied to a patch which is affixed to the skin. Zynex began selling the products during Q4 and indicated on the call that the reception has been encouraging. Management believes these lontophoresis products could also be a meaningful contributor to revenue growth going forward.\n",
      " Sales Rep Growth: Management noted on the call that they now have approximately 200 reps selling their products in 38 states, up from about 100 one year ago. The company expects to continue to add to their sales force, which we believe will remain the main catalyst driving sales over the near-to-mid term.\n",
      " Shareholder Lawsuit Settlement: As a reminder, on April 9, 2009 Zynex announced that it would restate their financial statements for the first three quarters of 2008. A class-action lawsuit was subsequently brought by shareholders of Zynex common stock (as of May 21, 2008 - March 31, 2009). The suit essentially alleged that the CEO and former CFO intentionally reported inflated revenue figures (which basically accused them of booking accounts receivable and revenue that they knew was likely not collectible) covering the restatement period. Revenue through the first nine months of 2008 was restated from $12,292k to $7,828k (36% haircut). Accounts receivable as of 9/30/2008 was restated from $9,433k to $4,970k. We cited this lawsuit as a concern and one that would likely limit the upside in the shares until it was favorably resolved.\n",
      "In their Q3 10-Q Zynex announced that on November 11, 2011 an agreement was entered into to settle the lawsuit for a payment to the plaintiffs in the amount of $2.5 million. Zynex expects the settlement to be fully funded by insurance. We view settlement of this lawsuit as a significant positive.\n",
      " 2012 Guidance: Management provided initial guidance for 2012 on the Q4 call. While revenue guidance is right in-line with our current (as well as prior to Q4 results announcement) estimate, EPS guidance came in well below what we were forecasting. Zynex's 2012 guidance is revenue between $38MM and $40MM and diluted EPS of between $0.06 and $0.08. Prior to Q4 results, we were looking for revenue and EPS of $39.1MM and $0.13. We now model revenue and EPS of $39.7MM and $0.08, both on the high side of management's guidance. The change in our EPS estimate reflects trimming of both gross margin and the extent of improvement in SG&A leverage (we still expect SG&A leverage to improve in 2012 and beyond, just not at the rate we had previously modeled).\n",
      "VALUATION\n",
      "We model EPS to grow at a five-year CAGR of about 12% through 2014. We use a PE/G ratio of 1.6x to value Zynex. This represents a 10% discount to the approximate 1.8x PE/G that the industry currently trades at. Our discount reflects the remaining concerns and risks that we have outlined in our initiation report on Zynex (2/14/2011). Our current 10% discount has been trimmed from the 33% we used when we initiated on Zynex and the 20% when we last published on the company (11/3/2011) which reflects what we believe is continued progress by management with de-risking. Several of our initial concerns have been mitigated, either completely or at least in large part, such as the Anthem lawsuit, the shareholder lawsuit, and the company's liquidity situation. Resolution of other concerns and/or mitigation of risks would likely warrant an even lower PE/G discount and, therefore, a higher price target. Meaningful progress with commercialization of Zynex's pipeline, including their blood monitoring device, could provide some upside relative to our current revenue and EPS estimates. Actual EPS falling short of our estimates and/or adverse consequences related to risks/concerns could prompt us to lower our valuation for Zynex.\n",
      "Applying the 1.6x PE/G and estimated five-year EPS CAGR of 12% to our 2012 EPS estimate of $0.08, results in a value of approximately $1.50 / share. As such, our price target has moved up by $0.10 from $1.40 to $1.50.\n",
      "To view a free copy of our most recent research report on ZYXIor subscribe to our daily morning email alert, visit Brian Marckx's coverage page at .\n",
      "ZYNEX INC ( ZYXI ): Free Stock Analysis Report\n",
      "To read this article on Zacks.com click here.\n",
      "Zacks Investment Research\n",
      "\n",
      "   Gaz de France  - Suez     . ,        Suez    Enel,  AFX. 23  Enel SpA     Suez.  ,            .     Suez        Veolia Environnement       Suez.  Veolia         Enel.      E.ON AG  29,1      Endesa SA.   E.ON   Gas Natural SDG SA,      . The French daily Les Echos, which carried the same information this morning, said that Veolia denied any plan to participate directly or indirectly in an offer for Suez. Finanza & Mercati added that Electricite de France is ready to delay a nuclear cooperation deal with Enel as a result of its interest in Suez. Enel's interest in Suez - which the French government insisted it would oppose - emerged yesterday. Gaz de France and Suez look at tie-up to combat Enel EDFGaz de France and Suez, the Franco-Belgian utility, are considering an alliance in what appears to be a government-backed bid to fend off a hostile approach from Italy's Enel. The move, which could be imminent, comes as Europe's energy sector has been thrown into turmoil by Eon's 29bn (19.8bn) cash bid for Endesa of Spain. On Thursday, France's heavily indebted electricity giant EDF sought to take centre stage by insisting it would not be left out of the current wave of industry deals and that it still had the financial flexibility to take part in consolidations.\n",
      "\n",
      "\"Billie Jean\"- Michael Jackson\"I Feel Love\" - Donna Summer\"Get Up (I Feel Like Being A) Sex Machine\" - James Brown\"Strings Of Life\" - Rhythim Is Rhythim\"Where Love Lives\" - Alison Limerick\"Keep On Movin'\" - Soul II Soul\"Can You Feel It\" - Fingers Inc.\n",
      "\"Big Fun\" - Inner City\"Theme From S'Express\" - S'Express\"Key To My Happiness\" - The Charades\n",
      "\n",
      "Garbage: \"Witness to Your Love\"\n",
      "Radiohead: \"House of Cards\"\n",
      "Of Montreal: \"Jimmy\" (Parvati Khan/M.I.A. cover)\n",
      "Bat for Lashes: \"What's a Girl to Do? (Plaid Remix)\"\n",
      "Oasis: \"Falling Down (Chemical Brothers Remix)\"\n",
      "Rilo Kiley: \"Draggin' Around\"\n",
      "Bloc Party: \"Flux (JKL remix)\"\n",
      "The Faint: \"The Geeks Were Right\" (DIOYY Remix)\"\n",
      "CSS: \"Rat Is Dead (Rage)\"\n",
      "The Decemberists: \"Billy Liar\" (live)\n",
      "Ra Ra Riot: \"Can You Tell (Little Ones Remix)\"\n",
      "Ladytron: \"Ghosts (Modwheelmood Mix)\"\n",
      "The Little Ones: \"I Don't Want to Dance\"\n",
      "Other Lives: \"Paper Cities\"\n",
      "Two Sheds: \"You\"\n",
      "Jack Johnson: \"All at Once\" (live at Bumbershoot 2008)  2: Silversun Pickups: \"Table Scraps\"\n",
      "Eulogies: \"Is There Anyone Here?\"\n",
      "Darker My Love: \"Blue Day\"\n",
      "The Dears: \"Crisis 1 & 2\"\n",
      "Sea Wolf: \"The Promise\"\n",
      "The Curse of Company: \"All the Mines\"\n",
      "The One AM Radio: \"Old Men\"\n",
      "Ed Laurie: \"Albert\"\n",
      "Eric Avery: \"All Remote and No Control\"\n",
      "Dappled Cities: \"Vision Bell\"\n",
      "La Rocca: \"Cross the River\"\n",
      "\n",
      "Exitmusic - \"Space Oddity\"\n",
      "Vivian Girls - \"John, I'm Only Dancing\"\n",
      "Megapuss - \"Sound + Vision\"\n",
      "  - \"Absolute Beginners\"\n",
      "Lights - \"World Falls Down\"\n",
      "VOICEsVOICEs - \"Heroes\"\n",
      "Duran Duran - \"Boys Keep Swinging\"\n",
      "Chairlift - \"Always Crashing in the Same Car\"\n",
      "Aska with Moon & Moon - \"African Night Flight\"\n",
      "A Place to Bury Strangers - \"Suffragette City\"\n",
      "Polyamorous Affair - \"Theme From Cat People\"\n",
      "  - \"Life on Mars\"\n",
      "Swahili Blonde    - \"Red Money\"\n",
      "  - \"Art Decade\"\n",
      "Corridor - \"Be My Wife\"\n",
      "Aquaserge - \"The Supermen\"\n",
      "Warpaint - \"Ashes to Ashes\"\n",
      "Rainbow Arabia - \"Quicksand\"\n",
      "We Are the World - \"Afraid of Americans\"\n",
      "LacoSte - \"Within You\"\n",
      "  - \"Ziggy Stardust\"\n",
      "Pizza! - \"Modern World\"\n",
      "St. Clair Board - \"Secret Life of Arabia\"\n",
      "  - \"Starman\"\n",
      "   - \"The Man Who Sold the World\"\n",
      "  - \"Ashes to Ashes\".      ,     MGMT  Soulwax     .         ,       ,  .      2010 .\n",
      "\n",
      "\n",
      "--- End of File Sample ---\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import logging\n",
    "\n",
    "# --- Configuration ---\n",
    "\n",
    "# Configure logging\n",
    "logging.basicConfig(level=logging.INFO, format='%(asctime)s - %(levelname)s - %(message)s')\n",
    "\n",
    "# Base output directory (MUST MATCH your scraper script)\n",
    "# !! IMPORTANT: Update this path !!\n",
    "BASE_OUTPUT_DIR = r'D:\\market_data\\text_data' # <-- MAKE SURE THIS PATH IS CORRECT\n",
    "USA_OUTPUT_DIR = os.path.join(BASE_OUTPUT_DIR, 'USA')\n",
    "USA_CORPUS_FILE = os.path.join(USA_OUTPUT_DIR, 'corpus_cleaned.txt')\n",
    "\n",
    "# How many bytes to read from the end (approx 5000 characters)\n",
    "# Adjust if needed. 1 char ~ 1 byte in UTF-8 for basic English text.\n",
    "BYTES_TO_READ = 1000000 # Read slightly more to account for multi-byte chars or partial lines\n",
    "\n",
    "# --- Script ---\n",
    "\n",
    "def inspect_tail(filepath, num_bytes):\n",
    "    \"\"\"Reads and prints the last `num_bytes` of a file.\"\"\"\n",
    "    logging.info(f\"Attempting to read the last ~{num_bytes} bytes from: {filepath}\")\n",
    "    try:\n",
    "        with open(filepath, 'rb') as f: # Open in binary read mode ('rb')\n",
    "            f.seek(0, os.SEEK_END) # Go to the end of the file\n",
    "            filesize = f.tell()\n",
    "            logging.info(f\"File size: {filesize:,} bytes\")\n",
    "\n",
    "            if filesize == 0:\n",
    "                logging.warning(\"File is empty.\")\n",
    "                return\n",
    "\n",
    "            seek_position = max(0, filesize - num_bytes) # Calculate position, ensure non-negative\n",
    "            f.seek(seek_position, os.SEEK_SET) # Jump near the end\n",
    "\n",
    "            last_chunk = f.read() # Read from seek position to the end\n",
    "\n",
    "            # Decode the bytes into text, ignoring errors for potentially cut-off characters at the beginning\n",
    "            # Using UTF-8, which is what the scraper saves in\n",
    "            decoded_text = last_chunk.decode('utf-8', errors='ignore')\n",
    "\n",
    "            print(\"\\n--- Last ~5000 Characters ---\")\n",
    "            # Print the decoded text. It might start mid-word/mid-sentence, which is expected.\n",
    "            print(decoded_text)\n",
    "            print(\"--- End of File Sample ---\")\n",
    "\n",
    "    except FileNotFoundError:\n",
    "        logging.error(f\"Error: File not found at {filepath}\")\n",
    "    except Exception as e:\n",
    "        logging.error(f\"An error occurred while reading the file: {e}\", exc_info=True)\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    if not os.path.exists(USA_CORPUS_FILE):\n",
    "        logging.error(f\"Corpus file does not exist: {USA_CORPUS_FILE}\")\n",
    "        logging.error(\"Please ensure the BASE_OUTPUT_DIR is correct and the scraper has run.\")\n",
    "    else:\n",
    "        inspect_tail(USA_CORPUS_FILE, BYTES_TO_READ)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "f0651ee5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "8090090\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "\n",
    "BASE_OUTPUT_DIR = r'D:\\market_data\\text_data'\n",
    "USA_OUTPUT_DIR = os.path.join(BASE_OUTPUT_DIR, 'USA')\n",
    "USA_CORPUS_FILE = os.path.join(USA_OUTPUT_DIR, 'corpus.txt')\n",
    "\n",
    "count = 0\n",
    "chunk_size = 1024 * 1024 * 64  # 64 MB chunks\n",
    "buffer = \"\"\n",
    "\n",
    "with open(USA_CORPUS_FILE, 'r', encoding='utf-8', errors='ignore') as f:\n",
    "    while True:\n",
    "        chunk = f.read(chunk_size)\n",
    "        if not chunk:\n",
    "            break\n",
    "        # Prepend the last few chars from the previous buffer\n",
    "        chunk = buffer + chunk\n",
    "\n",
    "        # Count occurrences\n",
    "        count += chunk.count('\\n\\n')\n",
    "\n",
    "        # Keep only the last character in case '\\n' is split across chunks\n",
    "        buffer = chunk[-1:]\n",
    "\n",
    "print(count)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0e97a614",
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "invalid syntax. Perhaps you forgot a comma? (1725159904.py, line 3)",
     "output_type": "error",
     "traceback": [
      "  \u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[1]\u001b[39m\u001b[32m, line 3\u001b[39m\n\u001b[31m    \u001b[39m\u001b[31m{'loss': 1.4536, 'grad_norm': 6.79431676864624, 'learning_rate': 4.746605301545849e-05, 'epoch': 0.15}\u001b[39m\n    ^\n\u001b[31mSyntaxError\u001b[39m\u001b[31m:\u001b[39m invalid syntax. Perhaps you forgot a comma?\n"
     ]
    }
   ],
   "source": [
    "data = {\n",
    "    \n",
    "{'loss': 1.4536, 'grad_norm': 6.79431676864624, 'learning_rate': 4.746605301545849e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4583, 'grad_norm': 6.5994462966918945, 'learning_rate': 4.74633017098264e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4758, 'grad_norm': 7.309181213378906, 'learning_rate': 4.746055040419432e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4782, 'grad_norm': 7.764740943908691, 'learning_rate': 4.745779909856222e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4527, 'grad_norm': 10.764654159545898, 'learning_rate': 4.7455047792930135e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4587, 'grad_norm': 11.2777681350708, 'learning_rate': 4.745229648729805e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4756, 'grad_norm': 10.040223121643066, 'learning_rate': 4.744954518166596e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4681, 'grad_norm': 7.98757266998291, 'learning_rate': 4.7446793876033873e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4635, 'grad_norm': 21.996435165405273, 'learning_rate': 4.744404257040179e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4822, 'grad_norm': 7.241261959075928, 'learning_rate': 4.74412912647697e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4739, 'grad_norm': 8.585515975952148, 'learning_rate': 4.743853995913761e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4781, 'grad_norm': 8.846548080444336, 'learning_rate': 4.743578865350553e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4857, 'grad_norm': 8.616715431213379, 'learning_rate': 4.7433037347873436e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4869, 'grad_norm': 11.389678955078125, 'learning_rate': 4.7430286042241344e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4758, 'grad_norm': 8.24552059173584, 'learning_rate': 4.742753473660926e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4808, 'grad_norm': 6.947010517120361, 'learning_rate': 4.7424783430977174e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4833, 'grad_norm': 49.08424377441406, 'learning_rate': 4.742203212534508e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4528, 'grad_norm': 8.930402755737305, 'learning_rate': 4.7419280819713e-05, 'epoch': 0.15},\n",
    "{'loss': 1.4744, 'grad_norm': 10.954212188720703, 'learning_rate': 4.741652951408091e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4728, 'grad_norm': 16.19570541381836, 'learning_rate': 4.741377820844882e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4806, 'grad_norm': 9.774336814880371, 'learning_rate': 4.7411026902816736e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4755, 'grad_norm': 12.006851196289062, 'learning_rate': 4.740827559718465e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4613, 'grad_norm': 10.727494239807129, 'learning_rate': 4.740552429155256e-05, 'epoch': 0.16},\n",
    "{'loss': 1.48, 'grad_norm': 10.045310974121094, 'learning_rate': 4.740277298592047e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4812, 'grad_norm': 9.043827056884766, 'learning_rate': 4.7400021680288383e-05, 'epoch': 0.16},\n",
    "{'loss': 1.4542, 'grad_norm': 13.474766731262207, 'learning_rate': 4.739727037465629e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4962, 'grad_norm': 9.363969802856445, 'learning_rate': 4.739451906902421e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4913, 'grad_norm': 9.69883918762207, 'learning_rate': 4.739176776339212e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4841, 'grad_norm': 9.489829063415527, 'learning_rate': 4.738901645776003e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4769, 'grad_norm': 11.249781608581543, 'learning_rate': 4.7386265152127946e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4693, 'grad_norm': 10.347302436828613, 'learning_rate': 4.738351384649586e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4778, 'grad_norm': 9.758716583251953, 'learning_rate': 4.738076254086377e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4737, 'grad_norm': 6.0282883644104, 'learning_rate': 4.7378011235231684e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4815, 'grad_norm': 8.643651008605957, 'learning_rate': 4.737525992959959e-05, 'epoch': 0.16}\n",
    "{'loss': 1.475, 'grad_norm': 7.774406909942627, 'learning_rate': 4.73725086239675e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4688, 'grad_norm': 11.211589813232422, 'learning_rate': 4.7369757318335416e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4721, 'grad_norm': 7.872531414031982, 'learning_rate': 4.736700601270333e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4941, 'grad_norm': 10.49804401397705, 'learning_rate': 4.736425470707124e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4732, 'grad_norm': 8.337812423706055, 'learning_rate': 4.7361503401439155e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4987, 'grad_norm': 9.663531303405762, 'learning_rate': 4.735875209580707e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4932, 'grad_norm': 7.8786396980285645, 'learning_rate': 4.735600079017498e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4706, 'grad_norm': 9.960122108459473, 'learning_rate': 4.7353249484542893e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4616, 'grad_norm': 7.0666728019714355, 'learning_rate': 4.735049817891081e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4764, 'grad_norm': 10.718029022216797, 'learning_rate': 4.734774687327872e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4838, 'grad_norm': 11.897994995117188, 'learning_rate': 4.7344995567646625e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4751, 'grad_norm': 13.172527313232422, 'learning_rate': 4.734224426201454e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4572, 'grad_norm': 6.765641689300537, 'learning_rate': 4.7339492956382456e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4548, 'grad_norm': 8.282583236694336, 'learning_rate': 4.7336741650750364e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4794, 'grad_norm': 10.229754447937012, 'learning_rate': 4.733399034511828e-05, 'epoch': 0.16}\n",
    "{'loss': 1.486, 'grad_norm': 11.479272842407227, 'learning_rate': 4.7331239039486194e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4816, 'grad_norm': 6.574367523193359, 'learning_rate': 4.73284877338541e-05, 'epoch': 0.16}\n",
    "{'loss': 1.475, 'grad_norm': 8.249167442321777, 'learning_rate': 4.732573642822202e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4763, 'grad_norm': 11.061763763427734, 'learning_rate': 4.7322985122589926e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4733, 'grad_norm': 8.99709701538086, 'learning_rate': 4.7320233816957835e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4485, 'grad_norm': 9.03708553314209, 'learning_rate': 4.731748251132575e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4789, 'grad_norm': 7.607971668243408, 'learning_rate': 4.7314731205693665e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4816, 'grad_norm': 10.690608978271484, 'learning_rate': 4.731197990006157e-05, 'epoch': 0.16}\n",
    "{'loss': 1.5158, 'grad_norm': 7.525801181793213, 'learning_rate': 4.730922859442949e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4607, 'grad_norm': 6.880888938903809, 'learning_rate': 4.7306477288797404e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4676, 'grad_norm': 7.290761947631836, 'learning_rate': 4.730372598316531e-05, 'epoch': 0.16}\n",
    "{'loss': 1.5065, 'grad_norm': 9.399045944213867, 'learning_rate': 4.730097467753323e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4745, 'grad_norm': 8.392634391784668, 'learning_rate': 4.729822337190114e-05, 'epoch': 0.16}\n",
    "{'loss': 1.49, 'grad_norm': 9.712846755981445, 'learning_rate': 4.729547206626905e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4738, 'grad_norm': 8.620290756225586, 'learning_rate': 4.729272076063696e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4788, 'grad_norm': 6.871674060821533, 'learning_rate': 4.7289969455004874e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4816, 'grad_norm': 8.319815635681152, 'learning_rate': 4.728721814937279e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4936, 'grad_norm': 11.031319618225098, 'learning_rate': 4.72844668437407e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4819, 'grad_norm': 6.931077480316162, 'learning_rate': 4.728171553810861e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4956, 'grad_norm': 10.174436569213867, 'learning_rate': 4.727896423247653e-05, 'epoch': 0.16}\n",
    "{'loss': 1.484, 'grad_norm': 11.743756294250488, 'learning_rate': 4.7276212926844436e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4673, 'grad_norm': 13.401228904724121, 'learning_rate': 4.727346162121235e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4923, 'grad_norm': 27.867998123168945, 'learning_rate': 4.7270710315580267e-05, 'epoch': 0.16}\n",
    "{'loss': 1.476, 'grad_norm': 8.426937103271484, 'learning_rate': 4.726795900994817e-05, 'epoch': 0.16}\n",
    "{'loss': 1.466, 'grad_norm': 9.039795875549316, 'learning_rate': 4.726520770431608e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4634, 'grad_norm': 9.012330055236816, 'learning_rate': 4.7262456398684e-05, 'epoch': 0.16}\n",
    "{'loss': 1.488, 'grad_norm': 6.839291095733643, 'learning_rate': 4.725970509305191e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4501, 'grad_norm': 7.381160259246826, 'learning_rate': 4.725695378741982e-05, 'epoch': 0.16}\n",
    "{'loss': 1.5043, 'grad_norm': 7.075179100036621, 'learning_rate': 4.725420248178774e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4889, 'grad_norm': 12.77310562133789, 'learning_rate': 4.7251451176155645e-05, 'epoch': 0.16}\n",
    "{'loss': 1.4964, 'grad_norm': 8.807293891906738, 'learning_rate': 4.724869987052356e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4864, 'grad_norm': 11.664904594421387, 'learning_rate': 4.7245948564891476e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4895, 'grad_norm': 11.657865524291992, 'learning_rate': 4.7243197259259384e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4882, 'grad_norm': 9.069992065429688, 'learning_rate': 4.724044595362729e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4903, 'grad_norm': 11.038657188415527, 'learning_rate': 4.723769464799521e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4621, 'grad_norm': 9.848742485046387, 'learning_rate': 4.7234943342363116e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4985, 'grad_norm': 9.173456192016602, 'learning_rate': 4.723219203673103e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4835, 'grad_norm': 6.993440628051758, 'learning_rate': 4.7229440731098946e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4705, 'grad_norm': 10.926280975341797, 'learning_rate': 4.7226689425466855e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4854, 'grad_norm': 7.930708885192871, 'learning_rate': 4.722393811983477e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4857, 'grad_norm': 9.801553726196289, 'learning_rate': 4.7221186814202685e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4659, 'grad_norm': 8.580015182495117, 'learning_rate': 4.721843550857059e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4793, 'grad_norm': 9.681512832641602, 'learning_rate': 4.721568420293851e-05, 'epoch': 0.17}\n",
    "{'loss': 1.5136, 'grad_norm': 11.841506958007812, 'learning_rate': 4.721293289730642e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4617, 'grad_norm': 9.392284393310547, 'learning_rate': 4.721018159167433e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4967, 'grad_norm': 10.530618667602539, 'learning_rate': 4.720743028604224e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4746, 'grad_norm': 8.618043899536133, 'learning_rate': 4.7204678980410155e-05, 'epoch': 0.17}\n",
    "{'loss': 1.499, 'grad_norm': 7.976864337921143, 'learning_rate': 4.720192767477807e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4752, 'grad_norm': 9.879810333251953, 'learning_rate': 4.719917636914598e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4781, 'grad_norm': 11.524188041687012, 'learning_rate': 4.7196425063513894e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4896, 'grad_norm': 7.185775279998779, 'learning_rate': 4.719367375788181e-05, 'epoch': 0.17}\n",
    "{'loss': 1.469, 'grad_norm': 7.966792106628418, 'learning_rate': 4.719092245224972e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4853, 'grad_norm': 9.657007217407227, 'learning_rate': 4.718817114661763e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4474, 'grad_norm': 8.677680015563965, 'learning_rate': 4.718541984098554e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4749, 'grad_norm': 7.666914463043213, 'learning_rate': 4.718266853535345e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4762, 'grad_norm': 14.173002243041992, 'learning_rate': 4.7179917229721365e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4842, 'grad_norm': 10.791522026062012, 'learning_rate': 4.717716592408928e-05, 'epoch': 0.17}\n",
    "{'loss': 1.488, 'grad_norm': 7.679072380065918, 'learning_rate': 4.717441461845719e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4868, 'grad_norm': 9.732560157775879, 'learning_rate': 4.71716633128251e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4703, 'grad_norm': 10.155884742736816, 'learning_rate': 4.716891200719302e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4647, 'grad_norm': 5.959256649017334, 'learning_rate': 4.716616070156093e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4532, 'grad_norm': 11.353148460388184, 'learning_rate': 4.716340939592884e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4884, 'grad_norm': 10.36120319366455, 'learning_rate': 4.716065809029675e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4711, 'grad_norm': 4.827858924865723, 'learning_rate': 4.7157906784664666e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4808, 'grad_norm': 9.368616104125977, 'learning_rate': 4.7155155479032574e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4955, 'grad_norm': 10.763655662536621, 'learning_rate': 4.715240417340049e-05, 'epoch': 0.17}\n",
    "{'loss': 1.5057, 'grad_norm': 8.108057975769043, 'learning_rate': 4.7149652867768404e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4808, 'grad_norm': 7.08778715133667, 'learning_rate': 4.714690156213631e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4785, 'grad_norm': 11.921842575073242, 'learning_rate': 4.714415025650423e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4684, 'grad_norm': 14.769454956054688, 'learning_rate': 4.714139895087214e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4701, 'grad_norm': 8.66366195678711, 'learning_rate': 4.713864764524005e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4945, 'grad_norm': 8.049585342407227, 'learning_rate': 4.7135896339607966e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4763, 'grad_norm': 9.080016136169434, 'learning_rate': 4.7133145033975875e-05, 'epoch': 0.17}\n",
    "{'loss': 1.482, 'grad_norm': 6.91448974609375, 'learning_rate': 4.713039372834378e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4644, 'grad_norm': 10.197025299072266, 'learning_rate': 4.71276424227117e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4954, 'grad_norm': 10.107752799987793, 'learning_rate': 4.7124891117079613e-05, 'epoch': 0.17}\n",
    "{'loss': 1.501, 'grad_norm': 9.560768127441406, 'learning_rate': 4.712213981144752e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4838, 'grad_norm': 13.69091796875, 'learning_rate': 4.711938850581544e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4691, 'grad_norm': 10.135381698608398, 'learning_rate': 4.711663720018335e-05, 'epoch': 0.17}\n",
    "{'loss': 1.485, 'grad_norm': inf, 'learning_rate': 4.711388589455126e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4716, 'grad_norm': 12.192312240600586, 'learning_rate': 4.7111134588919176e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4716, 'grad_norm': 8.330598831176758, 'learning_rate': 4.710838328328709e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4987, 'grad_norm': 10.034501075744629, 'learning_rate': 4.7105631977655e-05, 'epoch': 0.17}\n",
    "{'loss': 1.5176, 'grad_norm': 10.290061950683594, 'learning_rate': 4.710288067202291e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4654, 'grad_norm': 12.0889253616333, 'learning_rate': 4.710012936639082e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4819, 'grad_norm': 7.820587635040283, 'learning_rate': 4.709737806075874e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4775, 'grad_norm': 8.150120735168457, 'learning_rate': 4.7094626755126646e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4909, 'grad_norm': 12.647221565246582, 'learning_rate': 4.709187544949456e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4908, 'grad_norm': 12.30191707611084, 'learning_rate': 4.7089124143862476e-05, 'epoch': 0.17}\n",
    "{'loss': 1.485, 'grad_norm': 6.438595771789551, 'learning_rate': 4.7086372838230385e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4859, 'grad_norm': 9.41541576385498, 'learning_rate': 4.70836215325983e-05, 'epoch': 0.17}\n",
    "{'loss': 1.4721, 'grad_norm': 9.583277702331543, 'learning_rate': 4.708087022696621e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4596, 'grad_norm': 10.226386070251465, 'learning_rate': 4.707811892133412e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4703, 'grad_norm': 10.9879732131958, 'learning_rate': 4.707536761570203e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4899, 'grad_norm': 9.273009300231934, 'learning_rate': 4.707261631006995e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4842, 'grad_norm': 11.721781730651855, 'learning_rate': 4.7069865004437855e-05, 'epoch': 0.18}\n",
    "{'loss': 1.499, 'grad_norm': 10.819595336914062, 'learning_rate': 4.706711369880577e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4787, 'grad_norm': 9.173372268676758, 'learning_rate': 4.7064362393173686e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4973, 'grad_norm': 10.156161308288574, 'learning_rate': 4.7061611087541594e-05, 'epoch': 0.18}\n",
    "{'loss': 1.487, 'grad_norm': 11.506617546081543, 'learning_rate': 4.705885978190951e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4788, 'grad_norm': 7.292954444885254, 'learning_rate': 4.7056108476277424e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4901, 'grad_norm': 12.675764083862305, 'learning_rate': 4.705335717064533e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5067, 'grad_norm': 9.394784927368164, 'learning_rate': 4.705060586501324e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4632, 'grad_norm': 8.5784273147583, 'learning_rate': 4.7047854559381156e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4907, 'grad_norm': 9.689364433288574, 'learning_rate': 4.7045103253749065e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4692, 'grad_norm': 6.408139705657959, 'learning_rate': 4.704235194811698e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4672, 'grad_norm': 11.811112403869629, 'learning_rate': 4.7039600642484895e-05, 'epoch': 0.18}\n",
    "{'loss': 1.475, 'grad_norm': 8.478165626525879, 'learning_rate': 4.70368493368528e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4584, 'grad_norm': 10.520864486694336, 'learning_rate': 4.703409803122072e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4652, 'grad_norm': 6.6351776123046875, 'learning_rate': 4.7031346725588633e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4642, 'grad_norm': 6.784965515136719, 'learning_rate': 4.702859541995654e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4601, 'grad_norm': 9.554871559143066, 'learning_rate': 4.702584411432446e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4504, 'grad_norm': 6.760406970977783, 'learning_rate': 4.7023092808692365e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4832, 'grad_norm': 9.797229766845703, 'learning_rate': 4.702034150306028e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4803, 'grad_norm': 11.899965286254883, 'learning_rate': 4.701759019742819e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4553, 'grad_norm': 9.460926055908203, 'learning_rate': 4.7014838891796104e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4895, 'grad_norm': 12.171648979187012, 'learning_rate': 4.701208758616402e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4791, 'grad_norm': 8.858613967895508, 'learning_rate': 4.700933628053193e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4736, 'grad_norm': 8.259005546569824, 'learning_rate': 4.700658497489984e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4715, 'grad_norm': 7.4567060470581055, 'learning_rate': 4.700383366926776e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4636, 'grad_norm': 8.023266792297363, 'learning_rate': 4.7001082363635666e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4639, 'grad_norm': 7.393029689788818, 'learning_rate': 4.6998331058003575e-05, 'epoch': 0.18}\n",
    "{'loss': 1.48, 'grad_norm': 8.07656478881836, 'learning_rate': 4.699557975237149e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4859, 'grad_norm': 9.26103687286377, 'learning_rate': 4.69928284467394e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4593, 'grad_norm': 17.236347198486328, 'learning_rate': 4.699007714110731e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4804, 'grad_norm': 10.634861946105957, 'learning_rate': 4.698732583547523e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4967, 'grad_norm': 8.00877857208252, 'learning_rate': 4.698457452984314e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4791, 'grad_norm': 10.931817054748535, 'learning_rate': 4.698182322421105e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4762, 'grad_norm': 8.090311050415039, 'learning_rate': 4.697907191857897e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4928, 'grad_norm': 10.221521377563477, 'learning_rate': 4.6976320612946875e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4889, 'grad_norm': 9.890180587768555, 'learning_rate': 4.697356930731479e-05, 'epoch': 0.18}\n",
    "{'loss': 1.53, 'grad_norm': 8.632936477661133, 'learning_rate': 4.69708180016827e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4666, 'grad_norm': 8.986140251159668, 'learning_rate': 4.6968066696050614e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4551, 'grad_norm': 9.966825485229492, 'learning_rate': 4.696531539041852e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4706, 'grad_norm': 7.881124973297119, 'learning_rate': 4.696256408478644e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4696, 'grad_norm': 11.763664245605469, 'learning_rate': 4.695981277915435e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4793, 'grad_norm': 7.786286354064941, 'learning_rate': 4.695706147352226e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4839, 'grad_norm': 9.363397598266602, 'learning_rate': 4.6954310167890176e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4783, 'grad_norm': 6.5223469734191895, 'learning_rate': 4.695155886225809e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5021, 'grad_norm': 7.594969749450684, 'learning_rate': 4.6948807556626e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4867, 'grad_norm': 8.833131790161133, 'learning_rate': 4.6946056250993915e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5043, 'grad_norm': 11.668055534362793, 'learning_rate': 4.694330494536182e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4879, 'grad_norm': 9.198160171508789, 'learning_rate': 4.694055363972973e-05, 'epoch': 0.18}\n",
    "{'loss': 1.487, 'grad_norm': 11.395952224731445, 'learning_rate': 4.693780233409765e-05, 'epoch': 0.18}\n",
    "{'loss': 1.518, 'grad_norm': 11.178462028503418, 'learning_rate': 4.693505102846556e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5018, 'grad_norm': 9.681427001953125, 'learning_rate': 4.693229972283347e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4779, 'grad_norm': 9.515279769897461, 'learning_rate': 4.6929548417201385e-05, 'epoch': 0.18}\n",
    "{'loss': 1.4811, 'grad_norm': 7.066597938537598, 'learning_rate': 4.69267971115693e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5181, 'grad_norm': 9.136130332946777, 'learning_rate': 4.692404580593721e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5306, 'grad_norm': 10.587213516235352, 'learning_rate': 4.6921294500305124e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5076, 'grad_norm': 8.466611862182617, 'learning_rate': 4.691854319467304e-05, 'epoch': 0.18}\n",
    "{'loss': 1.5411, 'grad_norm': 11.098169326782227, 'learning_rate': 4.691579188904095e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5042, 'grad_norm': 9.542279243469238, 'learning_rate': 4.6913040583408856e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5021, 'grad_norm': 7.32064151763916, 'learning_rate': 4.691028927777677e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5042, 'grad_norm': 11.357136726379395, 'learning_rate': 4.690753797214468e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4923, 'grad_norm': 15.599925994873047, 'learning_rate': 4.6904786666512595e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4941, 'grad_norm': 10.199986457824707, 'learning_rate': 4.690203536088051e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5081, 'grad_norm': 11.672343254089355, 'learning_rate': 4.689928405524842e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5333, 'grad_norm': 8.436853408813477, 'learning_rate': 4.689653274961633e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5135, 'grad_norm': 11.152113914489746, 'learning_rate': 4.689378144398425e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5298, 'grad_norm': 8.186738014221191, 'learning_rate': 4.689103013835216e-05, 'epoch': 0.19}\n",
    "{'loss': 1.9076, 'grad_norm': 93.35053253173828, 'learning_rate': 4.6888278832720065e-05, 'epoch': 0.19}\n",
    "{'loss': 1.8955, 'grad_norm': 10.346670150756836, 'learning_rate': 4.688552752708798e-05, 'epoch': 0.19}\n",
    "{'loss': 1.7773, 'grad_norm': 40.081153869628906, 'learning_rate': 4.6882776221455895e-05, 'epoch': 0.19}\n",
    "{'loss': 1.9108, 'grad_norm': 8.335807800292969, 'learning_rate': 4.6880024915823804e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6543, 'grad_norm': 13.320844650268555, 'learning_rate': 4.687727361019172e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6799, 'grad_norm': 9.502729415893555, 'learning_rate': 4.6874522304559634e-05, 'epoch': 0.19}\n",
    "{'loss': 1.7083, 'grad_norm': 12.644293785095215, 'learning_rate': 4.687177099892754e-05, 'epoch': 0.19}\n",
    "{'loss': 1.7456, 'grad_norm': 9.0537748336792, 'learning_rate': 4.686901969329546e-05, 'epoch': 0.19}\n",
    "{'loss': 1.8664, 'grad_norm': 192.17393493652344, 'learning_rate': 4.686626838766337e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6837, 'grad_norm': 8.501562118530273, 'learning_rate': 4.6863517082031274e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6652, 'grad_norm': 11.648345947265625, 'learning_rate': 4.686076577639919e-05, 'epoch': 0.19}\n",
    "{'loss': 1.862, 'grad_norm': 8.574299812316895, 'learning_rate': 4.6858014470767105e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6497, 'grad_norm': 14.104843139648438, 'learning_rate': 4.685526316513501e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6712, 'grad_norm': 9.884845733642578, 'learning_rate': 4.685251185950293e-05, 'epoch': 0.19}\n",
    "{'loss': 1.7077, 'grad_norm': 10.854574203491211, 'learning_rate': 4.684976055387084e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5445, 'grad_norm': 11.276516914367676, 'learning_rate': 4.684700924823875e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5192, 'grad_norm': 8.07763671875, 'learning_rate': 4.684425794260667e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4786, 'grad_norm': 7.137641906738281, 'learning_rate': 4.684150663697458e-05, 'epoch': 0.19}\n",
    "{'loss': 1.566, 'grad_norm': 8.415364265441895, 'learning_rate': 4.683875533134249e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5324, 'grad_norm': 9.531322479248047, 'learning_rate': 4.68360040257104e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5375, 'grad_norm': 8.40423583984375, 'learning_rate': 4.6833252720078314e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5435, 'grad_norm': 10.160860061645508, 'learning_rate': 4.683050141444623e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5152, 'grad_norm': 6.032065391540527, 'learning_rate': 4.682775010881414e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4874, 'grad_norm': 10.506930351257324, 'learning_rate': 4.682499880318205e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4968, 'grad_norm': 8.855704307556152, 'learning_rate': 4.682224749754997e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5144, 'grad_norm': 10.082674026489258, 'learning_rate': 4.6819496191917876e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4852, 'grad_norm': 12.586864471435547, 'learning_rate': 4.681674488628579e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4763, 'grad_norm': 7.962011337280273, 'learning_rate': 4.6813993580653706e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5224, 'grad_norm': 12.36872673034668, 'learning_rate': 4.6811242275021615e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4949, 'grad_norm': 19.2633113861084, 'learning_rate': 4.680849096938952e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5625, 'grad_norm': 8.47352123260498, 'learning_rate': 4.680573966375744e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4659, 'grad_norm': 8.851982116699219, 'learning_rate': 4.6802988358125347e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4729, 'grad_norm': 10.110154151916504, 'learning_rate': 4.680023705249326e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4697, 'grad_norm': 10.0674467086792, 'learning_rate': 4.679748574686118e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5067, 'grad_norm': 9.866599082946777, 'learning_rate': 4.6794734441229085e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4634, 'grad_norm': 8.901447296142578, 'learning_rate': 4.6791983135597e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5622, 'grad_norm': 8.106250762939453, 'learning_rate': 4.6789231829964916e-05, 'epoch': 0.19}\n",
    "{'loss': 1.528, 'grad_norm': 12.805727005004883, 'learning_rate': 4.6786480524332824e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5656, 'grad_norm': 6.691972732543945, 'learning_rate': 4.678372921870074e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5801, 'grad_norm': 8.517285346984863, 'learning_rate': 4.678097791306865e-05, 'epoch': 0.19}\n",
    "{'loss': 1.6256, 'grad_norm': 11.097503662109375, 'learning_rate': 4.677822660743656e-05, 'epoch': 0.19}\n",
    "{'loss': 1.546, 'grad_norm': 9.937793731689453, 'learning_rate': 4.677547530180447e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5192, 'grad_norm': 12.662639617919922, 'learning_rate': 4.6772723996172386e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5439, 'grad_norm': 9.136960983276367, 'learning_rate': 4.67699726905403e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5495, 'grad_norm': 8.76932430267334, 'learning_rate': 4.676722138490821e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5815, 'grad_norm': 7.700368881225586, 'learning_rate': 4.6764470079276125e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4917, 'grad_norm': 46.947364807128906, 'learning_rate': 4.676171877364404e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5453, 'grad_norm': 11.348325729370117, 'learning_rate': 4.675896746801195e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5022, 'grad_norm': 9.228842735290527, 'learning_rate': 4.6756216162379863e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5007, 'grad_norm': 9.173401832580566, 'learning_rate': 4.675346485674777e-05, 'epoch': 0.19}\n",
    "{'loss': 1.4727, 'grad_norm': 8.030966758728027, 'learning_rate': 4.675071355111568e-05, 'epoch': 0.19}\n",
    "{'loss': 1.5039, 'grad_norm': 11.022141456604004, 'learning_rate': 4.6747962245483595e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4892, 'grad_norm': 8.06417179107666, 'learning_rate': 4.674521093985151e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5393, 'grad_norm': 7.556422233581543, 'learning_rate': 4.674245963421942e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4908, 'grad_norm': 8.32551097869873, 'learning_rate': 4.6739708328587334e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4788, 'grad_norm': 10.179616928100586, 'learning_rate': 4.673695702295525e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5584, 'grad_norm': 12.20495319366455, 'learning_rate': 4.673420571732316e-05, 'epoch': 0.2}\n",
    "{'loss': 1.7769, 'grad_norm': 7.421200752258301, 'learning_rate': 4.673145441169107e-05, 'epoch': 0.2}\n",
    "{'loss': 1.6271, 'grad_norm': 11.927038192749023, 'learning_rate': 4.672870310605899e-05, 'epoch': 0.2}\n",
    "{'loss': 1.6474, 'grad_norm': 17.31012535095215, 'learning_rate': 4.672595180042689e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5029, 'grad_norm': 10.42601203918457, 'learning_rate': 4.6723200494794805e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5191, 'grad_norm': 12.56181812286377, 'learning_rate': 4.672044918916272e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5535, 'grad_norm': 10.608118057250977, 'learning_rate': 4.671769788353063e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4849, 'grad_norm': 9.677628517150879, 'learning_rate': 4.671494657789854e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4775, 'grad_norm': 11.383793830871582, 'learning_rate': 4.671219527226646e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4922, 'grad_norm': 6.574410438537598, 'learning_rate': 4.670944396663437e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4967, 'grad_norm': 6.476960182189941, 'learning_rate': 4.670669266100228e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4754, 'grad_norm': 21.84545135498047, 'learning_rate': 4.67039413553702e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4947, 'grad_norm': 51.138301849365234, 'learning_rate': 4.6701190049738105e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5092, 'grad_norm': 11.48706340789795, 'learning_rate': 4.6698438744106014e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4539, 'grad_norm': 11.139127731323242, 'learning_rate': 4.669568743847393e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4896, 'grad_norm': 9.863777160644531, 'learning_rate': 4.6692936132841844e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4993, 'grad_norm': 5.85535192489624, 'learning_rate': 4.669018482720975e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4774, 'grad_norm': 6.875484466552734, 'learning_rate': 4.668743352157767e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5068, 'grad_norm': 8.826404571533203, 'learning_rate': 4.668468221594558e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5018, 'grad_norm': 25.342987060546875, 'learning_rate': 4.668193091031349e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4647, 'grad_norm': 10.56624984741211, 'learning_rate': 4.6679179604681406e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5389, 'grad_norm': 11.435686111450195, 'learning_rate': 4.667642829904932e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5091, 'grad_norm': 8.88365650177002, 'learning_rate': 4.667367699341722e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4885, 'grad_norm': 13.210683822631836, 'learning_rate': 4.667092568778514e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4779, 'grad_norm': 10.250344276428223, 'learning_rate': 4.666817438215305e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4792, 'grad_norm': 10.49502944946289, 'learning_rate': 4.666542307652096e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4862, 'grad_norm': 8.006745338439941, 'learning_rate': 4.666267177088888e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5362, 'grad_norm': 12.33854866027832, 'learning_rate': 4.665992046525679e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4911, 'grad_norm': 7.550539016723633, 'learning_rate': 4.66571691596247e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4813, 'grad_norm': 9.693655014038086, 'learning_rate': 4.6654417853992615e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5151, 'grad_norm': 9.536276817321777, 'learning_rate': 4.665166654836053e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4702, 'grad_norm': 10.375001907348633, 'learning_rate': 4.664891524272844e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4821, 'grad_norm': 7.297208309173584, 'learning_rate': 4.664616393709635e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4725, 'grad_norm': 11.78661823272705, 'learning_rate': 4.664341263146426e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4885, 'grad_norm': 8.633804321289062, 'learning_rate': 4.664066132583218e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5008, 'grad_norm': 10.768777847290039, 'learning_rate': 4.6637910020200086e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5125, 'grad_norm': 10.527606010437012, 'learning_rate': 4.6635158714568e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5313, 'grad_norm': 7.249996185302734, 'learning_rate': 4.6632407408935916e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5132, 'grad_norm': 12.20798397064209, 'learning_rate': 4.6629656103303825e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5028, 'grad_norm': 9.748438835144043, 'learning_rate': 4.662690479767174e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4627, 'grad_norm': 11.743308067321777, 'learning_rate': 4.6624153492039655e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4882, 'grad_norm': 5.335226535797119, 'learning_rate': 4.662140218640756e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5034, 'grad_norm': 10.862408638000488, 'learning_rate': 4.661865088077547e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5033, 'grad_norm': 11.236479759216309, 'learning_rate': 4.661589957514339e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4635, 'grad_norm': 10.117016792297363, 'learning_rate': 4.6613148269511295e-05, 'epoch': 0.2}\n",
    "{'loss': 1.527, 'grad_norm': 9.85024356842041, 'learning_rate': 4.661039696387921e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4805, 'grad_norm': 13.97513484954834, 'learning_rate': 4.6607645658247125e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4973, 'grad_norm': 8.44267463684082, 'learning_rate': 4.6604894352615034e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4923, 'grad_norm': 9.009334564208984, 'learning_rate': 4.660214304698295e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4731, 'grad_norm': 6.029156684875488, 'learning_rate': 4.6599391741350864e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4995, 'grad_norm': 9.995012283325195, 'learning_rate': 4.659664043571877e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4675, 'grad_norm': 8.99931812286377, 'learning_rate': 4.659388913008669e-05, 'epoch': 0.2}\n",
    "{'loss': 1.4417, 'grad_norm': 14.868406295776367, 'learning_rate': 4.6591137824454596e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5127, 'grad_norm': 122.35354614257812, 'learning_rate': 4.6588386518822504e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5306, 'grad_norm': 7.160025596618652, 'learning_rate': 4.658563521319042e-05, 'epoch': 0.2}\n",
    "{'loss': 1.5244, 'grad_norm': 9.472847938537598, 'learning_rate': 4.6582883907558335e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5013, 'grad_norm': 5.863465785980225, 'learning_rate': 4.658013260192624e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4813, 'grad_norm': 10.023730278015137, 'learning_rate': 4.657738129629416e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4905, 'grad_norm': 8.052207946777344, 'learning_rate': 4.657462999066207e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5143, 'grad_norm': 8.764335632324219, 'learning_rate': 4.657187868502998e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4435, 'grad_norm': 9.455279350280762, 'learning_rate': 4.65691273793979e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4669, 'grad_norm': 7.035670280456543, 'learning_rate': 4.6566376073765805e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4746, 'grad_norm': 8.831449508666992, 'learning_rate': 4.656362476813372e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4951, 'grad_norm': 8.050838470458984, 'learning_rate': 4.656087346250163e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5062, 'grad_norm': 9.838800430297852, 'learning_rate': 4.6558122156869544e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4938, 'grad_norm': 10.127032279968262, 'learning_rate': 4.655537085123746e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4679, 'grad_norm': 14.958271980285645, 'learning_rate': 4.655261954560537e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4939, 'grad_norm': 8.895020484924316, 'learning_rate': 4.654986823997328e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4916, 'grad_norm': 8.870376586914062, 'learning_rate': 4.65471169343412e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5054, 'grad_norm': 10.156817436218262, 'learning_rate': 4.6544365628709106e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4903, 'grad_norm': 7.338503360748291, 'learning_rate': 4.654161432307702e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4827, 'grad_norm': 10.142105102539062, 'learning_rate': 4.653886301744493e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4637, 'grad_norm': 8.157305717468262, 'learning_rate': 4.653611171181284e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5269, 'grad_norm': 8.939006805419922, 'learning_rate': 4.653336040618075e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5061, 'grad_norm': 6.322612285614014, 'learning_rate': 4.653060910054867e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4899, 'grad_norm': 5.562066555023193, 'learning_rate': 4.6527857794916577e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4808, 'grad_norm': 8.341944694519043, 'learning_rate': 4.652510648928449e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4783, 'grad_norm': 8.12209701538086, 'learning_rate': 4.652235518365241e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4899, 'grad_norm': 9.313494682312012, 'learning_rate': 4.6519603878020315e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4542, 'grad_norm': 9.043065071105957, 'learning_rate': 4.651685257238823e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4886, 'grad_norm': 8.712642669677734, 'learning_rate': 4.6514101266756146e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4733, 'grad_norm': 9.540613174438477, 'learning_rate': 4.6511349961124054e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4868, 'grad_norm': 9.108193397521973, 'learning_rate': 4.650859865549196e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4904, 'grad_norm': 8.8296537399292, 'learning_rate': 4.650584734985988e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5213, 'grad_norm': 10.029557228088379, 'learning_rate': 4.650309604422779e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5025, 'grad_norm': 9.390090942382812, 'learning_rate': 4.65003447385957e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4637, 'grad_norm': 7.117425918579102, 'learning_rate': 4.6497593432963616e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4751, 'grad_norm': 8.363322257995605, 'learning_rate': 4.649484212733153e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4599, 'grad_norm': 10.302263259887695, 'learning_rate': 4.649209082169944e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4986, 'grad_norm': 9.331538200378418, 'learning_rate': 4.6489339516067355e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5, 'grad_norm': 9.322526931762695, 'learning_rate': 4.648658821043527e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4982, 'grad_norm': 10.244661331176758, 'learning_rate': 4.648383690480317e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5009, 'grad_norm': 10.29520320892334, 'learning_rate': 4.6481085599171087e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4845, 'grad_norm': 7.543183326721191, 'learning_rate': 4.6478334293539e-05, 'epoch': 0.21}\n",
    "{'loss': 1.463, 'grad_norm': 7.254530429840088, 'learning_rate': 4.647558298790691e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4948, 'grad_norm': 11.944664001464844, 'learning_rate': 4.6472831682274825e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4939, 'grad_norm': 7.752316951751709, 'learning_rate': 4.647008037664274e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4782, 'grad_norm': 8.744604110717773, 'learning_rate': 4.646732907101065e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4904, 'grad_norm': 9.648715019226074, 'learning_rate': 4.6464577765378564e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4479, 'grad_norm': 6.574150085449219, 'learning_rate': 4.646182645974648e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4715, 'grad_norm': 8.33734130859375, 'learning_rate': 4.645907515411439e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4609, 'grad_norm': 11.586155891418457, 'learning_rate': 4.6456323848482296e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4653, 'grad_norm': 7.397571563720703, 'learning_rate': 4.645357254285021e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4596, 'grad_norm': 10.615427017211914, 'learning_rate': 4.6450821237218126e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4696, 'grad_norm': 9.06356143951416, 'learning_rate': 4.6448069931586034e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4722, 'grad_norm': 9.998895645141602, 'learning_rate': 4.644531862595395e-05, 'epoch': 0.21}\n",
    "{'loss': 1.477, 'grad_norm': 7.664145469665527, 'learning_rate': 4.6442567320321865e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4636, 'grad_norm': 9.377935409545898, 'learning_rate': 4.643981601468977e-05, 'epoch': 0.21}\n",
    "{'loss': 1.487, 'grad_norm': 8.7444429397583, 'learning_rate': 4.643706470905769e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4732, 'grad_norm': 10.724617004394531, 'learning_rate': 4.64343134034256e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4616, 'grad_norm': 7.904392242431641, 'learning_rate': 4.643156209779351e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4898, 'grad_norm': 9.215457916259766, 'learning_rate': 4.642881079216142e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4892, 'grad_norm': 10.040008544921875, 'learning_rate': 4.6426059486529335e-05, 'epoch': 0.21}\n",
    "{'loss': 1.4847, 'grad_norm': 11.141857147216797, 'learning_rate': 4.6423308180897244e-05, 'epoch': 0.21}\n",
    "{'loss': 1.476, 'grad_norm': 8.10831069946289, 'learning_rate': 4.642055687526516e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5314, 'grad_norm': 7.447622776031494, 'learning_rate': 4.6417805569633074e-05, 'epoch': 0.21}\n",
    "{'loss': 1.5091, 'grad_norm': 9.051900863647461, 'learning_rate': 4.641505426400098e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5322, 'grad_norm': 13.149503707885742, 'learning_rate': 4.64123029583689e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4824, 'grad_norm': 12.60035514831543, 'learning_rate': 4.640955165273681e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4694, 'grad_norm': 7.625150680541992, 'learning_rate': 4.640680034710472e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4676, 'grad_norm': 11.66402816772461, 'learning_rate': 4.640404904147263e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4851, 'grad_norm': 10.459420204162598, 'learning_rate': 4.6401297735840545e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4729, 'grad_norm': 7.236877918243408, 'learning_rate': 4.639854643020845e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5116, 'grad_norm': 9.437895774841309, 'learning_rate': 4.639579512457637e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4709, 'grad_norm': 8.532658576965332, 'learning_rate': 4.639304381894428e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4961, 'grad_norm': 6.428638935089111, 'learning_rate': 4.639029251331219e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4806, 'grad_norm': 13.005111694335938, 'learning_rate': 4.638754120768011e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4633, 'grad_norm': 8.010013580322266, 'learning_rate': 4.638478990204802e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4792, 'grad_norm': 12.167726516723633, 'learning_rate': 4.638203859641593e-05, 'epoch': 0.22}\n",
    "{'loss': 1.465, 'grad_norm': 11.41462516784668, 'learning_rate': 4.6379287290783845e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4701, 'grad_norm': 10.661958694458008, 'learning_rate': 4.6376535985151754e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4821, 'grad_norm': 11.021636009216309, 'learning_rate': 4.637378467951967e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4838, 'grad_norm': 10.259963989257812, 'learning_rate': 4.637103337388758e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4825, 'grad_norm': 11.887959480285645, 'learning_rate': 4.636828206825549e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4761, 'grad_norm': 11.39128303527832, 'learning_rate': 4.636553076262341e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5032, 'grad_norm': 6.628098964691162, 'learning_rate': 4.6362779456991316e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4902, 'grad_norm': 8.262263298034668, 'learning_rate': 4.636002815135923e-05, 'epoch': 0.22}\n",
    "{'loss': 1.508, 'grad_norm': 5.7857666015625, 'learning_rate': 4.6357276845727146e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5461, 'grad_norm': 7.572531700134277, 'learning_rate': 4.6354525540095055e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4808, 'grad_norm': 11.629980087280273, 'learning_rate': 4.635177423446297e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4647, 'grad_norm': 7.554471969604492, 'learning_rate': 4.634902292883088e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4529, 'grad_norm': 10.249889373779297, 'learning_rate': 4.6346271623198786e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4975, 'grad_norm': 8.791023254394531, 'learning_rate': 4.63435203175667e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4882, 'grad_norm': 7.121941089630127, 'learning_rate': 4.634076901193462e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4973, 'grad_norm': 9.473983764648438, 'learning_rate': 4.6338017706302525e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5224, 'grad_norm': 10.169795036315918, 'learning_rate': 4.633526640067044e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5211, 'grad_norm': 8.621929168701172, 'learning_rate': 4.6332515095038355e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5502, 'grad_norm': 7.361867427825928, 'learning_rate': 4.6329763789406264e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4592, 'grad_norm': 9.78110408782959, 'learning_rate': 4.632701248377418e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4682, 'grad_norm': 7.897862434387207, 'learning_rate': 4.6324261178142094e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4677, 'grad_norm': 8.572824478149414, 'learning_rate': 4.632150987251e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4675, 'grad_norm': 9.870251655578613, 'learning_rate': 4.631875856687791e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4456, 'grad_norm': 8.607908248901367, 'learning_rate': 4.6316007261245826e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4696, 'grad_norm': 9.137561798095703, 'learning_rate': 4.631325595561374e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4684, 'grad_norm': 11.375115394592285, 'learning_rate': 4.631050464998165e-05, 'epoch': 0.22}\n",
    "{'loss': 1.482, 'grad_norm': 7.724959850311279, 'learning_rate': 4.6307753344349565e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4543, 'grad_norm': 9.329253196716309, 'learning_rate': 4.630500203871748e-05, 'epoch': 0.22}\n",
    "{'loss': 1.454, 'grad_norm': 10.029367446899414, 'learning_rate': 4.630225073308539e-05, 'epoch': 0.22}\n",
    "{'loss': 1.509, 'grad_norm': 6.999165058135986, 'learning_rate': 4.62994994274533e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4691, 'grad_norm': 11.942953109741211, 'learning_rate': 4.629674812182122e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4662, 'grad_norm': 8.789701461791992, 'learning_rate': 4.629399681618912e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4774, 'grad_norm': 9.00161361694336, 'learning_rate': 4.6291245510557035e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4512, 'grad_norm': 6.3880228996276855, 'learning_rate': 4.628849420492495e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4636, 'grad_norm': 8.105249404907227, 'learning_rate': 4.628574289929286e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4831, 'grad_norm': 8.385421752929688, 'learning_rate': 4.6282991593660774e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4957, 'grad_norm': 8.495889663696289, 'learning_rate': 4.628024028802869e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4986, 'grad_norm': 7.787834644317627, 'learning_rate': 4.62774889823966e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4828, 'grad_norm': 7.487082481384277, 'learning_rate': 4.627473767676451e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4828, 'grad_norm': 8.544161796569824, 'learning_rate': 4.627198637113243e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4867, 'grad_norm': 8.719870567321777, 'learning_rate': 4.6269235065500336e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4821, 'grad_norm': 8.463547706604004, 'learning_rate': 4.6266483759868244e-05, 'epoch': 0.22}\n",
    "{'loss': 1.455, 'grad_norm': 13.30632209777832, 'learning_rate': 4.626373245423616e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4658, 'grad_norm': 9.16640567779541, 'learning_rate': 4.626098114860407e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4773, 'grad_norm': 10.534026145935059, 'learning_rate': 4.625822984297198e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4662, 'grad_norm': 10.130373001098633, 'learning_rate': 4.62554785373399e-05, 'epoch': 0.22}\n",
    "{'loss': 1.4553, 'grad_norm': 6.849843978881836, 'learning_rate': 4.6252727231707807e-05, 'epoch': 0.22}\n",
    "{'loss': 1.5194, 'grad_norm': 10.49138069152832, 'learning_rate': 4.624997592607572e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4985, 'grad_norm': 9.515944480895996, 'learning_rate': 4.624722462044364e-05, 'epoch': 0.23}\n",
    "{'loss': 1.5206, 'grad_norm': 6.127353668212891, 'learning_rate': 4.6244473314811545e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4597, 'grad_norm': 9.24634838104248, 'learning_rate': 4.6241722009179454e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4747, 'grad_norm': 8.973910331726074, 'learning_rate': 4.623897070354737e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4737, 'grad_norm': 8.043646812438965, 'learning_rate': 4.6236219397915284e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4563, 'grad_norm': 9.818717002868652, 'learning_rate': 4.623346809228319e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4594, 'grad_norm': 9.994940757751465, 'learning_rate': 4.623071678665111e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4804, 'grad_norm': 7.8014373779296875, 'learning_rate': 4.622796548101902e-05, 'epoch': 0.23}\n",
    "{'loss': 1.482, 'grad_norm': 10.560070991516113, 'learning_rate': 4.622521417538693e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4526, 'grad_norm': 7.225388050079346, 'learning_rate': 4.6222462869754846e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4856, 'grad_norm': 8.416998863220215, 'learning_rate': 4.621971156412276e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4586, 'grad_norm': 7.0118303298950195, 'learning_rate': 4.621696025849067e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4719, 'grad_norm': 7.503939151763916, 'learning_rate': 4.621420895285858e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4621, 'grad_norm': 14.529010772705078, 'learning_rate': 4.621145764722649e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4885, 'grad_norm': 12.775609970092773, 'learning_rate': 4.62087063415944e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4628, 'grad_norm': 8.490446090698242, 'learning_rate': 4.6205955035962317e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4869, 'grad_norm': 10.967869758605957, 'learning_rate': 4.620320373033023e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4809, 'grad_norm': 8.537841796875, 'learning_rate': 4.620045242469814e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4762, 'grad_norm': 9.563363075256348, 'learning_rate': 4.6197701119066055e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4831, 'grad_norm': 13.707825660705566, 'learning_rate': 4.619494981343397e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4857, 'grad_norm': 8.526674270629883, 'learning_rate': 4.619219850780188e-05, 'epoch': 0.23}\n",
    "{'loss': 1.5176, 'grad_norm': 6.382627487182617, 'learning_rate': 4.6189447202169794e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4633, 'grad_norm': 17.349328994750977, 'learning_rate': 4.61866958965377e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4895, 'grad_norm': 12.780815124511719, 'learning_rate': 4.618394459090562e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4759, 'grad_norm': 8.523032188415527, 'learning_rate': 4.6181193285273526e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4759, 'grad_norm': 10.701325416564941, 'learning_rate': 4.617844197964144e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4664, 'grad_norm': 8.213004112243652, 'learning_rate': 4.6175690674009356e-05, 'epoch': 0.23}\n",
    "{'loss': 1.443, 'grad_norm': 10.548017501831055, 'learning_rate': 4.6172939368377264e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4859, 'grad_norm': 8.217314720153809, 'learning_rate': 4.617018806274518e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4543, 'grad_norm': 6.141848087310791, 'learning_rate': 4.6167436757113095e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4692, 'grad_norm': 8.64680290222168, 'learning_rate': 4.6164685451481e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4578, 'grad_norm': 10.007878303527832, 'learning_rate': 4.616193414584892e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4428, 'grad_norm': 9.764575004577637, 'learning_rate': 4.6159182840216827e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4595, 'grad_norm': 16.265975952148438, 'learning_rate': 4.6156431534584735e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4496, 'grad_norm': 9.682488441467285, 'learning_rate': 4.615368022895265e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4713, 'grad_norm': 8.668978691101074, 'learning_rate': 4.6150928923320565e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4626, 'grad_norm': 10.50040340423584, 'learning_rate': 4.6148177617688474e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4702, 'grad_norm': 11.752323150634766, 'learning_rate': 4.614542631205639e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4776, 'grad_norm': 9.522810935974121, 'learning_rate': 4.6142675006424304e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4657, 'grad_norm': 8.836688041687012, 'learning_rate': 4.613992370079221e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4878, 'grad_norm': 9.4932222366333, 'learning_rate': 4.613717239516013e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4851, 'grad_norm': 6.8865461349487305, 'learning_rate': 4.613442108952804e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4688, 'grad_norm': 8.226765632629395, 'learning_rate': 4.613166978389595e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4648, 'grad_norm': 6.919748783111572, 'learning_rate': 4.612891847826386e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4746, 'grad_norm': 8.012988090515137, 'learning_rate': 4.6126167172631774e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4957, 'grad_norm': 12.104554176330566, 'learning_rate': 4.612341586699969e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4494, 'grad_norm': 8.386191368103027, 'learning_rate': 4.61206645613676e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4939, 'grad_norm': 8.85997486114502, 'learning_rate': 4.611791325573551e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4568, 'grad_norm': 8.371213912963867, 'learning_rate': 4.611516195010342e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4757, 'grad_norm': 9.596835136413574, 'learning_rate': 4.611241064447134e-05, 'epoch': 0.23}\n",
    "{'loss': 1.621, 'grad_norm': 8.08952808380127, 'learning_rate': 4.610965933883925e-05, 'epoch': 0.23}\n",
    "{'loss': 1.481, 'grad_norm': 10.563883781433105, 'learning_rate': 4.610690803320716e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4854, 'grad_norm': 10.059640884399414, 'learning_rate': 4.610415672757507e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4711, 'grad_norm': 15.335091590881348, 'learning_rate': 4.6101405421942984e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4524, 'grad_norm': 11.274651527404785, 'learning_rate': 4.60986541163109e-05, 'epoch': 0.23}\n",
    "{'loss': 1.5522, 'grad_norm': 8.781759262084961, 'learning_rate': 4.609590281067881e-05, 'epoch': 0.23}\n",
    "{'loss': 1.5329, 'grad_norm': 9.327632904052734, 'learning_rate': 4.609315150504672e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4869, 'grad_norm': 10.452779769897461, 'learning_rate': 4.609040019941464e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4993, 'grad_norm': 10.846524238586426, 'learning_rate': 4.6087648893782546e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4536, 'grad_norm': 8.913724899291992, 'learning_rate': 4.608489758815046e-05, 'epoch': 0.23}\n",
    "{'loss': 1.4802, 'grad_norm': 9.135912895202637, 'learning_rate': 4.6082146282518376e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4833, 'grad_norm': 7.868535041809082, 'learning_rate': 4.607939497688628e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4973, 'grad_norm': 9.592262268066406, 'learning_rate': 4.607664367125419e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4849, 'grad_norm': 7.722249507904053, 'learning_rate': 4.607389236562211e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4934, 'grad_norm': 8.138383865356445, 'learning_rate': 4.6071141059990016e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4633, 'grad_norm': 10.631941795349121, 'learning_rate': 4.606838975435793e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4582, 'grad_norm': 8.537137985229492, 'learning_rate': 4.606563844872585e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4979, 'grad_norm': 7.053224086761475, 'learning_rate': 4.6062887143093755e-05, 'epoch': 0.24}\n",
    "{'loss': 1.5143, 'grad_norm': 9.510153770446777, 'learning_rate': 4.606013583746167e-05, 'epoch': 0.24}\n",
    "{'loss': 1.498, 'grad_norm': 8.986166000366211, 'learning_rate': 4.6057384531829585e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4781, 'grad_norm': 8.281599998474121, 'learning_rate': 4.6054633226197494e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4963, 'grad_norm': 8.489436149597168, 'learning_rate': 4.60518819205654e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4633, 'grad_norm': 7.932962894439697, 'learning_rate': 4.604913061493332e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4889, 'grad_norm': 8.4878511428833, 'learning_rate': 4.604637930930123e-05, 'epoch': 0.24}\n",
    "{'loss': 1.478, 'grad_norm': 7.318838596343994, 'learning_rate': 4.604362800366914e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4897, 'grad_norm': 7.214949607849121, 'learning_rate': 4.6040876698037056e-05, 'epoch': 0.24}\n",
    "{'loss': 1.476, 'grad_norm': 5.823390007019043, 'learning_rate': 4.603812539240497e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4688, 'grad_norm': 8.012323379516602, 'learning_rate': 4.603537408677288e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4806, 'grad_norm': 8.988447189331055, 'learning_rate': 4.6032622781140795e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4723, 'grad_norm': 7.997750759124756, 'learning_rate': 4.602987147550871e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4804, 'grad_norm': 9.810667991638184, 'learning_rate': 4.602712016987662e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4895, 'grad_norm': 7.129015922546387, 'learning_rate': 4.6024368864244526e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4861, 'grad_norm': 9.675742149353027, 'learning_rate': 4.602161755861244e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4901, 'grad_norm': 7.425166606903076, 'learning_rate': 4.601886625298035e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4635, 'grad_norm': 7.185835361480713, 'learning_rate': 4.6016114947348265e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4748, 'grad_norm': 7.644229888916016, 'learning_rate': 4.601336364171618e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4366, 'grad_norm': 10.08251953125, 'learning_rate': 4.601061233608409e-05, 'epoch': 0.24}\n",
    "{'loss': 1.452, 'grad_norm': 8.061382293701172, 'learning_rate': 4.6007861030452004e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4872, 'grad_norm': 7.733463764190674, 'learning_rate': 4.600510972481992e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4716, 'grad_norm': 43.97593307495117, 'learning_rate': 4.600235841918783e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4607, 'grad_norm': 10.977044105529785, 'learning_rate': 4.599960711355574e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4606, 'grad_norm': 7.237864017486572, 'learning_rate': 4.599685580792365e-05, 'epoch': 0.24}\n",
    "{'loss': 1.475, 'grad_norm': 6.848369598388672, 'learning_rate': 4.5994104502291566e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4577, 'grad_norm': 9.732434272766113, 'learning_rate': 4.5991353196659474e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4608, 'grad_norm': 10.578377723693848, 'learning_rate': 4.598860189102739e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4854, 'grad_norm': 9.27191162109375, 'learning_rate': 4.5985850585395305e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4491, 'grad_norm': 6.6596221923828125, 'learning_rate': 4.598309927976321e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4692, 'grad_norm': 56.48979949951172, 'learning_rate': 4.598034797413113e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4868, 'grad_norm': 11.266121864318848, 'learning_rate': 4.597759666849904e-05, 'epoch': 0.24}\n",
    "{'loss': 1.456, 'grad_norm': 8.077472686767578, 'learning_rate': 4.597484536286695e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4732, 'grad_norm': 4.380825519561768, 'learning_rate': 4.597209405723487e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4741, 'grad_norm': 11.372743606567383, 'learning_rate': 4.5969342751602775e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4568, 'grad_norm': 7.648576259613037, 'learning_rate': 4.5966591445970684e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4887, 'grad_norm': 7.626880168914795, 'learning_rate': 4.59638401403386e-05, 'epoch': 0.24}\n",
    "{'loss': 1.5337, 'grad_norm': 8.329614639282227, 'learning_rate': 4.5961088834706514e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4842, 'grad_norm': 11.79711627960205, 'learning_rate': 4.595833752907442e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4787, 'grad_norm': 10.647479057312012, 'learning_rate': 4.595558622344234e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4864, 'grad_norm': 9.071717262268066, 'learning_rate': 4.595283491781025e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4706, 'grad_norm': 7.1928510665893555, 'learning_rate': 4.595008361217816e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4566, 'grad_norm': 9.749197959899902, 'learning_rate': 4.5947332306546076e-05, 'epoch': 0.24}\n",
    "{'loss': 1.5413, 'grad_norm': 6.411102294921875, 'learning_rate': 4.5944581000913984e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4955, 'grad_norm': 9.609704971313477, 'learning_rate': 4.594182969528189e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4674, 'grad_norm': 8.786553382873535, 'learning_rate': 4.593907838964981e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4847, 'grad_norm': 8.995070457458496, 'learning_rate': 4.593632708401772e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4838, 'grad_norm': 12.607708930969238, 'learning_rate': 4.593357577838563e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4752, 'grad_norm': 23.049734115600586, 'learning_rate': 4.5930824472753547e-05, 'epoch': 0.24}\n",
    "{'loss': 1.478, 'grad_norm': 8.028285026550293, 'learning_rate': 4.592807316712146e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4842, 'grad_norm': 6.952579975128174, 'learning_rate': 4.592532186148937e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4539, 'grad_norm': 8.546637535095215, 'learning_rate': 4.5922570555857285e-05, 'epoch': 0.24}\n",
    "{'loss': 1.455, 'grad_norm': 9.245615005493164, 'learning_rate': 4.59198192502252e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4565, 'grad_norm': 9.009268760681152, 'learning_rate': 4.591706794459311e-05, 'epoch': 0.24}\n",
    "{'loss': 1.4788, 'grad_norm': 10.611557960510254, 'learning_rate': 4.591431663896102e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4596, 'grad_norm': 8.485103607177734, 'learning_rate': 4.591156533332893e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4818, 'grad_norm': 6.814709186553955, 'learning_rate': 4.590881402769685e-05, 'epoch': 0.25}\n",
    "{'loss': 1.479, 'grad_norm': 11.109850883483887, 'learning_rate': 4.5906062722064756e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4557, 'grad_norm': 9.295619010925293, 'learning_rate': 4.590331141643267e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4468, 'grad_norm': 9.908978462219238, 'learning_rate': 4.5900560110800586e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4931, 'grad_norm': 11.96489143371582, 'learning_rate': 4.5897808805168494e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4362, 'grad_norm': 8.942054748535156, 'learning_rate': 4.589505749953641e-05, 'epoch': 0.25}\n",
    "{'loss': 1.48, 'grad_norm': 6.227571487426758, 'learning_rate': 4.5892306193904325e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4672, 'grad_norm': 7.482460975646973, 'learning_rate': 4.5889554888272226e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4719, 'grad_norm': 7.525750160217285, 'learning_rate': 4.588680358264014e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4723, 'grad_norm': 10.178977012634277, 'learning_rate': 4.5884052277008057e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4592, 'grad_norm': 10.663661003112793, 'learning_rate': 4.5881300971375965e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4676, 'grad_norm': 7.286592960357666, 'learning_rate': 4.587854966574388e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4719, 'grad_norm': 33.26529312133789, 'learning_rate': 4.5875798360111795e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4477, 'grad_norm': 8.513075828552246, 'learning_rate': 4.5873047054479704e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4535, 'grad_norm': 8.451760292053223, 'learning_rate': 4.587029574884762e-05, 'epoch': 0.25}\n",
    "{'loss': 1.51, 'grad_norm': 8.794035911560059, 'learning_rate': 4.5867544443215534e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4879, 'grad_norm': 9.401087760925293, 'learning_rate': 4.586479313758344e-05, 'epoch': 0.25}\n",
    "{'loss': 1.471, 'grad_norm': 9.223701477050781, 'learning_rate': 4.586204183195135e-05, 'epoch': 0.25}\n",
    "{'loss': 1.5255, 'grad_norm': 5.832275390625, 'learning_rate': 4.5859290526319266e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4951, 'grad_norm': 9.344109535217285, 'learning_rate': 4.585653922068718e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4662, 'grad_norm': 9.746687889099121, 'learning_rate': 4.585378791505509e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4579, 'grad_norm': 8.846099853515625, 'learning_rate': 4.5851036609423004e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4829, 'grad_norm': 6.005495548248291, 'learning_rate': 4.584828530379092e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4746, 'grad_norm': 7.332201957702637, 'learning_rate': 4.584553399815883e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4881, 'grad_norm': 14.217522621154785, 'learning_rate': 4.584278269252674e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4796, 'grad_norm': 9.945682525634766, 'learning_rate': 4.584003138689466e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4407, 'grad_norm': 7.896058559417725, 'learning_rate': 4.5837280081262567e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4931, 'grad_norm': 10.546810150146484, 'learning_rate': 4.5834528775630475e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4621, 'grad_norm': 8.565665245056152, 'learning_rate': 4.583177746999839e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4716, 'grad_norm': 8.441402435302734, 'learning_rate': 4.58290261643663e-05, 'epoch': 0.25}\n",
    "{'loss': 1.5257, 'grad_norm': 9.486259460449219, 'learning_rate': 4.5826274858734214e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4517, 'grad_norm': 11.916622161865234, 'learning_rate': 4.582352355310213e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4846, 'grad_norm': 13.474347114562988, 'learning_rate': 4.582077224747004e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4706, 'grad_norm': 17.845237731933594, 'learning_rate': 4.581802094183795e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4573, 'grad_norm': 11.083505630493164, 'learning_rate': 4.581526963620587e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4845, 'grad_norm': 15.855786323547363, 'learning_rate': 4.5812518330573776e-05, 'epoch': 0.25}\n",
    "{'loss': 1.5011, 'grad_norm': 6.20281982421875, 'learning_rate': 4.580976702494169e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4584, 'grad_norm': 9.439833641052246, 'learning_rate': 4.58070157193096e-05, 'epoch': 0.25}\n",
    "{'loss': 1.46, 'grad_norm': 5.314873695373535, 'learning_rate': 4.5804264413677514e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4867, 'grad_norm': 9.55517864227295, 'learning_rate': 4.580151310804542e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4698, 'grad_norm': 10.989895820617676, 'learning_rate': 4.579876180241334e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4513, 'grad_norm': 10.390304565429688, 'learning_rate': 4.579601049678125e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4799, 'grad_norm': 10.698821067810059, 'learning_rate': 4.579325919114916e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4894, 'grad_norm': 8.512308120727539, 'learning_rate': 4.579050788551708e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4593, 'grad_norm': 8.42155647277832, 'learning_rate': 4.5787756579884985e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4615, 'grad_norm': 14.282062530517578, 'learning_rate': 4.57850052742529e-05, 'epoch': 0.25}\n",
    "{'loss': 1.5088, 'grad_norm': 7.208677291870117, 'learning_rate': 4.578225396862081e-05, 'epoch': 0.25}\n",
    "{'loss': 1.485, 'grad_norm': 8.498762130737305, 'learning_rate': 4.5779502662988724e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4836, 'grad_norm': 7.475222110748291, 'learning_rate': 4.577675135735663e-05, 'epoch': 0.25}\n",
    "{'loss': 1.458, 'grad_norm': 9.506437301635742, 'learning_rate': 4.577400005172455e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4508, 'grad_norm': 8.127285957336426, 'learning_rate': 4.577124874609246e-05, 'epoch': 0.25}\n",
    "{'loss': 1.458, 'grad_norm': 8.466217994689941, 'learning_rate': 4.576849744046037e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4654, 'grad_norm': 6.736040115356445, 'learning_rate': 4.5765746134828286e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4536, 'grad_norm': 6.578516006469727, 'learning_rate': 4.57629948291962e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4929, 'grad_norm': 14.460539817810059, 'learning_rate': 4.576024352356411e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4552, 'grad_norm': 8.351968765258789, 'learning_rate': 4.5757492217932025e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4671, 'grad_norm': 9.3458833694458, 'learning_rate': 4.575474091229993e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4532, 'grad_norm': 8.195968627929688, 'learning_rate': 4.575198960666784e-05, 'epoch': 0.25}\n",
    "{'loss': 1.4591, 'grad_norm': 8.927186012268066, 'learning_rate': 4.5749238301035756e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4774, 'grad_norm': 10.910115242004395, 'learning_rate': 4.574648699540367e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4785, 'grad_norm': 7.072763919830322, 'learning_rate': 4.574373568977158e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4569, 'grad_norm': 7.366036891937256, 'learning_rate': 4.5740984384139495e-05, 'epoch': 0.26}\n",
    "{'loss': 1.49, 'grad_norm': 8.703786849975586, 'learning_rate': 4.573823307850741e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4391, 'grad_norm': 9.07820987701416, 'learning_rate': 4.573548177287532e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4828, 'grad_norm': 8.27930736541748, 'learning_rate': 4.5732730467243234e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4595, 'grad_norm': 8.852511405944824, 'learning_rate': 4.572997916161115e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4689, 'grad_norm': 12.488775253295898, 'learning_rate': 4.572722785597906e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4607, 'grad_norm': 6.629610538482666, 'learning_rate': 4.5724476550346966e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4758, 'grad_norm': 8.492959022521973, 'learning_rate': 4.572172524471488e-05, 'epoch': 0.26}\n",
    "{'loss': 1.471, 'grad_norm': 7.4165873527526855, 'learning_rate': 4.5718973939082796e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4748, 'grad_norm': 7.831920623779297, 'learning_rate': 4.5716222633450704e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4591, 'grad_norm': 9.18654727935791, 'learning_rate': 4.571347132781862e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4688, 'grad_norm': 8.44622802734375, 'learning_rate': 4.5710720022186535e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4654, 'grad_norm': 13.243745803833008, 'learning_rate': 4.570796871655444e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4564, 'grad_norm': 7.853121280670166, 'learning_rate': 4.570521741092236e-05, 'epoch': 0.26}\n",
    "{'loss': 1.485, 'grad_norm': 17.77979850769043, 'learning_rate': 4.570246610529027e-05, 'epoch': 0.26}\n",
    "{'loss': 1.458, 'grad_norm': 8.105718612670898, 'learning_rate': 4.5699714799658175e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4546, 'grad_norm': 7.9392991065979, 'learning_rate': 4.569696349402609e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4706, 'grad_norm': 7.827721118927002, 'learning_rate': 4.5694212188394005e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4553, 'grad_norm': 7.341506004333496, 'learning_rate': 4.5691460882761913e-05, 'epoch': 0.26}\n",
    "{'loss': 1.483, 'grad_norm': 5.726408004760742, 'learning_rate': 4.568870957712983e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4786, 'grad_norm': 7.557697296142578, 'learning_rate': 4.5685958271497744e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4664, 'grad_norm': 9.84631633758545, 'learning_rate': 4.568320696586565e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4561, 'grad_norm': 7.206833362579346, 'learning_rate': 4.568045566023357e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4667, 'grad_norm': 7.3498759269714355, 'learning_rate': 4.567770435460148e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4372, 'grad_norm': 7.204351902008057, 'learning_rate': 4.567495304896939e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4579, 'grad_norm': 8.011987686157227, 'learning_rate': 4.56722017433373e-05, 'epoch': 0.26}\n",
    "{'loss': 1.474, 'grad_norm': 12.96658706665039, 'learning_rate': 4.5669450437705214e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4743, 'grad_norm': 8.299479484558105, 'learning_rate': 4.566669913207313e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4832, 'grad_norm': 9.075163841247559, 'learning_rate': 4.566394782644104e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4414, 'grad_norm': 7.752557277679443, 'learning_rate': 4.566119652080895e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4849, 'grad_norm': 7.062743186950684, 'learning_rate': 4.565844521517687e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4287, 'grad_norm': 7.927086353302002, 'learning_rate': 4.5655693909544776e-05, 'epoch': 0.26}\n",
    "{'loss': 1.438, 'grad_norm': 9.065506935119629, 'learning_rate': 4.565294260391269e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4375, 'grad_norm': 9.277286529541016, 'learning_rate': 4.565019129828061e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4709, 'grad_norm': 12.99593448638916, 'learning_rate': 4.564743999264851e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4572, 'grad_norm': 8.548603057861328, 'learning_rate': 4.5644688687016424e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4526, 'grad_norm': 7.3713459968566895, 'learning_rate': 4.564193738138434e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4613, 'grad_norm': 9.396247863769531, 'learning_rate': 4.563918607575225e-05, 'epoch': 0.26}\n",
    "{'loss': 1.473, 'grad_norm': 8.459238052368164, 'learning_rate': 4.563643477012016e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4688, 'grad_norm': 12.211153984069824, 'learning_rate': 4.563368346448808e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4439, 'grad_norm': 9.902155876159668, 'learning_rate': 4.5630932158855986e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4753, 'grad_norm': 10.116180419921875, 'learning_rate': 4.56281808532239e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4399, 'grad_norm': 6.7182745933532715, 'learning_rate': 4.5625429547591816e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4645, 'grad_norm': 5.847872257232666, 'learning_rate': 4.5622678241959724e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4614, 'grad_norm': 10.051958084106445, 'learning_rate': 4.561992693632763e-05, 'epoch': 0.26}\n",
    "{'loss': 1.469, 'grad_norm': 10.327495574951172, 'learning_rate': 4.561717563069555e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4479, 'grad_norm': 8.083680152893066, 'learning_rate': 4.5614424325063456e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4538, 'grad_norm': 9.374457359313965, 'learning_rate': 4.561167301943137e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4661, 'grad_norm': 6.288130760192871, 'learning_rate': 4.5608921713799287e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4756, 'grad_norm': 9.694746017456055, 'learning_rate': 4.5606170408167195e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4464, 'grad_norm': 4.56768274307251, 'learning_rate': 4.560341910253511e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4619, 'grad_norm': 10.027815818786621, 'learning_rate': 4.5600667796903025e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4628, 'grad_norm': 8.816747665405273, 'learning_rate': 4.5597916491270934e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4552, 'grad_norm': 7.834435939788818, 'learning_rate': 4.559516518563885e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4474, 'grad_norm': 7.945765972137451, 'learning_rate': 4.559241388000676e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4872, 'grad_norm': 6.999059677124023, 'learning_rate': 4.558966257437467e-05, 'epoch': 0.26}\n",
    "{'loss': 1.4721, 'grad_norm': 9.312894821166992, 'learning_rate': 4.558691126874258e-05, 'epoch': 0.26}\n",
    "{'loss': 1.457, 'grad_norm': 8.400811195373535, 'learning_rate': 4.5584159963110496e-05, 'epoch': 0.26}\n",
    "{'loss': 1.465, 'grad_norm': 10.949821472167969, 'learning_rate': 4.558140865747841e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4401, 'grad_norm': 8.06319808959961, 'learning_rate': 4.557865735184632e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4654, 'grad_norm': 8.923135757446289, 'learning_rate': 4.5575906046214234e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4549, 'grad_norm': 9.015380859375, 'learning_rate': 4.557315474058215e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4787, 'grad_norm': 9.590959548950195, 'learning_rate': 4.557040343495006e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4531, 'grad_norm': 8.33353042602539, 'learning_rate': 4.556765212931797e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4724, 'grad_norm': 7.695148468017578, 'learning_rate': 4.556490082368588e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4716, 'grad_norm': 8.761918067932129, 'learning_rate': 4.556214951805379e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4627, 'grad_norm': 7.387304306030273, 'learning_rate': 4.5559398212421705e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4631, 'grad_norm': 8.911149024963379, 'learning_rate': 4.555664690678962e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4607, 'grad_norm': 8.053589820861816, 'learning_rate': 4.555389560115753e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4609, 'grad_norm': 8.217938423156738, 'learning_rate': 4.5551144295525444e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4511, 'grad_norm': 8.838197708129883, 'learning_rate': 4.554839298989336e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4894, 'grad_norm': 7.156284809112549, 'learning_rate': 4.554564168426127e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4672, 'grad_norm': 8.701504707336426, 'learning_rate': 4.554289037862918e-05, 'epoch': 0.27}\n",
    "{'loss': 1.462, 'grad_norm': 9.391708374023438, 'learning_rate': 4.55401390729971e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4544, 'grad_norm': 8.357171058654785, 'learning_rate': 4.5537387767365006e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4463, 'grad_norm': 10.056334495544434, 'learning_rate': 4.5534636461732914e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4713, 'grad_norm': 10.274479866027832, 'learning_rate': 4.553188515610083e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4389, 'grad_norm': 9.474105834960938, 'learning_rate': 4.5529133850468744e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4442, 'grad_norm': 6.790122032165527, 'learning_rate': 4.552638254483665e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4323, 'grad_norm': 8.092194557189941, 'learning_rate': 4.552363123920457e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4805, 'grad_norm': 7.500400066375732, 'learning_rate': 4.552087993357248e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4368, 'grad_norm': 8.937694549560547, 'learning_rate': 4.551812862794039e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4585, 'grad_norm': 10.50197696685791, 'learning_rate': 4.5515377322308307e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4597, 'grad_norm': 6.507939338684082, 'learning_rate': 4.551262601667622e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4812, 'grad_norm': 8.089361190795898, 'learning_rate': 4.550987471104412e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4727, 'grad_norm': 11.621830940246582, 'learning_rate': 4.550712340541204e-05, 'epoch': 0.27}\n",
    "{'loss': 1.468, 'grad_norm': 7.5070390701293945, 'learning_rate': 4.5504372099779954e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4455, 'grad_norm': 7.025522708892822, 'learning_rate': 4.550162079414786e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4483, 'grad_norm': 8.620267868041992, 'learning_rate': 4.549886948851578e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4404, 'grad_norm': 10.082969665527344, 'learning_rate': 4.549611818288369e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4558, 'grad_norm': 9.269762992858887, 'learning_rate': 4.54933668772516e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4418, 'grad_norm': 8.844417572021484, 'learning_rate': 4.5490615571619516e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4794, 'grad_norm': 8.270543098449707, 'learning_rate': 4.548786426598743e-05, 'epoch': 0.27}\n",
    "{'loss': 1.431, 'grad_norm': 8.304194450378418, 'learning_rate': 4.548511296035534e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4571, 'grad_norm': 9.044967651367188, 'learning_rate': 4.548236165472325e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4623, 'grad_norm': 10.538127899169922, 'learning_rate': 4.547961034909116e-05, 'epoch': 0.27}\n",
    "{'loss': 1.444, 'grad_norm': 7.597245216369629, 'learning_rate': 4.547685904345908e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4376, 'grad_norm': 7.364052772521973, 'learning_rate': 4.5474107737826986e-05, 'epoch': 0.27}\n",
    "{'loss': 1.437, 'grad_norm': 6.774776458740234, 'learning_rate': 4.54713564321949e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4736, 'grad_norm': 10.122713088989258, 'learning_rate': 4.546860512656281e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4498, 'grad_norm': 8.690244674682617, 'learning_rate': 4.5465853820930725e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4394, 'grad_norm': 10.221277236938477, 'learning_rate': 4.546310251529864e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4542, 'grad_norm': 13.029943466186523, 'learning_rate': 4.546035120966655e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4494, 'grad_norm': 9.339994430541992, 'learning_rate': 4.545759990403446e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4382, 'grad_norm': 7.779630661010742, 'learning_rate': 4.545484859840237e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4629, 'grad_norm': 7.528447151184082, 'learning_rate': 4.545209729277029e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4543, 'grad_norm': 7.721797466278076, 'learning_rate': 4.5449345987138196e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4531, 'grad_norm': 10.655647277832031, 'learning_rate': 4.544659468150611e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4627, 'grad_norm': 8.45132827758789, 'learning_rate': 4.5443843375874026e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4772, 'grad_norm': 10.250021934509277, 'learning_rate': 4.5441092070241934e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4668, 'grad_norm': 11.772461891174316, 'learning_rate': 4.543834076460985e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4543, 'grad_norm': 6.897887706756592, 'learning_rate': 4.5435589458977765e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4543, 'grad_norm': 8.563858032226562, 'learning_rate': 4.543283815334567e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4415, 'grad_norm': 9.569244384765625, 'learning_rate': 4.543008684771358e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4538, 'grad_norm': 7.998226642608643, 'learning_rate': 4.5427335542081496e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4512, 'grad_norm': 11.40449047088623, 'learning_rate': 4.5424584236449405e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4382, 'grad_norm': 7.025571346282959, 'learning_rate': 4.542183293081732e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4536, 'grad_norm': 6.469700336456299, 'learning_rate': 4.5419081625185235e-05, 'epoch': 0.27}\n",
    "{'loss': 1.4515, 'grad_norm': 7.555152416229248, 'learning_rate': 4.5416330319553143e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4479, 'grad_norm': 7.006507396697998, 'learning_rate': 4.541357901392106e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4446, 'grad_norm': 8.472725868225098, 'learning_rate': 4.5410827708288974e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4687, 'grad_norm': 8.722235679626465, 'learning_rate': 4.540807640265688e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4664, 'grad_norm': 9.367838859558105, 'learning_rate': 4.54053250970248e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4478, 'grad_norm': 8.149343490600586, 'learning_rate': 4.5402573791392706e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4469, 'grad_norm': 7.9044904708862305, 'learning_rate': 4.539982248576062e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4693, 'grad_norm': 9.665281295776367, 'learning_rate': 4.539707118012853e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4385, 'grad_norm': 7.060789585113525, 'learning_rate': 4.5394319874496444e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4458, 'grad_norm': 7.036242961883545, 'learning_rate': 4.539156856886436e-05, 'epoch': 0.28}\n",
    "{'loss': 1.436, 'grad_norm': 8.203239440917969, 'learning_rate': 4.538881726323227e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4614, 'grad_norm': 8.283976554870605, 'learning_rate': 4.538606595760018e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4668, 'grad_norm': 7.3492350578308105, 'learning_rate': 4.53833146519681e-05, 'epoch': 0.28}\n",
    "{'loss': 1.444, 'grad_norm': 10.535237312316895, 'learning_rate': 4.5380563346336006e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4467, 'grad_norm': 10.418097496032715, 'learning_rate': 4.537781204070392e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4527, 'grad_norm': 10.546502113342285, 'learning_rate': 4.537506073507183e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4491, 'grad_norm': 8.340408325195312, 'learning_rate': 4.537230942943974e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4521, 'grad_norm': 6.847714900970459, 'learning_rate': 4.5369558123807653e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4653, 'grad_norm': 7.7623748779296875, 'learning_rate': 4.536680681817557e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4409, 'grad_norm': 8.91409683227539, 'learning_rate': 4.536405551254348e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4733, 'grad_norm': 7.391883373260498, 'learning_rate': 4.536130420691139e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4597, 'grad_norm': 10.386221885681152, 'learning_rate': 4.535855290127931e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4463, 'grad_norm': 6.121020793914795, 'learning_rate': 4.5355801595647216e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4243, 'grad_norm': 10.046622276306152, 'learning_rate': 4.535305029001513e-05, 'epoch': 0.28}\n",
    "{'loss': 1.4418, 'grad_norm': 11.562287330627441, 'learning_rate': 4.5350298984383046e-05, 'epoch': 0.28}\n",
    "\n",
    "}\n",
    "\n",
    "import re\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# If your cell `data = {...}` exists and contains strings like \"{'loss': 1.45, ...}\"\n",
    "losses = []\n",
    "epochs = []\n",
    "for i, item in enumerate(data):\n",
    "    if not isinstance(item, str):\n",
    "        continue\n",
    "    m_loss = re.search(r\"'loss':\\s*([+-]?\\d+(?:\\.\\d+)?(?:[eE][+-]?\\d+)?|inf)\", item)\n",
    "    m_epoch = re.search(r\"'epoch':\\s*([0-9]+(?:\\.[0-9]+)?)\", item)\n",
    "    if not m_loss:\n",
    "        continue\n",
    "    val = m_loss.group(1)\n",
    "    loss = float('inf') if val == 'inf' else float(val)\n",
    "    losses.append(loss)\n",
    "    epochs.append(float(m_epoch.group(1)) if m_epoch else float(i))\n",
    "\n",
    "# Build DataFrame, sort by epoch\n",
    "df = pd.DataFrame({'epoch': epochs, 'loss': losses})\n",
    "df = df.sort_values('epoch').reset_index(drop=True)\n",
    "\n",
    "# Plot raw loss and smoothed loss (rolling window)\n",
    "plt.figure(figsize=(10,4))\n",
    "plt.plot(df.index, df['loss'], marker='.', ms=3, lw=0.6, alpha=0.8, label='loss')\n",
    "# replace infinities for smoothing, forward-fill then rolling mean\n",
    "series_for_smooth = df['loss'].replace([float('inf')], pd.NA).fillna(method='ffill').astype(float)\n",
    "df['loss_smooth'] = series_for_smooth.rolling(window=50, min_periods=1).mean()\n",
    "plt.plot(df.index, df['loss_smooth'], color='orange', lw=1.2, label='rolling(50)')\n",
    "plt.xlabel('Iteration (index)')\n",
    "plt.ylabel('Loss')\n",
    "plt.title('Training loss over iterations')\n",
    "plt.grid(alpha=0.3)\n",
    "plt.legend()\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
